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Abstract 
During inflammatory reactions, leukocytes migrate from the circulation into extra- 
vascular tissues. Chemokines, 7-10 KDa proteins, immobilised on the endothelial cell 
surface bound to glycosaminoglycans, such as heparan sulphate, on proteoglycans have 
been implicated in this process. Evidence suggests that chemokines are functional in 
multimeric form bound to heparan sulphate. In this form, endothelial bound RANTES is 
a T-cell, monocyte and eosinophil chemoattractant. T-cell accumulation in respiratory 
tissue is a feature of asthma, cystic fibrosis and chronic obstructive pulmonary disease 
where T-cell derived cytokines orchestrate the inflammatory response. Central to 
inflammation, platelets migrate into tissues, augmenting the inflammatory response by 
degranulating and releasing their contents, including RANTES on activation. Since both 
copper and dityrosine links have been implicated in the multimerisation of the amyloid 
protein in Alzheimer's disease, chemokines including RANTES, IL-8 and ENA-78 
were investigated for the possibility of copper-induced dityrosine formation within 
chemokine multimers. The addition of CuC12 and H202 to human recombinant 
RANTES induces multimerisation and dityrosine cross-linking, confirmed by 
fluorimetry, liquid chromatography mass spectroscopy and staining Western blots with 
a dityrosine specific monoclonal antibody. In addition, RANTES multimers actively 
induce chemotaxis in Boyden chambers. This finding led to the investigation of the T- 
cell response to endothelial and platelet derived RANTES in the absence and presence 
of copper chelators as potential anti-inflammatory agents in transendothelial migration 
assays, a physiological model of the vascular endothelium. Migration of activated T- 
cells across monolayers of human lung microvascular endothelial cells was RANTES- 
dependent and RANTES derived from thrombin stimulated platelets is active as a T-cell 
chemoattractant in this model of the lung microvascular endothelium. The copper 
chelators neocuproine, bathocuproine, D-penicillamine and tobramycin significantly 
inhibited T-cell migration indicating a pro-inflammatory role for copper and suggesting 
the use of copper chelators as potential anti-inflammatory agents. 
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1. General Introduction 
1.1. Leukocyte recruitment across the vascular endothelium 
The endothelium is the first barrier to leukocyte recruitment to tissue sites of 
inflammation, a process that is mediated through the interaction of inflammatory cells 
with endothelial cell adhesion molecules and chemoattractants (Butcher, 1991). The 
transendothelial migration of leukocytes from the blood, across the endothelial 
monolayer and basement membrane into the underlying tissue is an important 
component of the normal inflammatory process, and is also important for some 
inflammatory disease states. 
The vascular endothelium is a continuous single-cell lining of the cardiovascular system 
that forms a critical interface between the blood and its components on one side and the 
tissues and organs on the other (Gimbrone, 1987). The vascular endothelium is central 
to the cellular and molecular events that initiate the response of the body to infection, 
immune reactions and tissue injury (Rao et al, 2007). Endothelial cell activation by a 
variety of stimuli including the pro-inflammatory cytokines interleukin (IL)-ß1, tumor 
necrosis factor (TNF)-a and interferon (IFN)-'y leads to local thrombosis, loss of vessel 
barrier function and leukocyte recruitment, a fundamental event in the inflammatory 
response that localises blood leukocyte subsets to tissues and organs through endothelial 
mechanisms (Gimbrone, 1999). 
Leukocyte recruitment is a multi-step process (see Figure 1.1) involving adhesion 
molecules that support leukocyte tethering (step 1), firm adhesion (step 2) and 
transmigration (step 3). The migration of leukocytes across the endothelium is referred 
to as chemotaxis. This is the directional motility of leukocytes along a gradient of 
cellular adhesion sites or toward a chemical attractant (chemoattractant). Chemotaxis is 
the sum of the cell migration induced by soluble (chemotactic) and surface bound 
(haptotactic) gradients of the attractant. Haptotaxis refers to the side-side movements of 
cells in response to surface-bound chemoattractant (Rot, 1993). 
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Figure I. I. The multistep process of leukocyte recruitment. Initial attachment and rolling, arrest, 
and migration to cell-cell borders and transmigration across the vascular endothelium, shown here 
for monocytes. The leukocytes initially attach via selectin-mediated mechanisms along with 
contributions from the a4 and ß2 integrins interacting with their ligands VCAM-1 and ICAM-1, 
respectively. The next step is stable arrest; (32-integrins become activated by arrest chemokines and 
trigger cell arrest at or near cell-cell junctions. Leukocytes then migrate to junctions and 
transmigrate across the vascular endothelium at both junctional and nonjunctional locations. The 
symbols used to represent adhesion molecules in endothelial cells are identified below each 
component of the figure (Rao et al, 2007). 
The first event to occur in chemotaxis is leukocyte tethering and rolling on the 
endothelium (step 1), which is classically mediated by endothelial cell expressed 
selectins, and interactions with their leukocyte expressed ligands. There are three types 
of selectin. Leukocyte selectin (L-selectin) is found on leukocytes, and binds to 
endothelial ligands such as CD34, a sialomucin highly expressed in lymph nodes. 
Endothelial ligands are often induced by lipopolysaccharide (LPS) or cytokine exposure 
(Wagner & Roth, 2000). Platelet selectin (P-selectin) is expressed by endothelial cells in 
response to inflammatory stimuli. Stored intra-cellularly in endothelial cells and also in 
platelets, it is mobilised to the cell surface, and binds to P-selectin glycoprotein ligand-1 
(PSGL-1) on leukocytes, although PSGL-1 has a dominant role as a ligand for all three 
selectins (Ley et al, 2007). L-selectin binding occurs first and is more rapid and short 
lived than P-selectin binding and reversible if additional adhesive events are not soon 
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invoked. The binding of PSGL-1 to L-selectin mediates leukocyte-leukocyte 
interactions, by which adherent leukocytes can facilitate secondary leukocyte capture or 
tethering, enabling leukocytes that do not express ligands for E- or P-selectin to reach 
sites of inflammation. 
Endothelial selectin (E-selectin) is not stored, requiring gene transcription for 
expression following exposure of endothelial cells to inflammatory cytokines. E- 
selectin binds to leukocyte expressed PSGL-1, CD44, E-selectin ligand-1 (ESL-1) (Ley 
et al, 2007) and the T-cell expressed adhesion molecule, conjugated linoleic acid 
(CLA), supporting the rolling and tethering of leukocytes in a fashion similar to P- 
selectin (Sallusto & Baggiolini, 2008; Wagner & Roth, 2000). 
L-selectin and P-selectin initiate the migration process during inflammation. The initial 
tethering of leukocytes to the endothelium is a weak interaction that, without additional 
adhesion steps, cannot lead to leukocyte migration. Due to the shear stress of the blood 
flow, the selectin-mediated adhesion results in leukocyte rolling on the endothelial cell 
surface (Rot et al, 1996). These reversible selectin-ligand interactions allow time for 
leukocytes to associate with endothelial cells and respond to stimuli on the endothelial 
surface. 
The interactions of selectins with their ligands enables leukocytes to adhere to inflamed 
endothelium under conditions of flow as they bind with high on- and off-rates, the speed 
at which bonds are formed and broken (Ley et al, 2007). Chemokines, a large super- 
family of proteins with chemotactic properties and molecular masses of between 7 and 
10 KDa, are immobilised on the luminal endothelial cell surface, bound by 
glycosaminoglycans and presented to the rolling leukocytes. This mechanism allows the 
exposure to chemokines of only those leukocytes that have already established their first 
adhesive interaction with the endothelium. Soluble chemokines would activate 
leukocytes in the circulation before their adhesion to the endothelial surface, blocking 
migration (Rot et al, 1996). Chemokine signalling through G-protein coupled receptors 
(GPCRs) leads to expression and activation of leukocyte integrins and results in firm 
adhesion (step 2). 
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Integrins are glycoproteins found on leukocytes that mediate cell-cell adhesion during 
cell recruitment. The CD 18 containing integrins (ß2-integrins) such as the T-cell 
expressed lymphocyte-associated function antigen-1 (LFA-1) mediate binding to 
activated endothelium. Intercellular adhesion molecules (ICAMs) on endothelial cells 
are ligands for integrins on leukocytes. The intercellular adhesion molecules ICAM-1 
and ICAM-2 can bind to the ß2-integrins such as macrophage antigen-1 (MAC-1) or the 
T-cell expressed integrin LFA-1 (Wagner & Roth, 2000). Vascular cell adhesion 
molecule-1 (VCAM-1) is another Ig-like molecule found on endothelial cells, binding 
selectively to X31-integrins (CD29) such as VLA-4, or u4ß1 expressed by T-cells, rather 
than ß2-integrins (CD 18) (Davenpeck et al, 1998; Reinhardt et al, 1997; Sallusto & 
Baggiolini, 2008). 
L-selectin and T-cell PSGL-1 can activate CD18 (ß2) integrins on inflammatory cells. 
Prolonged engagement of endothelial ICAM-1 with integrin ligands causes further 
expression of both ICAM-1 and VCAM-1 on endothelial cells (Clayton et al, 1998). 
Thus, T-cell migration in vivo might involve both ICAM-1 and VCAM-1 adhesive 
pathways. 
Following arrest, leukocytes migrate into tissues either through or between the 
endothelial cell barrier and its associated basement membrane and pericyte sheath, a 
process known as transmigration (step 3). The ligation of intercellular adhesion 
molecules and integrins triggers the extension of leukocyte membrane protrusions into 
the endothelial cell body and endothelial cell junctions. Leukocyte migration can occur 
through the paracellular or transcellular route. 
Paracellular migration through endothelial junctions involves the release of endothelial- 
expressed vascular endothelial cadherin (VE-cadherin) and is facilitated by endothelial 
cell junctional molecules localised at the borders between adjacent endothelial cells 
such as platelet/endothelial-cell adhesion molecule-1 (PECAM-1), the junctional 
adhesion molecules (JAM) A, B and C or ICAM-2 (Marelli-Berg et al, 2008). 
Leukocytes migrate through endothelial cell monolayers at tricellular junctions. 
Transmigration occurs through leukocyte spreading and diapedesis, associated with 
pseudopod formation (Sallusto & Baggiolini, 2008). 
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Transcellular migration occurs in thin parts of the endothelium where there is less 
distance to migrate and involves actin and caveolae containing ICAM-1 molecules that 
form an intracellular channel through which leukocytes can migrate. The paracellular 
route is generally considered the principal route of leukocyte extravasation. Migration 
through the basement membrane and pericyte sheath can occur through gaps between 
adjacent pericytes and regions of low protein disposition within the extracellular matrix 
(ECM) (Ley et al, 2007). This response is facilitated by a6ß1-integrin and proteases 
since adhesion and migration is accompanied by release of leukocyte proteases, such as 
matrix metalloproteases (MMPs) and heparanases. These enzymes are capable of 
digesting collagen, laminin and proteoglycans of the dense basement membrane 
amongst other extracellular components present in the vascular wall. 
1.2. Chemokines 
The chemotaxis process is predominantly directed by chemokines. These molecules 
play a key role in the selective activation and recruitment of a large variety of cell types 
in inflammation, inducing changes in shape, a transient rise in intracellular free Cat+, 
granule exocytosis, integrin upregulation, formation of bioactive lipids and mediating 
the respiratory burst (Wells et al, 1996). 
Chemokines can be divided into subfamilies on the basis of structural motifs and are 
sub-classified according to the number and spacing of the conserved cysteines near the 
N terminus within their primary structure (Murphy, 2002). There are two major groups 
known as the CC and CXC classes, and two minor groups, the C and CX3C classes. The 
CXC, CC and CX3C chemokines all have four conserved cysteines, whereas C 
chemokines have only two, corresponding to the second and fourth cysteines in the 
other groups. CXC and CX3C chemokines are distinguished by the presence of one 
(CXC) or three (CX3C) amino acids between the first and second cysteines, whereas the 
first two cysteines of the CC chemokines are adjacent (Murphy et al, 2000). 
The CXC cytokines, including interleukin-8 (IL-8), have been shown to have pro- 
inflammatory properties mainly through their actions on neutrophils, (Schall, 1991). 
The discovery of the neutrophil-targeted chemokine, IL-8, in 1987 represents a 
landmark in immunology because it was the first leukocyte subtype-selective 
chemoattractant to be found (Baggiolini & Dahinden, 1994; Walz et al, 1987; 
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Yoshimura et al, 1987). The discovery of IL-8 stimulated the search for new family 
members and functions for other chemokines in leukocyte chemotaxis (Murphy et al, 
2000). Interest in the field grew with subsequent reports of monocyte chemotactic 
protein-1 (MCP-1), RANTES and eotaxin, the first important monocyte-, T-cell-. and 
eosinophil-directed chemokines (chemotactic cytokines), respectively (Jose et al, 1994; 
Matsushima et al, 1989; Schall et al, 1990; Yoshimura et al, 1989). 
The majority of chemokines are highly potent and bind their receptors at nanomolar 
concentrations, exerting their physiological responses in the subnanomolar 
concentration range. Chemokines have been implicated in a variety of clinically 
important inflammatory diseases to include chronic diseases such as allergic asthma, 
psoriasis, atopic dermatitis, arthritis and atheroma (Wells et al, 1996). 
1.3. Chemokine receptors 
The Bordella pertussis (PT) toxin which specifically inhibits GTP-binding proteins 
prevents the responses of basophils, T-cells, eosinophils and monocytes to CC 
chemokines suggesting that this class of chemokines mediate their biological effects via 
interactions with GTP-protein coupled 7-transmembrane domain receptors (GPCRs) 
present on these cells. These receptors are comprised of approximately 350 amino acids, 
have a molecular weight of around 40 kDa and have a core domain consisting of seven 
trans-membrane helices (Baggiolini & Dahinden, 1994; Mellado et al, 2001). 
The extra-cellular domain consists of the N-terminus and three extracellular loops that 
act together to bind the chemokine ligand. The intracellular region is comprised of three 
loops and the C-terminus which collaborate to transduce the chemokine signal (Mellado 
et al, 2001). Based on the amino acid sequence, GPCRs belong to the class A 
rhodopsin-like family. Chemokine receptors have a number of conserved motifs, 
including the DRYLAIV motif in the second intracellular loop domain which is 
necessary for receptor G-protein coupling and signal transduction events leading to a 
chemotactic response (Ward et al, 1998). As with the chemokines, chemokine receptors 
can be classified according to their structure. The four major families, CR, CCR, CXCR 
and CX3CR interact with C, CC, CXC and CX3C chemokines, respectively (Mellado et 
al, 2001). Following chemokine-receptor binding, a number of responses occur 
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including gene expression, cell polarisation and chemotaxis. Conformational changes in 
the trans-membrane domain are believed to be responsible for receptor activation. 
A large variety of molecular mechanisms induce activation since these conformational 
changes are elicited by a wide variety of ligands including light, Cat+, pheromones, and 
small molecules (amino acids, amines, nucleotides, prostaglandins, peptides) or proteins 
(glycoproteins, interleukins and chemokines). It has been observed that chemokine 
receptors, like other GPCRs initiate their ligand-induced signalling cascades by receptor 
dimerisation and that many chemokine receptors induce signalling cascades via G- 
coupling and JAK/STAT as well as tyrosine and Ser/Thr kinase pathways (Mellado et 
al, 2001). 
Receptor specificity is restricted to some extent by chemokine subfamily name (C, CC, 
CXC, CX3C). In general, the CXC chemokines such as IL-8, GRO-a, ENA-78 or 
platelet factor-4 (PF4) are potent chemoattractants and activators of neutrophils but not 
monocytes, whereas the CC chemokines such as MIP-1 ß/ l a, MCP-1 and RANTES 
exhibit chemoattractant potential for monocytes and lymphocytes but not neutrophils 
(Clore & Gronenborn, 1995). However, each receptor subtype typically binds multiple 
chemokines, and therefore receptor selectivity is more likely due to the distribution of 
hydrophobic sequences on the monomer surface since analysis of hydrophobicity shows 
that the distribution of hydrophobic regions is preserved in CC or CXC chemokines 
(Wells et al, 1996). Table 1.1 outlines the known chemokine receptors and their ligands, 
and shows that RANTES binds to CCR1,3 and 5 receptors, mediating chemotaxis and 
activation of the various cell types bearing these receptors. 
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Table I 
CXC, C, CX3C and CC chemokine/receptor families 
Systematic name Human chromosome Human Ggand Mouse ligand Chemokine receptor(s) 
CXC chemokine/receptor family 
CXCLI 4g21.1 
CXCL2 4q21.1 
CXCL3 4g21.1 
CXCL4 4q21.1 
CXCL5 4g21.1 
CXCL6 4g21.1 
CXCL7 4g21.1 
CXCL8 4q21.1 
CXCL9 4g21.1 
CXCL ]0 4g21.1 
CXCL I1 4g21.1 
CXCL12 IOg11.21 
CXCL 13 4q21.1 
CXCL 14 5g31.1 
(CXCL 15) 
CXCL16 17p13 
C chemokine/receptor family 
XCLI l g24.2 
XCL2 1 g24.2 
CX3C chemokine/receptor family 
CX3CLI 16g13 
CC chemokine/receptor family 
CCLI ]7g11.2 
CCL2 17q11.2 
CCL3 l 7q 12 
CCL3L1 17g12 
CCL4 Pq 12 
CCL5 17g12 
(CCL6) 
CCL7 Nq 11.2 
CCL8 17q 11.2 
(CCL9J10) 
CCL11 17q11.2 
(CCL 12) 
CCLI 3 l 7q 11.2 
CCL14 17g12 
CCL15 17q12 
CCLI6 ]7g12 
CCL 17 16q13 
CCL18 Pq 12 
CCL19 9p 13.3 
CCL20 2g36.3 
CCL21 9p13.3 
CCL22 16q 13 
CCL23 17q 12 
CCL24 7g11.23 
CCL25 19p 13.3 
CCL26 7q] 1.23 
CCL27 9p 13.3 
CCL28 5p12 
GROa/MGSA-a 
GROß/MGSA-ß 
GROy/MGSA-y 
PF4 
ENA-78 
GCP-2 
NAP-2 
IL-8 
Mg 
[P-l0 
I-TAC 
SDF-1 a/ß 
BCA-1 
BRAK/bolekine 
Unknown 
Lymphotactin/SCM-1 a/ 
ATAC 
SCM-1 ß 
Fractalkine 
I-309 
MCP-1/MCAF/TDCF 
M1P-1 a/LD 78a 
LD78ß 
MIP-1 ß 
RANTES 
Unknown 
MCP-3 
MCP-2 
Unknown 
Eotaxin 
Unknown 
MCP-4 
HCC-1 
HCC-2/Lkn-1/IMP-1 
HCC-4/LEC/LCC- I 
TARC 
DC-CK1/PARC/AMAC-1 
MIP-3ß/ELC/exodus-3 
MIP-3a. /LARC/exodus-1 
6Ckine/SLC/exodus-2 
MDC/STCP-1 
MPIF-1 /CKß8/CKß8-1 
Eotaxin-2/MPIF-2 
TECK 
Eotaxin-3 
CTACK/ILC 
MEC 
GRO/MIP-2/KC? 
GRO/MIP-2/KC? 
GRO/MIP-2/KC? 
PF4 
GCP-2/LIX? 
GCP-2/LIX? 
Unknown 
Unknown 
Mig 
IP-I O/CRG-2 
I-TAC 
SDF-1/PBSF 
BLC 
BRAK 
Lungkine/WECHE 
Lymphotactin 
Unknown 
Neurotactin/ABCD-3 
TCA-3/P500 
JE? 
MIP-1a 
Unknown 
MIP-1(3 
RANTES 
CIO/MRP-1 
MARC? 
MCP-2? 
MRP-2/CCF18/MIP-1 y 
Eotaxin 
MCP-5 
Unknown 
Unknown 
Unknown 
Unknown 
TARC/ABCD-2 
Unknown 
MIP-3ß/ELC/exodus-3 
M[P-3a/LARC/exodus- I 
6 Clin e/S LC/exodus- 2/ 
TCA-4 
ABCD-1 
Unknown 
MPIF-2 
TECK 
Unknown 
ALP/CTACK/ILC/ESkine 
CXCR2> CXCRI 
CXCR2 
CXCR2 
Unknown 
CXCR2 
CXCRI, CXCR2 
CXCR2 
CXCRI, CXCR2 
CXCR3a 
CXCR3a 
CXCR3a 
CXCR4b 
CXCRS 
Unknown 
Unknown 
CXCR6 
XCRI 
XCRI 
CX3CRI 
CCR8 
CCR2 
CCRI, CCR5 
CCRI, CCR5 
CCR53 
CCRI, CCR3, CCR5° 
Unknown 
CCRI, CCR2, CCR3 
CCR3, CCR5° 
CCRI 
CCR3 
CCR2 
CCR2, CCR3 
CCR 1, CCR5 
CCRI, CCR3 
CCR1, CCR2 
CCR4 
Unknown 
CCR7d 
CCR6 
CCR7d 
a CD 183. 
b CD 184. 
CD 195. 
d CD, 197. 
CCR4 
CCRI 
CCR3 
CCR9 
CCR3 
CCR 10 
CCR3/CCR 10 
Table I. I. Human chemokine receptor expression and ligand specificity (Murphy et al, 2003). 
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The following table (table 1.2. ) outlines chemokine ligand-receptor specificity and 
inflammatory cell expression for some of the best known chemokines and inflammatory 
cells, to include B-cell attracting chemokine-1 (BCA-1); dendritic cells (DC); EBI 1 
ligand chemokine (ELC); epithelial-cell-derived neutrophil attractant-78 (ENA-78); 
granulocyte chemotactic protein-2 (GCP-2); growth-related oncogene (GRO); 
interleukin-8 (IL-8); interferon-inducible protein-10 (IP-10); interferon-inducible T-cell 
alpha chemoattractant (I-TAC); liver and activation-regulated chemokine (LARC); 
monocyte chemotactic protein-1 (MCP-1); macrophage-derived chemokine (MDC); 
monokine induced by interferon-y (Mig); macrophage inflammatory protein-la (MIP- 
1 a); neutrophil-activating peptide-2 (NAP-2); stromal cell derived factor-la (SDF-1 a); 
secondary lymphoid tissue chemokine (SLC); thymus and activation-regulated 
chemokine (TARC); T-helper type 1 cell (Th 1) and T-helper type 2 cell (Th2) (Sallusto 
et al, 1998a). 
Chemokines bound 
Inflammatory Constitutive 
0 
0- 
0 
E 
a) 
U 
CCR1 
CCR2 
CCR3 
CCR5 
CCR6 
CXCR1 
CXCR2 
CXCR3 
cj 
r- U- 
NczQ 
uKW (V V . ý. ý 
LLJ ~ in (D C\j 
aaQUUUppQ 
cr Q Oý 0J CLL 
ý 
)U 
SS Of 222 WW J : 0Z d_ 2W (f) co 
Expression on 
Ü 
0 
2 
C 
O 
.Z z 
N 
m 
N 
i- 
0 
(7f 
w° 
Qp 
tý 
m 
- 
h- 
O 
p 
2 
Ö 
U7 
z 
EN_ 'liT 
.. CCR4 ýi 
7--T CCR7 
CXCR4 
CXCR5 
Table 1.2. Receptor expression and ligand specifities (Sallusto et al, 1998a) 
Within the CC chemokine family, RANTES is most effective as a chemoattractant for 
T-cells, monocytes, eosinophils and basophils than as a stimulator of mediator release, 
whereas monocyte chemotactic protein-3 (MCP-3) and MCP-1 are effective as inducers 
of mediator release in basophils as well as effective chemoattractants for T-cells, 
monocytes, eosinphils and basophils. Whilst MCP-3 has the same chemoattractant 
properties as RANTES, it shares only 25 % sequence identity. Divergent effects were 
observed for the highly homologous pair macrophage inflammatory protein-la (MIP- 
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I a) and MIP-1 ß, of which only MIP-1 a activates basophils and eosinophils and MIP-1 ß 
is inactive. This suggests that sequence similarity is not necessarily predictive for the 
capacity of different chemokines to elicit one or other effector functions (Baggiolini & 
Dahinden, 1994. ) The table shows that RANTES is not constitutively expressed, but 
when induced can recruit immature dendritic cells, monocytes, eosinophils, basophils, 
and both Thl and Th2 type T-cells, but not neutrophils or B-cells through interactions 
with CCR1,3 and 5 receptors expressed on these cells. 
The focus of this thesis is the chemokine RANTES and its structure and function. 
1.4. Discovery of Regulated on Activation Normal T-cell Expressed and Secreted 
(RANTES) 
The chemokine regulated and normal T-cell expressed and secreted (RANTES), now 
more commonly known as regulated on activation normal T-cell expressed and 
secreted, was first isolated and characterised by Schall et al., in 1988 (Schall et al, 
1988). It was shown that RANTES was expressed by mitogen-activated T-cell clones 
that function in vitro as helper or cytotoxic cells. Several of its characteristics suggested 
that it had an important role in lymphocyte regulation and differentiation and that 
RANTES transcription in T-cells was regulated by cellular activation (Schall et al, 
1988). 
The discovery that RANTES was highly homologous to macrophage inflammatory 
protein (MIP) indicated that both molecules belonged to the same family (Schall et al, 
1988). Following its discovery, the biological function of RANTES was investigated 
which led to the finding that RANTES belonged to the CC class of cytokines, associated 
by primary structure similarities and by the conservation of the four cysteine motif. 
1.5. RANTES in inflammation 
The synthesis and release of RANTES was initially identified in a search for genes 
expressed late (3-5 days) after T-cell activation with an antigen or mitogen (Schall et al, 
1988). It has since been demonstrated that naive (CD45RA+) CD4+ (helper) and CD8+ 
(cytotoxic/killer) T-cells constitutively express RANTES and that RANTES expression 
is also further inducible in mature (CD45RO+) CD4+ T-cells of the Thl phenotype and 
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CD8+ T-cells upon activation with the mitogen, phytohaemagglutinin (PHA) (Nelson et 
al, 1993). However, the CD45RO+/CD4+ cells of the Th2 phenotype express RANTES 
constitutively and do not show inducibility (Kawai et al, 1999; Nelson et al, 1993). It 
has also been shown that CD45RO+/CD8+ T-cells are the more dominant source of 
RANTES over CD45RO+/CD4+ T-cells (Catalfamo et al, 2004; Conlon et al, 1995). 
Many other cell types have also been shown to synthesise and release RANTES. 
RANTES is reported to be inducible in macrophages upon stimulation with IFN-y or 
TNF-a, monocytes upon stimulation with TNF-a (Devergne et al, 1994; Fattal-German 
et al, 1998; Lane et al, 1999), eosinophils upon stimulation with IFN-'y (Ying et al, 
1996), normal human bronchial epithelial cells and nasal epithelial cells upon 
stimulation with IFN--y and TNF-a respectively (Olszewska-Pazdrak et al, 1998; Terada 
et al, 1996), the endothelium including human lung-microvascular, human umbilical 
vein and human mucosal microvascular endothelial cells upon stimulation with IL-1 ß or 
TNF-a plus IFN-y (Ebnet et al, 1996; Kawai et al, 1999; Marfaing-Koka et al, 1995; 
Sundstrom et al, 2001; Terada et al, 1996) and in fibroblasts upon stimulation with IL- 
1 P, TNF- a or IFN- y (Meyer et al, 1998; Teran et al, 1999). RANTES is expressed 
early (12-24 hours) and RANTES mRNA is quickly up-regulated in these cells after 
stimulation with proinflammatory soluble mediators such as IL-1 P, TNF- a or IFN-y in 
contrast to the late expression of RANTES in T-cells, 3-5 days after activation, 
implying that RANTES is more likely involved in late T-cell activation events or 
development of late T-cell effector function. 
Unusually, RANTES mRNA levels are reduced on T-cell activation (Fitzgerald, 2001) 
but an increase in mRNA levels 3-7 days after T-cell activation (figure 1.2) suggests 
that human peripheral blood T-cells secrete chemokines for prolonged periods after 
activation, thus recruiting fresh cells to inflammatory sites (Conlon et al, 1995). 
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Figure 1.2. RANTES is up-regulated late after T-cell activation. The figure shows the sequence of 
gene expression events after T-cell triggering by antigen. Abbreviations: CTL (cytotoxic T- 
lymphocyte), IL (interleukin) and IL-2Ra (IL-2 receptor a chain) (Ortiz et al, 1997). 
RANTES is also released from thrombin-stimulated platelets (Kameyoshi et al, 1992; 
Schroder et al, 1994) and constitutively produced by natural killer (NK) cells and 
megakaryocytes (Nelson et al, 1993). 
It has been proposed that during inflammatory responses, RANTES is produced mainly 
by macrophages and endothelial cells (Devergne et al, 1994; Marfaing-Koka et al, 
1995). Endothelial cells are known sources of both CXC and CC chemokines and the 
production of such chemokines may serve to initiate, augment and modify inflammatory 
responses (Thienel et al, 1999). Activated vascular endothelial cells are also known to 
affect the development of excessive inflammatory responses by secreting 
proinflammatory cytokines and chemokines (Dinarello et al, 1993). 
Increased chemotactic activity and raised RANTES production has been associated with 
a wide range of inflammatory disorders and pathologies. The list is extensive, and 
includes allogenic transplant rejection (Sekine et al, 2000), atherosclerosis (Pattison et 
al, 1996), atopic dermatitis (Kaburagi et al, 2001), inflammatory airway disorders such 
as bronchial asthma (Conti & DiGioacchino, 2001; Devalia et al, 1999), cystic fibrosis 
(CF) (Schwiebert et al, 1999), sarcoidosis (Ziora et al, 1999), chronic eosinophilic 
pneumonia (Kurashima et al, 1997), idiopathic interstitial pneumonia (Panoskaltsis- 
Mortari et al, 2000) and chronic obstructive pulmonary disease (COPD) (Barnes, 2008; 
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n 
O'Donnell et al, 2006), viral infections including respiratory syncytial virus infection 
(Culley et al, 2006), delayed-type hypersensitivity reactions (Devergne et al, 1994), 
glomerulonephritis, endometriosis, neurological diseases such as Alzheimer's disease 
(Tripathy et al, 2008), angiogenesis, rheumatoid arthritis (Volin et al, 1998) and certain 
malignancies (Hebert, 1999; Reale et al, 2002; Sugasawa et al, 2008; Tsukishiro et al, 
2006; Vaday et al, 2006). In all of these pathologies, RANTES is thought to act by 
promoting leukocyte infiltration to sites of inflammation. 
1.6. RANTES structure 
RANTES is present in normal healthy tissues at physiological concentrations in the 
nanomolar range (Vives et al, 2002) and in normal plasma, physiological concentrations 
of 708 pg/ml have been reported (Lumpkins et al, 2008). The monomeric form is the 
major species found at physiological concentrations. RANTES is a highly basic non- 
glycosylated 7.8 kDa, 68 amino acid polypeptide (figure 1.3). Monomers consist of a 3- 
stranded anti-parallel ß-sheet with the C-terminal a-helix packed across the sheet by 
hydrophobic interactions (figure 1.4) (Chung et al, 1995). The N-terminal region is the 
most important for high affinity chemokine-receptor interactions of individual 
monomers for both the CC and CXC chemokines. The N-terminal amino acids 
preceding the first conserved cysteine have a large degree of movement. 
The highly charged amino acids in the a-helix at the carboxyl terminus appear to be 
important for low affinity binding and are known as the heparin or glycosaminoglycan 
binding domain (McFadden & Kelvin, 1997). 
1 SPYSSDTTPC CFAYIARPLP RAHIKEYFYT 
31 SGKCSNPAVV FVTRKNRQVC ANPEKKWVRE 
61 YINSLEMS 
Figure 1.3. The amino acid sequence of the 68 amino acid chemokine human RANTES. 
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1.7. RANTES binding to chemokine receptors 
Chemokines utilise both high affinity and low affinity interactions to elicit full 
biological activity (McFadden & Kelvin, 1997). The binding of chemokine ligands to 
high affinity (500 pM to 10 nM) cell surface 7-transmembrane chemokine receptors is a 
two step process involving two spatially distinct sites on the ligand, one necessary for 
receptor binding and the other necessary for signal transduction (Ward & Westwick, 
1998). 
The first step is the binding of the core of the ligand to the outer surface of the receptor, 
and the second is the orientation of the flexible tail of the ligand. RANTES can interact 
with each of its receptors CCR1,3 and 5 in a distinct and specific manner. Thus Arg-17 
is necessary for binding to CCR 1, Phe-12 for CCR3 and both Phe-12 and Ile-15 for 
CCR5 binding (Ward & Westwick, 1998). 
The proposed interaction between the RANTES core and its receptors involves firstly 
the interaction of the amino terminus of the receptor with the structured portion of the 
chemokine (the region beyond the first disulphide bridge) which is believed to be driven 
by electrostatic interactions between the acidic portion of the receptor amino terminus 
and the basic regions of the chemokine. In addition, the outer edge of the chemokine ß- 
sheet is also involved in the interaction. This first interaction results in the orientation of 
the flexible amino terminus of the chemokine, effectively raising its local concentration 
and causing it to interact at a second site inside the receptor. The flexible amino 
terminal regions of both CC and CXC chemokines are important for the activity of the 
ligand. Specific residues near the N-terminus have been identified that are involved in 
activating signal transduction via CCR1 (Pro-2, Asp-6, Thr-7), CCR3 (Pro-2 and Tyr-3) 
and CCR5 (Tyr-3 and Asp-6) (Ward & Westwick, 1998; Wells et al, 1995) 
RANTES induces T-cell expression of adhesion molecules during chemotaxis and 
regulates T-cell cytokine release and T-cell proliferation. The mechanism involves 
biphasic calcium mobilisation. Following the binding of RANTES to its receptor, a 
rapid and transient rise in intracellular calcium [Ca2+]i is observed as one of the early 
events associated with the chemotaxis functional response. This initial calcium 
elevation is initiated by nanomolar concentrations and mediated by a heterotrimeric G- 
protein coupled pathway. The second peak of calcium influx is sustained, elicited by 
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micromolar concentrations of RANTES and protein tyrosine kinase (PTK) dependent 
pathways. This second peak is associated with Ca 2+ channel opening, cytokine release. 
IL-2 receptor expression and T-cell proliferation. PTK activation by RANTES results in 
a number of downstream biochemical events that influence T-cell activation. 
chemotaxis, gene transcription, mediator release and cell cycle progression (Figure 1.5). 
RANTES induced calcium mobilisation is dependent on CD3 expression. The [Ca2+]i 
changes induced by different CC chemokines are similar in extent and kinetics and 
coincide with receptor activation (Ward et al, 1998). 
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Figure 1.5. RANTES receptor and downstream processing (Ward et a!, 1998) 
1.8. Glycosaminoglycans 
In order to activate integrins only on those leukocytes that have already established their 
initial interaction with the endothelium, chemokines must be bound to the surface of 
endothelial cells (Rot, 1996). The ECM surrounding human cells is a complex structure 
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T cell proliferation 
containing carbohydrates and proteins, and important complex macromolecules called 
proteoglycans (Carter et al, 2003). Proteoglycans are expressed in all tissues and play a 
vital role in cell function and connective tissue formation. They are found within the 
cell plasma membrane, the basement membrane and the ECM (Cockwell et al, 1996). 
The proteoglycans are a diverse family consisting of a core protein containing a 
membrane spanning domain to which one or more oligosaccharide members of the 
glycosaminoglycan (GAG) family are attached, linked to the core protein via a serine 
residue (Carter et al, 2003). GAGs are the side chains of proteoglycans and are 
ubiquitous components of cell surfaces (Goger et al, 2002). GAGs are long un-branched 
polysaccharides containing a repeating disaccharide unit and are generally highly 
sulphated and negatively charged, their rigidity providing structural integrity to cells 
and providing passageways between cells for cell migration (Yanagishita & Hascall, 
1992). Their primary role is believed to be functional interactions with proteins. They 
have been shown to bind a variety of chemokines, cytokines, extra-cellular matrix 
molecules and growth factors (Cockwell et al, 1996). 
When bound to the endothelial cell surface, RANTES is pro-inflammatory, stimulating 
leukocyte migration across a layer of endothelial cells (Proudfoot et al, 2003). It is 
believed that proteoglycans protect chemokine molecules from degradation, act as 
storage sites and present chemokines to their receptors (Bernfield et al, 1999). It is 
widely known that most chemokines, including RANTES, bind to cell surface GAGs 
through a low-affinity interaction (500 nM to 10 mM range). These interactions are 
normally highly specific (Spillmann et al, 1998) and an important aspect in maintaining 
a chemokine concentration gradient for the presentation of chemokines to high-affinity 
cell surface receptors and selective leukocyte trafficking during diapedesis and 
migration within tissue (McFadden & Kelvin, 1997; Skelton et al, 1995). 
There are four classes of glycosaminoglycans, including heparin/heparan sulphate (HS), 
chondroitin sulphate/dermatan sulphate, keratan sulphate and hyaluronan (Frevert et al, 
2003). All four classes are found in normal human lungs, and with the exception of 
hyaluronan, all are present as side chains on the core proteins of the proteoglycans. 
RANTES binds selectively to GAG families with different affinities: heparin > 
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dermatan sulphate > heparan sulphate > chondroitin sulphate (Kuschert et al, 1999; 
Martin et al, 2001). 
In the lungs, proteoglycans are found on the surface of endothelial cells (eg. syndecan), 
in the extracellular matrix (eg. Decorin, perlecan and versican) and also in the 
intracellular locations (eg. serglycin). RANTES binds mainly to HS side chains of 
proteoglycans (Hillyer & Male, 2005) and HS is the most ubiquitous GAG (50 - 90 % 
of all GAGs) and the most predominant GAG found in the lungs, followed by 
chondroitin sulphate/dermatan sulphate, hyaluronan and heparin (Cockwell et al, 1996; 
Frevert et al, 2003; Ihrcke et al, 1993). 
1.9. Chemokine binding to Heparan Sulphate 
Highly specific cell surface receptors often use cell surface HS to recognise their 
ligands or to regulate their activation. The association of a number of chemokines 
including RANTES with heparan sulphate has been demonstrated and in this form it is 
presented to specific receptors (Ali et al, 2002; Hillyer & Male, 2005; Kuschert et al, 
1999; Proudfoot et al, 2001; Proudfoot et al, 2003). The binding of RANTES to HS 
possibly induces self aggregation and allows a higher surface concentration of the 
chemokine (Skelton et al, 1995). 
Chemokines are highly basic, and all are able to bind heparin with varying affinities. In 
addition, nearly all chemokines bind to HS which has an average molecular weight of 
29 KDa with a range of 5 to 50 KDa and a structure similar to heparin, except heparin 
is more uniformly sulphated making it the most negatively charged molecule in the 
body (Hileman et al, 1998). Like heparin, HS is a strongly anionic linear 
polysaccharide, synthesized in the Golgi apparatus as a repeating linear co-polymer of 
variably sulphated uronic acid and glucosamine residues. HS has an average of one 
sulphate per disaccharide and is predominantly composed of glucuronic acid 1-4 linked 
to glucosamine. HS contains greater structural variation than is present in heparin 
(Yanagishita & Hascall, 1992). 
Although HS contains all of the disaccharide sequences found in heparin, the amount of 
these minor sequences is greater in HS making it structurally and sequentially more 
complex. HS N-deacetylase/N-sulphotransferase (NDST) enzymes catalyse the reaction 
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that initiates sulphation and subsequent modification of HS. The sulphation pattern of 
GAGs is of great importance and plays a role in the regulation of cellular function and 
immunity and the extent and distribution of sulphation on HS is vital to regulate the 
range of proteins that it can bind. Specific sulphated disaccharides on heparan sulphate 
expressed by human microvascular endothelial cells provide the low-affinity binding 
site for RANTES (Carter et al, 2003). 
The interaction between chemokines and sulphated domains on HS is ionic in nature 
and forms between basic amino acid sequences near the C-terminus of the chemokine 
and anionic sulphated domains on the GAG. RANTES has a higher affinity for HS 
compared to other CC chemokines (Kuschert et al, 1999). A conserved concensus 
sequence of basic amino acids has been described in the form of the BBXB motif which 
is found on the 40s loop of RANTES, where B represents either of the basic amino 
acids arginine or lysine, and X represents any other amino acid. In addition, a BBXXB 
sequence has been described further upstream toward the C terminal in RANTES. These 
sequences have been shown to play a major role in the specific low-affinity binding of 
RANTES to HS (Ali et al, 2002; Proudfoot et al, 2001). 
HS is found consistently on two major families of membrane bound proteoglycans 
(PGs), the syndecans and the glypicans (Bernfield et al, 1999). These are referred to as 
heparan sulphate proteoglycans (HSPGs). The syndecans carry the bulk of the HS 
(Kainulainen et al, 1998). By way of their HS chains, syndecans and glypicans can bind 
a wide variety of soluble and insoluble extracellular ligands. Glypicans are covalently 
linked to phosphatidyl inositol in the outer leaflet of the plasma membrane and the HS 
chains are likely located near the plasma membrane bound to an extended protein 
domain (figure 1.6) (Bernfield et al., 1999). 
Syndecans are trans-membrane proteins that bear ligand-binding HS chains distal from 
the plasma membrane. There are four types of syndecan, syndecan-1 through to 
syndecan-4. Syndecan-1 is predominantly expressed by epithelial cells and plasma cells, 
and to a lesser extent by endothelial cells, monocytes and fibroblasts among other cell 
types. Syndecan-2 is abundantly expressed by endothelial cells and mesenchymal cells 
whilst syndecan-3 expression is mostly restricted to cells of neural crest origin. 
Syndecan-4 is expressed ubiquitously, although at lower levels than any of the other 
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syndecans. RANTES binds to syndecan-1 and syndecan-4 (Bartlett et al, 2007), and 
syndecans localise at adherens junctions (Bernfield et al, 1999). 
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Figure 1.6. Schematic depiction of cell surface heparan sulphate (HS) proteoglcans (Bernfield et al., 
1999). 
Virtually all adhesive cells express at least one of the four syndecans (syndecans 1-4) 
and most express multiple syndecans. Glypicans are expressed predominantly in the 
central nervous system. Proteoglycans act as co-receptors for both insoluble (e. g. extra- 
cellular matrix components) and soluble ligands (e. g. growth factors and chemokines), 
have involvement in the internalisation of receptors, and also play a role as soluble 
paracrine effectors, produced by the shedding of the HSPG from the cell surface 
(Bernfield et al, 1999) 
Although immobilised GAGs may aid in the presentation of chemokines, soluble GAGs 
can form complexes with chemokines and play a specific inhibitory role (Kuschert et al, 
1999; Martin et al, 2001). All four syndecans can exist as soluble HSPGs as they can be 
proteolytically cleaved and secreted into the ectodomain environment by ectodomain 
shedding. This is not unique to syndecans and occurs in the secretion of many other cell 
surface components. Cultured cells shed syndecan ectodomains as a part of normal 
turnover, and this shedding is regulated as an inflammatory mechanism by several 
inflammatory factors, and activated under certain inflammatory conditions (Bartlett et 
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al, 2007). Shedding is accelerated by agonists that enhance the activity of a tissue 
inhibitor of matrix metalloproteinase (TIMP)-3 sensitive metalloproteinase (Fitzgerald 
et al, 2000). Agonists of syndecan cleavage include the EGF family growth factors 
(protein tyrosine kinase receptor mediated), thrombin and chemokines including 
RANTES (G-protein coupled receptor mediated), heparanase, stress mediators and 
second messengers (Bartlett et al, 2007). The activation of multiple signaling pathways 
leads to increased activity of membrane-bound metalloproteinase and cleavage of the 
syndecan core protein on the cell surface, close to the plasma membrane. Plasmin can 
activate MMPs and induce syndecan shedding. Plasmin is cleaved from plasminogen in 
the presence of plasminogen activator (PA). The activation of plasminogen is inhibited 
by plasminogen activator inhibitors including platelet derived plasminogen activator 
inhibitor-1 (PAI-1), resulting in an increase in cell associated chemokine (Kucharewicz 
et al, 2003). PAI-1 released from platelets is capable of stabilising the chemoattractant 
gradient on the endothelial cell surface (Taylor & Gallo, 2006). Conversely, the 
inhibition of PAI-1 results in syndecan shedding, and a reduction in cell-associated 
chemokine (Marshall et al, 2003). 
Shedding of syndecans into the extra-cellular environment reduces the concentration of 
chemokines on the endothelial cell surface. Soluble HSPGs, although no longer able to 
bind and localise chemokines on the endothelial cell surface, can compete with 
endothelial bound HSPGs for soluble chemokines, playing an inhibitory role and 
indicating a requirement for chemokine presentation to high-affinity receptors by 
endothelial cell associated GAGs (Cockwell et al, 1996; Kuschert et al, 1999; Martin et 
al, 2001). Soluble chemokines can also bind leukocytes, desensitising specific receptors 
and preventing their adherence to endothelial cells and consequently their 
transendothelial migration. 
GAGs are also present on leukocytes, and may therefore play a role in the presentation 
of chemokines to the GPCRs on the same cell (Kuschert et al., 1999), or possibly cells 
of the same type. Following interaction with an immobilised GAG, a chemokine can be 
presented in either cis or trans fashion. In cis mode, the chemokine, GAG and specific 
receptor are all present on the same cell surface whereas the trans mode occurs when a 
chemokine binds to a GAG within the ECM or on an adjacent cell and then presented to 
a second cell expressing a specific receptor (Ali et al, 2002). 
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The presence of IFN-y and TNF-a has been shown to up-regulate HS expression 
compared to other GAGS. It has been shown that cytokine activation of the endothelium 
increases RANTES binding to the endothelial cell surface and therefore it is likely that 
endothelial cell activation is necessary for efficient chemokine sequestration and 
presentation by the endothelium leading to leukocyte migration from the apical to the 
basal surface of the endothelium (Kennedy et al, 1998; von Hundelshausen et al, 2001). 
In addition, HSPGs are found on both the luminal and basal endothelial cell surface and 
have been implicated in the binding and transcytosis of chemokines across the 
endothelial cell barrier from the abluminal to the luminal surface of endothelial cells 
(Parish, 2005). 
Almost all chemokines studied to date appear to bind to HS, suggesting that this 
interaction represents a fundamental aspect of these proteins (Vives et al, 2002). It has 
been shown that T-cells secrete CC chemokines including RANTES in vivo as a 
complex with PGs (Wagner et al, 1998a). This would strongly suggest that this form is 
physiologically relevant. It has been clearly demonstrated that GAG expression is not 
necessary for the biological function of RANTES in vitro, but the presence of cell 
surface GAGs does enhance the activity of low concentrations of these chemokines, 
indicating that the immobilisation of GAGs is functionally important (Ali et al, 2002). 
In addition, loss of cell surface GAGs reduces the affinity of leukocytes for many 
chemokines (Kuschert et al., 1999). RANTES mutants that cannot bind to GAGs were 
unable to induce leukocyte migration in vivo, even at 10,000 fold higher doses than 
those at which the wild type RANTES was able to induce statistically significant 
recruitment (Proudfoot et al, 2003). This confirms that RANTES must interact with 
GAGs to elicit cell migration in vivo. Without this mechanism, chemokines would be 
washed away from the local production site, especially under flow conditions and 
diluted to a concentration below the threshold required for receptor binding. They 
would become widely distributed such that no localised chemotactic signal would be 
generated for leukocytes to follow (Proudfoot et al, 2003). 
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1.10. Chemokine dimerisation 
A characteristic feature of chemokines is the observation that they are able to form 
dimers and higher order multimers. Growing evidence suggests that GAGs facilitate the 
chemokine-receptor binding process by inducing chemokine self-aggregation, referred 
to as oligomerisation or multimerisation (Hoogewerf et at, 1997; Proudfoot et at, 2003; 
Vives et at, 2002). The aggregation of RANTES is not unique among the CC 
chemokines. Both MIP-1 a and MIP-18 have been shown to form high molecular weight 
aggregates in solution at neutral pH (Skelton et at, 1995). In fact many CC and CXC 
chemokines including IL-8, RANTES and MCP-1 multimerise on interaction with cell 
surface HS (Bernfield et al, 1999; Hoogewerf et at, 1997). 
It is believed that chemokines dimerise and multimerise as a regulation mechanism for 
activity. GAG binding reduces the chemokine dimerisation constant, enhancing surface- 
bound dimer formation (Williams et at, 2005). Cell surface GAGs, including heparin 
and heparan sulphate (HS) sequester chemokines and induce chemokine 
multimerisation at the cell surface (Hoogewerf et at, 1997; Vives et at, 2002), thus 
promoting local high concentrations and establishing a stable chemotactic gradient in 
the vicinity of GPCRs and facilitating chemokine-receptor binding on leukocytes. The 
formation of stable chemotactic gradients gives a longer duration of action by 
preventing diffusion into the bloodstream (figures 1.7a and b). In addition, chemokine 
multimerisation and GAG binding may protect chemokines from proteolytic 
degradation (Hoogewerf et at, 1997; Proudfoot, 2006; Proudfoot et al, 2003). 
Fig. 1.7a 
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Figure 1.7a; Chemokines require immobilisation on cell-surface GAGs in order to initiate the 
transmigration process from the circulation (Proudfoot, 2006). 
Figure 1.7b; RANTES requires a minimal tetrameric structure in order to provide a directional 
signal to circulating leucocytes (Proudfoot, 2006). 
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Maintaining a RANTES gradient that is sufficient for the pro-inflammatory stimulation 
of leukocyte migration across endothelial cells into tissues is crucial for their 
recruitment to an inflammatory site. The formation of aggregates may also have a 
physiological role in limiting the amount of active RANTES circulating in the blood 
stream (Proudfoot, 2006; Skelton et al, 1995). 
1.11. Duffy antigen receptor for chemokines (DARC) 
RANTES can also bind to the Duffy antigen receptor for chemokines (DARC) (Choe et 
al, 2005; Neote et al, 1994). DARC is a 48 KDa protein that belongs to the family of 
`silent' chemokine receptors known also as interceptors (internalising receptors). These 
are 7 trans-membrane molecules present on endothelial cells and erythrocytes with high 
homology to the GPCRs (Colditz et al, 2007; Rot, 2005). 
DARC binds a broad spectrum of chemokines of the CXC and CC groups but, just like 
other chemokine interceptors, does not activate G-protein mediated signalling cascades 
(Colditz et al, 2007; Ward et al, 1998) as it lacks the DRYLAIV motif in the second 
intracellular loop and therefore cannot couple to G-proteins and does not elicit any 
detectable signal transduction events (Ward et al, 1998). DARC has less than 20 % 
amino acid identity with CXC and CC chemokine receptors and is the only known 
chemokine receptor that can bind both CC and CXC chemokines. However, DARC is 
clearly distinct from the chemokine interceptor D6, which binds chemokines and leads 
to chemokine degradation (Pruenster & Rot, 2006). 
The chemokine transport activity of DARC enhances chemokine-induced leukocyte 
migration across biological barriers which express this interceptor, and may play a role 
in inflammation since evidence suggests that DARC is up-regulated in many 
inflammatory diseases (Colditz et al, 2007). Chemokines that are produced in the tissue 
have to appear on the luminal endothelial surface in order to induce firm leukocyte 
adhesion. This is achieved by DARC mediated transcytosis of chemokines from the 
abluminal to the luminal surface of the endothelium. 
The binding of chemokines to DARC on the endothelial cell surface also results in their 
neutralisation and thus prevents the systemic stimulation of circulating leukocytes 
48 
which would result in leukocyte desensitisation and temporary loss of their ability to 
migrate. Erythrocyte expressed DARC has been well documented as a chemokine sink, 
and in addition, prevents the loss of chemokines from the blood into the kidneys and 
other organs thus DARC also functions as a chemokine depot (Colditz et al, 2007). 
1.12. T-cell recruitment 
T-cells are normally present in almost every tissue of the body. They scan dendritic 
cells in lymphoid organs in search of specific antigens and, after priming, they migrate 
to follicles to help B-cells produce antibodies and to sites of antigen exposure to deliver 
the appropriate effector or regulatory function, thus inducing or dampening 
inflammation. Once the antigen is eradicated, central memory and effector memory T- 
cells remain in lymphoid organs and peripheral tissue to react rapidly if a second 
exposure to antigen should occur (Sallusto & Baggiolini, 2008). 
The migratory pattern of T-cells changes during the transition from naive T-cells to 
memory T-cells. Naive T-cells traffic through lymphoid tissue waiting to be primed, 
whereas memory T-cells have acquired the ability to infiltrate non-lymphoid sites where 
antigen is located. In addition, primed T-cells are able to establish homing receptors for 
tissue-selective molecules and chemokines that allow them access to specific tissues 
(Marelli-Berg et al, 2008). 
1.13. T-cell activation 
It is generally accepted that the mitotic activation of T-cells in vivo is a result of a two- 
step signalling mechanism, initially triggered by a specific antigen presented in 
association with products of the major histocompatibility complex (MHC) at the surface 
of an antigen presenting cell. Binding of antigen-MHC to the clonotypic T-cell antigen 
receptor triggers the T-cell to express receptors for the second mitotic signal, the growth 
factor interleukin-2 (IL-2) (Mire-Sluis et al, 1987). IL-2 is secreted by T-cells in 
response to IL-1, which is produced by cells of the monocyte-macrophage lineage in 
response to an antigen-dependent interaction between monocytes and T-cells (Mire- 
Sluis et al, 1987; Mizel, 1982). 
However in vitro, the initial signal for polyclonal activation of T-cells can be achieved 
by substituting a variety of agents, including the lectin phytohaemagglutinin (PHA) for 
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antigen-MHC and the second signal can be delivered by recombinant IL-2 (Mire-Sluis 
et al, 1987; Palacios, 1982). The stimulation of naive T-cells results in activation, 
maturation, proliferation and cytokine release (Dairaghi et al, 1998; Loetscher et al, 
1996). Activation involves the up-regulation of T-cell surface receptors. 
1.14. T-cell differentiation 
The maturation of resting cells into specific effector CD4+ Thl and Th2 phenotype T- 
helper cells is a process of maturation that takes 3-7 days and involves the influence of 
cytokines. Interferon-a (IFN-a) promotes the Thl phenotype, whereas transforming 
growth factor-ß (TGF- ß) promotes differentiation into the Th2 phenotype (Ortiz et al, 
1997; Ward et al, 1998). 
There has been intense effort to determine which chemokine receptors (CCR) are 
expressed on different leukocytes. It is now established that T-cells express most of the 
known CC, CXC and CX3C chemokine receptors (table 1.1. ) The precise pattern of 
chemokine expression depends entirely on the activation state of the T-cell. Following 
mitogenic stimulation/activation and/or prolonged treatment with interleukin-2 (IL-2), 
the chemokine receptors CCR1, CCR2, CCR5, CXCR4 and CX3CR1 are markedly up- 
regulated (Loetscher et al, 1996; Ward & Westwick, 1998) (see table 1.1). Some 
receptors are restricted to activated T-cells, such as CXCR3. Chemokine receptor 
expression correlates well with the known chemotactic effects of the respective ligands 
on T lymphocyte subsets. For example, the CXCR4 receptor is predominantly expressed 
on CD45RA+ naive T-cells. Its ligand, stromal cell derived factor-1 (SDF-1), is 
involved in the basal trafficking of naive lymphocytes. 
In contrast, CCR5 is expressed mainly on mature CD45RO+ CD4+ T-cells, which 
migrate in response to RANTES, the major ligand for CCR5 (Bleul et al, 1997). The 
expression of CCR4, CCR3 and CCR7 has been observed specifically on differentiating 
Th2 type T-helper cells following activation and differentiation (Gerber et al, 1997) 
whereas CCR5 and CXCR3 is preferentially expressed on Thl type T-helper cells 
(Loetscher et al, 1998; Sallusto et al, 1998b). CXCR4, CCR1 and CCR2 are expressed 
on both Thl and Th2 type cells (figure 1.8). In addition, CD8+ cytotoxic T-cells of the 
Tc2 subtype also express CCR1 and CCR3, with CCR1 and CCR5 expressed by CD8+ 
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cytotoxic T-cells of the Tcl subtype (D'Ambrosio et al, 1998; Sallusto et al, 1998b; 
Ward & Westwick, 1998; Weber et al, 2001). 
The pattern of receptor expression on Th 1 and Th2 T-cells correlates with the efficient 
attraction of Thl T-cells by the T-cell ligands MIP- l a, MIP- lb and RANTES. SDF-1 
and MCP-1 bind to CXCR-4 and CCR-2 respectively and exert chemotactic effects on 
both Thl and Th2 type T-cells (Ward et al, 1998). However, there is evidence to 
suggest that differential expression of chemokine receptors may influence functional T- 
cell responses other than chemotaxis, since RANTES, MIP-1 a and MCP-1 also promote 
lymphocyte activation and differentiation (Ward et al, 1998). 
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Figure 1.8. Schematic model for chemokine receptors as markers of T-cell differentiation (Ward et 
al, 1998). 
1.15. The role of RANTES in T-cell migration 
As an immediate early response to stress, RANTES is produced by inflamed tissues and 
deposited on the endothelium as a solid phase gradient (Figure 1.9a). It is proposed that 
chemokines induce the transition from selectin-mediated tethering and rolling to 
integrin-mediated firm attachment and spreading. Chemokines present on both the 
luminal and abluminal endothelial cell side can induce transendothelial migration, and 
in addition are required for the interaction of VLA-4 with fibronectin, which is 
important for migration of T-cells into the tissue (Sallusto et al, 1998a). 
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Chemokines induce the surface expression of endothelial cell adhesion molecules 
including P- and E-selectins, and Ig superfamily members, but this is an indirect effect. 
Chemokines trigger other cells, e. g. mast cells, T-cells or monocytes to degranulate and 
release multiple inflammatory mediators to include histamine and TNF-a which binds 
to receptors on the surface of the same cells, resulting in their activation and the 
expression of P- and E- selectin respectively (Colditz et al, 2007). TNF-a also induces 
the strong expression of intercellular adhesion molecules including ICAM-1. ICAM-1 
expressed on the macrophage surface interacts with its ligand LFA-1 on resting T-cells, 
resulting in their activation and proliferation (Fattal-German et al, 1998). 
RANTES on the endothelial cell surface is recognised by passing monocytes (figure 
1.9b). Monocytes are induced to produce more RANTES transiently by tumor necrosis 
factor-a (TNF-a) and interleukin-1 ß (IL-1p), amplifying the response (figure 1.9c). T- 
cells are activated by target antigens and produce early genes such as IL-2 receptor-a 
chain and adhesion molecules such as leukocyte function-associated molecule-1 (LFA- 
1). RANTES promotes monocyte and T-cell adherence to, and entrance into the tissue 
(figure 1.9d). Days later, T-cells up-regulate sustained RANTES production, creating a 
`trail' into the tissue. This assists the formation of a gradient in order to recruit more T- 
cells and monocytes to the site of inflammation and promotes their entrance into the 
tissue (Ortiz et al, 1997). 
52 
ýa) TN F-a IL 1ß 
RANTES 
i 
Endothelium 
(b) " TN F-a 
T cell Mýý IL 1(3 
S1 
'ii 
(C) IL-219u 
Activated 
aT cell 
IL-2 -ý LFA-1 
! 41M f 
(d) 
`ý rrý 
r 
. 
:c 1 
5Y55 
r ý. 
ýýi b, J 
r". -* 1 
i 
ý_. ý. _) 
ý___ 
Figure 1.9. The role of RANTES in inflammatory responses (Ortiz et al, 1997) 
For a T-cell cell to migrate, it must first acquire polarised morphology that will allow 
locomotion. This morphology is also required for a number of other processes including 
cell differentiation, recognition and binding of antigen presenting cells (APCs) by T- 
cells and cytolytic granule secretion for cell-killing. Chemokines induce T-cell 
polarisation, which is a change in cell distribution of filamentous F-actin from a radial 
symmetrical pattern to concentration in specific cell regions. As a result, two 
differentiated edges are established within the cell, namely, the leading edge and the 
uropod. The leading edge concentrates several chemoattractant receptors including 
CCR3, and CCR5. A number of adhesion molecules are concentrated in the uropod, 
including ICAMs, L-selectin, and PSGL-1. This serves as a method to promote the 
binding of other cells to enhance leukocyte recruitment and trans-endothelial migration 
(Mellado et al, 2001). 
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1.16. RANTES induced T-cell accumulation in lung inflammation 
RANTES monomers have been shown to be functional ligands of CCR1, CCR3 and 
CCR5 in vitro, the biological activity dependent on the integrity of the N-terminal 
domain (Proudfoot et al, 2003). RANTES has been shown to stimulate T-cell and 
monocyte migration in vitro at an optimal concentration of 10 nM (Ali et al, 2002) and 
half-maximal migration at 2 nM (Kameyoshi et al, 1994). 
RANTES can selectively attract naive (CD45RA+) CD4+ (helper) and mature 
(CD45RO+) human CD4+ T-cells including Thl (Kawai et al, 1999) and Th2 subtypes 
(Gerber et al, 1997; Sallusto et al, 1997) and CD8+ (cytotoxic/killer) T-cells of the Tc 1 
and Tc2 subtype (Iijima et al, 2003; Sallusto et al, 1998a; Sallusto et al, 1998b), natural 
killer cells and immature DCs (Appay & Rowland-Jones, 2001; Barnes, 2008; Conti et 
al, 2001; O'Neill et al, 2004), monocytes (Schall et al, 1990), eosinophils (Rot et al, 
1992; Schroder et al, 1994) and basophils (Yoshimura et al, 1987) and could be of 
particular importance in those inflammatory diseases in which these cells are present in 
affected tissues. However, T-cell infiltration during inflammation is of particular 
importance since T-cells are central to adaptive immunity, establishing and maximising 
the immune response by activating and directing other immune cells. 
In addition to RANTES, many other CC chemokines may induce the chemotaxis of 
CD4+ and CD8+ T-cells through binding to CCR1 expressed on CD4+ and CD8+ T-cells 
(MIP- l a, MCP-2, MCP-3, MIP-5, MIP-1 ß, MIP-1 y and MCP-1), CCR2 expressed on 
activated memory T-cells (MCP-1 and MCP-5), CCR3 expressed on CD4+ Th2 and 
CD8+ Tc2 T-cells (eotaxin, eotaxin-2, eotaxin-3, MCP-2, MCP-3, MCP-4 and MIP-5) 
and CCR5 expressed on CD4+ Th 1 and CD8+ Tcl T-cells (MIP-1 a, MIP-1 ß and MCP- 
2, MCP-4, MCP-1 and eotaxin) (Murphy et al, 2000). 
T-cell infiltration is associated in particular with several major inflammatory diseases of 
the lung. Bronchial biopsies from asthmatics show infiltration with eosinophils, 
activated mast cells, and activated T-helper (CD4+) T-cells that are predominantly Th2 
cells. CD4+ lymphocytes predominate over CD8+ cells and neutrophils are sparse 
(reviewed in Barnes, 2008, Holgate, 2007 and Jeffery, 1999). In bronchial biopsies from 
patients with COPD, it has been reported that there is an infiltration of activated T- 
helper (CD4+) T-cells (predominantly Thi and cytotoxic Tcl cells) and increased 
54 
numbers of neutrophils and macrophages (Barnes, 2008). CD8+ lymphocytes 
predominate over CD4+ cells and there are increased numbers of subepithelial 
macrophages and intra-epithelial neutrophils (reviewed in Barnes, 2008 and Jeffery, 
1999). In addition, the infiltration of T-cells of the CD8+ subset again predominates in 
severe peribronchiolitis (Jeffery, 1999) and analysis of infiltrate in the CF airway 
implicates neutrophils, B-cells and T-cells, with increased numbers of CD4+ T-cells 
appearing as the most encountered population in the CF bronchial wall (Hausler et al, 
2002; Hubeau et al, 2001). 
There is much evidence to suggest that RANTES predominantly induces T-cell 
transendothelial migration in the lung during inflammation. Using inhibitors of 
RANTES function and also by measuring RANTES expression, studies have shown that 
RANTES is a major chemoattractant in the asthmatic lung (Venge et al, 1996) and that 
RANTES induces the migration of T-cells into lung tissue in sarcoidosis, COPD, 
asthma, interstitial lung disease and fibrosing alveolitis (Barnes, 2008; Brozyna et al, 
2009; Petrek et al, 1997; Psarras et al, 2005; Saetta et al, 1998; Ziora et al, 1999). T-cell 
accumulation in the lung has been associated with increased levels of RANTES 
detected in the bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis 
(Kadota et al, 2001) and in addition, the neutralisation of RANTES receptors with 
receptor antagonists significantly decreases T-cell infiltration into lung tissue and 
decreases RANTES mRNA expression (Gonzalo et al, 1998). 
1.17. Chemokine clearance 
Chemokines which diffuse in blood and appear in plasma can be bound by DARC on 
red blood cells, which internalises from the cell surface following ligand binding. 
DARC serves as a chemokine reservoir in the blood circulation but DARC may also 
contribute to chemokine clearance from tissues into blood (Colditz et al, 2007; Rot, 
2005). However, more likely, chemokines passively diffuse into the lymphatic vessels 
along pressure gradients and are cleared into the lymph nodes. Evidence shows that 
chemokines can induce leukocyte migration from the blood into the lymph nodes. 
Chemokines may also be scavenged by enzymes or by chemokine interceptor D6 
expressed on lymphatic endothelium and leukocytes. D6 binds multiple inflammatory 
CC chemokines and aids degradation by facilitating transport into lysosomal 
compartments (Colditz et al, 2007; Ward et al, 1998). In addition to chemokine 
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interceptors, GPCRs may also be involved in chemokine clearance through uncoupling 
from conventional signalling responses (Colditz et al, 2007). 
1.18. Copper 
Copper (Cu) is an essential trace element existing in divalent, oxidised (Cu II) and 
reduced (Cu I) states. Widely distributed in the body, it is required for human survival, 
incorporated into organic complexes such as metallo-protein enzymes which are 
involved in such fundamental functions as redox reactions, iron absorption, free radical 
scavenging (superoxide dismutase), the cytochrome chain of mitochondrial oxidation 
(cytochrome oxidase), the synthesis of complex proteins of collagenous tissues in the 
skeleton and blood vessels, the synthesis of neurotransmitters and elastin cross-linking 
by lysyl oxidase. The total content of Cu in the human body is around 50-120 mg, 40 % 
of which is located in muscle and the highest concentration of 6.6 µg/g is found in the 
liver (Garrow, 2000; Osterberg, 1980). In plasma, over 90 % of Cu is bound to 
caeruloplasmin, 10 % to albumin and the rest to transcuprein, and amino acids (Tapiero 
et al, 2003; Twomey et al, 2007). In blood, Cu is bound into the metalloenzyme 
superoxide dismutase, which is involved in free radical scavenging. Caeruloplasmin 
binding to Cu occurs in the liver whereas albumin can bind and release Cu outside the 
liver (Garrow, 2000). 
Total normal plasma or serum levels of Cu have been estimated using many different 
analytical techniques. The reported values range between 8.3 and 26.48 µM (Gonzalez 
et al, 1999; Versieck, 1980). In biological systems including water, free Cu tends to be 
in the cupric (divalent) state, although it is also found as Cu (I). However, in plasma, 
there is little or no free Cu in solution (Brewer, 2007). Free Cu (II) is estimated in 
plasma at 10 -7 tM (Linder & Hazegh-Azam, 1996) and in eukaryotic cells at 10-18 M 
(Jackson et al, 2001), which is less than a single atom per cell (10-10 M). 
Caeruloplasmin bound Cu is not available as part of the exchangeable plasma copper 
pool, and cannot directly bind Cu ions in the plasma. Cu is only added during 
caeruloplasmin synthesis in the liver. 
Cu appears to be exchanged directly between albumin and transcuprein which, of the 
two, has higher affinity for Cu. Cu bound to either of these two proteins is available as 
part of the exchangeable plasma Cu pool. Amino acids and small peptides in blood and 
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plasma are not a significant source of copper for cells (Linder & Hazegh-Azam, 1996). 
Cells can take up Cu from both caerulpolasmin (caeruloplasmin-Cu complex) and non- 
caeruloplasmin sources like albumin, transcuprein, Cu-cysteine and Cu-histidine 
complexes. The uptake of Cu is thought to involve interaction with cell surface 
receptors and metallochaperones. Within cells, copper is mostly bound to 
macromolecules including metallothionein and glutathione and it is thought that very 
few free Cu ions exist in the cytoplasm (Leary & Winge, 2007; Tapiero et al, 2003). 
Dietary Cu is known to be essential for cardiovascular function and haemostasis, which 
is associated with over 30 Cu-dependent enzymes. A Cu deficient diet has major effects 
on both structural and functional aspects of the heart and vasculature. Interactions 
between endothelial cells and blood components in the micro circulation are intricately 
involved with Cu dependent processes. Cu deficiency results in prolonged haemostasis 
and inhibition of NO-dependent vasodilation (Schuschke, 1997). Some studies have 
indicated that Cu is required for the maintenance of appropriate signal transduction 
processes that are essential for the physiological function of platelets in haemostasis and 
thrombosis. Cu deficiency causes an increase in granule secretion from thrombin- 
activated platelets and it has been indicated that it is the direct effect of Cu deficiency 
on signalling pathways that leads to secretion (Johnson, 1999). Cu deficiency also leads 
to diminished platelet adhesion to endothelial cells and inhibits thrombus formation 
(Schuschke, 1997) but increases platelet aggregation, possibly the result of decreased 
platelet vWF and increased fibrinogen (Lominadze et al, 1996). It is clear that Cu is 
important for normal platelet aggregation and is involved in numerous microvascular 
functions. In excess, Cu can cause cellular damage. As a result, free Cu is normally 
present at very low levels in cells, approximately 10-13 - 10-18 M (Jackson et al, 2001; 
Linder & Hazegh-Azam, 1996). 
1.19. Hydrogen Peroxide (H202) 
Hydrogen peroxide (H202) is a covalent liquid that is generated in vivo by the 
dismutation of the superoxide radical (02") and can cross cell membranes readily. H202 
is generated during oxidative stress and also released at sites of inflammation by the 
endothelium (Kinnula et al, 1992c), activated phagocytes and other inflammatory cells 
during inflammation (Halliwell et al, 2000a; Halliwell et al, 2000b). 
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High levels of H202 (>50 µM) are cytotoxic and it is widely thought that H202 is very 
toxic in vivo and is rapidly eliminated by enzymes such as catalases, peroxidases and 
thioredoxin linked systems (Halliwell et al, 2000a). However, H202 is poorly reactive in 
chemical terms, and can act as a mild oxidising or reducing agent but does not oxidise 
lipids, DNA or proteins readily. 
The toxicity of H202 arises from its ability to form the highly reactive hydroxyl radical 
(OH) either by exposure to ultraviolet light or by interaction with transition metal ions 
in vivo (Halliwell et al, 2000a). Transition metal ions are usually sequestered into 
protein-bound forms that cannot catalyse the formation of OH' radicals, but H202 still 
contributes to redox chemistry by liberating transition metals from haem proteins. The 
addition of H202 can lead to transition metal mediated oxidative damage in cultured 
cells, however levels of H202 at or below 20-50 µM appear to have limited cytotoxicity 
to many cell types (Halliwell et al, 2000a) and some studies have claimed levels of 
H202 of up to 35 µM in human plasma (Deskur et al, 1998; Lacy et al, 1998; Varma & 
Devamanoharan, 1991). H202 can activate NF-KB, modulating the inflammatory process 
by up-regulating adhesion molecule expression and platelet aggregation (Halliwell et al, 
2000b). 
1.20. Copper and inflammation 
Raised circulating Cu levels and mildly acidic conditions are common during 
inflammation (Atwood, et al., 1998). Abnormally high Cu levels are seen in 
inflammation, infection, cancer and angiogenesis, cardiovascular diseases, rheumatoid 
arthritis, Alzheimer's disease and cystic fibrosis, chronic obstructive pulmonary disease, 
adult respiratory distress syndrome and asthma indicating that Cu is pro-inflammatory 
(Brewer, 2005; Karadag et al, 2004; Madaric et al, 1994; Milanino & Buchner, 2006; 
Percival et al, 1999; Rice et al, 2001; Squitti et al, 2002; Tapiero et al, 2003). 
Particulate air pollution results in an increase in respiratory symptoms including the 
exacerbation of bronchoconstriction in asthma sufferers, increased hospitalisation rates 
for respiratory disorders and decreased lung function (Pope, 1989; Pope et al, 1991). Cu 
has been shown to be highly toxic for the lung when instilled in the airway, and it has 
been shown that Cu ions cause some of the effects of inhaled air pollution through NF- 
kB activation which results in cytokine (IL-6) and chemokine (IL-8) production, 
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indicating that pollutant-induced lung inflammation is Cu-dependent (Hirano et al, 
1993; Hirano et al, 1990; Kennedy et al, 1998). 
Furthermore, acute and chronic inflammation have been characterised by a significant 
increase of total serum copper, which can be regarded as a factor capable of worsening 
pathological processes, including oxidative stress (Milanino & Buchner, 2006) and Cu 
also induces endothelial IL-8 synthesis (Bar-Or et al, 2003). 
1.21. Copper and peptide multimerisation 
Copper, especially in the presence of H202 has been shown to induce aggregation and 
cross-linking of the amyloid-ß peptide and prion protein (PrPc). The multimerisation of 
the fragment amyloid-ß (Aß) by incubation with Cu was found to induce a fluorescent 
signal characteristic of tyrosine cross-linking (Atwood et at, 2004). The addition of 
H202 strongly promoted Cu-induced dityrosine cross-linking of Aß 1-28, API-40 and 
API-42, suggesting that the oxidative coupling is induced by a Cu/H202 oxidative 
mechanism. In addition, it was previously shown that the binding of the PrPc to GAGs 
is Cu dependent (Gonzalez-Iglesias et at, 2002), suggesting a possible role for Cu in the 
binding of chemokines to GAGs. 
These findings have led to the hypothesis tested in this thesis that Cu may play a role in 
the multimerisation of chemokines through Cu-mediated dityrosine cross-links. It is 
proposed that the generation of H202 in inflammation, and its interaction with Cu 
coordinated to tyrosine residues of chemokines oxidises these residues through 
reactions that lead to covalent cross-linking, resulting in the formation of dityrosine 
cross-linked active chemokine multimers. 
As yet there has been no documentation on the involvement of Cu forming covalent 
links with chemokines and GAGs, or the involvement of tyrosine residues in chemokine 
multimers. Recent therapeutic strategies have been directed to limiting excessive 
cytokine secretion from endothelial cells (Bar-Or, Thomas et al. 2003). 
As well as providing a new therapeutic angle for the treatment of conditions such as 
rheumatoid arthritis, COPD, and CF, the theory that Cu is causative of chemokine 
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multimerisation and inflammation also provides insight to the possibility of treating 
other diseases. 
1.22. Copper chelators 
Cu chelators have been implemented for the treatment of many inflammatory disorders. 
Cu has been implicated in tumour growth and angiogenesis and the Cu chelator 
tetrathiomolybdate has been studied extensively in clinical trials as a therapy for cancer 
and angiogenesis. The anti-angiogenic mechanism of tetrathiomolybdate was found to 
involve the inhibition of angiogenic promoting cytokines, which led to the hypothesis 
that Cu chelators may inhibit cytokines that are associated with excessive fibrosis and 
inflammation (Brewer, 2005; Brewer, 2008). The mechanism is thought to be due to 
NF-KB inhibition resulting in reduced chemokine synthesis. Tetrathiomolybdate has 
also been shown in clinical trials to be successful in treating many other diseases of 
inflammation and fibrosis to include pulmonary fibrosis, hepatitis and liver cirrhosis 
(Brewer, 2005). Other Cu complexes, including Cu complexed to Cu-binding proteins 
have also been shown to attenuate redox reactions and subsequent NF-KB activation 
(Rael et al, 2007). 
Cu chelators such as tetrathiomolybdate, D-penicillamine and trientine are clinically 
effective in the treatment of Wilson's disease, an inherited disease of copper toxicity. 
These drugs are known to remove excess copper accumulated in the liver and other 
organs in Wilson's disease patients (Cui et al, 2005; Gupte & Mumper, 2007; Schilsky, 
1996). The accumulation results in neurologic symptoms of tremors, spasticity, rigidity 
and chorea, dystonia, unsteady gait and psychosis (Cui et al, 2005). Specific Cu 
chelators have also been shown to strongly inhibit protein oxidation that occurs in the 
presence of Cu (Zhu et al, 2002). 
Copper chelators have also been shown to be effective in the treatment of rheumatoid 
arthritis. The active forms of anti-arthritic drugs are complexes extemporaneously 
formed with endogenous Cu in vivo. These include the current drugs, D-penicillamine, 
salicylate, aspirin, and trientine (Cui et al, 2005; Milanino & Buchner, 2006). 
The Cu chelators trientine, D-penicillamine, bathocuproine and bathophenanthroline 
were reported to be effective in solubilising brain 
Aß (Cherry et al, 2000) and in 
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addition, the metal chelation of Cu with clioquinol markedly inhibits Aß aggregation in 
Alzheimer's disease transgenic mice (Cherny et al, 2001). 
It has been found that Cu chelation delays the onset of prion disease in mice, and it has 
been suggested that the removal of Cu reduces the interaction of PrPC with GAGs 
(Sigurdsson et al, 2003). From a clinical perspective, this suggests a possible role for 
chelators in AD and prion disease, and also potential for Cu chelators as anti- 
inflammatory agents. Since Cu is an essential trace element, Cu-lowering therapy must 
decrease Cu levels to a midrange therapeutic window where Cu deficiency does not 
occur (Brewer, 2005). 
In addition, GAGs such as heparin and hyaluronic acid have been shown to exhibit 
antioxidant capacity and have a protective effect against Cu induced lipid peroxidation 
and oxidative damage in fibroblast and liposome cultures (Albertini et al, 2000; 
Albertini et al, 1996; Balogh et al, 2003; Campo et al, 2004; Volpi & Tarugi, 1999). 
1.23. Hypothesis 
This thesis tests the hypothesis that Cu is pro-inflammatory and promotes chemokine 
multimerisation, inducing covalent dityrosine cross-linking between chemokine 
monomers in the presence of H202- 
1.24. Aims 
To identify a proinflammatory role for Cu and investigate the potential for Cu chelators 
as anti-inflammatory therapy. 
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1.25. Objectives 
1. To establish the effect of Cu and H202 on chemokine multimerisation 
2. To determine the biochemical nature of chemokine-chemokine interactions 
3. To detect the formation of dityrosine cross-links between chemokine 
multimers 
4. To test the effect of chemokine multimers in lymphocyte migration assays 
5. To determine the effect of Cu and H202 on RANTES synthesis and release 
by endothelial cells, T-cells and platelets 
6. To establish assays for T-cell transendothelial migration and investigate the 
effect of Cu chelators on lymphocyte migration 
7. With reference to the scientific literature, put the results into context and 
indicate the therapeutic potential for Cu chelators with particular reference to 
pulmonary inflammatory diseases 
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Chapter 2 
The effect of CuC12 and H202 on 
multimerisation of isolated 
recombinant chemokines 
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2. The effect of CuC12 and H202 on multimerisation of isolated recombinant 
chemokines 
2.1. Introduction 
2.1.1. Chemokine multimerisation on endothelial cell surfaces 
The immobilisation of chemokines to endothelial cell surfaces by proteoglycans has 
been demonstrated both in vitro (Hoogewerf et al, 1997) and in vivo (Rot, 1993). The 
interaction is thought to facilitate the retention of chemokines on cell surfaces and 
enable the localisation of high concentrations of chemokines under shear blood flow 
conditions (Proudfoot et al, 2003). RANTES is immediately bound to HS in vitro and 
rapidly dissociates in equilibrium. The immediate binding of RANTES to HS may be 
necessary for localisation of activity at the site of secretion but it can also be mobilised 
to extend the concentration gradient at the cell surface, an aspect of functional 
importance (Vives et al, 2002). 
Growing evidence suggests that proteoglycans facilitate chemokine-receptor binding by 
inducing chemokine self-aggregation, also known as oligomerisation or multimerisation 
which may increase the local concentration of chemokines on cell surfaces (Hoogewerf 
et al, 1997; Vives et al, 2002). 
RANTES binds to HS at a length of dp 16 - dp 18 (no. of saccharides upon 
depolymerisation (dp) of HS). Such a length suggests that optimum binding occurs with 
multimers of the chemokine. Binding studies have shown that RANTES multimerises 
along the GAG chain and that the binding of RANTES monomers depends on one 
another indicating a cooperative mechanism (Vives et al, 2002). 
RANTES binds to HS in the nanomolar range, at physiological concentrations. Since 
the dimer dissociation constant of RANTES is 35 µM in the absence of HS (Skelton et 
al, 1995), this suggests RANTES is predominantly monomeric at physiological 
concentrations. Evidence shows that at nanomolar concentrations, chemokine multimers 
form on cell surface GAGs (Vives et al, 2002), and therefore it is likely that those 
chemokines that are monomeric at physiological concentrations may dimerise or 
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multimerise under physiological conditions but only in the presence of 
glycosaminoglycans (GAGs) in vivo (Proudfoot, 2006). 
It is suggested that this may be a method of collecting and dimerising RANTES at low 
and physiological concentrations (Vives et al, 2002). However, it has also been 
suggested that the formation of high molecular weight aggregates in vivo may have a 
physiological role in limiting the amount of active chemokines circulating in the 
bloodstream since aggregation probably reduces the number of surface sites on 
chemokines that are accessible to receptors (Skelton et al, 1995). 
Chemokines do not need to multimerise to elicit a chemotactic response in vitro, as 
mutant monomeric variants of RANTES, IL-8, MIP-1 ß, MCP-1 and MCP-3 are able to 
interact with receptors and induce leukocyte recruitment in vitro (Czaplewski et al, 
1999; Laurence et al, 2000; Paavola et al, 1998; Proudfoot et al, 2003; Rajarathnam et 
al, 1994). However in vivo, these mutants do not induce leukocyte recruitment 
(Proudfoot et al, 2003) indicating that multimerisation is required for the in vivo 
chemotactic activity of these chemokines. 
It has also been shown that wild-type RANTES binds to heparin and HS as a tetramer in 
vitro (Hoogewerf et al, 1997) and using RANTES mutants that are not able to 
multimerise it has been shown that RANTES has a minimal tetrameric quaternary 
structure for cell attractant activity in vivo. Both the monomeric and dimeric forms of 
RANTES are devoid of in vivo chemotactic activity (Proudfoot et al, 2003) indicating 
that multimerisation to the tetramer may be required for in vivo RANTES activity. In 
addition, a RANTES mutant that is unable to bind to immobilised GAGs was also 
unable to induce leukocyte recruitment in vivo, although it retained wild-type receptor 
binding to CCR1 and CCR5 in vitro (Proudfoot et al, 2003). This indicates that both 
multimerisation and GAG binding are necessary for the in vivo activity of RANTES. 
Interestingly, chemokines that occur naturally as monomers such as eotaxin and MCP-3 
have not been reported to multimerise as shown by structural and biophysical studies 
(Crump et al, 1998; Keizer et al, 2000; Kim et al, 1996), but both are able to recruit 
leukocytes in vivo, although it is not known whether or not these chemokines 
multimerise on cell surface proteoglycans (Proudfoot et al, 2003). However, it is 
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possible that these chemokines can achieve higher order multimers in vivo due to GAG 
induced multimerisation and they may interact with leukocyte receptors as dimers, 
trimers or tetramers. 
2.1.2. Chemokine multimerisation in solution 
The CXC and CC chemokines IL-8, MIP- l a, RANTES and MCP-1 all multimerise on 
interaction with cell surface HS (Bernfield et al, 1999; Hoogewerf et al, 1997) but many 
chemokines can also aggregate in the absence of proteoglycans. Such chemokines 
include human IL-8, RANTES, MIP-1 a and MIP-1 ß all of which have been shown to 
self associate and form stable high molecular weight aggregates in solution at neutral 
pH (Burrows et al, 1994; Clore et al, 1990; Czaplewski et al, 1999; Schnitzel et al, 
1994; Skelton et al, 1995). 
Most chemokines are reported to be present in normal healthy tissues at physiological 
concentrations in the nanomolar range (Burrows et al, 1994; Vives et al, 2002) and 
many chemokines exist in dimeric form at these nanomolar concentrations. 
Multimer formation has been shown to be concentration and pH dependent. At 
concentrations greater than 1 mM (Skelton et al, 1995) larger aggregates of RANTES 
are predominant and chemokines have been shown to participate in monomer-multimer 
equilibrium in solution (Burrows et al, 1994; Mayo & Chen, 1989). Both the dilution of 
RANTES from 3.9 to 0.08 mM and the lowering of the pH below 3.7 results in dimer 
dissociation. Evidence shows that RANTES dimers are very stable at neutral pH and 
also very soluble (Skelton et al, 1995). 
Whilst RANTES is predominantly monomeric at physiological concentrations in vitro, 
studies have revealed that IL-8 exists as both a monomer and dimer at nanomolar 
concentrations with dimer dissociation constants in the region of 100 nM - 100 µM 
(Williams et al, 2005). Structural studies have revealed that whilst the monomeric 
tertiary structure of the chemokines is very similar, the dimeric structure of members of 
the CC and CXC subfamilies is completely different, as typified by MIP-1 ß and IL-8 
respectively. The MIP-1 ß dimer is elongated and cylindrical whereas the IL-8 dimer is 
globular in shape (Clore & Gronenborn, 1995). The structure of the monomers of CC 
and CXC chemokines appears to be similar despite the 
low level of sequence identity 
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between the two classes of chemokines and although the C-terminal helices are shorter 
for the CC chemokines. 
The dimer topologies of both RANTES and MIP-1 ß are completely different from those 
of the CXC chemokines. The RANTES dimer most closely resembles that of MIP-1 B. 
For the CC chemokines, the dimer interface is formed by the N-terminal ß-strand of the 
protein rather than the second ß-strand in CXC chemokines (Clore & Gronenborn, 
1995). In RANTES, dimerisation occurs through interaction of the region N-terminal to 
the CC motif of one monomer with residues in the 30s loop and strand-ß3 of the other 
monomer (figure 2.1). Key hydrophobic residues at the N termini dictate the mode of 
dimerisation. Evidence shows that for MIP- l a, MIM P and RANTES the substitution 
of Glu26 or Glu66 causes substantial disaggregation, suggesting that these residues are 
key elements in the self-association process (Czaplewski et al, 1999). All CC 
chemokines dimerise in a fashion similar to that of RANTES. The CXC chemokines 
dimerise through hydrophobic residues in strand ß1 (Skelton et al, 1995). 
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Figure 2.1. Schematic ribbon drawings of the IL-8 dimer (A) and the RANTES dimer (B). One 
subunit is shown in blue and the other in red (Clore & Gronenborn, 1995). 
2.1.3. Amyloid-ß peptide multimers 
Alzheimer's disease is the most common senile dementing disorder, characterised 
pathologically by the accumulation of neurofibrillary tangles and senile plaques in the 
neocortex and cerebral vasculature (Huang et al, 2000b; Squitti et al, 2002). The A13- 
peptide (Aß) is the main constituent of senile plaques, a4 KDa protein consisting of 39- 
43 amino acid residues that is produced from its precursor, the amyloid protein 
precursor (APP). 
The Aß-peptides are a group of soluble proteins of considerable amino and carboxyl 
terminal heterogeneity found in all biological fluids. API - 40 is the major soluble Aß 
species and Aß 1-42 the minor but more fibrillogenic species (Huang et al, 2004; Huang 
et al, 2000b). The cortical deposition of the amyloid-ß peptide (Aß) that occurs in AD 
also occurs in Down's syndrome, head injury and normal ageing (Atwood et al, 1998). 
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Although Aß-peptide from biological fluids is a4 KDa monomeric protein, Aß-peptide 
extracted from post mortem brain specimens is found as formic acid resistant oligomers 
and both Aß 1-40 and Aß 1-42 form multimers upon incubation. 
It was found that Cu is detectable within the neuropil (the region between neuronal cell 
bodies in the gray matter of the brain and spinal cord) of the AD-affected brain, where it 
is highly concentrated within amyloid plaque deposits and neurofibrillary tangles with 
total concentrations reaching 0.4 mM. It was also found that Cu (II) and oxidative 
systems promote the oligomerisation/aggregation of Aß-peptide in a reaction that is 
reversible with Cu chelation (Atwood et al, 2000a; Atwood et al, 2004; Huang et al, 
1999). It was observed that Cu ' induced Aß-peptide aggregation is enhanced in the 
presence of H202 and the involvement of a Cu/H202 oxidative system has been 
suggested (Liu et al, 2006). In addition, covalent links between Aß-peptide monomers 
have been confirmed as dityrosine cross-links (Atwood et al, 2004). 
2.1.4. Prion Protein multimers 
Like the Aß-peptide, the prion protein (PrP) has been shown to aggregate and form 
multimers in the presence of Cu. PrP has a monomeric molecular weight of 35-36 KDa. 
Prion proteins trigger a group of neurodegenerative diseases. A conformational isomer 
of the normal prion protein (PrPc), denoted as PrPsc is thought to be responsible for 
fatal diseases such as bovine spongiform encephalopathy (BSE) in cattle and 
Creutzfeldt-Jakob disease (CJD) in humans. 
The prion protein is characterised by the presence of a flexible and `unstructured' 
region, roughly 100-residue N terminal `tail', and of a globular domain of nearly 
identical size (Brown et al, 2004). As yet the function of the protein is unknown, but has 
been identified that Cu plays a key role in the biology of PrPC. 
It is well documented that the prion protein interacts with GAGs. HS binding sites in the 
PrPc have been identified. It has been reported that 2-0-sulphate groups are essential for 
heparin recognition, and that there are three regions of the prion protein capable of 
independent binding to heparin and heparan sulphate (Warner et al, 2002). 
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The interaction of the prion protein with GAGs occurs due to the formation of 
oligomeric complexes stabilised by Cu (II) bridges (Gonzalez-Iglesias et al, 2002). The 
interaction of the octapeptide spanning peptide motif with heparin, interestingly, is 
enhanced by Cu (II) ions. A peptide with the same motif (residues 53-93) inhibits the 
binding of the full-length prion protein to GAGs (Warner et al, 2002). 
2.1.5. A possible role for Cu in chemokine multimerisation 
Chemokines are essential for directing the inflammatory response, mediating leukocyte 
chemotaxis and migration from the bloodstream into the tissues at sites of inflammation. 
Previous findings have suggested that aggregation and multimerisation is important for 
chemokine binding and presentation on endothelial cell surfaces and that multimer 
formation is mediated by cell surface GAGs. It is also suggested that chemokine 
multimer formation and GAG binding is necessary to induce chemotaxis in vivo under 
shear blood flow conditions and that the binding of multimers to cell-surface GAGs 
concentrates and localises chemokine gradients to prevent diffusion into the 
bloodstream. 
Chemokines self-aggregate and also bind to endothelial cell surface GAGs including 
HS. Previous research directed to both the amyloid-ß peptide and the prion protein has 
revealed that Cu promotes amyloid-ß peptide aggregation and dityrosine formation, 
which is enhanced by H202, and that Cu has a role in the formation of oligomeric PrP 
complexes and their binding to GAGs including heparin. 
The discovery of these proinflammatory roles for Cu has led to the current investigation 
of the ability of Cu to induce chemokine aggregation and chemokine-GAG binding. The 
number of tyrosine residues in the primary sequence varies depending on the 
chemokine. There are none in ENA-78, one in IL-8 and five in RANTES, suggesting 
the chemokines may oligomerise differently under the same Cu and H202 redox 
conditions. Therefore, the experiments described in this chapter also investigate the 
possible involvement of dityrosine cross-linking in chemokine multimerisation. 
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2.2. Materials 
Recombinant human RANTES, human IL-8 and human ENA-78 were obtained from 
Peprotech EC, London, UK. Dimethyl sulphoxide (DMSO), guanidine hydrochloride 
(G-HC1), copper chloride (CuC12), hydrogen peroxide (H202), heparan sulphate (HS) 
from pig mucosa, TRIS, glycine, sodium dodecyl sulphate (SDS), ammonium 
persulphate (APS), coloured MLW markers (Colorburst) and biotinylated SDS markers 
were obtained from Sigma-Aldrich Inc., Poole, Dorset, UK. 
Polyacrylamide mini-gels were cast using the Bio-Rad Protean II system. The 
polymerising catalyst solution N, N, N', N' - tetramethylethylenediamine (TEMED), 45 
µm nitrocellulose and a 30 % acrylamide solution containing 0.8 % bis-acrylamide were 
obtained from Bio-Rad Laboratories Ltd, Hemel Hempstead, Hertfordshire, UK. 
Phosphate buffered Saline (PBS) without added calcium or magnesium was obtained 
from Invitrogen Ltd, Paisley, UK. Methanol, ethanol and acetone were obtained from 
Fisher Scientific UK Ltd., Loughborough, Leicestershire, UK. All buffers and reagents 
were prepared in ultra-high quality (UHQ) water unless otherwise stated. 
Biotinylated primary IL-8, RANTES and ENA-78 antibodies were obtained from 
Peprotech EC, London, UK. A streptavidin-biotinylated horseradish peroxidase 
complex (StreptABC) was obtained from Dako UK Ltd, Ely, Cambridgeshire, UK. A 
commercial enhanced chemiluminescence (ECL) kit, SuperSignal, was obtained from 
Pierce Biotechnology Inc., Rockford, IL 61105, USA. Tween-20, PBS (-Ca 2+ /Mg 2+ ) and 
Super RX Fuji medical X-Ray film were obtained from Fisher Scientific, 
Loughborough, Leicestershire, UK. 
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2.3. Methods 
2.3.1. Sample preparation 
IL-8, RANTES and ENA-78 were incubated at 37 °C in 0.5 ml Safe-Lock eppendorf 
tubes for 1 (IL-8 and ENA-78) or 2 days (RANTES) at a final concentration of 5x 10-7 
M in PBS (-Ca2+/Mg2+), final volume 40 µl with CuC12 (1.25 - 100 PM), H202 (0.5 - 
400µM) and HS (0.1 mg/ml) final concentration. Safe-Lock eppendorf tubes eliminate 
the risk of sample evaporation during incubation. Following incubation, chemokines 
were analysed using SDS polyacrylamide gel electrophoresis (SDS-PAGE) and Western 
blotting. 
2.3.2. Dimethyl sulphoxide 
The hydroxyl radical scavenger, DMSO (0.4,2 and 4 µl), was added to 0.5 ml 
eppendorfs, followed by the addition of chemokines, CuC12, H202 and HS as described 
in section 2.3.1. The final concentration of DMSO was 1,5 and 10 % (v/v) respectively, 
in a final volume of 40 µl. 
2.3.3. Guanidine hydrochloride and ethanol precipitation 
Guanidine hydrochloride (GHC1) was added to samples following 1 or 2 day incubation 
at 37 °C. An equal volume (40 µl, referred to as volume A) of 12 M guanidine 
hydrochloride (G-HC1) in PBS (-Ca t+/Mg2+) was added to the samples resulting in a 
final concentration of 6M G-HCl . and the samples were 
incubated overnight at 4°C. 360 
µl of cold 100 % (v/v) ethanol (kept at -20 °C) was added to the protein solution (80 µl) 
- the final volume (400 µl) was referred to as volume B. The protein/ethanol solution 
was incubated at -20 °C for at least 1 hr, or left overnight. Following incubation, 
samples were centrifuged for 15 minutes at 4 °C in a micro-centrifuge at maximum 
speed (15,000 g). The supernatant was discarded and the pellet retained. The pellet was 
washed by re-suspending in 90 % (v/v) cold ethanol (kept at -20°C) - the final volume 
was equal to volume B. Samples were vortexed and re-pelleted by centrifugation at 
15,000 g for 15 minutes. 90 % of the supernatant was removed by aspiration. The 
remaining 10 % of the samples was dried in a rotary evaporator for 30 minutes at 45 °C. 
The pellet was reconstituted in volume A (40 µl), of 1x sample buffer. 
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2.3.4. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were separated by electrophoresis on 1 mm thick 14 % polyacrylamide gels. 
Resolving gels were prepared with 2.33 ml 30 % acrylamide solution, 1.5 ml 1.5 M 
TRIS-resolving gel buffer (18.17 g TRIS in 100 ml H2O, adjusted to pH 8.8 with 
concentrated HC1), 1.35 ml UHQ water, 50 µl 10 % (w/v) SDS, 25 µ1 10 % (w/v) APS 
(both prepared by adding 1g to 10 ml deionised water. APS was stored in 1 ml aliquots 
at -20 °C and SDS stored at room temperature), and 2.5 µl TEMED per 1 gel. The 
resolving gel solution was poured between the glass plates and the solution was overlaid 
with 100% ethanol or water to ensure a flat interface. Resolving gels were allowed to 
set for 30 minutes before the addition of the stacking gel. At this stage, gels were either 
used straight away or stored at 4 °C prior to the addition of a stacking gel, overlaid in 
resolving gel buffer diluted 1: 4. 
Stacking gels were prepared with 0.65 ml 30 % acrylamide solution, 1.25 ml 0.5 M 
TRIS-stacking gel buffer (6.057 g TRIS in 100 ml H2O, adjusted to pH 6.8 with 
concentrated HC1), 3.05 ml UHQ water, 50 µl 10 % (w/v) SDS, 50 µl 10 % (w/v) APS 
and 5µl TEMED per 1 gel. The buffer overlay was removed and approximately 5 ml of 
stacking gel was added to the top of each resolving gel. A clean plastic spacer was 
immediately added to form 10 sample wells. 
A IOx concentrated (1 M) TRIS-glycine running buffer was prepared by dissolving 
15.15 g TRIS, 72 g glycine and 5g SDS in 500 ml deionised water. The lOx solution 
was diluted 1: 10 to 100 mM on the day of the experiment. A 4x non-reducing sample 
buffer containing bromophenol blue as a tracer dye allowed visualisation of samples in 
the resolving gel (8 ml of 4x running buffer, 2 ml glycerol and 1 mg bromophenol blue) 
The 4x running buffer was prepared by adding 4 ml of 1 Ox running buffer to 6 ml 
deionised H2O. The samples were prepared by the addition of 51 4x non-reducing 
sample buffer to 15 µl of sample, diluting the buffer to a final concentration of Ix and 
pH 8.3. The 4x non-reducing sample buffer was stored at -20 °C in 0.5 ml aliquots. 
Samples were loaded in the sample wells in the stacking gel (15 µl per well. ) One lane 
of biotinylated molecular weight markers and one lane of colour markers (Sigma- 
Aldrich Inc., Poole, Dorset, UK) was analysed on each gel (5-10 µl per lane. ) 
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The samples were run slowly through the stacking gel at 40 V for 15 minutes. When the 
dye front reached the resolving gel the voltage was increased to 120 V. Electrophoresis 
was terminated when the bromophenol blue dye front reached the bottom of the gel, 
after approximately 1.5 hours. 
2.3.5. Western blotting 
Following electrophoresis, the stacking gel was removed and discarded. The resolving 
gel was equilibrated in SDS-PAGE running buffer containing 20 % (v/v) methanol and 
placed onto a 45 µm nitrocellulose membrane, between 2 paper filters pre-soaked in 
SDS-PAGE running buffer containing 20 % (v/v) methanol. The gel was marked by 
removing the corner of the gel on one side. This ensured it was transferred the correct 
way round. 
Proteins were transferred by BioRad semi-dry electrophoretic transfer at 15 V, current 
limit 1.76 A, for 15 minutes per mini-gel at room temperature. Following transfer, the 
non-specific binding of antibodies to the membrane during staining was blocked by the 
immersion of Western blots in blocking buffer (PBS -Ca/Mg /2% (v/v) Tween-20) and 
overnight incubation at 4 °C. 
Prior to staining, the membranes were washed three times for 10 minutes each in 1x 
PBS (-Ca2+/Mg2+) /0.05 % (v/v) Tween-20 (Sigma, UK). They were then incubated in 
biotinylated primary antibody (rabbit polyclonal anti-human RANTES, goat polyclonal 
anti-human IL-8 or rabbit polyclonal anti-human ENA-78), at 0.1 µg/ml in PBS /2% 
(v/v) Tween-20,5 ml per blot) for 90 minutes at room temperature. The membranes 
were washed three times as before, and then incubated with a 1: 20,000 (v/v) dilution (1 
µl of each of tubes A and B in 10 ml 2% (v/v) Tween-20 / PBS) of a streptavidin- 
biotinylated horseradish peroxidase complex (StreptABC, DAKO, UK) for 45 minutes 
at room temperature. 
Following incubation with StreptABC, membranes were washed five times in lx PBS (- 
Ca2+/Mg2+) /0.05 % (v/v) Tween-20 for 10 minutes each and the blots developed using 
SuperSignal ECL kit (Pierce) and placed against X-Ray film for 1 and 5 minutes, and 
overnight to visualise results. 2.5 ml of each of the developer and enhancer were mixed 
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together, 5 ml per blot. Chemiluminescence is a chemical reaction between an enzyme 
(horseradish peroxidase, HRP), and a chemiluminescent chemical, such as luminol, 
resulting in emission of light. HRP is oxidised in the presence of H202, the oxidised 
HRP is then capable of oxidising the luminol. Once oxidised the luminol exists in an 
excited state, which then decays to its ground state via the emission of light. In the kit 
used, an enhancer has been added allowing increased intensity and duration of light 
production. 
2.3.6. Scanning and density analysis 
If the intensity of staining was sufficiently consistent to allow for semi-quantitative 
analysis, the blots were scanned using Quantiscan software. 
2.4. Statistical analysis 
Data were compared with a1 or 2-way ANOVA followed by either a Dunnet's or 
Tukey's post-hoc test where p<0.05 was the minimum accepted level of significance. 
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2.5. Results 
2.5.1. RANT ES 
To investigate the form of freshly prepared RANTES prior to incubation, recombinant 
human RANTES (Peprotech, UK) was prepared in the concentration range 10-10 - 10-6 
M in PBS (-Ca t+/Mg2+), in a final volume of 40 µl, and analysed by SDS-PAGE. The 
Western blot was stained for human RANTES (figure 2.2). RANTES has a dimer 
dissociation constant of 35 µM, and therefore it was expected that RANTES would be 
predominantly monomeric. 
116 
97 
58 
39 
29 
20 
14 
6 
M 10-6M 10-IM 10-11M 10-9M 10-1'M 
Figure 2.2. The form of recombinant RANTES in solution at 10-10 M to 10-6 M, analysed by SDS- 
PAGE on a 14 % polyacrylamide gel. Arrows show 8 KDa monomers (A) and 16 KDa dimers (B). 
M: Molecular weight markers. Representative of two independent experiments. 
RANTES was present in monomeric form (8 KDa) at 10-10 - 10-8 M (figure 2.2). 
Dimers (16 KDa) appeared at the higher concentrations of 10-7 and 10-6 M RANTES, 
with maximum dimer formation seen at 10-6 M. No higher order multimers greater than 
dimer were seen. A concentration of 5x 10-7 M RANTES was used in all further 
experiments to test the effect of Cu and H202 on multimerisation. 
To investigate the effect of copper on RANTES multimerisation, RANTES (5 x 10-7 M) 
was incubated with CuC12. Incubation of RANTES with CuCl2 for 1 day did not induce 
multimer formation above the dimer present in the sample (data not shown). Therefore 
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RANTES (5 x 10-7 M) was incubated at 37 °C for 2 days in the presence of increasing 
concentrations of CuC12 (1.25 - 100 µM). 
Dimer 
Monomer 
Figure 2.3. The effect of CuC12 on the form of recombinant RANTES (5 x 10-7 M) following 
incubation at 37°C for 2 days analysed by SDS-PAGE on a 14 % polyacrylamide gel. M: molecular 
weight markers. Lane 1: RANTES only, lane 2: RANTES and 1.25 µM CuCI2, lane 3: RANTES and 
2.5 µM CuCI2, lane 4: RANTES and 12.5 pM CuCI2, lane 5: RANTES and 25 µM CuCI2, lane 6: 
RANTES and 50 µM CuCI2, lane 7: RANTES and 75 µM CuCI2 and lane 8: RANTES and 100 µM 
CuCl2. Representative of two independent experiments. 
CuC12 (50 - 100 µM) induced the appearance of multimers of higher order than dimers. 
Analysis showed the formation of RANTES trimers (24 KDa) (figure 2.3, lanes 6- 8), 
and the effect appears to be dose dependent. 
A CuC12 / H202 redox mechanism has been implicated in the formation of amyloid-ß 
multimers (Atwood et al, 2004; Kato et al, 2001), and therefore H202 (1 - 400 µM) was 
added to the samples, in the presence of 25 µM CuC12. This concentration of CuC12 is a 
physiological concentration (Versieck, 1980). 
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Figure 2.4. The effect of H202 on the form of recombinant RANTES (5 x 10-7 M) in the presence of 
25 µM CuC12 following incubation at 37°C for 2 days analysed by SDS-PAGE on a 14 % 
polyacrylamide gel. M: molecular weight markers. Lane 1: RANTES and 25 µM CuCl2, lane 2: 
RANTES, 25 µM CuCl2 and 1 pM H202, lane 3: RANTES, 25 µM CuCI2 and 5 pM H202, lane 4: 
RANTES, 25 µM CuC12 and 12.5 µM H202, lane 5: RANTES, 25 µM CuCl2 and 25 µM H202, lane 
6: RANTES, 25 µM CuCl2 and 50 µM H202, lane 7: RANTES, 25 µM CuC12 and 100 µM H202, lane 
8: RANTES, 25 µM CuC12 and 200 µM H202 and lane 9: RANTES, 25 µM CuC12 and 400 PM H202. 
Representative of two independent experiments. 
In the absence of H202, RANTES was seen in the presence of 25 µM CuC12 
predominantly as a monomer with a small proportion of dimer (figure 2.4, lane 1). 
Multimerisation of RANTES was strongly enhanced with increasing concentrations of 
H202. At physiological concentrations, Cu (25 µM) and H202 (5-25 µM) promote the 
higher order multimerisation of chemokines in a dose dependent manner (lanes 3-5) and 
promote dimer formation at the expense of the monomer (lanes 1-8). Increased H202 
concentrations (50 - 200 µM) resulted in further dose-dependent multimer formation 
(lanes 6- 8). Multimerisation is maximal at 100 µM H202 (lane 7). At 200 µM H202 
(lane 8), RANTES multimers were diminished and at 400 µM H202 (lane 9), the 
monomer, dimer and multimers were completely destroyed. 
Since chemokines bind to heparan sulphate (HS), the effect of HS on CuCl2 induced 
multimer formation was investigated. RANTES was incubated in the presence of CuC12 
(0.5 - 100 µM) and HS (0.1 mg/ml). 
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Figure 2.5. The effect of CuCI2 on the form of recombinant RANTES (5 x 10-7 M) in the presence of 
HS (0.1 mg/ml) following incubation at 37°C for 2 days, final volume 40 µl and analysis by SDS- 
PAGE on a 14 % polyacrylamide gel. M: molecular weight markers. Lane 1: RANTES and HS, 
lane 2: RANTES, HS and 0.5 pM CuC12, lane 3: RANTES, HS and 1.25 µM CuCI2, lane 4: 
RANTES, HS and 2.5 µM CuCl2, lane 5: RANTES, HS and 12.5 µM CuC12, lane 6: RANTES, HS 
and 25 µM CuC12, lane 7: RANTES, HS and 50 µM CuC12, lane 8: RANTES, HS and 75 µM CuCI2 
and lane 9: RANTES, HS and 100 µM CuC12. Representative of two independent experiments. 
The addition of HS (0.1 mg/ml) resulted in the attenuation of CuC12 induced RANTES 
multimer and dimer formation. The addition of 1.25 - 400 µM CuC12 resulted in an 
increase in RANTES dimer (16 KDa) formation but there was no higher order multimer 
formation (trimer (24 KDa) and above). The proportion of dimer is reduced and 
RANTES exists mainly in monomeric (8 KDa) and dimeric (16 KDa) form in the 
presence of HS (0.1 mg/ml) and 0.5 - 100 µM CuC12 (figure 2.5 lanes 2- 9). It appears 
that HS has attenuated multimer formation compared with the effect of CuC12 in the 
absence of HS (figure 2.3). 
As a further investigation of the effect of HS on RANTES multimer formation, 
RANTES was incubated with 25 µM CuC12 and increasing concentrations of H202 (1 - 
400 µM) in the presence of HS (0.1 mg/ml). 
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Figure 2.6. The effect of H202 on the form of recombinant RANTES (5 x 10-7 M) in the presence of 
CuCI2 (25 µM) and HS (0.1 mg/ml) following incubation at 37°C for 2 days, analysed by SDS-PAGE 
on a 14 % polyacrylamide gel. Lane 1: RANTES, HS and 25 µM CuCl2, lane 2: RANTES, HS, 25 
µM CuCI2 and 1 µM H202, lane 3: RANTES, HS, 25 µM CuC12 and 5 µM H202, lane 4: RANTES, 
HS, 25 µM CuC12 and 12.5 µM H202, lane 5: RANTES, HS, 25 pM CuC12 and 25 µM H202, lane 6: 
RANTES, HS, 25 µM CuC12 and 50 µM H202, lane 7: RANTES, HS, 25 µM CuC12 and 100 µM 
H202, lane 8: RANTES, HS, 25 µM CuCI2 and 200 µM H202 and lane 9: RANTES, HS, 25 µM 
CuCI2 and 400 µM H202. Representative of two independent experiments. 
In the presence of HS (figure 2.6), H202 (5 - 400 µM) promoted RANTES multimer 
formation in a dose-dependent manner in the presence of 25 µM CuC12. In both the 
presence (figure 2.6) and absence (figure 2.4) of HS (0.1 mg/ml), RANTES trimers (24 
KDa) occurred at 25 µM CuC12 and 5- 12.5 µM H202 (figures 2.4 and 2.6, lanes 3- 4). 
In the absence of HS (figure 2.4), RANTES tetramers (32 KDa) and higher order 
multimers appeared at 25 - 200 µM H202 (figure 2.4, lanes 5- 8), but were diminished 
at 200 µM and absent at 400 µM H202 (lane 9). However, in the presence of HS (0.1 
mg/ml), RANTES tetramers and higher order multimers were seen at 25 - 400 µM 
H202 (figure 2.6 lanes 5- 9) and were not diminished even at 400 µM H202 (lane 9). 
Thus, multimers were able to withstand higher concentrations of H202 in the presence 
of 0.1 mg/ml HS (figure 2.6, lane 9) compared to in the absence of HS (figure 2.4, lane 
9). 
In order to quantify the degree of multimerisation, RANTES was incubated in the 
presence and absence of physiological concentrations of CuC12 (25 µM) and H202 (50 
µM), and in the presence and absence of HS (0.1 mg/ml). Multimers of higher order 
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than dimer were quantified by scanning densitometry and presented as the % of total 
RANTES including the monomer. 
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Figure 2.7A: RANTES (5 x 10-7 M) incubated at 37°C for 2 days and analysed by SDS-PAGE on a 
14 % polyacrylamide gel. ± CuCI2 (25 µM), H202 (50 µM) and HS (0.1 mg/ml). Lane 1: RANTES 
only, lane 2: RANTES + HS, lane 3: RANTES + CuCI2, lane 4: RANTES + H202, lane 5: RANTES 
+ CuC12 and H202, lane 6: RANTES + HS + CuC12, lane 7: RANTES + HS + H202 and lane 8: 
RANTES + HS, CuC12 and H202. Representative of three independent experiments. 
Figure 2.7B: Quantitative analysis of supra-dimeric RANTES intensity (higher order complexes of 
RANTES including tetramer (24 KDa) as % of total analysed using density analysis (Quantiscan). 
Lane l: RANTES only, lane 2: RANTES + HS, lane 3: RANES + CuC12, lane 4: RANTES + H202, 
lane 5: RANTES + CuC12 and H202, lane 6: RANTES + HS + CuC12, lane 7: RANTES + HS + 
H202 and lane 8: RANTES + HS, CuCI2 and H202. * indicates p<0.05, ** indicates p<0.01, (n = 
3). 
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Formation of RANTES multimers greater than the dimer increased significantly in the 
presence of 25 µM CuC12 (lane 3,17.52 ± 9.46 % of total RANTES is in supra-dimeric 
form, p<0.05) compared to the control (RANTES only, lane 1). The addition of 50 µM 
H202 with copper resulted in significant formation of high molecular weight multimers 
greater than dimers (lane 5,62.51 ± 9.76 % of RANTES is in supra-dimeric form, p< 
0.01). The presence of HS (0.1 mg/ml) significantly reduced the multimerisation effect 
of CuCl2 and H202 (lane 8,33.78 + 7.22 % of RANTES is in supra-dimeric form, p< 
0.01). 
In order to investigate the stability of RANTES multimers, RANTES was incubated for 
2 days at 37 °C in the presence and absence of 25 µM CuC12 and 50 µM H202 and, 
following incubation, the chaotropic agent, guanidine hydrochloride (G-HCl), was 
added to the samples, final concentration 6 M. The G-HCl was removed by EtOH 
precipitation before the samples were analysed by SDS-PAGE and Western blots 
stained for RANTES. G-HCl is capable of disrupting non-covalent 3-dimensional 
structure of proteins, including hydrogen bonds, van der Waals forces and hydrophobic 
effects (Lu et al, 2001; Neet & Timm, 1994). 
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Figure 2.8. The effect of G-HCl (6 M) and EtOH precipitation on the form of recombinant 
RANTES (5 x 10-7 M) in the presence of CuCl2 (25 µM) plus H202 (50 µM) following incubation at 
37°C for 2 days, analysed by SDS-PAGE on a 14 % polyacrylamide gel. Lane 1: RANTES only with 
G-HCI and EtOH precipitation, lane 2: RANTES and 25 µM CuCI2 with G-HCI and EtOH 
precipitation, lane 3: RANTES, 25 pM CuCI2 and 50 µM H202 with G-HCI and EtOH precipitation. 
Representative of two independent experiments. 
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Monomers, dimers and higher order RANTES multimers (trimers (24 KDa) and 
tetramers (32 KDa)) generated in the presence of 25 µM CuC12 plus 50 µM H202 were 
found to remain following treatment with G-HC1 (6 M) (figure 2.8, lane 3), indicating 
that the links in RANTES multimers were covalent. 
To ensure that the technique of EtOH precipitation had not affected the stability of 
RANTES multimers, RANTES was incubated with 25 µM CuC12 plus 50 µM H202 to 
generate higher order multimers, which were then EtOH precipitated, dried, 
reconstituted in lx sample buffer and analysed by SDS-PAGE, Western blotting and 
staining for RANTES. 
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Figure 2.9. The effect of EtOH precipitation on the form of recombinant RANTES (5 x 10-7 M) in 
the presence of CuCI2 (25 µM) plus H202 (50 µM) following incubation at 37°C for 2 days, analysed 
by SDS-PAGE on a 14 % polyacrylamide gel. M: molecular weight markers. Lane 1: RANTES 
only, lane 2: RANTES and 25 µM CuCI2, lane 3: RANTES, 25 µM CuC12 and 50 µM H202, lane 4: 
RANTES only with EtOH precipitation, lane 5: RANTES and 25 µM CuCI2 with EtOH 
precipitation, lane 6: RANTES, 25 µM CuCI2 and 50 µM H202 with EtOH precipitation. 
Representative of two independent experiments. 
Higher order multimers are generated in the presence of 25 µM CuC12 plus 50 µM H202 
(figure 2.9, lane 3). It appears that EtOH precipitation does not affect the stability of 
RANTES multimers, which remain after the RANTES multimers are precipitated. 
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As further investigation into the mechanism of multimer generation by the Cu/H202 
system, RANTES multimers were generated by the incubation of RANTES for 2 days 
at 37 °C with 25 µM CuC12 plus 50 µM H202 in the presence of the hydroxyl radical 
scavenger, dimethyl sulphoxide (DMSO) at final concentrations of 1,5 and 10 % (v/v). 
DMSO was used to discern which radicals were involved in the mechanism. 
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Figure 2.10. The effect of DMSO (1,5 and 10 % (v/v)) on the form of recombinant RANTES (5 x 
10"7 M) in the presence of CuC12 (25 µM) plus H202 (50 µM) following incubation at 37°C for 2 days, 
analysed by SDS-PAGE on a 14 % polyacrylamide gel. M: molecular weight markers. Lane 1: 
RANTES with CuC12 plus H202, lane 2: RANTES with CuC12, H202 and 1% (v/v) DMSO, lane 3: 
RANTES with CuCl2, H202 and 5% (v/v) DMSO, lane 4: RANTES with CuCl2, H202 and 10 % 
(v/v) DMSO. Representative of two independent experiments. 
Higher order multimers were generated in the absence of DMSO by 25 µM CuC12 plus 
50 µM H202 (figure 2.10, lane 1). Trimers and tetramers are diminished upon treatment 
with 1% (v/v) DMSO (lane 2) and are not generated in the presence of 5 and 10 % (v/v) 
DMSO (lanes 3 and 4). 
2.5.2. IL-8 
The neutrophil chemoattractant, IL-8, was of significant interest as this chemokine has 
only one tyrosine residue compared to five in the amino acid sequence of RANTES. 
Therefore, if tyrosine was involved in multimerisation of chemokines it was expected 
that IL-8 should be less sensitive to CuC12 and H202 than RANTES. First, the effect of 
CuC12 on IL-8 multimer formation was investigated. Recombinant human IL-8 
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(Peprotech, UK) was incubated with CuCl2 (1.25 - 100 µM) at the same concentration 
as RANTES (5 x 10-7 M) at 37 °C but for 1 day only, as it was found that multimers 
were diminished after 2 days, unlike RANTES where maximum multimer formation 
was seen after 2 days of incubation. IL-8 multimers were analysed by SDS-PAGE, and 
Western blots were stained with anti-human IL-8 antibody (Peprotech, UK). 
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Figure 2.11. The effect of CuCI2 on the form of recombinant IL-8 (5 x 10-7 M) following incubation 
at 37°C for 1 day, analysed by SDS-PAGE on a 14 % polyacrylamide gel. M: molecular weight 
markers. Lane 1: IL-8 only, lane 2: IL-8 and 1.25 µM CuCl2, lane 3: IL-8 and 2.5 µM CuCI2, lane 4: 
IL-8 and 12.5 µM CuC12, lane 5: IL-8 and 25 µM CuC12, lane 6: IL-8 and 50 µM CuCI2, lane 7: IL-8 
and 75 µM CuC12 and lane 8: IL-8 and 100 µM CuC12. Representative of two independent 
experiments. 
IL-8 (5 x 10-7 M) in the absence of CuC12 exists mainly as a monomer and dimer with 
some appearance of trimers (figure 2.11, lane 1). CuCl2 alone (50 - 100 µM) induced a 
small increase in higher order multimers, resulting in an increase in the formation of IL- 
8 trimers (figure 2.11, lanes 6- 8) and tetramers (75 µM CuCl2 lane 7). The effect 
appears to be dose dependent with maximum multimer formation occurring at 75 µM 
CuC12 (lane 7). 
Subsequently, the effect of H202 (1 - 400 µM) in the presence of 25 µM CuC12 on IL-8 
multimer formation was investigated. 
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Figure 2.12. The effect of H202 on the form of recombinant IL-8 (5 x 10-7 M) in the presence of 
CuCI2 (25 µM) following incubation at 37°C for 1 day, analysed by SDS-PAGE on a 14 % 
polyacrylamide gel. Lane 1: IL-8 and 25 µM CuCl2, lane 2: IL-8,25 µM CuC12 and 1 µM H2021 
lane 3: IL-8,25 µM CuCl2 and 5 µM H202, lane 4: IL-8,25 µM CuCI2 and 12.5 µM H202, lane 5: 
IL-8,25 µM CuCI2 and 25 µM H202, lane 6: IL-8,25 pM CuCl2 and 50 µM H202, lane 7: IL-8,25 
µM CuCI2 and 100 µM H202, lane 8: IL-8,25 µM CuC12 and 200 µM H202 and lane 9: IL-8,25 µM 
CuCI2 and 400 µM HZOZ. Representative of two independent experiments. 
In the absence of H202, IL-8 was seen predominantly as a monomer and dimer (lane 1). 
In the presence of 25 µM CuC12 with increasing concentrations of H202, IL-8 
multimerisation was strongly enhanced (fig 2.12). At physiological concentrations, Cu 
(25 µM) and H202 (5 - 25 µM) promoted the multimerisation of chemokines to higher 
order multimers (trimers and tetramers - lanes 3- 5). Increasing H202 concentrations 
above physiological plasma levels (50 - 100 µM) also resulted in higher order multimer 
formation (lanes 6- 7). Multimerisation was maximal at 100 µM H202 (lane 7). At 200 
µM H202 (lane 8), IL-8 multimers were diminished and at 400 µM H202 (lane 9), the 
higher order multimers were destroyed. 
The effect of heparan sulphate (HS) on CuC12 induced multimer formation was then 
investigated. IL-8 was incubated in the presence of CuC12 (0.5 - 100 µM) and HS (0.1 
mg/ml). 
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Figure 2.13. The effect of CuCI2 on the form of recombinant IL-8 (5 x 10-' M) in the presence of HS 
(0.1 mg/ml) following incubation at 37°C for I day, analysed by SDS-PAGE on a 14 % 
polyacrylamide gel. M: molecular weight markers. Lane 1: IL-8 and HS, lane 2: IL-8, HS and 1.25 
µM CuCI2, lane 3: IL-8, HS and 2.5 µM CuCI2, lane 4: IL-8, HS and 5 µM CuC12, lane 5: IL-8, HS 
and 12.5 µM CuCl2, lane 6: IL-8, HS and 25 µM CuCI2, lane 7: IL-8, HS and 50 µM CuC12, lane 8: 
IL-8, HS and 75 µM CuCl2 and lane 9: IL-8, HS and 100 µM CuCI2. Representative of two 
independent experiments. 
The addition of HS (0.1 mg/ml) resulted in the attenuation of CuC12 induced IL-8 
multimer formation. Trimers were less predominant in the presence of HS (figure 2.13) 
than in the absence of HS (figure 2.11). The addition of 12.5 - 75 µM CuC12 resulted in 
an increase in IL-8 trimer formation (figure 2.13, lanes 5- 8) and at 100 µM CuC12, 
tetramers were formed (lane 9). However, IL-8 remained monomeric and dimeric in the 
presence of HS (0.1 mg/ml) and 1.5 -5 µM CuC12 (lanes 2- 4). As observed with 
RANTES, it appears that HS attenuated IL-8 multimer formation. 
Subsequently the effect of HS (0.1 mg/ml) on IL-8 multimerisation in the presence of 
25 µM CuC12 and increasing concentrations of H202 (0.5 - 400 µM) was investigated. 
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Figure 2.14. The effect of H202 (0.5 - 400 µM) on the form of recombinant IL-8 (5 x 10-7 M) in the 
presence of CuCI2 (25 µM) and HS (0.1 mg/ml) following incubation at 37°C for I day, analysed by 
SDS-PAGE on a 14 % polyacrylamide gel. Lane 1: IL-8, HS and 25 µM CuCI2, lane 2: IL-8, HS, 25 
µM CuCI2 and 0.5 µM H202, lane 3: IL-8, HS9 25 µM CuC12 and I µM H202, lane 4: IL-8, HS9 25 
µM CuC12 and 5 µM H202, lane 5: IL-8, HS, 25 µM CuC12 and 12.5 gM H202, lane 6: IL-8, HS9 25 
µM CuC12 and 25 µM H202, lane 7: IL-8, HS9 25 µM CuCI2 and 50 gM H202, lane 8: IL-8, HS, 25 
µM CuC12 and 100 µM H202, lane 9: IL-8, HS, 25 µM CuC12 and 200 µM H202 and lane 10: IL-8, 
HS9 25 µM CuC12 and 400 µM H202, Representative of two independent experiments. 
In the absence of HS (figure 2.12), H202 (12.5 - 50 µM) promoted IL-8 trimer and 
tetramer formation in the presence of 25 µM CuC12 (figure 2.12, lanes 4- 6) In the 
presence of HS (0.1 mg/ml), IL-8 trimers and tetramers did not occur at 12.5 - 50 µM 
H202, but only at higher concentrations of H202 (50 - 200 . tM, figure 2.14, lanes 7 -9). 
In the absence of HS (figure 2.12), IL-8 tetramers (32 KDa) were diminished at 200 - 
400 µM H202 (figure 2.12, lanes 8- 9). However, in the presence of HS (0.1 mg/ml), 
IL-8 tetramers occured at 200 - 400 µM H202 (figure 2.14 lanes 9- 10) and were not 
diminished by 400 µM H202 (lane 9). The multimers were able to withstand higher 
concentrations of H202 in the presence of 0.1 mg/ml HS (figure 2.14, lane 10). This 
suggests that HS was protecting high order multimers from damage by high 
concentrations of H202. 
In order to quantify the degree of multimerisation, IL-8 was incubated in the presence 
and absence of physiological concentrations of CuC12 (25 µM) and H202 (50 µM), and 
in the presence and absence of HS (0.1 mg/ml). Multimers of higher order than dimer 
were quantified by scanning densitometry and presented as the % of total RANTES 
including the monomer. 
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Figure 2.15A. IL-8 (5 x 10-7 M) incubated at 37°C for 1 day and analysed by SDS-PAGE on a 14 % 
polyacrylamide gel. f CuC12 (25 µM), H202 (50 µM) and HS (0.1 mg/ml). M: molecular weight 
markers. Lane 1: IL-8 only, lane 2: IL-8 + HS, lane 3: IL-8 + CuC12, lane 4: IL-8 + H202, lane 5: IL- 
8+ CuC12 and H202, lane 6: IL-8 + HS + CuCI2, lane 7: IL-8 + HS + H202 and lane 8: IL-8 + HS, 
CuCI2 and H202. Representative of three independent experiments. 
Figure 2.15B: Quantitative analysis of supra-dimeric IL-8 intensity (higher order complexes of IL-8 
including tetramer (24 KDa) as % of total analysed using density analysis (Quantiscan). Lane 1: IL- 
8 only, lane 2: IL-8 + HS, lane 3: RANES + CuCI2, lane 4: IL-8 + H202, lane 5: IL-8 + CuCI2 and 
H202, lane 6: IL-8 + HS + CuCI2, lane 7: IL-8 + HS + H202 and lane 8: IL-8 + HS, CuCI2 and H202. 
* indicates p<0.05, (n = 3). 
The addition of 25 µM CuC12 plus 50 µM H202 increased trimer formation (lane 5). The 
addition of 0.1 mg/ml HS with 50 µM H202 decreased multimerisation (lane 7). 
Multimerisation was significantly increased by adding 0.1 mg/ml HS and 25 µM CuC12 
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together (lane 6,12.67 ± 4.36 % is in supra-dimeric form, p<0.05) compared to the 
control (IL-8 only, lane 1). The maximum effect was seen where HS was added with 
both 25 µM CuCl2 and 50 µM H202 (lane 8,14.65 ± 5.86 % was in supra-dimeric form, 
p<0.05). HS enhanced the effect of CuCl2 plus H202 alone, promoting the formation of 
tetramers. 
In order to investigate the stability of IL-8 multimers, IL-8 was incubated for 1 day at 
37 °C in the presence and absence of 25 µM CuC12,50 µM H202 and 0.1 mg/ml HS. 
Following incubation, the chaotropic agent, guanidine hydrochloride (G-HCI), was 
added to the samples, final concentration 6 M. The G-HC1 was removed by EtOH 
precipitation before the samples were analysed by SDS-PAGE and Western blots 
stained for IL-8. 
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Figure 2.16. The effect of G-HCl (6 M) and EtOH precipitation on the form of recombinant IL-8 (5 
x 10-7 M) in the presence of CuC12 (25 µM) plus H202 (50 µM) following incubation at 37°C for 1 
day, analysed by SDS-PAGE on a 14 % polyacrylamide gel. Lane 1: IL-8 + G-HCI, lane 2: IL-8,25 
µM CuCI2 and 25 µM H202 with G-HCI and EtOH precipitation. Representative of two 
independent experiments. 
The higher order IL-8 multimers (above and including trimers) generated in the 
presence of 25 µM CuC12 plus 50 µM H202 were found to remain following treatment 
with G-HCl (6 M) (figure 2.16, lane 2). Monomers and dimers were also found to 
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remain following treatment with G-HCl, indicating that the 3-dimensional structure of 
IL-8 was not disrupted and that multimers are highly stable. 
The effect of the hydroxyl radical scavenger DMSO on IL-8 multimerisation was then 
investigated. IL-8 multimers were generated by the incubation of IL-8 for 1 day at 37 °C 
with 25 µM CuC12 plus 50 µM H202 in the presence of the hydroxyl radical scavenger, 
dimethyl sulphoxide (DMSO) at concentrations 1,5 and 10 % (v/v). 
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Figure 2.17. The effect of DMSO (1,5 and 10 % (v/v)) on the form of recombinant IL-8 (5 x 10-7 M) 
in the presence of CuCI2 (25 µM) plus H202 (25 µM) following incubation at 37°C for I day, 
analysed by SDS-PAGE on a 14 % polyacrylamide gel. M: molecular weight markers. Lane 1: IL-8 
only, lane 2: IL-8 with CuC12, lane 3: IL-8 with CuC12 and H202, lane 4: IL-8 with CuCI2, H202 and 1 
% (v/v) DMSO, lane 5: IL-8 with CuC12, H202 and 5% (v/v) DMSO, lane 6: IL-8 with CuCI2, H202 
and 10 % (v/v) DMSO. Representative of two independent experiments. 
IL-8 trimers were generated in the absence of DMSO by 25 µM CuCl2 plus 50 µM H202 
(figure 2.17, lane 3) but were diminished upon treatment with 1,5 and 10 % (v/v) 
DMSO (lanes 4 -6) indicating that hydroxyl radicals may be involved in the mechanism 
of multimer formation. 
2.5.3. ENA-78 
ENA-78, another neutrophil chemoattractant, was also of interest as this chemokine has 
no tyrosine residues in its amino acid sequence. Since it was suspected that dityrosine 
cross-linking could be involved in the mechanism of multimerisation, and as there are 
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no tyrosine residues in ENA-78, it was expected that ENA-78 should not be sensitive to 
CuC12 and H202 First, the effect of CuC12 on ENA-78 multimer formation was 
investigated. Recombinant human ENA-78 (Peprotech, UK) was incubated with CuC12 
(1.25 - 100 µM) at the same concentration as RANTES and IL-8 (5 x 10-7 M) at 37 °C 
for 1 day only, as it was found that multimers are diminished after 2 days, as with IL-8. 
ENA-78 was analysed by SDS-PAGE, and Western blots were stained with anti-human 
ENA-78 antibody (Peprotech, UK). 
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Figure 2.18. The effect of CuC12 on the form of recombinant ENA-78 (5 x 10-7 M) following 
incubation at 37°C for 1 day, analysed by SDS-PAGE on a 14 % polyacrylamide gel. M: molecular 
weight markers. Lane 1: ENA-78 only, lane 2: ENA-78 and 1.25 µM CuCl2, lane 3: ENA-78 and 2.5 
µM CuCl2, lane 4: ENA-78 and 12.5 µM CuC12, lane 5: ENA-78 and 25 µM CuCI2, lane 6: ENA-78 
and 50 µM CuCl2, lane 7: ENA-78 and 75 µM CuC12 and lane 8: ENA-78 and 100 µM CuC12. 
Representative of two independent experiments. 
It was observed that CuCl2 alone had no effect on ENA-78 multimer formation. ENA-78 
was monomeric and dimeric in the presence of 1.25 - 100 µM CuCl2. 
The effect of H202 (1 - 400 µM) on multimerisation of ENA-78 in the presence of 25 
µM CuCl2 was then investigated. 
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Figure 2.19. The effect of H202 on the form of recombinant ENA-78 (5 x 10-7 M) in the presence of 
CuC12 (25 µM) and H202 (1 - 400 µM) following incubation at 37°C for 1 day, analysed by SDS- 
PAGE on a 14 % polyacrylamide gel. Lane 1: ENA-78 and 25 µM CuCI2, lane 2: ENA-78,25 pM 
CuC12 and 0.5 pM H202,, lane 3: ENA-78,25 µM CuCl2 and 1 µM H202,, lane 4: ENA-78,25 µM 
CuC12 and 5 µM H202, lane 5: ENA-78,25 µM CuC12 and 12.5 µM H202, lane 6: ENA-78,25 µM 
CuC12 and 25 µM H202, lane 7: ENA-78,25 µM CuC12 and 50 pM H202, lane 8: ENA-78,25 µM 
CuC12 and 100 µM H202, lane 9: ENA-78,25 µM CuC12 and 200 µM H202 and lane 10: ENA-78,25 
µM CuC12 and 400 µM H202. Representative of two independent experiments. 
In the absence of H202, ENA-78 was seen predominantly as a monomer and dimer 
(figure 2.19, lane 2). ENA-78 multimerisation was enhanced in the presence of 25 µM 
CuC12 and 12.5 - 100 µM H202 in a dose dependent manner (lanes 5- 8). At 
physiological concentrations, Cu (25 µM) plus H202 (12.5 - 25 µM, lanes 5- 6) 
promote the multimerisation of ENA-78 to tetramers - lanes 5- 6). Increased H202 
concentrations (50 - 200 µM) resulted in further higher order multimer 
formation (lanes 
6- 9). Multimerisation is maximal at 100 µM H202 (lane 8). At 200 µM H202 ENA-78 
multimers were diminished and at 400 µM H202 ENA-78 multimers were destroyed. 
The effect of heparan sulphate (HS) on CuC12 induced multimer formation was then 
investigated. ENA-78 was incubated in the presence of CuC12 (0.5 - 100 µM) and HS 
(0.1 mg/ml). 
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Figure 2.20. The effect of CuCI2 on the form of recombinant ENA-78 (5 x 10-7 M) in the presence of 
HS (0.1 mg/ml) following incubation at 37°C for I day, analysed by SDS-PAGE on a 14 % 
polyacrylamide gel. M: molecular weight markers. Lane 1: ENA-78 and HS, lane 2: ENA-78, HS 
and 1.25 µM CuC12, lane 3: ENA-78, HS and 2.5 µM CuCI2, lane 4: ENA-78, HS and 5 µM CuCl2, 
lane 5: ENA-78, HS and 12.5 µM CuCI2, lane 6: ENA-78, HS and 25 µM CuCI2, lane 7: ENA-78, HS 
and 50 µM CuCI2, lane 8: ENA-78, HS and 75 µM CuCI2 and lane 9: ENA-78, HS and 100 µM 
CuCI2. Representative of two independent experiments. 
In the presence of HS (figure 2.20), there was little change in the form of ENA-78 in the 
presence of CuC12 compared to the absence of HS (figure 2.18). ENA-78 appeared only 
in monomeric and dimeric form. 
Subsequently, the effect of HS (0.1 mg/ml) on ENA-78 multimer formation in the 
presence of 25 µM CuC12 and increasing concentrations of H202 (1 - 400 µM) was 
investigated. 
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Figure 2.21. The effect of H202 on the form of recombinant ENA-78 (5 x 10-7 M) in the presence of 
CuC12 (25 µM) and HS (0.1 mg/ml) following incubation at 37°C for 1 day, analysed by SDS-PAGE 
on a 14 % polyacrylamide gel. Lane 1: ENA-78, HS and 25 µM CuC12, lane 2: ENA-78, HS, 25 µM 
CuC12 and 0.5 µM H202, lane 3: ENA-78, HS, 25 µM CuC12 and 1 pM H202, lane 4: ENA-78, HS, 25 
µM CuC12 and 5 µM H202, lane 5: ENA-78, HS, 25 µM CuC12 and 12.5 µM H202, lane 6: ENA-78, 
HS9 25 µM CuC12 and 25 µM H202, lane 7: ENA-78, HS, 25 µM CuC12 and 50 µM H202, lane 8: 
ENA-78, HS, 25 µM CuC12 and 100 µM H202, lane 9: ENA-78, HS, 25 µM CuCI2 and 200 µM H202 
and lane 10: ENA-78, HS, 25 µM CuC12 and 400 IM H202. Representative of two independent 
experiments. 
In the absence of HS (figure 2.19), higher order multimer formation occurred in the 
presence of 25 µM CuC12 plus 12.5 - 100 µM H202 in a dose dependent manner (figure 
2.19, lanes 5- 8) and multimerisation was maximal at 100 µM H202 (figure 2.19, lane 
8). In the presence of HS (0.1 mg/ml), higher order multimer formation also occurred in 
the presence of 25 µM CuC12 plus 12.5 - 100 µM H202 in a dose dependent manner 
(figure 2.21, lanes 5- 8), but at 200 - 400 µM H202, multimers remained and were 
protected by HS. In the presence of 0.1 mg/ml HS, multimerisation was maximal at 200 
- 400 µM rather than at 100 µM H202 in the absence of 0.1 mg/ml HS (figure 2.19). HS 
appeared to protect high order multimers from damage by high concentrations of H202. 
The multimers were able to withstand higher concentrations of H202 (200 - 400 µM) in 
the presence of 0.1 mg/ml HS (figure 2.21, lanes 9 and 10). 
In order to quantify the degree of multimerisation, ENA-78 was incubated in the 
presence and absence of physiological concentrations of CuC12 (25 µM) plus H202 (50 
µM), and in the presence and absence of HS (0.1 mg/ml). Muttimers of higher order 
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than dimer were quantified by scanning densitometry and presented as the % of total 
RANTES including the monomer. 
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Figure 2.22A. ENA-78 (5 x 10"7 M) incubated at 37°C for 1 day and analysed by SDS-PAGE on a 14 
% polyacrylamide gel. ± CuC12 (25 µM), H202 (50 µM) and HS (0.1 mg/ml). Lane 1: ENA-78 only, 
lane 2: ENA-78 + HS, lane 3: ENA-78 + CuCI2, lane 4: ENA-78 + H202, lane 5: ENA-78 + CuCI2 and 
H202, lane 6: ENA-78 + HS + CuC12, lane 7: ENA-78 + HS + H202 and lane 8: ENA-78 + HS, CuCl2 
and H202. Representative of three independent experiments. 
Figure 2.22B: Quantitative analysis of supra-dimeric ENA-78 intensity (higher order complexes of 
ENA-78 including tetramer (24 KDa) as % of total analysed using density analysis (Quantiscan). 
Lane 1: ENA-78 only, lane 2: ENA-78 + HS, lane 3: RANES + CuCI2, lane 4: ENA-78 + H202, lane 
5: ENA-78 + CuCI2 and H202, lane 6: IL-8 + HS + CuCI2, lane 7: IL-8 + HS + H202 and lane 8: IL- 
8+"S, CuCI2 and H202. * indicates p<0.05, (n = 3). 
96 
The addition of 25 µM CuC12 plus 50 µM H202 significantly promoted trimer and 
tetramer formation (lane 5,26.32 + 12.11 % is in supra-dimeric form, p<0.05) 
compared to the control (ENA-78 only, lane 1). HS reduced the multimerisation effect 
of 25 µM CuC12 with 50 µM H202 (lane 8), only the trimer was formed. 
In order to investigate the stability of ENA-78 multimers, ENA-78 was incubated for 1 
day at 37 °C in the presence and absence of 25 µM CuC12,50 µM H202 and 0.1 mg/ml 
HS. Following incubation, the chaotropic agent, guanidine hydrochloride (G-HC1), was 
added to the samples, final concentration 6 M. The G-HC1 was removed by EtOH 
precipitation before the samples were analysed by SDS-PAGE and Western blots 
stained for ENA-78. 
Tetramer 
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Figure 2.23. The effect of G-HCI (6 M) and EtOH precipitation on the form of recombinant ENA- 
78 (5 x 10-7 M) in the presence of CuC12 (25 µM) plus H202 (50 µM) following incubation at 37°C for 
I day, analysed by SDS-PAGE on a 14 % polyacrylamide gel. M: molecular weight markers. Lane 
1: ENA-78 with 25 µM CuCI2 and 25 pM H202, lane 2: ENA-78,25 µM CuC12 and 25 pM H202 with 
6M GHCI and EtOH precipitation. Representative of two independent experiments. 
The higher order ENA-78 multimers (above and including trimers) generated in the 
presence of 25 µM CuC12 plus 50 µM H202 were found to remain following treatment 
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with G-HC1 (6 M) (figure 2.23, lane 2) compared to the control (ENA-78 in the 
presence of 25 µM CuC12 and 50 µM H202 but in the absence of G-HC1, lane 1). 
Monomers and dimers were also found to remain following treatment with G-HCI, 
indicating that the 3-dimensional structure of ENA-78 was not disrupted. 
The effect of the hydroxyl radical scavenger, dimethyl sulphoxide (DMSO) at 
concentrations 1,5 and 10 % (v/v) on ENA-78 multimerisation in the presence of 25 
µM CuCl2 plus 50 µM H202 was then investigated. 
Trimer 
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Figure 2.24. The effect of DMSO (1,5 and 10 % (v/v)) on the form of recombinant ENA-78 (5 x 10-7 
M) in the presence of CuCI2 (25 µM) plus H202 (50 µM) following incubation at 37°C for 1 day, 
analysed by SDS-PAGE on a 14 % polyacrylamide gel. M: molecular weight markers. Lane 1: 
ENA-78 with CuCl2, lane 2: ENA-78 with CuCl2 and H202, lane 3: ENA-78 with CuCl2, H202 and 1 
% (v/v) DMSO, lane 4: ENA-78 with CuCI2, H202 and 5% (v/v) DMSO, lane 5: ENA-78 with 
CuCI2, H202 and 10 % (v/v) DMSO. Representative of two independent experiments. 
ENA-78 trimers were generated in the absence of DMSO by 25 µM CuC12 plus 50 µM 
H202 (figure 2.24, lane 2) but were diminished upon treatment with 1,5 and 10 % (v/v) 
DMSO (lanes 4 -5) indicating that hydroxyl radicals may be involved in the mechanism 
of multimer formation. 
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2.6. Discussion 
CuC12 alone induces the formation of RANTES and IL-8 multimers of higher order than 
the dimer. In the presence of physiological concentrations of CuC12 the addition of H202 
further enhances the formation of higher order chemokine multimers in a dose- 
dependent manner. With the addition of Cu plus increasing concentrations of H202, 
dimer formation increases at the expense of the monomer (figure 2.4). 
Physiological levels of Cu in plasma have been reported ranging between 8.3 and 26.48 
µM (Gonzalez et al, 1999; Versieck, 1980) and some studies have claimed 
physiological levels of H202 of up to 35 µM in human plasma. During inflammatory 
reactions pathophysiological levels of H202 released by activated granulocytes of up to 
100 µM have been reported (Bucchieri et al, 2002; Deskur et al, 1998; Lacy et al, 1998; 
Varma & Devamanoharan, 1991). The observation that chemokines multimerise with 
optimal conditions of 25 µM CuCl2 plus 50 - 100 µM H202 indicates that chemokine 
multimerisation should occur in vivo, under inflammatory conditions. 
Chemokines appear to multimerise via a mechanism similar to the self-aggregation of 
the amyloid-ß (Aß) peptide. Evidence for an interaction between Cu and API-40 was 
first observed by the stabilisation of an Aß dimer by Cu (II) (Bush et al, 1994). A high 
affinity Cu binding site was observed on API-42 that mediates self-aggregation 
(Atwood et al, 2000b; Burrows et al, 1994; Clore et al, 1990; Schnitzel et al, 1994; 
Skelton et al, 1995). 
Chemokine multimerisation was found to occur optimally after 1 day for IL-8 and 
ENA-78 and 2 days of incubation for RANTES at 37 T. Similarly, the Aß peptide was 
found to multimerise optimally following 5 day incubation. This observation indicates 
the involvement of a slow oxidative system, with a requirement for the accumulation of 
free radicals. In addition, the hydroxyl radical scavenger DMSO attenuates chemokine 
multimerisation in a dose-dependent manner, indicating that hydroxyl radicals and 
therefore a redox mechanism may be involved in multimer formation. IL-8 and ENA-78 
may have a different mechanism of cross-linking to RANTES. Dityrosine formation 
was investigated and results reported in Chapter 3. 
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All Cu plus H202-induced higher order chemokine multimers were resistant to SDS and 
G-HC1 (6 M). The G-HC1 and SDS resistance of chemokine multimers indicates that 
multimers are covalently linked and highly stable. 
It is possible that in these in vitro conditions Cu contributes to the generation of free 
radicals/reactive oxygen species and mediates chemokine oligomerisation in a fashion 
similar to the mechanism involved in Cu-mediated Aß peptide oligomerisation. 
Evidence suggests that Cu firstly binds to the Aß-peptide via histidine residues and 
secondly, forms links between tyrosine residues (tyrosine-tyrosine links) that are 
covalent (Atwood et al, 2000a; Atwood et al, 1998; Atwood et al, 2000b). Senile 
plaques isolated from AD brain are predominantly composed of Aß-peptide bound to 
Cu (II) via high affinity interactions with histidine residues (Atwood et al, 2004). Cu- 
histidine binding is abolished by acidic pH or chemical blocking of histidine residues 
(Atwood et al, 2000a; Cuajungco et al, 2000). It has also been shown that Cu induced 
oxidative conditions promote the modification of both histidine and tyrosine residues in 
Aß. One of the oxidation products was identified as dityrosine by both fluorescence 
detection and detection with a specific dityrosine antibody (Atwood et al, 2000a; 
Atwood et al, 2004). 
It has been reported that following the binding of Cu (II) to histidine residues, Af3- 
peptide multimerisation is mediated through oxidation of tyrosine residues with the 
subsequent reduction of Cu (II) to Cu (I) (Atwood et al, 2000b; Huang et al, 1999), and 
it has now been shown that the P-amyloid protein reduces Cu (II) to Cu (I) with 
concurrent generation of H202 and hydroxyl radicals from 02 (Liu et al, 2006). It was 
confirmed that through this mechanism, Cu (II) induces the generation of dityrosine 
cross-linked, SDS-resistant multimers of human Aß peptide of 8.6,13 and 17 KDa 
(Atwood et al, 2004; Huang et al, 1999), see figure 2.25. 
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Figure 2.25. A simple model depicting the redox chemistry of dityrosine formation in Aß 
oligomerisation (Smith et al, 2007). The origin of the electron(s) could be the peptide itself or from 
other biological reducing agents such as dopamine and ascorbate (Opazo et al, 2002). Cu (II) binds 
Aß via histidine residues. Aß-peptide multimerisation is mediated through the oxidation of adjacent 
tyrosine residues with the subsequent reduction of Cu (II) to Cu (I) and concurrent generation of 
H202" As a consequence of the formation of a tyrosyl radical, dityrosine cross-links are generated 
giving rise to covalently linked soluble Aß oligomers (Atwood et al, 2000b; Huang et al, 1999; Liu et 
al, 2006; Smith et al, 2007). 
These findings reveal the requirement for both tyrosine and histidine residues for metal- 
mediated Aß-peptide assembly (Atwood et al, 2000b), which are both known to 
coordinate Cu in A(3 (Atwood et al, 2004). 
The hypothesis for the involvement of Cu in chemokine multimerisation is based on the 
known mechanism for dityrosine cross-link formation in the multimerisation of the ß- 
amyloid protein. The covalent binding of Cu and the formation of dityrosine cross-links 
is likely promoted by the presence of H202. The suggested mechanism is a Cu-redox 
system that occurs in the presence of Cu plus H202. 
The hypothesis is that Cu (II) binds and subsequently oxidises the chemokine (CK) to 
form oligomers, whilst Cu (II) is subsequently reduced to Cu (I). 
CK + Cu2+ º Cu+ + CK: CK+ 
Reduced Cu (I) reacts with molecular oxygen (02) generating the superoxide anion 
(02-). This recycles Cu (I) back to Cu (II). 
Cu+ + 02 º Cu 2+ + 02- 
The 02" generated in the recycling of Cu (I) back to Cu (II) undergoes dismutation to 
H202 and O2 spontaneously. 
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This shows that chemokines could multimerise without the addition of H202 to the 
reaction, as it is generated spontaneously in the presence of molecular oxygen. Indeed, 
Cu alone induced multimerisation of RANTES and IL-8, but not ENA-78, which 
implicates the tyrosine residue in the reaction. Similarly, it has been suggested that in 
the absence of added H202, the Aß-peptide directly produces H202 in the presence of 
CuC12 alone through Cu (II) reduction and redox in the presence of molecular oxygen 
(Huang et al, 1999). 
However, in the presence of H202 Cu (I) can be more efficiently oxidised back to Cu 
(II) in the Fenton reaction, providing more Cu (II) for the reaction and resulting in 
further multimerisation of CK. All chemokines were found to multimerise in the 
presence of Cu plus H202, indicating the involvement of other residues in the formation 
of stable covalent cross-links in ENA-78. 
Haber Weiss - Fenton reaction 
H202 + Cu+ --0 Cu 2+ + Off + OH- 
Cu 2+ +02- º 02 + Cu+ 
When both reactions above combine, further ROS are generated causing the redox to 
propagate: 
Cu+/Cu2+ 
H202+02- º 02+ OH- + OR 
DMSO scavenges OH- radicals and inhibits chemokine multimerisation, indicating the 
involvement of OH- radicals. Interestingly, investigation using lens proteins has shown 
that the H202/Cu ion system but not other metal-catalysed oxidation systems such as 
H202/Fe-EDTA produces protein-bound dityrosine (Kato et al, 2001). 
Chemokine multimer formation is enhanced in the presence of H202 but the effect does 
not occur in the presence of H202 alone. This is also true for the Aß-peptide (Atwood et 
al, 2004; Atwood et al, 2000b). The Cu is required for redox cycling to occur, and it is 
the redox that drives the reaction leading to multimer formation. 
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Since multimerisation in the presence of Cu plus H202 occurs in ENA-78 which has no 
tyrosine residues in its primary structure, there must be an additional mechanism that 
does not involve dityrosine formation (figure 2.18). As suggested with Aß-peptide 
multimer formation (Atwood et al, 2000a), chemokine multimerisation could occur via 
the involvement of histidine residues, of which ENA-78 has one, RANTES has one and 
IL-8 has two. Cu has been shown to bind to histidine residues with high affinity 
(Camakaris et al, 1999). Evidence implies that in addition to the involvement of Cu (II) 
in dityrosine formation, Cu (II) is coordinated to Aß via 3 histidine residues, with the 
formation of an intermolecular histidine bridge between Cu (II) atoms (Atwood et al, 
2000a; Huang et al, 2004; Smith et al, 2006). Binding of Cu to histidine may also 
explain the multimerisation of ENA-78 in the absence of tyrosine residues. 
Oligomer formation is also observed with the prion protein (PrP). Since 1995, 
investigations on Cu binding to PrPC have been focussed on peptides from the 
unstructured N-terminal segment of PrPC, consisting of a highly conserved repeat of 
four octarepeat units containing histidine and glycine residues with the concensus 
sequence PHGGGWGQ. Four Cu (II) ions have been found to bind in this region whilst 
a fifth Cu (II) ion has been proposed to bind to the prion protein in the region 
connecting the unstructured segment with the globular portion of the protein. This 
portion of the protein is characterised by the presence of helices. 
Cu (II) dependent PrP aggregation has been reported to occur through the coordination 
of Cu to His-111 as the key residue together with His-96, Met-112 and the N-terminal 
amino group (Brown et al, 2004; Jackson et al, 2001; Jobling et al, 2001; Kramer et al, 
2001; Qin et al, 2002; Wadsworth et al, 1999). This indicates the possible involvement 
of methionine residues in conjunction with histidine residues. Evidence suggests that 
the mechanism for PrP multimerisation involves Cu (II) ions coordinated with histidine 
to form a complex that also involves a tyrosine residue (Stanczak et al, 2005a; Stanczak 
et al, 2005b). 
This mechanism of Cu (II) - PrP histidine/methionine/tyrosine coordination is similar to 
the histidine/tyrosine involvement in Aß-peptide multimerisation, and this could also be 
a possible mechanism for chemokine multimerisation in those chemokines which 
contain histidine, methionine and tyrosine residues. This also explains why chemokines 
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with a higher number of tyrosine residues may multimerise more effectively than those 
with few or no tyrosine residues. Dityrosine cross-links may occur in addition to 
histidine bridges in those chemokines that have one or more tyrosine residues in their 
primary structure. 
There is also evidence suggesting that the prion-like protein `Doppel' binds Cu. Doppel 
exhibits 26 % sequence identity with the prion protein, but lacks the octarepeat region 
implicated as the major Cu-binding domain. Matrix-assisted laser desorption ionisation 
mass spectrometry of a doppel peptide revealed binding of Cu but not other metals (Qin 
et al, 2003) 
Alternatively, chemokine multimerisation may involve cysteine residues, since Cu is 
also known to bind cysteine residues as well as methionine and histidine with high 
affinity (Bopp et al, 2008). In addition, homocysteine, a thiol containing derivative of 
cysteine has been shown to interact with Cu (II) and reduce it to Cu (I) with subsequent 
H202 generation (White et al, 2001). ENA-78 has 4 cysteine residues and both IL-8 and 
RANTES have 5 in their primary structure. ENA-78 and RANTES have 1 methionine 
residue whilst IL-8 has none. Other amino acid residues may also be involved in 
multimerisation effects in conjunction with histidine, methionine or cysteine residues. 
It was speculated that the interaction of chemokines with GAGs may be via a similar 
mechanism to the interaction of the PrP with GAGs, i. e. through the covalent binding 
of Cu. PrP multimers stabilised by Cu (II) bridges interact with glycosaminoglycans 
(GAGs) and this protein-GAG interaction is mediated largely by protonated and Cu (II)- 
bound histidine side chains of PrP, occurring with the formation of a multimeric PrP 
complex (Gonzalez-Iglesias et al, 2002). 
The previous work of others leading to the discovery that Cu (II) coordinates the 
binding of PrP multimers to GAGs, together with the knowledge that chemokines bind 
to GAGs led to the investigation of heparan sulphate (HS) binding to chemokine 
multimers in the presence of Cu. It was speculated that the addition of HS to 
chemokines, in the presence of 25 µM CuC12 and increasing concentrations of H202 
would result in the formation of higher molecular weight GAG-chemokine multimer 
complexes. 
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However, no such complexes were detected. Instead, the evidence suggested that HS is 
acting as a free radical scavenger. GAGs including HS are well known as free radical 
scavengers and have been shown to have protective effects against Cu induced 
peroxidation and oxidative damage in fibroblast and liposome cultures (Albertini et al, 
2000; Albertini et al, 1996; Balogh et al, 2003; Campo et al, 2004; Volpi & Tarugi, 
1999). Following the addition of HS, higher concentrations of H202 were required for 
optimal multimer formation indicating that HS limits the availability of free radicals and 
the extent of multimerisation at any given H202 concentration. In addition, higher order 
multimers were protected from damage at high concentrations of H202 in the presence 
of HS. GAGs have also been shown to have a protective effect against lipid 
peroxidation in endothelial cells (Section 4.5.1, figure 4.13). 
The multimer limiting and protective effects of HS as a scavenger mirror the 
observation that the hydroxyl radical scavenger DMSO also limits chemokine multimer 
formation. Again, this indicates the involvement of free radicals and redox in the 
mechanism of chemokine multimer formation. 
It appears that HS has a biphasic effect dependent on the H202 concentration. 
Chemokines appear to have different susceptibilities to oxidative degradation induced 
by free radical attack at high H202 concentrations with IL-8 more susceptible than 
RANTES and ENA-78 (figures 2.7A, 2.15A and 2.22A). Chemokines such as RANTES 
or ENA-78 appear less susceptible to oxidative degradation by free radical attack at 
high concentrations of H202 and therefore the addition of HS attenuates multimer 
formation as the availability of free radicals is limited by HS. Chemokines such as IL-8 
appear to multimerise more effectively in the presence of HS and therefore may be 
more susceptible to oxidative degradation. The protective effect of HS may promote 
rather than attenuate IL-8 multimer formation. This may be why RANTES multimer 
formation was optimal after 2 days of incubation and IL-8 and ENA-78 multimer 
formation was optimal after 1 day of incubation, i. e. the multimers were more unstable 
and degraded after 2 days. 
High MW HS-chemokine complexes were not observed following the addition of 0.1 
mg/ml HS in the presence of CuC12 and H202. A possible explanation is that HS- 
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chemokine binding is electrostatic and disrupted in SDS-containing gels. Another 
explanation is that the addition of soluble HS is not a model of the endothelial bound 
HS that is present in vivo, but a model of the effect of soluble GAGs shed at sites of 
inflammation. IL-8 has been shown to bind to HS on endothelial cells, and shedding 
results in an IL-8 complex with HS-containing syndecan-1 ectodomains, a trimolecular 
complex with a mass of 140 KDa (Marshall et al, 2003). However it is possible that 
chemokines may not bind soluble HS in the absence of the core protein, and that soluble 
HS may be presented to chemokines in a form that causes the chemokine binding site to 
be inaccessible. 
Given the observation that CuC12 and H202 induce multimerisation in the chemokines 
RANTES, IL-8 and ENA-78 it seems likely that other chemokines may multimerise in a 
similar way. The most likely chemokines to form multimers in the presence of CuC12 
and H202 are those that contain tyrosine and histidine residues, in light of the previous 
reports that Cu induces multimer formation in Aß and PrP via coordination with 
histidine and tyrosine residues. Such chemokines include the monocyte, T-cell and 
basophil chemoattractant, monocyte chemoattractant protein (MCP)- l (contains 3 
tyrosines and 1 histidine), the monocyte, pre-B cell and T-cell chemoattractant stromal 
cell-derived factor (SDF)-1 (contains 2 tyrosines and 2 histidines) and the neutrophil 
chemoattractants haemoinfiltrate CC chemokine (HCC)-1 (contains 6 tyrosines and 2 
histidines) and macrophage inflammatory protein (MIP)-2ß (contains 2 histidines). 
These are some examples but the list is not exhaustive. 
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Chapter 3 
The contribution of dityrosines to 
RANTES, IL-8 and ENA-78 multimer 
formation under redox conditions 
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3. The contribution of dityrosines to RANTES, IL-8 and ENA-78 multimer 
formation under redox conditions 
3.1. Introduction 
3.1.1. Dityrosine formation 
Dityrosine cross-links occur naturally in proteins isolated from the elastic ligaments of 
insects, the cell walls of candida albicans and the fertilisation envelope of the sea 
urchin egg (Andersen, 1963; Foerder & Shapiro, 1977; Smail et al, 1995). Vertebrate 
animal proteins known to contain dityrosine links include elastin, collagen and a storage 
form of the prothyroid hormone, thyroglobulin (Herzog et al, 1992; LaBella et al, 1967; 
LaBella et al, 1968). Hydroxyl radicals have been shown to induce dityrosine formation 
(Karam et al, 1984) and dityrosine may be a useful marker for assessing oxidative 
damage to proteins (Giulivi & Davies, 1993; Giulivi & Davies, 1994). Exposure of 
metmyoglobin or oxyhaemoglobin to H202 results in the conversion of tyrosyl radicals 
to dityrosine (Giulivi & Davies, 1993; Tew & Ortiz de Montellano, 1988). 
The formation of dityrosine adducts in vivo is a sign of oxidative stress and a result of 
free radical reactions. The formation of dityrosine arises from the reaction of two 
tyrosine residues which form carbon centred radicals in the aromatic ring under redox 
conditions (figure 3.1). The formation of dityrosine results in the creation of a very 
stable, irreversible covalent bond (Smith et al, 2007). 
COOH COOH COOH COOH 
C-H H3N-C-H H3N-C-H H3N-C-H 
CH2 CH2 CH2 CH2 
Cu/H202 
\\\ 
OH O OH OH 
Tyrosine Unstable tyrosyl radical Stable dityrosine 
(9 carbons) (9 carbons) (18 carbons) 
Figure 3.1. Dityrosine formation under oxidative conditions. Adapted from (Smith et al, 2007). The 
tyrosyl radical is formed under oxidative conditions in the presence of Cu and H202, and leads to 
stable dityrosine formation. 
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The addition of H202 strongly promotes Cu-induced dityrosine cross-linking of amyloid 
peptides API-28, Aß 1-40 and Aß 1-42 and it is suggested that dityrosine cross-linking is 
dependent on a Cu (II) mediated oxidative mechanism (Atwood et al, 2004). It is 
proposed that Cu (II) binds to histidine residues of Aß, which acts as the reductant, 
reducing Cu (II) to Cu (I). Tyrosine residues in the vicinity of neighbouring histidine 
residues allows the extraction of an electron from Cu (I) to form a carbon centred 
radical which can then covalently link to another adjacent tyrosyl radical, forming a 
stable dityrosine cross-link (Malencik et al, 1996). 
3.1.2. Detecting dityrosines by fluorimetry 
Both isolated and protein bound dityrosines have characteristic emission spectra of 350- 
500 nm upon excitation at 284-315 nm (Andersen,. 1964), and emission spectra of 460 
and 538 nm upon excitation at 460 and 538 nm respectively (Ali et al, 2006; Ali et al, 
2005). Excitation wavelengths of 280 and 320 nm have also been shown to be effective 
for detecting dityrosines with emission wavelengths in the 350-500 nm range at acidic 
and alkaline pH respectively, and an excitation wavelength of 301 Mn has been shown 
to effective for detecting dityrosines in boric acid/sodium-borate buffers with emission 
spectra in the 350-500 nm range (Malencik et al, 1996). The emission spectra are quite 
distinct from those of tyrosine and trytophan which do not fluoresce at these 
wavelengths. With an excitation wavelength of 280 nm, tyrosine fluoresces at an 
emission of 300-305 nm (Malencik et al, 1996). 
The oligomerisation of Aß by incubation with Cu was found to induce a fluorescent 
signal characteristic of tyrosine cross-linking (Atwood et al, 2004). Using an excitation 
wavelength of 300 nm it has been shown that there is a linear increase in fluorescence at 
400 nm with increasing dityrosine concentrations between 0-5 µM (Atwood et al, 
2004). Dityrosines have been detected in Aß-peptide oligomers using this method and 
in addition, dityrosine cross-linked oligomers of Aß have been detected using excitation 
wavelengths of 355 and 485, with emission spectra of 460 and 538 nm respectively (Ali 
et al, 2006; Ali et al, 2005). 
3.1.3. Detecting dityrosines using a specific monoclonal antibody 
The specific monoclonal antibody IC3 has been used to detect protein bound dityrosine 
in isolated bovine lens proteins exposed to Cu plus H202 in vitro by enzyme-linked 
immunosorbent assay (ELISA) and in mouse atherosclerotic tissue using an 
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immunohistochemical method (Kato et al, 2001; Kato et al, 2000). IC3 preferentially 
recognises protein bound dityrosines compared to free dityrosines (Kato et al, 2000). 
IC3 was also successful in detecting Cu/H202 induced dityrosine cross-links formed in 
recombinant Aß-peptide oligomers in vitro and analysed by Western blot (Atwood et al, 
2004). 
The IC3 antibody was used in the experiments described in this chapter, and was a kind 
gift from Yoji Kato, University of Hyogo, JAPAN. 
3.1.4. Detecting dityrosines using liquid chromatography-mass spectroscopy/mass 
spectroscopy (LC-MS/MS) 
Protein dityrosines have been well characterised by liquid chromatography-mass 
spectroscopy/mass spectroscopy (LC-MS/MS) analysis. The collision-induced 
dissociation of protonated native dityrosine (mass 361.2, contains 18 x carbon atoms) 
produced product ions of 315,298,283,269,254 and 237, detected by mass 
spectroscopy. Multiple-reaction monitoring (MRM) transitions of 361/315 and 361/237 
were used to detect protein dityrosines in oxidised wheat-flour dough. The pairings of 
361/315 and 361/237 among the product ions showed outstanding sensitivity and 
selectivity (Takasaki et al, 2005). 
A stable isotopic standard was required to quantify dityrosines in wheat-flour dough by 
LC-MS/MS. Stable isotopic dityrosine (C13 x 18) was prepared from isotopic tyrosine 
(C 13 x 9). The MRM transitions for the internal standard of C 13 x 18 dityrosine were 
selected as 379.2/332.1 and 379.2/253.1, which corresponds respectively to 361.2/315.1 
and 361.2/237.1 for native (C12 x 18) dityrosine (Takasaki et al, 2005). 
3.1.5. Other metals 
It may be possible for other metals to substitute for Cu in free radical generation via the 
mechanism discussed in Chapter 2, Section 2.6. Lead, cadmium, silver, mercury, copper 
and nickel have all been shown to stimulate lipid peroxidation and tissue damage 
through redox mechanisms (Horton & Fairhurst, 1987). 
Metals with a variety of oxidative properties were compared with Cu using LC-MS/MS, 
namely, iron (Fe), zinc (Zn), mercury (Hg) and nickel (Ni), all of which are found in the 
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d-block of the periodic table, often referred to as the transition metals. Unlike the metals 
of group 1 and group 2, ions of the transition elements can exist in multiple stable 
oxidation states. They are capable of losing d electrons without a high energetic penalty. 
A transition metal is defined as an element whose atom has an incomplete d sub-shell, 
or which can give rise to cations with an incomplete d sub-shell. Although Cu, Fe and 
Ni are true transition metals, Zn and Hg could be excluded from this category as they 
have a complete d sub-shell configuration (d'°). Whilst Zn exists only in one oxidation 
state (oxidation state 2), Hg can exist in oxidation states 1 and 2, but both elements 
retain the dl ° configuration. 
a) 
co 
.x 
0 
Atomic Number 
Table 3.1. Some of the oxidation states found in compounds of the transition-metal elements. A 
solid circle represents a common oxidation state, and a ring represents a less common (less 
energetically favourable) oxidation state (Wikipedia 2008, Transition metal, retrieved on Dec 19th, 
2008). Arrows indicate the metals used in the experiments described in this chapter for comparison 
with Cu. 
3.1.5.1. Iron (Fe) 
Fe exists in five possible oxidation states. Fe can exist as Fee+, Fei+, Fe 4+ Fe 5+ and Fe 
6+ 
although oxidation states 4 and 6 are rare. It is well established that Fe generates free 
radicals, and plays a significant part in redox cycling. Fe (II) has been shown to react 
with H202 or molecular oxygen itself to generate the superoxide ion, and hydroxyl 
radical. The iron-dependent decomposition of H202 was originally postulated by 
Fenton, and has become known as the Fenton reaction (Imlay et al, 1988). 
The Fenton reaction 
Fe 2+ + H202 w Fe 3+ + OH- + OH 
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Because Fe is fundamental to redox cycling and peroxidation, and because of its ability 
to exist in many oxidation states, it was important to investigate its effect on dityrosine 
formation in RANTES. 
3.1.5.2. Mercury (Hg) 
Hg has very similar oxidative properties to Cu. Hg, like Cu, exists in oxidation states 1 
and 2, and is one of 2 elements to do so. The other is silver (Ag), which can exist in 
oxidation states 1 and 2. However oxidation state 2 in Ag is uncommon and so Hg was 
used in preference, to equate with Cu. 
3.1.5.3. Zinc (Zn) 
Zn, atomic number 30, is found next to Cu, atomic number 29, in the periodic table. 
Zinc exists almost exclusively in the +2 state and therefore it was useful as a control. 
Since Cu exists in oxidation states 1 and 2, Zn (II) was used to determine whether this 
oxidative property of Cu was paramount for the formation of dityrosines in chemokine 
multimers by means of a redox system. 
3.1.5.4. Nickel (Ni) 
Ni is also found next to Cu in the periodic table, but having different oxidative 
properties to Cu, existing predominantly in oxidation states 2 (Ni II) and 3 (Ni III). 
Interestingly, Ni (II) is known to induce oxidative stress. Studies have indicated that 
reactive oxygen species (ROS) are generated as one of the main mechanisms in the 
carcinogenicity and cytotoxicity of Ni (II) exposure (Jia & Chen, 2008). Nickel induced 
oxidative stress has also been shown to result in the activation of lymphocyte death 
signalling pathways (M'Bemba-Meka et al, 2005). Considering the reported generation 
of ROS caused by nickel, and similarities of nickel and copper, it was speculated that 
nickel might generate free radicals and participate in redox cycling 
3.1.6. Chemokine multimerisation 
Cu plus H202 were shown to induce chemokine multimerisation in RANTES, IL-8 and 
ENA-78 (Chapter 2). A redox mechanism involving dityrosine cross-links was 
suggested as a potential mechanism for chemokine multimer formation. RANTES has 
five tyrosine residues, IL-8 has one and ENA-78 none and therefore it was expected that 
dityrosines should be detectable in RANTES and possibly IL-8 multimers but not in 
ENA-78 multimers. 
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The contribution of dityrosine cross-links to multimer formation was investigated using 
fluorimetry, Western blotting and liquid chromatography mass spectroscopy/mass 
spectroscopy (LCMS/MS). 
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3.2. Materials 
Bovine serum albumin, copper chloride (CuC12), hydrogen peroxide (H202,30 % (v/v)), 
CuC12, NiC12, HgC12, FeC13, ZnC12 sodium dihydrogen phosphate, disodium hydrogen 
phosphate, heparan sulphate (HS) from pig mucosa and glutaraldehyde were obtained 
from Sigma-Aldrich Inc., Poole, Dorset, UK. Phosphate buffered saline (PBS) (- 
Ca2+/Mg2+), guanidine hydrochloride (G-HC1) and 2-mercaptoethanol (2-ME) were 
obtained from Invitrogen Ltd, Paisely, UK). A Far UV quartz 10 x4 mm light path, 1.5 
ml fluorimetry cuvette was obtained from Jencons Ltd, East Grinstead, West Sussex, 
UK. Recombinant human-RANTES, human IL-8 and human ENA-78 were obtained 
from Peprotech EC, London, UK. 
Polyacrylamide mini-gels were cast using the Bio-Rad Protean II system and markers 
and reagents for electrophoresis were obtained and prepared as previously described in 
chapter 2. Primary I C3 antibody from ascites was obtained as a gift from Yoji Kato, 
University of Hyogo, Japan. Secondary biotinylated rabbit anti-mouse (Fab)2 antibodies 
and biotinylated primary rabbit anti-human RANTES antibodies were obtained from 
Peprotech EC, London, UK. Streptavidin-biotinylated horseradish peroxidase complex 
(StreptABC) was obtained from Dako UK Ltd, Ely, Cambridgeshire, UK. A 
commercial enhanced chemiluminescence (ECL) kit, SuperSignal, was obtained from 
Pierce Biotechnology Inc., Rockford, IL 61105, USA. Tween-20, PBS (-Ca 2+ /Mg 2+ ) and 
Super RX Fuji medical X-Ray film were obtained from Fisher Scientific, 
Loughborough, Leicestershire, UK. 
Dityrosine was a gift from Yoji Kato, University of Hyogo, JAPAN and was used to 
make the dityrosine-BSA standard for Western blotting. Normal tyrosine and stable 
isotopic tyrosine, horseradish peroxidise (HRP), borate buffer, trifluoroacetic acid 
(TFA), hydrochloric acid (HCl), methanol, L-methionine, ammonium acetate and acetic 
acid were used by Yoji Kato in the analysis of dityrosine by LCMS/MS. 
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3.3. Methods 
3.3.1. Conjugation of dityrosine and BSA 
A dityrosine-BSA standard was prepared as a positive control for Western blot analyses 
of dityrosine by dissolving dityrosine (1.7 mg) and BSA (2.4 mg) in 0.85 ml of 0.1 M 
phosphate buffer (pH 7.4). Glutaraldehyde solution (20 % (y/v), 200 . il) was added to 
the vessel, little by little with stirring (final concentration 3.8 % (v/v)). The reaction 
continued overnight with stirring at room temperature. The sample was then dialyzed 
against 500 ml PBS (-Ca t+/Mg2+) at 4 °C for 2 days changing the buffer on day 2. The 
concentration of albumin was finally adjusted to 1 mg/ml by diluting to 2.4 ml. 
3.3.2. Preparation of samples for fluorimetry 
Human recombinant RANTES was incubated for 2 days in PBS (-Ca t+/Mg2+) at 2.5 x 
10-6 M (20 µg/ml) with 50 µM CuC12 plus 200 µM H202 in a total volume of 400 µ1 to 
allow the formation of cross-links in multimers. 
3.3.3. Analysis of dityrosines by fluorimetry 
40 µl of dityrosine-BSA standard (1 mg/ml) was diluted to 40 µg/ml in 1 ml of PBS (- 
Ca2+/Mg2+, Fisher UK, pH 7.4). Post-incubation samples containing RANTES (400 µl) 
were diluted to 10 µg/ml by the addition of 400 µl PBS (-Ca t+/Mg2+) and analysed at 37 
°C using a Varian fluorescence spectrophotometer and Cary Eclipse Software. Analysis 
was performed using a Hellma far UV quartz 10 x4 mm light path, 1.5 ml cuvette. The 
fluorescence spectra were scanned at different excitation wavelengths (table 3.2). 
The following excitation wavelengths were used to detect dityrosines: 
Excitation / nm Expected emission k/ nm 
280 Detection of singular tyrosine at 300-305 
284 400 
300 400 at pH 7.4 
301 377-378 at high pH (pH 9) 
315,320 400 at high pH (pH 9) 
325 407 
355 460 
485 538 
Table 3.2. Excitation wavelengths suitable for the detection of dityrosines and the expected emission 
wavelengths (Ali et al, 2006; Atwood et al, 2004; Kato et al, 2000; Malencik et al, 1996). 
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3.3.4. Sample preparation for SDS-PAGE and Western blotting 
In order to detect dityrosines by Western blotting, chemokines were incubated at higher 
concentrations than those used for the detection of the chemokines per se. RANTES, IL- 
8 and ENA-78 (2.5 x 10-6 M (20 µg/ml)) were incubated with CuC12 (1.25 - 100 UM), 
H202 (0.5 - 400µM) and HS (0.1 mg/ml) in PBS (-Ca t+/Mg2+), final volume 200 µl. 
RANTES was incubated for 2 days at 37 T. IL-8 and ENA-78 were incubated for 1 day 
at 37 °C, since a1 day incubation was found to be optimum for multimer formation. 
Incubated samples were frozen at -80 °C, freeze dried, reconstituted to 20 µ1 in Ix 
sample buffer (prepared as described in Chapter 2) and 15 µl of each sample analysed 
by SDS polyacrylamide gel electrophoresis and Western blotting as described in 
Chapter 2, Sections 2.3.4 and 2.3.5. 
3.3.5. Guanidine hydrochloride treatment of samples 
In order to establish the stability and covalent nature of dityrosine cross-links an equal 
volume of guanidine hydrochloride (G-HCI, 12 M) was added to samples (final 
concentration 6 M) following 1 or 2 day incubation at 37 °C, and removed by ethanol 
precipitation of proteins as previously described in Chapter 2, section 2.3.3. 
3.3.6.2-mercaptoethanol treatment of samples 
Samples were reduced with 2-mercaptoethanol (2-ME) to investigate the presence of 
disulphide links. Following freeze drying of samples the lyophilised protein was re- 
constituted in 20 µl 1x sample buffer containing 5% (v/v) 2-mercaptoethanol (4.8 ml 
UHQ water, 0.4 ml 2-mercaptoethanol (2-ME), 0.8 ml glycerol, 1.6 ml 10 % (w/v) 
sodium dodecyl sulphate (SDS), 1 mg bromophenol blue) and boiled at 95 °C for 5 
minutes. Once cooled, samples were loaded onto a 14 % polyacrylamide gel (15 µl per 
well). 
3.3.7. SDS-PAGE and Western blotting 
Proteins were separated on 14 % (w/v) polyacrylamide gels and transferred to 0.45 µm 
nitrocellulose as previously described in Chapter 2, sections 2.3.4 and 2.3.5. 
3.3.8. Blocking Western blots 
Following transfer to nitrocellulose membrane, Western blots were immersed in 
blocking buffer (PBS (phosphate buffered saline (-Ca/Mg)) /2% v/v Tween-20 at room 
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temperature) overnight prior to staining for RANTES as previously described in 
Chapter 2, section 2.3.5. 
3.3.9. Dityrosine staining on Western blots 
The membranes were first washed three times for 10 minutes each in 1x PBS / 0.05 % 
(v/v) Tween-20, and then incubated with primary antibody (mouse monoclonal anti- 
dityrosine (1C3) kept at -80 °C) at a working concentration of 1 µg/ml, 5 ml per blot in 
5% (v/v) rabbit serum for 90 minutes. Blots were again washed three times for 10 
minutes each in PBS/0.05 % (v/v) Tween-20 and incubated for 60 minutes with 
biotinylated rabbit polyclonal anti-mouse (Fab)2 antibody (Dako, UK) kept at 4 °C 
diluted 1: 2000 v/v in PBS (-Ca/Mg) /2% Tween-20 (2.5 µl/5 ml per blot). The 
membranes were washed as before, 3 times for 10 minutes, and then incubated with a 
1: 20,000 (v/v) dilution (1 µl of each of tubes A and B in 10 ml) of a streptavidin- 
biotinylated horseradish peroxidase complex (StreptABC, DAKO) for 45 minutes at 
room temperature. Membranes were washed as before, 5 times for 10 minutes each and 
the blots developed using an ECL kit (Pierce) and placed against X-Ray film to 
visualise results. 2.5 ml of each of the developer and enhancer were mixed together (5 
ml per blot). 
3.3.10. Preparation of internal standard (IS) for liquid chromatography mass 
spectroscopy/mass spectroscopy (LCMS/MS) 
The internal standard (IS) was prepared by Yoji Kato. As an IS, stable isotopic DiY 
(containing 18 x C13 atoms ['3C18]) was prepared from stable isotopic tyrosine (contains 
9x C13 atoms [13C9]) by treatment with horseradish peroxidase (HRP) and H202. The IS 
had a different molecular weight than that of normal dityrosine (the IS parent ion had 
MW 379.2 whereas normal dityrosines have a parent ion MW 361.2). Therefore the IS 
and dityrosine were separately quantified. 
L-tyrosine (5 mg) was incubated for 1 hr with 75 µg of horseradish peroxidase (HRP) in 
the presence of 5 µl of 30 % (v/v) H202 in 5 ml of 0.1 M borate buffer (pH 9.0). The 
mixture was acidified by the addition of 500 µl of 6N HCI and 100 µl of trifluoroacetic 
acid (TFA) and then applied to a solid phase extraction (SPE) column (Supelco 
Spelclean ENVI-18,500 mg solid). The column was then washed with 2 ml of 0.1 % 
(v/v) TFA, and the sample was eluted with 1 ml of 0.1 % (v/v) TFA/CH3OH (1: 3 ). The 
eluate was concentrated and then further purified by reverse-phase HPLC. The reaction 
117 
was terminated by the addition of L-methionine (final concentration 3 mM). The crude 
reaction mixture was acidified by the addition of a bolus of TFA solution. The reaction 
mixture was then applied to an SPE ENVI-18 column, which was washed with 2 ml of 
0.1 % (v/v) TFA, and the sample was then eluted with 2 ml of methanol. 
3.3.11. Sample preparation for LCMS/MS 
Recombinant RANTES (Peprotech, UK) was incubated in triplicate for 2 days at 37 °C 
at a final concentration of 2.5 x 10 -6M (0.02 mg/ml) in the presence and absence of a 
final concentration of 50 µM CuC12, NiC12, HgC12, FeCl3 or ZnC12 and in the presence 
and absence of final concentrations of either 25 or 200 pM H202. The final volume was 
80 pl in lx D-PBS (-Ca t+/Mg2+). Following 2 day incubation, samples were frozen at - 
80 °C for 3 hours and freeze dried overnight. Freeze-dried samples were shipped to 
Hyogo University, JAPAN. 
Each lyophilized sample was dissolved in 80 . il of water, and 40 µ1 was hydrolysed at 
105 °C for 24 hours. Following hydrolysis the sample was dried and dissolved in 50 µl 
of 2 mM ammonium acetate in H2O. For dityrosine analysis, 0.4 µ1 of IS was added to 
40 µ1 of the sample. The analysis of dityrosines was done using 10 µ1 in duplicate. For 
tyrosine analysis, 5 µl was taken and diluted x 20, and 1 µl of IS was added to the 100 
µ1 of solution for tyrosine analysis. 
To identify and confirm that the peak is dityrosine, four traces were used for the 
analysis: two native dityrosine and two IS fragments. The IS allows quantification of 
the results. 
3.3.12. LCMS/MS analysis for tyrosine and dityrosine 
The LCMS/MS analysis was performed by Yoji Kato. Each sample was analysed using 
10 µl in duplicate using an electrospray-ionisation quadrupole tandem mass 
spectrometer (API-3000, Applied Biosystems Co. ) connected to an Agilent 1100 HPLC 
system. Data were calculated from the averages of two serial analyses of one sample. 
For the DiY and tyrosine analyses, HPLC was done by gradient systems using solvent A 
(0.1 % acetic acid) and solvent B (acetonitrile). The separation was performed using a 
reverse phase octadecyl silane (ODS-HG-3) high performance liquid chromatography 
(HPLC) column (2 x 50 mm). The gradient program was as follows: 0 min (A100 %), 2 
min (A100 %), 7 min (A50 %), 7.1 min (AlOO 
%), 15 min (A100 %). The positive 
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mode was used for the electrospray ionisation (ESI). To reduce possible contamination 
of the ion source, the flow was separated by a Valco switching valve using the 
following program: 0 min (waste), 2 min (mass), 7 min (waste). 
The spectrometer had three serial quadrapoles. Using the first quadrapole, the parent ion 
361 was formed by ionisation of dityrosine. The protonated dityrosine was fragmented 
by N2 gas at the second quadrapole in the mass spectrometer. (This process is known as 
collision-induced dissociation or collision-induced fragmentation). The fragment ions 
were detected by the third quadrapole in the mass spectrometer. 
Native dityrosine (DiY) [C12 x 18] has a MW of 360 (figure 3.2). To detect dityrosines 
by LCMS/MS, dityrosines were positively ionised and protonated (MW 360 --> 361, 
figure 3.2). The protonated parent ion, mass 361, can theoretically be detected by a 
mass spectrometer. However, many ionised molecules have a mass of 361 as the parent 
or fragment ion, therefore simple scanning of 361 will detect high background noise. To 
resolve this problem, multiple reaction monitoring (MRM) transitions were used, which 
involves scanning for both the parent ion and fragments of known mass simultaneously. 
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Figure 3.2. Proposed mechanism for Collision-Induced Dissociation of Dityrosine. These are the 
fragments of protonated dityrosine MW 361. The parent ion 361 is formed by ionisation of 
dityrosine. The observed protonated product ions were at m/z 315,298,283,269,254 and 237. The 
protonated dityrosine can be fragmented by N2 gas in the mass spectrometer to form fragments of 
known size. Boxes indicate the selected MRM transitions (Takasaki et al, 2005). 
Trace amounts of native DiY were analysed by LCMS/MS using stable isotopic 
methods. Several fragments, which occurred owing to the collision-induced 
fragmentation of native DiY, were observed. Of these, the combination of ions 361/237 
and 361/315 (for native DiY) were similar and had good sensitivity. 
Both fragments (MW 315 (de-carboxylated) and MW 237 (unknown structure)) were 
previously shown to be very suitable as MRMs for dityrosine (Takasaki et al, 2005) and 
both fragments had a good yield. Scanning for these two fragments (315 and 237) as 
well as the parent ion (MW 361) to detect dityrosines lowers the background compared 
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to a parent ion only scan at MW 361. For example, molecules with the MRM 
combination of MW 361/237 or MW 361/315 are extremely less abundant than 
molecules of MW 361 as ions. The result of using MRM transitions was that the 
background became very low resulting in high sensitivity and selectivity. The use of 
two MRMs (315 and 237) in one molecule gave greater accuracy for the identification 
of dityrosines. 
Native DiY was quantified using an internal standard (IS) of isotopic DiY [C13 x 18]. 
The parent ion and subsequent collision induced fragments of isotopic DiY are of higher 
molecular weight than those formed by the native DiY. The collision-induced 
dissociation of protonated isotopic DiY (mass 379.2) produced product ions of 332.1 
and 253.1 which correspond respectively to 315.1 and 237.1 for native DiY. MRMs of 
379.2/332.1 and 379.2/253.1 were used to detect the isotopic IS as they had good 
sensitivity. 
The detection limit of DiY was 1 nM and the calibration curve of DiY was linear 
(R=0.999) over a concentration range of 1-300 nM. Using the selected MRM 
transitions, the DiY in RANTES samples was estimated by LC/MS/MS. 
Thus, the four multiple reaction monitoring (MRM) transitions used for the 
measurement of DiY were as follows: 379.2/332.1 (internal standard, ['3C18] DiY-1), 
379.2/253.1 (internal standard, [13C18] DiY-2), 361.2/315.1 (native [12C18] DiY-1), and 
361.2/237.1 (native [12C18] DiY-2). The two MRM combinations for one molecule 
showed a similar sensitivity. The use of two MRMs on one molecule is meaningful for 
the identification of DiY. To estimate tyrosine [ 12C9], the analyte was diluted 100-fold 
by a solution of 2 mM ammonium formate with an additional IS (500 nM [13C9] 
tyrosine) and then analysed separately. Two MRMs 182.2/136.1 ([12C9] tyrosine) and 
188.1/142.1 ([13C9] tyrosine) were used for the analysis. To check for artifact formation 
of DiY during sample preparation, the MRM of the [13C9] tyrosine-derived DiY [13C18J 
was also determined regularly. To avoid a decrease in the signal/noise ratio, the MRM 
scan program for the [1309] tyrosine-derived DiY was omitted in routine analyses. 
Importantly, the scanning of an MRM transition takes only about 100 msec. So many 
MRM combinations (and therefore many compounds) can be analysed in a single 
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experiment, almost simultaneously. The first MRM scans during the first 100 msec and 
then next MRM scans in the next 100 msec and this process is repeated. 
3.4. Statistical analysis 
Data were compared with a1 or 2-way ANOVA followed by either a Dunnet's or 
Tukey's post-hoc test where p<0.05 was the minimum accepted level of significance. 
3.5. Results 
3.5.1. Fluorimetry 
The dityrosine-BSA standard was analysed by fluorimetry as a positive control. Of the 
excitation wavelengths used, 300 nm was found to give the best sensitivity for 
dityrosines in the dityrosine-BSA standard with an emission peak in the 390-420 nm 
range. This was similar to the findings of Atwood, et al. and Kato, et al. (Atwood et al, 
2004; Kato et al, 2000). Therefore both the dityrosine standard and RANTES samples 
were analysed using an excitation wavelength of 300 nm. 
1100 
900 
700 
y 
500 
o 
E 300 
w 
100 
-10030 
370 390 410 430 450 
Wavelength / nm 
M 20 ug/ml 
440 ug/ml 
A 10 ug/ml 
---5 ug/ml 
CIF 2.5 ug/m i 
0 1.25 ug/ml 
I 0.625 ug/mI 
470 490 
Figure 3.3. Emission spectra of dityrosine standard in PBS (0.625 - 40 µg/ml), analysed by 
fluorimetry at an excitation wavelength of 300 nm. Representative of two independent experiments. 
a. u. = arbitrary units. 
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The emission peak at 410 nm is characteristic of dityrosines (Atwood et al, 2004; Kato 
et al, 2000; Takasaki et al, 2005) and was detectable in the dityrosine standard at a limit 
of 1.25-2.5 µg/ml BSA. Recombinant human RANTES (Peprotech, UK) was incubated 
for 2 days in PBS (-Ca t+/Mg2+) at 2.5 x 10-6 M (20 µg/ml) with 50 µM CuC12 plus 200 
µM H202 in a total volume of 400 µl, to generate multimers. Following 2 day 
incubation, the samples were diluted to 10 µg/ml in 800 µl PBS (-Ca 2+/Mg2+) and 
samples were analysed by fluorimetry at an excitation wavelength of 300 nm. 
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Figure 3.4. Fluorescence spectra for dityrosines detected in RANTES multimers. RANTES was 
incubated for 2 days in PBS at 2.5 x 10-6 M and 37 °C with CuC12 (50 µM) Plus H202 (200 µM), 
diluted to 1.56 x 10-7 M-1.25 x 10"6 M (1.25 - 10 pg/m1) following incubation and analysed by 
fluorimetry at an excitation wavelength of 300 nm. 
The emission spectra observed at 404 nm is characteristic to dityrosines, indicating that 
dityrosines were present in RANTES multimers. The detection limit for dityrosines was 
1.25 µg/m1. The concentration of dityrosines in RANTES multimers as detected by 
LCMS/MS was subsequently found to be small (Section 3.5.2.3). The peak at 404 nm 
was not detected in RANTES incubated for 2 days in PBS (-Ca 
t+/Mg2+) at 2.5 x 10-6 M 
(20 µg/ml) in the absence of CuC12 plus H202 (data not shown). This suggests that 
dityrosine cross-links are present in RANTES multimers formed in the presence of 
Cu/H202. 
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However, at the concentrations used and in the absence of CuC12 and H202, RANTES 
was dimeric (Chapter 2, Section 2.5.1), and it would be expected that some dityrosines 
would be detected in the dimer. It was suspected that in the absence of multimers, 
dityrosines in the RANTES dimer may be at very low concentrations that are not 
detectable by fluorimetry and therefore RANTES was analysed by Western blot and 
stained with the specific mouse monoclonal antibody IC3 to detect dityrosines. 
3.5.2. SDS-PAGE and Western blotting 
In order to determine the molecular weight of the RANTES multimers containing 
dityrosines, RANTES multimers were analysed using SDS-PAGE and Western blots 
were stained with the specific dityrosine antibody, IC3, a gift from Yoji Kato, 
University of Hyogo, JAPAN. 
Figure 3.5. Dityrosines in RANTES multimers. RANTES (2.5 x 10-6 M) was incubated with copper 
(50 µM) alone, and copper (50 µM) plus 5- 
400 µM H202 for 2 days at 37 °C, analysed by SDS- 
PAGE on a 14 % polyacrylamide gel and Western 
blots were stained for dityrosines. M: molecular 
weight markers. Dityrosine standard 
(dityrosine cross-linked BSA) in lane 9. Lane 1: RANTES 
only, lane 2: RANTES + 50 µM 
CuC12, lane 3: RANTES + 50 µM CuC12 +5 µM H202, lane 4: 
RANTES + 50 µM CuC12 + 25 µM H202, lane 5: RANTES + 50 µM CuC12 + 50 µM H202, lane 6: 
RANTES + 50 µM CuCl2 + 100 µM H202, lane 7: RANTES + 50 µM CuCl2 + 200 pM H202 and lane 
8: RANTES + 50 µM CuC12 + 400 pM H202. Representative of two independent experiments, 
showing similar results. 
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Positive staining for dityrosines in RANTES multimers indicates the involvement of 
dityrosine cross-links in multimerisation of the chemokine, RANTES. The IC3 antibody 
stained RANTES dimers (16 KDa) in RANTES incubated alone (figure 3.5, lane 1) and 
in the presence of 50 µM CuC12 (lane 2). In the presence of 50 µM CuC12 plus 5- 400 
µM H202 the dimer appeared more strongly stained (lanes 3- 8), with the maximum 
dityrosines detected in 16 KDa RANTES at 400 . tM H202 (lane 8). Dityrosines were 
detected in higher order multimers of RANTES (trimer (24 KDa) and above) in the 
presence of 50 µM CuC12 plus 25 - 200 µM H202 (lanes 4- 8), and maximum 
dityrosine formation was seen at 50 µM CuCl2 plus 200 µM H202 (lane 7, up to 
approximately 100 KDa). RANTES tetramers (32 KDa) were detected in lanes 4 -7 (50 
µM CuC12 plus 25 - 200 µM H202). H202 in the presence of 50 µM CuC12 promoted 
multimerisation in a dose dependent manner in lanes 4-7. However, at 50 µM CuC12 
plus 400 µM H202, the higher order multimers were depleted (lane 8). Dityrosines were 
not detected in monomeric RANTES (8 KDa). The BSA-dityrosine standard was used 
as a positive control (lane 9), at a concentration of 25 µg/ml and 10 µl / lane. The 
dityrosine standard stained positively for dityrosines. 
Since the multimers appear depleted by the high concentration (400 µM) of H202 in lane 
8, the protective effect of HS, a free radical scavenger, on dityrosine cross-link 
formation was determined. RANTES was incubated as before, but in the presence of 0.1 
mg/ml HS, analysed by SDS-PAGE, and Western blots were stained for dityrosines 
(figure 3.6). 
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Figure 3.6. The protective effect of HS on dityrosines in RANTES. RANTES (2.5 x 10-6 M) was 
incubated with copper (50 µM) alone, and copper (50 µM) plus 5- 400 µM H202 for 2 days at 37 °C 
in the presence of HS (0.1 mg/ml), analysed by SDS-PAGE on a 14 % polyacrylamide gel and 
Western blots were stained for dityrosines. M: molecular weight markers. Dityrosine standard 
(dityrosine cross-linked BSA) in lane 9. Lane 1: RANTES +HS, lane 2: RANTES + HS + 50 µM 
CuCl2, lane 3: RANTES + HS + 50 µM CuCI2 +5 µM H202, lane 4: RANTES + HS + 50 µM CuCI2 
+ 25 pM H202, lane 5: RANTES + HS + 50 µM CuCl2 + 50 pM H202, lane 6: RANTES + HS + 50 
µM CuCl2 + 100 pM H202, lane 7: RANTES + HS + 50 µM CuCI2 + 200 µM H202 and lane 8: 
RANTES + HS + 50 µM CuCI2 + 400 µM H2O2, Representative of two independent experiments. 
Positive staining for dityrosines in RANTES dimers and higher order complexes again 
indicates the involvement of dityrosine cross-links in RANTES multimer formation. 
However, higher concentrations of H202 were required to see this effect in the presence 
of HS (figure 3.6) compared to its absence (figure 3.5). In the absence of HS (figure 
3.5), dityrosine was observed to form at 25 µM H202 (lane 4) and maximum dityrosine 
formation was seen at 50 µM CuC12 plus 200 µM H202 (lane 7). However, in the 
presence of 0.1 mg/ml HS, dityrosine formed at concentrations of H202 greater than 100 
µM and the maximum effect was seen at 400 µM H202 (figure 3.6, lane 8). Higher order 
multimers were not depleted at the highest (400 µM) concentration of H202 in the 
presence of HS. The RANTES multimers can withstand higher concentrations of H202 
(up to 400 µM) indicating that HS may be scavenging free radicals (figure 3.6). Again, 
the dityrosine standard stained positively for dityrosines (lane 9). 
In order to investigate whether dityrosine cross-links were covalent links, RANTES was 
incubated for 2 days at 37 °C in the presence and absence of 50 µM CuC12,25 µM H202 
and 0.1 mg/ml HS, and 
following incubation, the chaotropic agent, guanidine 
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hydrochloride (G-HCl), was added to the samples at a final concentration of 6M and 
proteins were ethanol precipitated before analysis. G-HCl is capable of disrupting the 
non-covalent 3-dimensional structure of proteins, including hydrogen bonds, van der 
Waals forces and hydrophobic effects (Lu et al, 2001; Neet & Timm, 1994). 
Figure 3.7. The stability of dityrosines to G-HCI. RANTES (2.5 x 10-6 M) was incubated in the 
presence and absence of copper (50 µM), ± H202 (25 µM) and ± HS (0.1 mg/ml), for 2 days at 37 T. 
Samples were treated with 6M G-HCI, analysed by SDS-PAGE on a 14 % polyacrylamide gel and 
Western blots were stained for dityrosines. M: molecular weight markers. Dityrosine standard 
(dityrosine cross-linked BSA) in lane 9. Lane 1: RANTES only, lane 2: RANTES + 50 µM CuCI2 
and 25 pM H202 , lane 3: RANTES + HS, lane 4: RANTES + HS + 50 µM CuCl2 + 25 pM H202, 
lane 5: RANTES incubated with 6M G-HCI,, lane 6: RANTES + 50 µM CuC12 + 25 pM H202, 
incubated with 6M G-HCI , lane 7: RANTES + HS incubated with 6M G-HCI and lane 8: 
RANTES + HS + 50 µM CuCI2 + 25 µM H202 incubated with 6M G-HCI.. Representative of two 
independent experiments. 
Dityrosines were not detected in RANTES incubated without Cu or H202 (figure 3.7, 
lane 1) which would normally be present as a dimer (figure 3.5, lane 1). This is likely 
due to the ethanol precipitation of the proteins, through which some of the dimer may 
have been lost, and therefore not detected by the antibody. As previously observed, 
RANTES dimers (16 KDa), trimers (24 KDa) and tetramers (32 KDa) were formed 
following 2 day incubation of RANTES with 50 µM CuC12 plus 25 µM H202 and 
stained positively for dityrosines in the absence of HS (figure 3.7, lane 2). 
In the presence of HS, dimers (16 KDa) and trimers (24 KDa), but not tetramers (32 
KDa) were detected (lane 4). Again, the result indicates a free radical scavenging effect 
upon the addition of HS. RANTES multimers generated 
following 2 day incubation 
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with 50 µM CuC12 plus 25 µM H202 in the presence and absence of HS (0.1 mg/ml) 
remained following the addition of 6M G-HCl (lanes 6 and 8) when compared with the 
controls (RANTES incubated with 50 µM CuCl2 plus 25 µM H202 in the presence and 
absence of HS (0.1 mg/ml) but in the absence of 6M G-HC1 in lanes 2 and 4. ) The 
result indicates that RANTES multimers are covalently linked, and extremely stable. 
The dityrosine standard stained positively for dityrosines in lane 9. 
In addition, RANTES multimers were stained for dityrosines in the presence of 2- 
mercaptoethanol (2-ME), a compound used to reduce disulphide bonds. It is also known 
for its antioxidant activity. RANTES was incubated for 2 days at 37 °C, as previously, 
with 50 µM CuC12 plus 25 µM H202 in the presence and absence of HS (0.1 mg/ml). 2- 
ME (5 %) was added to samples following incubation, and prior to analysis by SDS- 
PAGE. Figure 3.8 shows the effect of 2-ME (5 %) on RANTES incubated in the 
presence and absence of 50 µM CuC12 plus 5- 400 µM H202 in the absence of HS. 
Figure 3.8. The stability of dityrosines to 2-ME. RANTES (2.5 x 10-6 M) was incubated with copper 
(50 µM) alone, and copper (50 µM) plus 5- 400 µM 
H202 for 2 days at 37 °C, treated with 2-ME (5 
% (v/v)), analysed by SDS-PAGE on a 14 % polyacrylamide gel and Western blots were stained for 
dityrosines. M: molecular weight markers. Dityrosine standard (dityrosine cross-linked BSA) in 
lane 9. Lane 1: RANTES only, lane 2: RANTES + 50 µM CuCl2, lane 3: RANTES + 50 µM CuC12 + 
5 µM H202, lane 4: RANTES + 
50 pM CuC12 + 25 pM H202, lane 5: RANTES + 50 µM CuCl2 + 50 
pM H202, lane 6: RANTES + 
50 µM CuCI2 + 100 pM H202, lane 7: RANTES + 50 pM CUC12 + 200 
µM H202 and lane 8: RANTES 
+ 50 pM CuC12 + 400 µM H202, Representative of two independent 
experiments. 
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The RANTES multimers and dityrosine cross-links remained following treatment with 
2-ME (figure 3.8), indicating that multimers were covalently linked, and that disulphide 
bonds were not responsible for multimer formation or dityrosine cross-linking. Higher 
order multimers appeared in the presence of 50 µM CuC12 only (24 KDa trimer in lane 
2), whereas in the absence of 2-ME, higher order multimers started to occur only in the 
presence of both 50 µM CuC12 and 25 µM H202 (figure 3.5, lane 4). Tetramers (32 
KDa) also appeared at lower concentrations of H202 (25 µM, lane 4) in the presence of 
2-ME than in the absence of 2-ME (figure 3.5,100 µM H202, lane 6). 
Maximum dityrosine formation occured at 50 µM CuC12 plus 200 µM H202 in both the 
absence (figure 3.5, lane 7), and presence (figure 3.8, lane 7) of 2-ME and dityrosines 
were diminished in the presence of at 50 µM CuC12 plus 400 µM H202 (lane 8) in both 
the absence and presence of 2-ME. 
Figure 3.9 shows the effect of 2-ME (5 %) on RANTES incubated in the presence and 
absence of 50 µM CuC12 and 5- 400 µM H202 in the presence of 0.1 mg/ml HS. 
Figure 3.9. Dityrosine formation in the presence of HS. RANTES (2.5 x 10-6 M) was incubated with 
copper (50 µM) alone, and copper (50 µM) plus 5- 
400 µM H202 for 2 days at 37 °C in the presence 
of HS (0.1 mg/ml) and 2-ME (5 % (v/v)), analysed 
by SDS-PAGE on a 14 % polyacrylamide gel and 
Western blots were stained for dityrosines. M: molecular weight markers. Lane 1: RANTES +HS, 
lane 2: RANTES + HS + 50 µM CuCI2, lane 3: RANTES + HS + 50 µM CuCI2 +5 pM H202, lane 4: 
RANTES + HS + 50 µM CuCl2 + 25 pM H202, lane 5: RANTES + HS + 50 pM CuCI2 + 50 pM H202, 
lane 6: RANTES + HS + 50 pM CuCI2 + 100 µM H202, lane 7: RANTES + HS + 50 µM CuC12 + 200 
pM H202 and lane 8: 
RANTES + HS + 50 pM CuCI2 + 400 µM H202. Representative of two 
independent experiments. 
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In the presence of 0.1 mg/ml HS (figure 3.9), maximum dityrosine formation was still 
seen at 50 µM CuC12 plus 200 µM H202 (lane 7), but higher order multimerisation (24 
KDa trimer and above) started to occur at higher concentrations of H202 in the presence 
of HS (figure 3.9, lane 5,50 µM H202) than in the absence of HS (figure 3.8, lane 3,5 
µM H202). Although higher order multimers were depleted at 400 µM H202 (figure 3.9, 
lane 8), some high MW multimers appeared to be protected from degradation (MW 
approx 100 KDa). The effect was also seen at 200 µM H202 (lane 7). Again, this 
indicates that HS may be scavenging free radicals, allowing high order RANTES 
multimers to withstand high concentrations of H202. 
Figure 3.10 shows RANTES incubated at 2.5 x 10-6 M and stained for RANTES rather 
than for dityrosines. The purpose was to compare the presence and absence of RANTES 
multimers and dityrosines in parallel, at the higher concentration of RANTES than used 
in experiments described in Chapter 2. 
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Figure 3.10. RANTES staining of multimers. RANTES (2.5 x 10-6 M) was incubated with copper (50 
µM) alone, and copper (50 µM) plus 100 - 400 µM H202 for 2 days at 37 
°C, analysed by SDS- 
PAGE on a 14 % polyacrylamide gel and Western blots were stained for RANTES. M: molecular 
weight markers. Lane 1: RANTES only, 
lane 2: RANTES + 50 µM CuC12, lane 3: RANTES + 50 
µM CuC12 + 100 µM H202, lane 
4: RANTES + 50 pM CuCI2 + 200 µM H202 and lane 5: RANTES + 
50 pM CuCI2 + 400 µM H202. Representative of two 
independent experiments. 
Maximum RANTES multimerisation occurred at 50 µM CuC12 plus 200 µM H202 in 
parallel with the observation that 
dityrosine formation occurred maximally under these 
conditions (figure 3.9). 
However, when staining for RANTES, the multimers appeared 
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relatively stable at 400 µM H202 (figure 3.10, lane 5) whereas dityrosines were depleted 
at this concentration of H202 (figure 3.5, lane 8). This indicates that another interaction 
is involved in RANTES multimerisation other than dityrosine cross-link formation. 
Given that dityrosines were detected in RANTES multimers, IL-8 and ENA-78 
multimers were also stained for dityrosines for comparison. Since ENA-78 has no 
tyrosine residues within its amino acid sequence, this made it useful as a negative 
control. IL-8 has only one tyrosine residue, whereas RANTES has five. 
Figure 3.11. IL-8 (2.5 x 10-6 M) incubated with copper (50 µM) alone, copper (50 µM) plus 5- 400 
µM H202 for 1 day at 37 °C, analysed by SDS-PAGE on a 14 % polyacrylamide gel and stained for 
dityrosines. M: molecular weight markers. Lane 1: IL-8 only, lane 2: IL-8 + 50 µM CuCI2, lane 3: 
IL-8 + 50 µM CuCI2 +5 µM H202, lane 4: IL-8 + 50 µM CuCI2 + 25 µM H202, lane 5: IL-8 + 50 µM 
CuCI2 + 50 µM H202, lane 6: IL-8 + 50 µM CuC12 + 100 µM H202, lane 7: IL-8 + 50 µM CuCI2 + 200 
µM H202 and lane 8: IL-8 + 50 µM CuCI2 + 400 µM H2O2, Representative of two independent 
experiments. 
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Figure 3.12. ENA-78 (2.5 x 10-6 M) incubated with copper (50 µM) alone, and copper (50 µM) plus 5 
- 400 µM H202 for 1 day at 37 °C, analysed by SDS-PAGE on a 14 % polyacrylamide gel and 
stained for dityrosines. M: molecular weight markers. Lane 1: ENA-78 only, lane 2: ENA-78 + 50 
µM CuCl2, lane 3: ENA-78 + 50 µM CuCI2 +5 pM H202, lane 4: ENA-78 + 50 pM CuCI2 + 25 pM 
H202, lane 5: ENA-78 + 50 µM CuCI2 + 50 pM H202, lane 6: ENA-78 + 50 pM CuCl2 + 100 pM H202, 
lane 7: ENA-78 + 50 pM CuCI2 + 200 pM H202 and lane 8: ENA-78 + 50 µM CuCI2 + 400 pM H202. 
Representative of two independent experiments. 
Dityrosines were not detected in either IL-8 (figure 3.11) or ENA-78 (figure 3.12) using 
this method. However, subsequent analysis of dityrosines by LCMS/MS confirmed the 
presence of low concentrations of dityrosine in IL-8 (section 3.5.3.3) but not ENA-78. 
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3.5.3. Liquid chromatography mass spectroscopy/mass spectroscopy (LCMS/MS) 
3.5.3.1. Analysis of native dityrosine-BSA standard 
The native dityrosine standard [C' 2x 18] and the IS (stable isotopic DiY) [C13 x 18] 
were measured using two MRM combinations for each. The native dityrosine was 
measured using MRMs of 361.2/315.1 and 361.2/237.1 and the IS was measured using 
MRMs of 379.2/332.1 and 379.2/253.1. 
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Figure 3.13. Trace showing dityrosine standards (both stable isotopic MY standard and native 
DiY). The blue and green traces correlate to the native dityrosine-BSA standard which contained 
18 x C12 [12C181 atoms. The red and gray traces correlate to the IS, which contained 18 x C13 I'3C181 
atoms. Both elute at 3 minutes. 
The IS and dityrosine standard eluted at approximately 3 minutes. The two IS parent ion 
/ fragment combinations (red and gray) are `paired' to the two dityrosine parent ion / 
fragment combinations (blue and green. ) Underlined and non-underlined numbers show 
a "pair" of fragments. For example, the IS with parent ion MW 379.2 / fragment MW 
332.1 (red) and dityrosine parent ion MW 361.2 / fragment MW 315.1 (blue) show a 
similar pattern. Similarly, the IS with the 
dityrosine parent ion MW 379.2 / fragment 
MW 253.1 (gray) and dityrosine parent ion MW 361.2 / fragment MW 237.1 (green) 
show a similar pattern. 
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The problem with quantification when using mass spectroscopy with liquid 
chromatography is that the ionisation efficiency and therefore the incorporation of these 
ions into the sample mass can be variable, affecting the retention times which are also 
variable as a result. However, because the isotopic IS and native dityrosine eluted at the 
same retention time, it was concluded that the ionisation efficiency and the 
incorporation into the sample of both the native dityrosine ions and the IS were similar. 
Therefore the IS used was very suitable, since it was ionised at the same efficiency as 
the dityrosine sample. 
3.5.3.2. Dityrosines in RANTES 
To confirm that RANTES incubated for 2 days in lx PBS (-Ca t+/Mg2+) at 37 °C in the 
absence of CuCl2 or H202 does not contain any dityrosines, recombinant RANTES was 
analysed without any additions, as a control. The following figure shows the trace 
recorded for RANTES incubated in the absence of CuCl2 or H202. 
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Figure 3.14. Trace showing RANTES (2.5 x 10-6M) in the absence of CuC12 and H202, The blue and 
green traces correlate to RANTES. The red and gray traces correlate to the stable 
internal 
standard, which contained 18 x C13 (13C181 atoms. 
The IS elutes at 3 minutes 
Figure 3.14 shows that no dityrosines were detected in the RANTES control (blue and 
green traces). The IS still elutes at 
3 minutes. 
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3.5.3.3. Dityrosines in RANTES multimers 
To determine whether dityrosines are present in RANTES multimers, recombinant 
RANTES was incubated for 2 days at 37 °C in Ix PBS (-Ca t+/Mg2+) in the presence of 
50 µM CuCl2 plus 25 µM H202. These are the concentrations at which RANTES is 
known to form multimers. The samples were freeze dried, and reconstituted in water. 
hydrolysed and analysed by LCMS/MS. 
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Figure 3.15. Trace showing dityrosines detected in RANTES (2.5 x 10-6M) incubated in the presence 
of 50 µM CuCI2 plus 25 µM H2O2, The blue and green traces correlate to dityrosines detected in 
RANTES multimers (RANTES incubated in the presence of 50 µM CuCl2 plus 25 µM H202. ) The 
red and gray traces correlate to the stable internal standard, which contained 18 x C13 I'3C181 
atoms. Both the I. S. and the RANTES sample eluted at 3 minutes. 
The analysis confirmed that dityrosines were formed following the incubation of 
RANTES with 50 µM CuC12 and 25 pM H202 for 2 days at 37 °C. Figure 3.15 shows 
that dityrosines [12C18] MW 361.2 with fragments 315.1 and 237.1 were detected in 
RANTES multimers generated by incubation with 50 µM CuC12 and 25 µM H202. 
Dityrosines were detected using the two MRM combinations, MW 361.2/315.1, and 
MW 361.2/237.1. The IS was detected using two MRMs (MW 379.2/332.1 and MW 
379.2/253.1), and used to quantify the data. 
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Dityrosine (nM) 
Control (RANTES only) 
RANTES 
+ 50 W CuC12 + 25 µM HZO') 
A 0 2.4 
B 0 9.4 
C 0 19.3 
Tyrosine (nM) 
Control (RANTES only) 
RANTES 
+ 50 M CuC12 + 25 µM H2O2 
A 347 266 
B 790 1605 
C 676 7490 
Tyr/DiY 
Control (RANTES only) 
RANTES 
+ 50 M CuC12 + 25 M H202 
A NA 112 
B NA 171 
C NA 388 
Mean NA 224 
SEM N/A 83.9 
Table 3.3. Tyrosine and dityrosine concentrations measured in RANTES (2.5 x 10-6M) incubated 
with 50 µM CuC12 plus 25 µM H202. Data was calculated in triplicate using LCMS/MS. The 
detection limit of MY was 1 nM and the calibration curve of DiY was linear (R=0.999) over a 
concentration range of 1-300 nM. Using the selected MRM transitions, the MY in RANTES 
samples was estimated (n = 3). NA = not available (because the amount of dityrosine is zero). The 
table shows dityrosines and tyrosines, detected in RANTES incubated with 50 µM CuC12 plus 25 
µM H202. The data is also expressed as a ratio of the number of tyrosine residues to dityrosines 
present (Y/DiY). 
The number of dityrosines formed depends on the number of tyrosines present in the 
chemokine. In order to make allowances for this, the number of dityrosines present is 
expressed as a ratio of tyrosines (Y) / dityrosines (DiY). A lower ratio indicates that 
there are more dityrosines in the chemokine per one tyrosine residue. 
Qualitative analysis of DiY by Western blotting indicated more DiY at higher 
concentrations of H202, up to 200 . tM (figure 3.5). Therefore RANTES was incubated 
for 2 days at 37 °C in the presence of 50 µM CuC12 plus 200 µM H202 and analysed by 
LCMS/MS for quantitative analysis of DiY. 
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Figure 3.16. Trace showing dityrosines detected in RANTES (2.5 x 10-6M) incubated in the presence 
of 50 µM CuCI2 plus 200 µM H2O2, The trace shows dityrosines detected in RANTES with a parent 
ion MW 361.2/ fragment MW 315.1. The dityrosines in the sample eluted at 3 minutes. 
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Dityrosine (nM) 
Control (RANTES only) 
RANTES 
+ 50 µM CuC1Z + 200 µM H207 
A 0 3.76 
B 0 8.00 
C 0 9.12 
Tyrosine (nM) 
Control (RANTES only) 
RANTES 
+ 50 M CuC12 + 200 M H202 
A 347 118.9 
B 790 800 
C 676 506 
Tyr/DiY 
Control (RANTES only) 
RANTES 
+ 50 M CuC12 + 200 M H202 
A NA 32 
B NA 100 
C NA 55 
Mean NA 62.3 
SEM N/A 20 
Table 3.4. Tyrosine and dityrosine concentrations measured in RANTES (2.5 x 10-6M) incubated 
with 50 µM CuC12 plus 200 µM H202. Data was calculated in triplicate using LCMS/MS. The 
detection limit of DiY was 1 nM and the calibration curve of DiY was linear (R=0.999) over a 
concentration range of 1-300 nM. Using the selected MRM transitions, the DiY in RANTES 
samples was estimated (n = 3). NA = not available (because the amount of dityrosine is zero. 
Dityrosines and tyrosines were detected in RANTES incubated with 50 µM CuC12 plus 200 µM 
H202. The data is also expressed as a ratio of the number of tyrosine residues to dityrosines present 
(Y/DiY). 
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Figure 3.17. Ratio of tyrosines / dityrosines in RANTES incubated in the presence of 50 µM CuCI2 
plus 25 or 200 µM H202. The results are displayed as a ratio of the number of tyrosine residues to 
dityrosines present (Y/DiY). A lower ratio depicts a higher number of dityrosines present compared 
to the number of tyrosine residues. Values are expressed as means ± SEM. * indicates a significant 
difference between RANTES incubated with 50 µM CuCl2 plus 25 µM H202 and RANTES 
incubated with 50 µM CuCI2 plus 200 µM H202 (n=3, p<0.05, one-tailed paired student's t-test). 
The data confirmed that incubation with Cu plus H202 was necessary for dityrosine 
formation in RANTES. An increase in the H202 concentration from 25 to 200 µM 
resulted in significantly greater dityrosine formation (p < 0.05). The ratio of Tyr/DiY 
decreased from 239.7 ± 83.9 to 62.3 ± 20.0, indicating more dityrosine formation. 
3.5.3.4. IL-8 and ENA-78 
In order to investigate whether dityrosine formation correlates to the number of tyrosine 
residues in the amino acid sequence of chemokines, IL-8, which contains one tyrosine 
residue, and ENA-78 which contains no tyrosine residues were incubated with 50 µM 
CuCl2 plus 200 µM H202 for comparison with RANTES which has five tyrosines. 
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Figure 3.18. Trace showing dityrosines detected in IL-8 (2.5 x 10-6M) incubated in the presence of 
50 µM CuC12 plus 200 µM H202. The trace shows dityrosines analysed in IL-8 with a parent ion 
MW 361.2/ fragment MW 315.1. The dityrosines in the sample eluted at 3 minutes. 
The trace shows minimal dityrosines detected in IL-8 incubated in the presence of 50 
µM CuC12 plus 200 µM H202. 
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Figure 3.19. Trace showing dityrosines detected in ENA-78 (2.5 x 10-6M) incubated in the presence 
of 50 µM CuCI2 plus 200 µM H202. The trace shows no dityrosines detected in ENA-78 with a 
parent ion MW 361.2/ fragment MW 315.1. 
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No dityrosines were detected in ENA-78 incubated in the presence of Cu plus H202 
(figure 3.19). 
Dityrosine (nM) 
IL-8 
+ 50 . tM CuCl2 + 200 µM H202 
ENA-78 
+ 50 M CuC12 + 200 µM H202 
A 0.87 0.00 
B 3.60 0.00 
C 0.59 0.09 
Tyrosine (nM) 
IL-8 
+ 50 µM CuCl2 + 200 M H202 
ENA-78 
+ 50 M CuC12 + 200 M H201 
A 211.7 0 
B 1811 229 
C 188.3 0 
Tyr/DiY 
IL-8 
+ 50 M CuC12 + 200 M H202 
ENA-78 
+504M CuCl2 + 200 M H202 
A 244 NA 
B 503 NA 
C 322 0 
Mean 356 N/A 
SEM 76.7 N/A 
Table 3.5. Tyrosine and dityrosine concentrations measured in IL-8 (2.5 x 10-6M) and ENA-78 (2.5 
x 10-6M) incubated with 509M CuC12 plus 200 µM H202. Data was calculated in triplicate using 
LCMS/MS. The detection limit of DiY was 1 nM and the calibration curve of DiY was linear 
(R=0.999) over a concentration range of 1-300 nM. Using the selected MRM transitions, the DiY in 
IL-8 and ENA-78 samples was estimated (n = 3). NA = not available (because the amount of 
dityrosine is zero). Dityrosines and tyrosines were detected in IL-8 and ENA-78 incubated with 50 
µM CuC12 plus 200 µM H202. The data is also expressed as a ratio of the number of tyrosine 
residues to dityrosines present (Y/DiY). 
In sample B, tyrosines were detected in ENA-78. This is likely due to contamination of 
the sample during preparation or analysis, since ENA-78 does not contain any tyrosine 
residues in its primary structure. 
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Figure 3.20. Dityrosines detected in RANTES (2.5 x 10-6M), IL-8 (2.5 x 10-6M) and ENA-78 (2.5 x 
10-6M) incubated with 50 µM CuCI2 plus 200 µM H202. * indicates a significant difference between 
RANTES and IL-8 incubated with 50 µM CuCI2 plus 200 µM H202 (p < 0.05). ** indicates a 
significant difference between RANTES alone and RANTES incubated with 50 µM CuCl2 plus 200 
µM H202 (p <0.01). Values are expressed as means f SEM (n =3). Data was compared using a 1- 
way ANOVA and Tukey's post-hoc test. 
Copper (50 µM) plus H202 (200 µM) induced significant (p < 0.01) dityrosine 
formation in RANTES (6.96 + 1.63 nM) compared to RANTES alone as a control (no 
dityrosines detected). Some dityrosine formation was observed in IL-8 under the same 
conditions, but it was not significantly higher than RANTES incubated alone as a 
control (1.69 + 0.96 nM). No dityrosine formation was detected in ENA-78. 
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The following table summarises the results as a ratio of Y/ DiY. These figures were 
calculated from nM concentrations of dityrosines and tyrosines detected in the samples. 
Sample 
Ratio (no. of Tyrosine residues :1 
Dityrosine detected) 
Mean (n = 3) 
RANTES No DiY detected 
RANTES + 50 µM CuC12 + 200 pM H202 62.3 ± 20 
IL-8 + 50 µM CuC12 + 200 pM H202 356.3 ± 76.7 
ENA-78 + 50 µM CuC12 + 200 µM H202 No DiY detected 
Table 3.6. Ratio of dityrosines / tyrosines in RANTES, IL-8 and ENA-78 incubated in the presence 
and absence of 50 µM CuCl2 and 200 µM H202. The data is displayed as a ratio of the number of 
tyrosine residues to dityrosines present (Y/DiY). A lower ratio depicts a higher number of 
dityrosines present compared to the number of tyrosine residues. Values are expressed as means (n 
= 3). 
3.5.3.5. The effect of other metals on dityrosine formation 
Recombinant human RANTES was incubated in the presence of other metals in 
chloride form (50 µM), plus 200 µM H202 for 2 days at 37 °C. Samples were prepared 
as before, and analysed by LCMS/MS. 
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Figure 3.21. The effect of nickel on DiY formation. Trace showing dityrosines detected in RANTES 
(2.5 x 10-6M) incubated in the presence of 50 µM NiCl2 plus 200 µM HZO2. The trace shows 
dityrosines analysed in RANTES with a parent ion MW 361.2/ fragment MW 315.1. The 
dityrosines in the sample eluted at 3 minutes. 
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Figure 3.22. The effect of mercury on DiY formation. Trace showing dityrosines detected in 
RANTES (2.5 x 10-6M) incubated in the presence of 50 µM HgCI2 plus 200 µM H202. The trace 
shows dityrosines analysed in RANTES with a parent ion MW 361.2/ fragment MW 315.1. The 
dityrosines in the sample eluted at 3 minutes. 
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Figure 3.23. The effect of zinc on DiY formation. Trace showing dityrosines detected in RANTES 
(2.5 x 10-6M) incubated in the presence of 50 µM ZnCl2 plus 200 µM H202. The trace shows 
dityrosines analysed in IL-8 with a parent ion MW 361.2/ fragment MW 315.1. The dityrosines in 
the sample eluted at 3 minutes. 
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Figure 3.24. The effect of iron on DiY formation. Trace showing dityrosines detected in RANTES 
(2.5 x 10-6M) incubated in the presence of 50 µM FeCI3 plus 
200 µM H202. The trace shows 
dityrosines analysed in RANTES with a parent ion MW 361.2/ fragment MW 315.1. The 
dityrosines in the sample eluted at 3 minutes. 
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Dityrosine, nM 
CuCI2 NiC12 HgC12 FeC13 ZnCl2 
A 3.76 0.69 0.00 0.00 0.00 
B 8.00 2.31 0.00 0.84 0.00 
C 9.12 0.00 0.00 0.00 0.00 
Tyrosine, nM 
CuC12 NiC12 HgCl2 FeCl3 ZnCl2 
A 118.9 1224 1168 1961 1411 
B 800 1733 1114 2080 1302 
C 506 1697 645 1617 1264 
Tyr/DiY 
CuC12 NiCl2 HgC12 FeCl3 ZnC12 
A 32 1783 NA NA NA 
B 100 750 NA 2245 NA 
C 55 NA NA NA NA 
Mean 62.3 1266.5 N/A 2245 N/A 
SEM 20 N/A N/A N/A N/A 
Table 3.7. Tyrosine and dityrosine concentrations measured in RANTES (2.5 x 10-6 M) incubated 
with Cu, Ni, Hg, Zn and Fe. Data was calculated in triplicate using LCMS/MS. The detection limit 
of MY was 1 nM and the calibration curve of DiY was linear (R=0.999) over a concentration range 
of 1-300 nM. Using the selected MRM transitions, the DiY in RANTES samples was estimated (n = 
3). NA = not available (because the amount of dityrosine is zero). The table shows dityrosines and 
tyrosines detected in RANTES incubated with metal chloride salts plus 200 µM H202. Data is also 
expressed as a ratio of the number of tyrosine residues to dityrosines present (Y/DiY). 
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Figure 3.25. The effect of metal ions on DiY formation. RANTES incubated with 50 µM CuCI2 
NiCl2 HgClz, FeCl3 or ZnCI2 plus 200 pM H202. ** indicates p<0.01, *** indicates p <0.001. Values 
are expressed as means ± SEM (n = 3). 
Although Hg, and Zn did not induce dityrosine formation, Fe and Ni both induced 
dityrosine formation in RANTES but at levels significantly lower than those induced by 
Cu. 
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RANTES RANTES + Cu RANTES + Ni + RANTES + Hg RANTES + Fe RANTES + Zn 
+ H202 H202 + H202 + H202 + H202 
3.6. Discussion 
In summary, fluorimetry, Western blotting and LCMS/MS were used to qualitatively 
and quantitatively analyse samples of RANTES, IL-8 and ENA-78 that had been 
incubated in the absence and presence of CuC12, NiC12, HgC12, FeC13 and ZnC12 Plus 
H202. Dityrosine formation was greatest in RANTES > IL-8 > ENA-78 and in 
RANTES, dityrosine formation was greatest in the presence of Cu > Ni > Fe > Hg = Zn 
plus H202. 
Of the three techniques used to detect dityrosines, sensitivity was greatest using 
LCMS/MS > Western blotting > fluorimetry. Fluorimetry was less sensitive than 
Western blotting, since no dityrosines were detected in RANTES incubated in the 
absence of Cu plus H202, whereas Western blotting detected dityrosines in dimers. 
However Western blotting did not detect any dityrosines in IL-8, indicating that 
LCMS/MS is a more sensitive technique. LCMS/MS is also quantitative and has 
previously been used to determine dityrosines in oxidised wheat-flour dough (Takasaki 
et al, 2005). The MRM pairings used in these previous studies showed outstanding 
sensitivity and selectivity, making this technique very useful for quantifying dityrosines 
in chemokine multimers. 
Both fluorimetry and Western blotting have previously been used to detect dityrosines 
in Aß-peptide multimers. Using an excitation wavelength of 300 nm, analysis of Aß- 
peptide incubated with CuC12 (25 µM) plus H202 (250 µM) for 1 day resulted in an 
increase in the characteristic fluorescence signal at 400 nm for dityrosine cross-links 
(Atwood et al, 2004). Dityrosines were detected by fluorimetry in the dityrosine-BSA 
standard with an emission peak at 410 nm and in RANTES multimers with an emission 
peak of 404 nm. Although the emission peaks are not identical, they are present in a 
similar range. The incorporation of aromatic residues into peptides has little direct effect 
on their absorbance properties, but the aromatic residues are very sensitive to their 
immediate environment (Wetlaufer, 1962). This suggests that dityrosines may have 
slightly varied spectral properties due to minute differences in the peptide environment 
in which they were analysed, resulting in a shift in the emission peaks. 
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The IC3 antibody was previously used to detect dityrosines in Aß-peptide multimers on 
Western blots. In these studies, Western blotting was also shown to be more sensitive 
than fluorimetry as Aß-peptide multimers were detected both in the presence of CuC12 
alone (without the addition of H202) and in the presence of CuC12 plus H202 (Atwood et 
al, 2004). 
Positive staining for dityrosines in RANTES multimers on Western blots was dependent 
on the presence of Cu and H202 during incubation of the chemokine, indicating that 
these oxidative conditions promote dityrosine formation. RANTES multimers were not 
detected in the presence of H202 alone (Section 2.5.1) and similarly, dityrosines were 
not detected in Aß-peptide oligomers in the presence of H202 alone (Atwood et al, 
2004), suggesting that both RANTES multimers and Aß-peptide muitimers contain 
dityrosine cross-links that are generated in the presence of Cu plus H202. Dityrosines 
were detected in RANTES multimers (including the dimer) but not in monomeric 
RANTES indicating that dityrosines are associated with multimer formation. In the 
absence of Cu plus H202 dityrosines were detectable in the RANTES dimer but staining 
was very faint indicating that dityrosines are present at lower concentrations than in the 
presence of Cu plus H202. 
While redox reactions contribute to the formation of dityrosines and multimerisation of 
RANTES, in excess, oxidative damage occurs to both RANTES (Section 2.5.1) and 
dityrosines (Section 3.5.2). The limiting effect of HS on dityrosine formation in 
RANTES multimers is similar to the effect observed with RANTES, IL-8 and ENA-78 
multimer formation in the presence of Cu plus H202 (Section 2.5.1) and it is speculated 
that the effect is due to the known free radical scavenging properties of HS, as discussed 
in Section 2.6. 
RANTES multimers are clearly linked by stable and covalent dityrosine links, as 
indicated by their resistance to SDS and both G-HCl and 2-ME treatment. The presence 
of dityrosine cross-linked residues confirms the formation of covalent links. This is 
similar to the result reported in section 2.5.1 where RANTES, IL-8 and ENA-78 
multimers were resistant to G-HCI. Previous studies have shown that GAG binding and 
RANTES multimerisation are essential for the chemotactic properties of RANTES in 
l'ivo. The dimeric form of RANTES was shown to be devoid of activity, whereas the 
149 
tetramer was fully active, indicating that a tetramer is required for in vivo activity of this 
chemokine (Proudfoot et al, 2003). GAG interaction and multimerisation is thought to 
facilitate the retention of chemokines on cell surfaces, thereby maintaining a chemokine 
gradient and a high local concentration for cell activation (Proudfoot, 2006). 
However, certain chemokines, such as MCP-3 and eotaxin which both have two 
tyrosine residues appear to be naturally occurring monomers, because structural and 
biophysical studies have failed to provide evidence of multimerisation and MCP-3 is 
fully active as a monomer but it is not known whether these chemokines multimerise on 
cell surface proteoglycans (Crump et al, 1998; Keizer et al, 2000; Kim et al, 1996). 
Thus, multimerisation may be important only for some chemokines, and may have 
functional implications or depend on the site of production. It has been suggested that 
chemokines that are functional in recruiting cells from the circulation into the 
underlying tissue may require multimerisation to function under flow conditions, 
whereas those produced within the extravascular space may not (Proudfoot et al, 2003). 
It has also been hypothesised that chemokines whose GAG binding sites overlap with 
receptor binding sites, as is the case for RANTES and MCP-1, may require 
multimerisation to bind GAGs through some of the subunits while exposing other 
subunit binding sites to the receptor. Interaction of chemokines with leukocyte receptors 
through the exposed binding site could then trigger release of chemokine monomers 
from the multimer complex, allowing the entire binding site, which is partially buried in 
the multimers, to interact with the receptor (Paavola et al, 1998; Proudfoot et al, 2003). 
The observation that RANTES multimers are covalently linked via dityrosine cross- 
links indicates that these multimers are highly stable and functionally relevant. The 
binding of stable RANTES multimers to endothelial expressed GAGs by electrostatic 
interaction may serve to concentrate RANTES on the endothelial cell surface, thereby 
maintaining a concentration gradient and a high local concentration of RANTES to 
facilitate leukocyte activation. In addition, the multimerisation and stabilisation of 
RANTES by covalent dityrosine cross-links may prevent proteolytic degradation, also 
facilitating the formation and maintenance of a stable chemotactic gradient, which is 
essential for leukocyte recruitment during inflammation. 
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The generation of dityrosine in proteins is a normal physiological process in specialised 
cases and a result of exposure to environmental agents in others (Malencik et al, 1996). 
Dityrosine cross-links are naturally occurring in certain proteins as discussed in Section 
3.1.2, however, the formation of dityrosines in vivo is a generalised sign of oxidative 
stress, and may be a useful marker for assessing oxidative damage to proteins. The 
occurrence of dityrosines is relatively common during free radical reactions, due to the 
oxidative modification of proteins (Malencik et al, 1996; Smith et al, 2007). Agents that 
promote the in vivo formation of dityrosine include ultraviolet irradiation, hydroxyl 
radicals, peroxynitrite, and lipid hydroperoxides (Karam et al, 1984; Kikugawa et al, 
1994; van der Vliet et al, 1997) and exposure to H202 results in the conversion of globin 
tyrosyl residues to dityrosine in the case of metmyoglobin or oxyhaemoglobin (Giulivi 
& Davies, 1993; Tew & Ortiz de Montellano, 1988). Thus, dityrosine formation may be 
more likely to occur under oxidative conditions, and the generation of H202 in oxidative 
stress during inflammation may promote dityrosine cross-link formation in chemokines, 
facilitating the formation and maintenance of stable chemotactic gradients. 
The occurrence of higher order multimers at lower concentrations of H202 in the 
presence of 2-ME was unexpected. A possible explanation may be that 2-ME is a thiol 
capable of converting oxygen radicals to reactive sulphur radicals with subsequent 
generation of H202 (Kim et al, 1989) as follows: 
HOCH2CH2SH + 02- + H+ 10 RS- + H202 
(2-ME) 
This generation of H202 by 2-ME could contribute to redox cycling and result in 
dityrosine cross-linked multimer generation, at lower concentrations of added H202. 
The antibody, IC3, has previously been shown to be highly specific for both protein 
dityrosine and free dityrosine (Kato et al, 2000). The specificity of the dityrosine 
antibody is confirmed since ENA-78 (which has no tyrosine residues) multimers did not 
stain positively for dityrosines, nor were dityrosines were detected by LCMS/MS 
in 
ENA-78 multimers, indicating the specificity of the technique. This indicates that ENA- 
78 multimers are not dityrosine cross-linked and that there is another interaction 
occurring in the formation of multimers in this chemokine that 
does not involve 
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dityrosines. In addition, RANTES multimers persist when dityrosines are degraded in 
the presence of high concentrations of H202 which also suggests that other links are also 
involved in RANTES multimer formation, in addition to dityrosine cross-links. 
Using LCMS/MS, dityrosines were detectable in IL-8 (which has one tyrosine residue) 
multimers but were more abundant in RANTES (which has five tyrosine residues) 
multimers. Since RANTES multimers contained a mean ratio of 68.2 tyrosines :1 
dityrosine, this indicates that only a small proportion of the tyrosine residues within 
RANTES form dityrosine cross-links, adding to the evidence that other interactions are 
involved in RANTES multimerisation. 
Non-dityrosine cross-links could form through the abstraction of hydrogen atoms from 
chemokines by free radicals. The sulphur containing amino acids are particularly 
susceptible. The amino acid radicals generated (such as cysteine or methionine radicals) 
can form disulphide bridges, protein-protein covalent bonds and cross-links (Horton & 
Fairhurst, 1987; Smith et al, 2007; Smith et al, 2006). In addition, non-dityrosine cross- 
linking could occur due to the formation of an intermolecular histidine bridge between 
Cu (II) atoms as discussed in Section 2.6. 
It would be useful to study the involvement of histidine residues by using histidine 
blocking to investigate the formation of histidine bridges in chemokine multimers in 
addition to dityrosine cross-links, since ENA-78 contains one and RANTES and IL-8 
have one and two histidine residues respectively, as described in Chapter 2, Section 2.6. 
Histidine blocking would involve the incubation of chemokines with compounds that 
are known to have histidine association capacity, such as imidazole (Arispe et al, 2008). 
Inhibited or diminished chemokine multimer formation would confirm the involvement 
of histidine residues in chemokine multimer formation. 
A mechanism has been proposed for Cu-induced dityrosine cross-linking of API-28, 
API-40 and API-42 that is dependent on a Cu (II) mediated oxidative mechanism 
(Atwood et al, 2004; Kato et al, 2001; Liu et al, 2006) as discussed in Section 2.6. 
Similarly, dityrosine cross-links could be induced in chemokine multimers by a Cu (II) 
mediated oxidative mechanism. 
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The initial driving force for dityrosine cross-link formation may be the coordination of 
Cu ions to histidine residues of RANTES or IL-8. Histidine residues have been 
implicated in dityrosine cross-link formation in the Aß-peptide (discussed in Section 
2.6). This is a likely mechanism for the formation of dityrosine cross-links in 
chemokine multimers. It is proposed that the chemokine acts as the reductant, reducing 
Cu (II) to Cu (I) upon binding to histidine residues. Tyrosine residues in the vicinity can 
extract an electron from Cu (I) to form a carbon centred radical which can then 
covalently link to another adjacent tyrosyl radical, forming a stable dityrosine cross-link 
(Malencik et al, 1996). 
It is postulated that Cu (I) can be oxidised to Cu (II) by molecular oxygen with the 
generation of the superoxide ion (figure 3.26, equation 1). Cu (II) is reduced to Cu (I) 
on interaction with RANTES or IL-8 histidine residues. The tyrosine oxidation that 
occurs from the interaction of Cu (I) with tyrosine residues would result in tyrosyl 
radical formation and subsequent dityrosine cross-link and RANTES or IL-8 multimer 
formation. It would also result in the oxidation of Cu (I) back to Cu (II) (2). 
(1) -U * O2 
(2) CK + Cu 2+ 
i3) 02-+02-+2H+ 
(4) H202 + Cul+ 
-º Cu2+ + 02- 
-º Cu' +CK: CK 
-º H202 + 02 
-º Cu2+ + OH- + OH- 
Figure 3.26. Suggested mechanism for the formation of Cu induced dityrosine cross-links in 
RANTES or IL-8 involving a Cu redox system. CK = chemokine. 
However, Cu (I) could be oxidised back to Cu (II) through an interaction with molecular 
oxygen (1), or with H202, which if present, will enhance the recycling of Cu. An 
interaction with H202 would produce hydroxyl radicals as observed by (Kawanishi et al, 
2002) (4). H202 can also form from the dismutation of superoxides (3). 
It has previously been reported that the Cu/H202 oxidative system but not H202/Fe- 
EDTA, ascorbate/Cu and ascorbate/Fe-EDTA systems induces dityrosine cross-linking 
in lens proteins (Kato et al, 2001). 
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However, the Aß-peptide aggregates in the presence of trace levels (< 0.8 µM) of Fe 
(III) (Huang et al, 2004), suggesting multimerisation effects are not restricted to Cu. 
The Aß-peptide can bind Cu (II), Fe (III) and Zn (II) and both Cu (II) and Fe (III) induce 
Aß-peptide aggregation. The interaction between the Aß-peptide and Cu (II) or Fe (III) 
results in redox chemistry due to the redox activity of the Aß-peptide that allows it to 
reduce Cu (II) to Cu (I) and Fe(III) to Fe(II). In the presence of oxygen, this leads to 
H202 production (Huang et al, 1999). It has also been suggested that other ions such as 
Ni (II) or Co (II) may cause Aß-peptide multimerisation, although Ni (II) is present at 
trace levels compared to Cu, Fe and Zn which are more abundant in biological systems, 
and Co (II) is not present in an ionic form in biological systems (Huang et al, 2004). 
Interestingly, both Ni and Fe were found to induce limited dityrosine formation in 
RANTES. It is possible that RANTES may bind Fe and Ni utilising a similar 
mechanism for dityrosine formation as that described for Cu, above. An interaction 
between RANTES and Fe (III) or Ni (II) could result in redox activity of RANTES and 
the reduction of Fe (III) to Fe (II) and Ni (II) to Ni (I) and in the presence of oxygen, 
this leads to H202 production which causes the redox to propagate. 
The toxic effects resulting from iron overload generally have been attributed to the 
generation by iron of intracellular free radicals causing lipid peroxidation (Horton & 
Fairhurst, 1987). It is well known that Fe participates in redox cycling and generates 
free radicals through a reaction with H202 or molecular oxygen to generate the 
superoxide ion, and hydroxyl radical. The iron-dependent decomposition of H202 was 
originally postulated by Fenton, and has become known as the Fenton reaction (Imlay et 
al, 1988). 
The Fenton reaction 
Fe 2+ + H202 º Fe 3+ + OH- + OH 
Generation of the superoxide radical 
Fe 3+ + H202 º Fe 2+ +02-+ 2H+ 
Fe 2+ + 02 º Fe3+ + 02- 
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The Fe catalysed generation and cycling of ROS leads to lipid peroxidation and cell 
damage. Furthermore, Fe 3+ can react with H202 to generate metal-oxygen complexes 
that induce DNA damage (Kawanishi et al, 2002). 
It has been reported than Fe generates Aß-peptide oligomers (Huang et al, 2004) and 
although no Fe redox mechanism was suggested, the following may be a possible 
mechanism for the generation of dityrosine cross-linked multimers of RANTES in the 
presence of molecular oxygen. This is a similar mechanism to that described for Cu, 
above. The reaction is propagated by H202 production. 
It is postulated that Fe (II) can be oxidised to Fe (III) by molecular oxygen with the 
generation of the superoxide ion (figure 3.27, equation 1). Fe (III) is reduced to Fe (II) 
on interaction with RANTES histidine residues. The tyrosine oxidation that occurs from 
the interaction of Fe (II) with tyrosine residues would result in tyrosyl radical formation 
and subsequent dityrosine cross-link and RANTES multimer formation (2). 
(1) Fe 2+ + 02 -º Fe 3++ 02- 
(2) RANTES + Fe 3+ -* Fe 
2+ + RANTES : RANTES 
(3) 02-+02-+2H* -º H202 + 02 
(4) H202 + Fe 2+ Fe 3+ + OH- + OH» 
Figure 3.27. Suggested mechanism for the formation of dityrosine cross-links in RANTES involving 
an iron redox system. 
In order to cycle Fe (II) back to Fe (III), Fe (II) might interact again, with molecular 
oxygen (1), or with H202, which if present, will enhance the recycling of Fe. An 
interaction with H202 would produce hydroxyl radicals (4). H202 can also form from 
the dismutation of superoxides (3). 
Ni (II) is known to cause oxidative DNA damage through the induction of DNA-DNA 
or DNA-protein cross-links (Wozniak & Blasiak, 2002). Ni (II) 
ions have been shown 
to bind DNA and subsequently react with H202 to cause strong DNA damage 
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(Kawanishi et al, 2002). It is also postulated that the genotoxic effects of Ni (II) can 
result from the generation of ROS in the reaction between metal and proteins. These 
radicals can subsequently interact with DNA, inducing damage to its bases, DNA strand 
breaks and DNA-protein cross-links (Wozniak & Blasiak, 2002). The DNA damage can 
be inhibited by hydroxyl radical scavengers such as DMSO, catalase or methionine 
(Kawanishi et al, 2002; M'Bemba-Meka et al, 2005), and Ni (II) induced DNA 
fragmentation and cell death is significantly diminished by the antioxidants ascorbic 
acid and N-acetyl cysteine (Jia & Chen, 2008). It is therefore generally accepted that 
ROS contribute to the carcinogenic and cytotoxic effect of Ni (II). 
The cytotoxic mechanism is believed to involve hydrogen peroxide and other ROS 
which are generated as a result of the reaction between metals and proteins. The 
hydroxyl radical can be generated by the reaction of Ni (II) with cysteine in the 
presence of molecular oxygen (Wozniak & Blasiak, 2002). Ni (II) was also shown to 
react with H202 to produce hydroxyl free radicals, superoxide and metal-oxygen 
complexes that cause site specific oxidative damage (Kawanishi et al, 2002). In addition 
it has been shown that Ni induces NF-kB through the generation of H202 (Kennedy et 
al, 1998). 
Since Ni (II) is capable of inducing DNA-protein cross-links, and can generate ROS on 
interaction with proteins (including the generation of the hydroxyl radical on interaction 
with cysteine residues, and the superoxide and hydroxyl radical on reaction with H202), 
it is proposed that Ni (II) may be able to induce cross-linking between the tyrosine 
residues of chemokines. 
An obvious mechanism for protein cross-linking would be the interaction of Ni (II) with 
cysteine residues in RANTES to induce cross-linking, with the subsequent generation of 
free radicals. However, this does not explain the observation that dityrosines, 
specifically, were formed following the incubation of RANTES with NiC12_ 
A possible explanation is also a similar mechanism to that described for Cu. Fe is 
substituted for Cu and the reaction is propagated by H202. 
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Redox mechanism involving Nickel 
(1) Ni" + 02 .* Ni3++ 02- 
(2) RANTES + Ni3+ -* Ni2+ + RANTES : RANTES 
(3) 02- + ()2-+2H' -º H202 + 02 
(4) H202 + Ni2+ -* Ni3+ + OH" + OH' 
Figure 3.28. Suggested mechanism for the formation of dityrosine cross-links in RANTES involving 
a nickel redox system. 
Cu exists in oxidation states 1 and 2 and Zn exists only in oxidation state 2 and cannot 
be reduced. It appears that this oxidative property of Cu is important for the formation 
of dityrosines by means of a redox system, as previously proposed. Interestingly, 
although Hg has very similar oxidative properties to Cu, existing in oxidation states 1 
and 2, it failed to induce dityrosine cross-linking. Zn (II) has been shown to bind and 
inhibit Aß-peptide aggregation through the inhibition of Aß-peptide mediated Cu (II) 
reduction and subsequent H202 production (Cuajungco et al, 2000). Therefore, it is 
possible that there is a similar effect where both Zn (II) and Hg (II) can bind RANTES 
but are unable to participate in redox reactions. A possible explanation for the failure of 
both Zn and Hg to induce dityrosine cross-linking is that both have a complete d sub- 
shell configuration (d10) and therefore they are not true transition metals. Their ability to 
retain a complete d sub-shell configuration may render them more chemically 
unreactive than Cu, Ni and Fe and prevent them from participating in redox reactions. 
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Chapter 4 
The role of copper in platelet-derived 
RANTES-induced T-cell chemotaxis 
and transendothelial migration 
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4. The role of copper in platelet-derived RANTES-induced T-cell chemotaxis and 
transendothelial migration 
4.1. Introduction 
4.1.1. Platelets in inflammation 
4.1.1.1. Platelets in haemostasis and thrombosis 
Platelets are anucleate cytoplasts of myeloid origin that have a life span of 8 -12 days 
and circulate in a resting state in the blood (Hartwig & Italiano, 2003). Two theories of 
platelet formation have been proposed based on studies conducted in model systems and 
in vivo. In one, platelets are produced in the bone marrow, following the cytoplasmic 
fragmentation of megakaryocytes which generates mature circulating platelets (Mandal 
et al, 2007; Zucker-Franklin & Philipp, 2000). A second model proposes that 
differentiated marrow megakaryocytes extend multiple elongated processes termed 
proplatelets. Platelets form at the ends of proplatelets after regulated translocation of 
intracellular constituents to proplatelet tips via microtubular tracks, and then bud off and 
circulate in the bloodstream (Hartwig & Italiano, 2003; Patel et al, 2005). Studies of 
differentiation of mouse and human haematopoietic stem cells to megakaryocytes in 
vitro support this second model (Choi et al, 1995; Cramer et al, 1997; Denis et al, 2005; 
Hartwig & Italiano, 2003; Patel et al, 2005; Weyrich et al, 2007). A study using 
intravital microscopy also reported proplatelet formation in mice in vivo (Junt et al, 
2007). 
The role of platelets in the coagulation cascade is mediated principally by thrombin. 
Thrombin is produced predominantly on the surface of circulating platelets as a result of 
the proteolytic activation of pro-thrombin which is constitutively synthesised by the 
liver and released into the circulation. Prothrombin binds to platelets and is 
proteolytically activated by factor Xa and its cofactor Va. The activation of Xa is 
mediated by both factor IV with its cofactor VIII and factor VII and its cofactor tissue 
factor, a membrane protein expressed at sites of vascular injury (Patterson et al, 2001). 
Activated thrombin has a central role in the coagulation cascade, inducing clot 
formation via its serine protease activity, which cleaves fibrinogen to fibrin, thereby 
mediating fibrin deposition. Thrombin activates factor XI, factor V and factor VIII 
accelerating the production of thrombin in a positive feedback mechanism. Thrombin 
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also activates factor XIII, which catalyses the formation of covalent bonds between 
lysine and glutamine residues in fibrin increasing the stability of the fibrin clot 
(Coughlin, 2000). 
In addition to its role in the coagulation cascade, thrombin also mediates the activation 
of platelets, facilitating thrombosis. Platelets can be activated by thrombin and ADP as 
well as antigens, platelet activating factor (PAF), collagen, antigen-antibody complexes, 
thromboxane A2, epinephrine, serotonin, micro-organisms and bacterial endotoxins 
including lipopolysaccharides (Derian et al, 2002; O'Sullivan & Michelson, 2006). 
Once activated, platelets adhere to the vascular wall via the binding of platelet 
expressed glycoprotein to exposed endothelial collagen, recruit circulating platelets and 
mediate platelet aggregation through expression of the integrin (11103 and its interaction 
with fibrinogen or von Willebrand factor, and release proinflammatory mediators 
including further thrombin secretion. Activated platelets aggregate to form a thrombus 
which seals the damaged blood vessel (Johnson, 1999; Weyrich et al, 2003). 
The cellular effects of thrombin are primarily mediated by protease-activated receptors 
(PARs). The PARs are a subfamily of related G-protein-coupled receptors that are 
activated by cleavage of the N-terminus of the receptor serine proteases. In the cleaved 
state, the newly formed N-terminus acts as the agonist, causing a physiological response 
(Coughlin, 2000). 
There are 4 known PARs, numbered 1-4. These receptors are expressed throughout the 
body but highly expressed in platelets, endothelial cells, myocytes and neurons. 
Thrombin acts on PARs 1,3 and 4, although thrombin mediated cleavage of PAR4 
occurs at higher concentrations than are required for the activation of PARI and PAR3 
(Patterson et al, 2001) and PAR2 is activated by multiple trypsin-like serine proteases 
including trypsin itself, mast cell tryptase, neutrophil proteinase 3, tissue factor, factor 
VIIa, factor Xa, and membrane-tethered serine protease-1 (Coughlin, 2000). Human 
platelets express PARI and PAR4, and activation of either is sufficient to trigger 
platelet activation, aggregation and degranulation causing the secretion of 
proinflammatory mediators. Thrombin signalling in platelets contributes to hemostasis 
and thrombosis whilst endothelial PARs 1 and 2 participate in the activation of the 
endothelium and promote vasodilatation, the adhesion and rolling of platelets and 
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leukocytes as well as leakage of plasma proteins to the extravascular space. Thrombin 
activation of endothelial PARI also triggers endothelial production of the neutrophil 
activator, platelet-activating factor, as well as the interleukins IL-6 and IL-8 (Coughlin, 
2000). 
4.1.1.2. The inflammatory role of platelets 
Whilst platelets are well known to play an important role in haemostasis and 
thrombosis, it is also apparent that they have a function in inflammation, including the 
release of proinflammatory mediators, and interactions with leukocytes and endothelial 
cells. Platelets have long been known to play a role in the pathogenesis of asthma and 
humans with asthma have increased numbers of circulating platelets as compared with 
control subjects (Moritani et al, 1998). It has been reported that platelets promote 
leukocyte trafficking from blood vessels into lung tissue in allergen-sensitised mice 
through leukocyte-aggregate formation which is dependent on P-selectin expression on 
the surface of platelets (De Sanctis et al, 1997; Pitchford et al, 2005; Pitchford et al, 
2003; Ulfman et al, 2003) and increased numbers of platelet-leukocyte aggregates were 
observed in the blood of human subjects with allergic asthma than healthy control 
subjects (Pitchford et al, 2003). 
Selectin interactions are required to induce leukocyte rolling prior to the firm 
attachment and diapedesis of leukocytes across the endothelium. Although endothelial 
P-selectin expression alone can lead to leukocyte rolling, this process is much more 
efficient in the presence of platelet expressed P-selectin. Activated platelets can bind to 
leukocytes, forming leukocyte-platelet aggregates including T-cell-platelet aggregates 
(de Bruijne-Admiraal et al, 1992). The interaction of platelet expressed P-selectin with 
PSGL-1 expressed on leukocytes results in the formation of platelet-leukocyte 
aggregates (McEver, 2002). The subsequent activation of leukocytes and up-regulation 
of leukocyte expressed integrin adhesion molecules including CD 11 b and VLA-4, lead 
to tight leukocyte-platelet adhesion. Expression of these adhesion molecules allows for 
firm attachment of leukocytes to vascular endothelium followed by diapedesis 
(O'Sullivan & Michelson, 2006; Pitchford et al, 2005; Pitchford et al, 2003; Weyrich et 
al, 2003). 
Platelets have been reported to undergo chemotaxis and can migrate out of blood 
vessels into lung tissue in vivo in allergen-sensitised mice in response to a sensitising 
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allergen (Pitchford et al, 2008; Pitchford et al, 2003). Platelets also contain and release 
adhesive proteins, activate other inflammatory cells and release vasoactive substances 
and pro-inflammatory mediators upon activation. Platelets contain three major secretory 
organelles: the lysosome, the dense granule, and the a-granule. Platelet-derived 
mediators are stored mainly in the a-granules of human platelets and released upon 
activation. Such mediators include interleukin-1 (IL-1) which activates the endothelium 
(Hawrylowicz et al, 1991), the prostaglandins and platelet activating factor as well as a 
host of chemokines (reviewed in O'Sullivan and Michelson, 2006). Among the 
mediators released from the a-granules is the chemokine RANTES (Kameyoshi et al, 
1992; Kameyoshi et al, 1994; Klinger et al, 1995; Schroder et al, 1994; von 
Hundelshausen et al, 2001). The less abundant dense granules, numbering three to eight 
per platelet contain several mediators including calcium, polyphosphates, adenosine 
diphosphate (ADP), adenosine triphosphate (ATP), and serotonin and the relatively 
scarce lysosomes contain acidic hydrolases (Rendu & Brohard-Bohn, 2001). 
Although platelets do not have nuclei, they do contain limited amounts of mRNA and, 
in addition, it has been shown that platelets are capable of protein synthesis and can not 
only release, but also synthesise RANTES (Power et al, 1995). Most importantly, 
platelet-derived RANTES has been shown to increase leukocyte arrest on the activated 
human lung microvascular endothelium and it was demonstrated that endothelial 
activation with IL-1 and TNF-a was essential to induce endothelial RANTES binding 
(Baltus et al, 2005; Schober et al, 2002; von Hundelshausen et al, 2001). In addition, 
platelets can secrete soluble GAGs. Platelet-derived chondroitin sulphate A has been 
shown to both increase the binding and presentation of RANTES on the microvascular 
endothelium and increase the interaction of RANTES with CCR5 bearing leukocytes, 
indicating another mechanism by which platelets may contribute to increased 
recruitment of leukocytes (Weingart et al, 2008). 
It is speculated that RANTES released by infiltrated T-cells and platelets and possibly 
also by other cells, could contribute significantly to selective T-cell/basophil/eosinophil 
recruitment (Schroder et al, 1994). Thus platelet activation, P-selectin expression and 
platelet chemotaxis with subsequent chemokine release may enhance leukocyte 
recruitment to sites of vascular injury or inflammation, indicating an important role for 
platelets in leukocyte recruitment. 
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4.1.2. RANTES presentation on heparan sulphate proteoglycans in multimeric 
form 
Heparan sulphate (HS) is the most ubiquitous glycosaminoglycan (GAG) (50 - 90 % of 
all GAGs) in the human body and is the most predominant GAG found in the lungs. It 
has been well documented that RANTES binds predominantly to HSPGs on human 
microvascular endothelial cells and HUVECs in vitro with a higher affinity than many 
other chemokines (Ali et al, 2002; Hillyer & Male, 2005; Hoogewerf et al, 1997; 
Proudfoot et al, 2001). RANTES must interact with GAGs to elicit cell migration in 
vivo, and it has been shown that RANTES multimerises on interaction with cell surface 
HS thereby increasing the local concentration, maintaining a chemotactic gradient and 
facilitating receptor binding on leukocytes. In addition it has been reported that 
RANTES has a minimal tetrameric structure for in vivo activity (reviewed in Sections 
1.10 and 2.1.1) and Cu has been shown to induce RANTES multimerisation (Chapters 2 
and 3). 
It has been reported that the clearance of chemokines differs dramatically in lungs and 
skin, with slow clearance from lungs and rapid clearance from skin (Frevert et al, 2002). 
It was reported that dimerisation of the neutrophil chemoattractant IL-8 is an important 
mechanism that prolongs retention of IL-8 in lungs but not in skin. These differences in 
IL-8 retention may be due to tissue-specific differences in the composition of GAGs or 
the binding affinity of a specific subset of GAGs, such as heparan sulphate and 
chondroitin sulphate for IL-8. Thus, the mechanisms that govern the fate of IL-8 in 
tissue depend on the site at which IL-8 is deposited (Frevert et al, 2002; Frevert et al, 
2003). It is speculated therefore that multimerisation may be an important mechanism 
for the retention of RANTES in lung tissue and that therapies that limit the 
multimerisation may be important for preventing excessive T-cell migration. 
The presentation of RANTES on endothelial cells and the release of RANTES by 
endothelial cells, T-cells and platelets has been extensively reported, but so far there has 
been little investigation on the form, monomer or multimer, of RANTES released by 
these cells, nor the effect of Cu on this form. There have also been no reports on the 
effect of Cu on the endothelial bound form of RANTES. 
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4.1.3. Copper induced endothelial chemokine synthesis 
Activated vascular endothelial cells are known to contribute to excessive inflammatory 
responses by secreting pro-inflammatory cytokines and chemokines including 
interleukin-1 (IL-1), IL-5, IL-6, IL-8, IL-11, IL-15, several colony-stimulating factors 
(CSF), granulocyte-CSF (G-CSF), macrophage CSF (M-CSF) and granulocyte- 
macrophage CSF (GM-CSF), and the chemokines, monocyte chemotactic protein-1 
(MCP-1), RANTES, and growth-related oncogene protein-alpha (GRO-alpha) 
(Dinarello et al, 1993; Krishnaswamy et al, 1999; Marfaing-Koka et al, 1995). IL-8 in 
particular has been studied extensively since the chemotactic activity of IL-8 and 
neutrophil accumulation has been associated with several inflammatory diseases 
including systemic inflammatory response syndrome, adult respiratory distress 
syndrome, and multiple organ failure (Partrick et al, 1996; Sablotzki et al, 2002). 
At physiologically relevant concentrations, cobalt, nickel and copper have been shown 
to stimulate greater IL-8 secretion from human endothelial cells than the 
proinflammatory cytokines TNF-a and IL-1p. Cu induces an increase in mRNA in 
HUVECs and HLMVECs within 24 hours, indicating early gene activation and new 
protein synthesis rather than IL-8 release from preformed storage sites (Bar-Or et al, 
2003; Wagner et al, 1998b). 
It has been shown that Cu activates the NF-kB pathway in vitro with subsequent TNF-a 
expression in the liver and lung tissues of rats (Persichini et al, 2006) and activation of 
NF-kB has been suggested as a possible mechanism for Cu induced endothelial IL-8 
synthesis (Bar-Or et al, 2003). It has also been postulated that Cu may induce NF-kB 
and subsequent IL-8 synthesis through the activation of the phosphatidylinositol S- 
kinase (PI3-kinase) pathway, which is activated by Cu independently of ROS 
generation in human fibroblasts (Bar-Or et al, 2003; Ostrakhovitch et al, 2002). P13- 
kinase activates Akt which is involved in the activation of the NF-kB transcription 
factor (Ozes et al, 1999). Alternatively, Cu may activate NF-kB via mitogen-activated 
protein kinases (MAPKs) since Cu exposure has been shown to induce TNF-a 
expression and activate the MAPKs, c-Jun N-terminal kinase (JNK) and p38 MAP 
kinase in human bronchial epithelial cells (Samet et al, 1998). 
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Whilst Cu can induce NF-kB independently of ROS (Ostrakhovitch et al, 2002), it has 
become clear that Cu-induced oxidative stress may also contribute to NF-kB activation. 
Despite previous conflicting reports it has now been clearly demonstrated that increased 
serum Cu induces oxidative stress, with the generation of ROS resulting in the 
activation of NF-kB and subsequent TNF-a synthesis in the liver and lung tissues of rats 
(Persichini et al, 2006). H202, which is generated by Cu-redox mechanisms (Section 
2.6) has also been shown to activate the P13-kinase/Akt pathway via oxidation of the 
tumor suppressor PTEN, an inhibitor of the P13-kinase/Akt pathway (Lee et al, 2002), 
but Cu 2+ itself may also have the ability to oxidise PTEN and activate NF-kB via the 
P13-kinase/Akt pathway. H202 is also a potent activator of MAPK (Fialkow et al, 1994) 
and therefore Cu-redox generated H202 may also activate NF-kB via MAPK pathways. 
Additionally, Cu (II)-oxidised low-density lipoproteins have been shown to 
independently initiate the activation of activator protein-1 (AP-1), another transcription 
factor that has been associated with endothelial IL-8 expression in endothelial cells 
(Maziere et al, 1997). 
The evidence that Cu induces cytokine and chemokine expression in human bronchial 
epithelial cells (Kennedy et al, 1998; Samet et al, 1998)(Section 1.20) and chemokine 
expression in HLMVECs in vitro (Bar-Or et al, 2003) together with evidence presented 
in this thesis to suggest that Cu promotes chemokine multimer formation (Chapters 2 
and 3) indicates that Cu may have an important pro-inflammatory role and could 
influence leukocyte trafficking during lung inflammation. It has been reported that 
RANTES synthesis induced by IL-1 ß in human epithelial cells (Manni et al, 1996) and 
IFN-y in HLMVECs (Sundstrom et al, 2001) is regulated by NF-kB, suggesting that 
RANTES synthesis in these cells may also be inducible by Cu, via the NF-kB pathway. 
In addition, Cu-binding peptides have been shown to be effective in preventing Cu- 
redox and IL-8 release from endothelial cells (Rael et al, 2007), suggesting that Cu 
chelators may have therapeutic potential in inhibiting cytokine and chemokine 
synthesis, and subsequent leukocyte recruitment during inflammation. 
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4.1.4. Copper-dependent semicarbazide-sensitive amine oxidase 
Lymphocyte trafficking is governed by adhesion molecules expressed both on 
lymphocytes and vascular endothelial cells (Section 1.1). One of the endothelial 
adhesion molecules involved in the multistep extravasation cascade is the copper- 
dependent ectoenzyme, vascular amine oxidase-1 (VAP-1). 
VAP-1 is a dimeric sialoglycoprotein with a molecular mass of 170-180 kDa (Salmi & 
Jalkanen, 1992; Salmi & Jalkanen, 1995; Salmi & Jalkanen, 1996). VAP-1 contains two 
atoms of copper per dimer co-ordinated by three conserved histidines - one His-X-His 
motif and another histidine near the N-terminus (reviewed in Jalkanen and Salmi, 
2001). VAP-1 is constitutively present in intracellular granules within endothelial cells 
(Salmi et al, 1993) but is only translocated lumenally from intracellular storage granules 
upon elicition of inflammation (Salmi et al, 1993). Animal studies, using an in vivo 
immunodetection method have provided convincing evidence that luminal VAP-1 is 
induced only upon elicitation of inflammation at lesion sites (Jaakkola et al, 2000). 
It has been reported that VAP-1 is important for both the rolling phase and also the 
transmigration step of leukocyte extravasation (figure 4.1) (Jalkanen & Salmi, 2001; 
Salmi et al, 2001). On endothelial cells, VAP-1 can serve as a traditional adhesion 
molecule (Lalor et al, 2002; Salmi & Jalkanen, 1992; Salmi & Jalkanen, 1996) but 
VAP-1 belongs to a distinctive group of cell surface-expressed amine oxidases known 
as semicarbazide-sensitive amine oxidases (SSAOs) and it has been shown that the 
SSAO activity of VAP-1 is also important for leukocyte adhesion (Jalkanen & Salmi, 
2001; Klinman & Mu, 1994; Salmi & Jalkanen, 2005). 
Mechanistic analyses have revealed that VAP-1 displays both enzyme-activity- 
dependent and enzyme-activity-independent adhesive functions. Thus, anti-VAP-1 
antibodies, which do not interfere with the SSAO activity of VAP-1, block leukocyte 
extravasation. On the other hand, SSAO inhibitors also suppress VAP-1-dependent 
extravasation without affecting the antibody-defined epitopes (Jalkanen & Salmi, 2001; 
Koskinen et al, 2004; Martelius et al, 2004). 
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It has been suggested that VAP-1 mediates adhesion and transmigration of lymphocytes 
through the binding of VAP-1 sialic acid residues to an unknown leukocyte-expressed 
lectin (Lalor et al, 2002; Salmi & Jalkanen, 1992; Salmi & Jalkanen, 1996). 
Previous in vitro and in vivo studies have shown that the SSAO activity of VAP-1 
mediates rolling, firm adhesion and transmigration of leukocytes under normal 
conditions and in inflammation (Koskinen et al, 2004; Marttila-Ichihara et al, 2006; 
Salmi & Jalkanen, 1996; Salmi & Jalkanen, 2001). 
VAP-1 possesses MAO activity and it is generally agreed that in vitro, SSAOs only 
accept primary amines as substrates, with benzylamine and methylamine being the 
preferred substrates in vitro (Salmi et al, 2001). It has also been reported that VAP-1 
binds to a primary amino group presented on the lymphocyte surface and oxidatively 
deaminates it in a reaction resulting in the formation of a transient covalent bond 
between the two cell types, which may be important in binding during the leukocyte 
rolling step (figure 4.1). 
The SSAOs mediate oxidative deamination of primary amines in a reaction that results 
in the production of aldehyde, ammonium and H202. All end-products of the SSAO- 
catalysed reaction are biologically active compounds that may alter the function of the 
endothelial cells or affect other nearby cells in a paracrine manner (Jalkanen & Salmi, 
2001). 
Probably the most important of the end-products is H202 which, although toxic at high 
concentrations, is becoming increasingly recognised as a signal-transducing molecule at 
lower concentrations. H202 is known to up-regulate the function of transcription factors, 
such as NF-kB (Section 4.1.3), and hence the expression of many genes, including 
chemokines, adhesion molecules, cytokines and metalloproteinases (Bogdan et al, 2000; 
Finkel, 1998; Kunsch & Medford, 1999). In the vascular wall, H202 regulates the 
adhesive properties of endothelial cells and it has been shown that VAP-1 enzyme 
activity induces E- and P-selectin expression in human and mouse endothelial cells in 
vitro and that the induced selectins are induced by H202 and are functionally active in 
supporting leukocyte adhesion (Jalkanen et al, 2007). 
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Figure 4.1. The leukocyte extravasation cascade. The different steps of the adhesion cascade and 
the involvement of VAP-1 are shown. The oligosaccharides of VAP-1 (purple extensions) can bind 
to an unknown lectin-like molecule (yellow) on lymphocytes. Alternatively, when endothelial VAP-1 
uses a lymphocyte surface amine as a substrate the catalytic reaction results in the formation of a 
transient covalent bond between the two cell types. This enzymatic reaction seems to be involved in 
the binding during the rolling step (Jalkanen & Salmi, 2001). 
4.1.5. Copper chelators 
Neocuproine (2,9-dimethyl-1,10-phenanthroline) is an intracellular Cu chelator that can 
cross cellular membranes as indicated by studies that report the uptake of radio-labelled 
neocuproine into mycoplasmal cells (Smit et al, 1982). Neocuproine binds selectively to 
Cu (I) as confirmed by specrophotometric studies (Smith & McCurdy, 1952). 
Specrophotometric studies have also confirmed that the neocuproine derivative, 
bathocuproine disodium salt (4,7-diphenyl-2,9-dimethyl-1,10-phenanthroline), binds to 
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Cu (I) (Klemens et al, 1989; Smith & Wilkins, 1953), but this compound does not 
permeate cell membranes and is therefore considered an extracellular Cu chelator. 
These two compounds, neocuproine and bathocuproine disodium salt, are highly 
specific chromogens that bind to Cu to give coloured complexes. Two molecules of 
each compound are associated with each Cu atom, via two nitrogen atoms in each 
molecule. 
Both neocuproine and bathocuproine disodium salt are useful in the spectrophotometric 
determination of Cu and also for extracting and concentrating Cu in the preparation of 
distilled water and reagents used in the analysis of Cu, thereby improving the certainty 
with which Cu determinations can be made (Buerge-Weiricht & Sulzberger, 2004; 
Guclu et al, 2005; Sozgen et al, 2006; Tutem et al, 1997; Williams et al, 1977; Yamini 
& Tamaddon, 1999). 
D-penicillamine is a metabolite of penicillin and a well known Cu-chelating agent, with 
binding affinity for Cu (I) (Cui et al, 2005). The Cu binding affinity of D-penicillamine 
has been confirmed using spectroscopic studies (Mohanakrishnan & Chignell, 1985) 
and it has long been thought that this property of D-penicillamine may contribute to its 
anti-inflammatory effects. Although the mechanism of action is not known, D- 
penicillamine induces urinary Cu excretion (Walshe, 1956), and it is thought that this 
may be the mechanism by which D-penicillamine exerts its anti-inflammatory effects in 
the treatment of Wilson's disease and possibly rheumatoid arthritis (McQuaid et al, 
1992). 
Tobramycin is an aminoglycaside antibiotic used to treat bacterial infections, 
particularly gram positive infections. Tobramycin works by binding to a site on the 
bacterial 30S and 50S ribosome, preventing formation of the 70S complex. As a result, 
mRNA cannot be translated into protein and cell death ensues. Using potentiometric and 
spectroscopic studies is has been shown that tobramycin binds Cu (II) via several 
distinct binding sites to form strong complexes (Jezowska-Bojczuk et al, 1998), 
however, as yet the role of transition metal ions in the biological activity of 
aminoglycoside antibiotics has not been determined. 
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4.1.6. Objectives 
The objectives of the experiments described in this chapter were to investigate: 
1. The form (monomer or multimer) of RANTES expressed by endothelial cells 
under basal and stimulated conditions 
2. The effect of CuCl2/H202 on the form of RANTES expressed by endothelial 
cells 
3. The effect of copper chelators on the form of RANTES expressed by endothelial 
cells 
4. The effect of CuC12/H202 on the amount of RANTES expressed by endothelial 
cells 
5. The concentration and form of RANTES released by unactivated and thrombin 
activated platelets 
6. The concentration of RANTES released by T-cells activated in vitro 
7. The response of T-cells to RANTES multimers, and definition of which 
receptors were involved 
8. The role of platelet-derived RANTES in T-cell transendothelial migration 
9. The effect of copper chelators on platelet-dependent T-cell transendothelial 
migration 
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4.2. Materials 
Human lung microvascular endothelial cells (HLMVECs) were obtained from Clonetics 
(Lonza Ltd., Slough, Berkshire, UK). EGM-2MV cell growth medium was prepared by 
supplementing 500 ml EGM-2 Basal Medium (CC-3156, Lonza, UK) with EGM-2MV 
BulletKit (CC-3202, Lonza, UK) (includes Basal Medium and SingleQuots). 
Trypsin/EDTA (TE) containing 0.025 % trypsin and 0.02 % EDTA and trypsin 
neutralising solution (TNS) were also obtained from Lonza, UK. Uncoated 75 cm2 
culture vessels and 24-well companion plates were obtained from Triple Red Ltd., Long 
Crendon, Buckinghamshire, UK. 5µm, PVP-free polycarbonate filters were obtained 
from Fisher Scientific, Loughborough, Leicestershire, UK and 3 µm fibronectin coated 
and uncoated cell culture inserts were obtained from BD Biosciences, Oxford, 
Oxfordshire, UK. 
Boyden chambers (48-well with 50 µl upper and 25 µl lower wells) were obtained from 
Neuro Probe, Maryland, USA. Anti-CCR3, anti-CCR5 neutralising antibodies, and 
isotype control (rat IgG2a and mouse IgG2b) antibodies were obtained from R&D 
Systems, Ltd., Abingdon, Oxfordshire, UK. 
Lymphoprep was obtained from Axis-Shield UK, Kimbolton, Cambridgeshire, UK. 
Phytohaemagglutinin (PHA), fetal calf serum (FCS, heat inactivated), antibiotics, L- 
glutamine, bovine serum albumin (30 %, cell culture tested), sodium pyruvate (1 M), 
trypan blue (0.4 % (w/v) in 0.9 % (w/v) NaCl), collagen IV, thrombin, NaCl, Tris base, 
EDTA, sodium dodecyl sulphate (SDS), tergitol nonidet P-40, copper chloride (CuCl2), 
hydrogen peroxide (H202), catalase, sodium phosphate (Na2HPO4), citric acid, 
dithiothreitol (DTT), sodium acetate, glacial acetic acid, tetramethylbenzidine (TMB), 
2,2'-Azino-bis(3-ethylbenzthiazoline- 6-sulfonic acid) (ABTS), dimethyl sulphoxide 
(DMSO), triton-X-100, sodium chlorate and the lactate dehydrogenase (LDH) (TOX-7) 
and plasmin enzyme assay kits were obtained from Sigma-Aldrich Inc., Poole, Dorset, 
UK. IOX Hanks balanced salt solution (HBSS) (-Ca t+/Mg2+), RPMI 1640 containing 25 
mM HEPES, and L-Glutamine and phosphate buffered saline (PBS) (-Ca t+/Mg2+) were 
obtained from Invitrogen Ltd, Paisley, UK. 
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Recombinant human RANTES, interferon (IFN)-y, tumor necrosis factor (TNF)-a, 
human interleukin-2 (IL-2) and the IFN-y and TNF-a enzyme-linked immunosorbant 
assay (ELISA) antibody duosets were obtained from Peprotech EC, London, UK. The 
RANTES enzyme linked immunosorbent assay (ELISA) duoset was obtained from R& 
D Systems, Ltd., Abingdon, Oxfordshire, UK. 0.2 µm sterile filters were obtained from 
BD Biosciences, Oxford, Oxfordshire, UK. All copper chelators were supplied by 
Sigma, UK. The PAI-1 inhibitor, XR5118 was a gift from Xenova. 
Polyacrylamide mini-gels were cast using the Bio-Rad Protean II system and markers 
and reagents for electrophoresis were obtained and prepared as previously described in 
Section 2.3.4. Gradient (4 - 15 %) polyacrylamide ready-gels were obtained from Bio- 
Rad Laboratories Ltd, Hemel Hempstead, Hertfordshire, UK. 
Non-biotinylated goat polyclonal anti-duffy antigen receptor complex (DARC) was 
obtained from Abcam plc., Cambridge, UK. Biotinylated primary polyclonal rabbit anti- 
human RANTES antibodies and rabbit polyclonal anti-RANTES (non-biotinylated) 
antibodies were obtained from Peprotech EC, London, UK. Rabbit anti-goat secondary 
biotinylated antibodies (for DARC staining) and the streptavidin-biotinylated 
horseradish peroxidase complex (StreptABC) were obtained from Dako UK Ltd, Ely, 
Cambridgeshire, UK. A commercial enhanced chemiluminescence (ECL) kit, 
SuperSignal, Restore Plus Western Blot Stripping Buffer and the FOX-2 assay kit were 
obtained from Pierce Biotechnology Inc., Chester, UK. Tween-20, Super RX Fuji 
medical X-Ray film, Hema Gurr staining reagents and 24 and 6-well culture plates were 
obtained from Fisher Scientific, Loughborough, Leicestershire, UK. 
Complete mini® Protease inhibitor tablets which when dissolved at double strength in 5 
ml of water contain (EDTA (2 mM, inhibits metalloproteases), aprotinin (0.6 µM, 
inhibits plasmin, kallikrein, trypsin, and chymotrypsin with high activity), bestatin [(2S. 
3R)-3-Amino-2-hydroxy-4-phenylbutanoyl]-L-leucin. e hydrochloride, (260 µM, an 
inhibitor of amino peptidases), calpain inhibitor I (N-Acetyl-Leu-Leunorleucinal, 34 
µg/ml, inhibits activity of Calpain I), calpain inhibitor II (N-Acetyl-Leu- 
Leumethioninal, 14 µg/ml, inhibits activity of Calpain II), chymostatin (200 µM, 
specific inhibitor of a, ß, y and 6-chymotrypsin), E-64 (N-(N-(L-3-Transcarboxirane-2- 
carbonyl)-Lleucyl)-agmatine. 56 µM, inhibits papain and other cysteine proteases such 
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as cathepsin B and L), leupeptin (Ac-Leu-Leu argininal x 1/2 H2SO4,2 µM, inhibits 
serine and cysteine proteases such as trypsin, papain, plasmin, and cathepsin B), a2 
macroglobulin (25 Inh. U, inhibits most endoproteinases, unit definition: One inhibitor 
unit inhibits 9.1 µg of trypsin), pefabloc SC 4-(2-Aminoethyl)-benzenesulfonyl-fluoride 
hydrochloride (AEBSF), 8 mM, irreversibly inhibits serine proteases. including trypsin, 
chymotrypsin, plasmin, plasma kallikrein, and thrombin, pepstatin (2 µM, inhibits 
aspartic (acid) proteases such as pepsin, renin, cathepsin D, chymosin, and many 
microbial acid proteases), Phenyl methyl sulfonyl fluoride (PMSF), 2 mM, inhibits 
serine proteases (chymotrypsin, trypsin, and thrombin) and also inhibits cysteine 
proteases such as papain, L-1-Chloro-3-(4-tosylamido)-7-amino-2-heptanone 
hydrochloride N-a-Tosyl-Llysine chloromethyl ketone (TLCK-HC1), 270 . iM, 
irreversibly and specifically inhibits trypsin and also inhibits many other serine and 
cysteine proteases such as bromelain, ficin, and papain, trypsin inhibitor from chicken 
egg white (200 pg/ml) and trypsin inhibitor from soyabean (200 pg/ml, also inhibits 
factor Xa, plasmin, and plasma kallikrein) were obtained from Roche Ltd., Welwyn 
Garden City, Hertfordshire, UK. A protein A agarose bead suspension was obtained 
from Merck Chemicals Ltd., Nottingham, Nottinghamshire, UK. Vacutainers (9 ml) 
containing EDTA for blood collection were obtained from Greiner-Bio-One Ltd., 
Stonehouse, Gloucestershire, UK. Plasmin substrate; S2251 (25 mg/vial) was purchased 
from Chromogenix (Lexington, MA, USA). 
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4.3. Methods 
4.3.1. Cell culture 
4.3.1.1. Growth medium for endothelial cell culture 
Endothelial full growth medium type 2 for microvascular cells (EGM-2MV) is 
optimised for use with human lung microvascular endothelial cells. The full medium 
was prepared from endothelial basal medium type 2 (EBM-2) and the EGM-2MV 
BulletKit supplements supplied by Lonza, UK. The final fully supplemented growth 
medium contained heat inactivated FBS (5 %), hydrocortisone (0.04 %), human 
fibroblastic growth factor (hFGF-2,0.4 %), vascular endothelial growth factor (VEGF, 
0.1 %), insulin-like growth factor (R3-IGF-1,0.1 %), ascorbic acid (0.1 %), human 
epidermal growth factor (hEGF, 0.1 %), gentamycin (50 ng/ml) and amphotericin-B (50 
µg/m1). The contents of each supplement vial was split into 5 aliquots and frozen at -20 
°C. 1 aliquot was added to 100 ml of the basal media in a sterile glass bottle, and the full 
medium stored at 4 °C for up to 1 week. 
4.3.1.2. Culture setup/seeding 
HLMVECs were seeded at 5000 cells / cm2 in 75 cm2 flasks with vented caps. The 
number of vessels to be set up was calculated with reference to the certificate of 
analysis and technical information supplied with the cryovial by Lonza, UK. Each flask 
was labelled with the passage number, cell type, lot number and date. Supplemented 
growth medium was aseptically transferred to uncoated culture vessels (Triple Red, 
UK), adding 1 ml growth medium for every 5 cm2 flask surface area. Vented caps were 
applied and culture vessels allowed equilibrate at 37 °C and 5% CO2 in a humidified 
incubator for at least 30 minutes. Cryovials were thawed one at a time. Once removed 
from liquid nitrogen storage, vials were sterilised and opened a quarter turn to relieve 
the internal pressure before retightening. The bottom 3/4 of the cryovial was dipped in 
the 37 °C water bath and swirled gently for 1-2 minutes until the contents were 
thawed, and then wiped dry. The cap was removed and the thawed cells in the vial (1 
ml) were resuspended with a pipette set to 800 µl. An equal amount of cells was 
dispensed into each of the flasks to be set up (number of flasks calculated from the 
certificate of analysis supplied with the cryovial for a final seeding density of 5000 
cells/ cm2) and the vented caps replaced. Flasks were returned to the incubator and cells 
allowed to adhere overnight. 
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4.3.1.3. Feeding 
The growth medium was changed one day after seeding to remove residual dimethyl 
sulphoxide (DMSO) from the freezing medium in which the cells were shipped and any 
unattached cells, and then every other day thereafter, examining them daily. Fully 
supplemented growth medium was warmed to 37 °C for 30 minutes. Old medium was 
removed from flasks by aspirating with a sterile pipette on the opposite side of the flask 
from where the cells were attached. New medium (15 ml) was added down the same 
side. 
The cells were fed a larger volume of medium as they became more confluent, 
according to the table below. 
Feeds: 
Under 25 % confluent Feed 0.67 ml per 5 cm2 (10 ml) 
From 25 - 45 % confluent Feed 1 ml per 5 cm2 (15 ml) 
Exceeding 45 % confluence Feed 1.5 ml per 5 cm2 (22.5 ml) 
Feeding was continued until cells were 60 - 90 % confluent. 
4.3.1.4. Subculture 
Cells were sub-cultured when they were 60 - 90 % confluent and displayed many 
mitotic figures throughout the flask. For each 75 cm2 of cells to be sub-cultured 2 ml of 
trypsin/EDTA (TE) (Lonza, UK) and 4 ml trypsin neutralising solution (TNS) (Lonza, 
UK) was thawed and allowed to reach room temperature. EGM-2MV growth medium 
was pre-warmed at 37 °C and 1 ml growth medium transferred to the flasks for every 5 
cm2 surface area. Flasks were equilibrated for 30 minutes in a humidified 37 °C 
incubator with 5% CO2. Medium was aspirated from one culture vessel at a time, and 
the adhered cells rinsed with 5 ml lx Hanks Balanced Salt Solution (HBSS) - 
Ca2+/Mg2+ (Invitrogen, UK) The HBSS was aspirated from the flask and the cells 
covered with 2 ml TE solution per 75 cm2. The cap was tightened and the cells 
monitored under a microscope. Trypsinisation continued until approximately 90 % of 
cells were rounded up. Cells were released from the culture surface by rapping the flask. 
The trypsin was neutralised with 4 ml of TNS per flask. The detached cells were 
transferred to a sterile 15 ml centrifuge tube and the flask rinsed with 2 ml of HBSS (- 
Ca2+/Mg2+) to collect residual cells which were added to the centrifuge tube. Cells were 
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centrifuged at 220 g for 5 minutes, and the supernatant aspirated. The pellet was re- 
suspended in 1-2 ml full growth medium and cells counted with a haemocytometer (10 
µl suspension was added to 90 µl Trypan Blue and 10 µl was loaded onto the 
haemocytometer). The total number of cells was calculated and cell viability assessed. 
The total number of viable cells was counted using the following formula: 
Total cell count x% viability = Total no. of viable cells 
Cells were diluted and seeded at the recommended seeding density (5000 cells/cm2 for 
HLMVECs. ) Flasks were labelled with the passage number, cell type, lot number and 
date and incubated at 37 °C, and 5% CO2 until 60 - 90 % confluent. 
4.3.1.5. Collagen coating 24 and 6-well plates 
The method for collagen coating was adapted from the supplier's instructions. 
Lyophilised collagen IV (Sigma, C5533) was reconstituted to 0.1 mg/ml in 3% (v/v) 
acetic acid and dissolved for several hours at 4 °C. 2 ml of collagen IV solution was 
added to each well of a 6-well plate, 500 . tl per well for a 24-well plate. Plates were 
incubated for 1 hour at room temperature. Excess collagen IV was removed, the plates 
dried and the wells washed 3 or more times with lx HBSS (-Ca/Mg) (Sigma) containing 
phenol red to remove acetic acid. Finally, plates were rinsed in 70 % (v/v) ethanol, air 
dried and stored at 4 °C under sterile conditions. 
4.3.1.6. Subculture of HLMVECs into collagen IV coated 6-well and 24-well 
plates 
Collagen IV coated 24-well and 6-well plates (Fisher Scientific, UK) were incubated at 
37 °C and 5% CO2 for a minimum of 30 minutes prior to subculture. One 75 cm2 
culture flask (1 -2x 106 cells) was harvested per 24/6-well plate to be seeded. Cell 
medium was aspirated from flasks, followed by washing with 5 ml lx HBSS (- 
Ca2+/Mg2+) and trypsinisation with 2 ml TE solution / 75 cm2flask. Flasks were 
incubated at 37 °C and 5% CO2 for 10 minutes to lift cells from the culture surface. 
Flasks were either rapped or scraped with a cell scraper to release remaining attached 
cells and trypsin was neutralised with 4 ml TNS / 75 cm2 flask. Harvested cells were 
aspirated, and flasks washed with 5 ml lx HBSS (-Ca 
t+/Mg2+) which was added to the 
harvested cells. Cells were centrifuged at 220 g for 5 minutes, the supernatant aspirated 
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and the pellet re-suspended in 1 ml growth medium (EGM-2MV, Lonza, UK. ) The total 
number of cells was calculated using a haemocytometer slide as previously described. 
24-well plates 
Cells were diluted to 2x 105 cells / ml in 6 ml growth medium per 24- well plate and 
seeded at 250 µl per well. The total number of cells was 50,000 per well. Plates were 
covered and incubated overnight at 37 °C and 5% CO2. Before use in an assay, the cells 
were examined for mitotic figures to ensure that they had resumed active growth. 
6-well plates 
Cells were diluted to 2x 105 /ml and seeded at 1.5 ml / well. This corresponded to a total 
cell number of 300,000 per well. Plates were covered and incubated overnight at 37 °C 
and 5% CO2. Before use in an assay, the cells were examined for mitotic figures to 
ensure that they had resumed active growth. 
4.3.1.7. Cryopreservation of cells 
Cells were harvested as previously described in section 4.3.1.4 and centrifuged at 220 g 
for 5 minutes. The supernatant was aspirated leaving 100-200 µl. The pellet was re- 
suspended in cold freezing solution composed of EGM-2MV (Lonza, UK) containing 
10 % (v/v) DMSO. Cells were counted and diluted to 500,000 - 2,000,000 cells/ml and 
aliquotted into freezing vials or ampoules and sealed. Cryovials were insulated in a 
Styrofoam or propanol freezing canister and stored at -80 °C overnight. Within 12-24 
hours, cells were placed in liquid nitrogen (-200 °C) for long term storage. 
4.3.1.8. Sodium chlorate 
HLMVECs were grown in full growth medium supplemented with 30 mM sodium 
chlorate for 3 days to inhibit glycosaminoglycan (GAG) synthesis. A lOx stock solution 
(300 mM) was prepared in EGM-2 MV medium. The stock solution was diluted to a 
final concentration of 30 mM in EGM-2 MV medium (1: 10 dilution). HLMVECs were 
re-suspended and diluted in the medium before seeding. 
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4.3.2. Induction of RANTES expression in HLMVECs and analysis by SDS- 
PAGE and Western blotting 
4.3.2.1. Subculture 
HLMVECs were subcultured as previously described (Section 4.3.1.6) into collagen IV 
coated 6-well plates in EGM-2MV culture medium, 1.5 ml / well and 2x 105/ml. This 
corresponded to a total cell number of 300,000 per well. Plates were covered and 
incubated for 24 hours at 37 °C and 5% CO2, 
4.3.2.2. Induction of RANTES synthesis 
Following incubation, spent medium was aspirated from wells, and adherent cells 
washed once with lx HBSS (-Ca t+/Mg2+) to remove non-adherent cells. New full 
culture medium (EGM-2MV) containing 100 U/ml IFN--y plus 10 ng/ml TNF-a was 
added to each well, total volume 1380 µl. The plates were incubated for 24 hours at 37 
°C and 5% CO2. 
4.3.2.3. HLMVEC culture in 6-well plates with 12.5 - 200 µM CuC12 
A 1.25 MM CuC12 (MW 134.45, Sigma, UK) solution was also prepared in serum and 
ascorbic acid free EGM-2MV. This was to prevent the removal of Cu through binding 
to serum components and the protective effects of ascorbic acid against oxidative stress, 
as observed by Bar-Or et al, 2003 (Bar-Or et al, 2003). The solution was filter- 
sterilised using a 0.2 µm filter (BD Biosciences, UK. ) Following incubation of 
HLMVECs for 24 hours, spent medium was aspirated from wells, and adherent cells 
washed once with lx HBSS (-Ca t+/Mg2+) to remove non-adherent cells. Serum and 
ascorbic acid free EGM-2MV was added to the cells. CuC12 was added to the wells (15, 
30,60,120 and 240 µl) and wells were adjusted to 1500 µl of medium per well resulting 
in final concentrations of 12.5,25,50,100 and 200 µM CuC12. Culture medium alone 
was added to the control wells. The plates were covered and incubated for a further 24 
hours at 37 °C and 5%CO2. 
4.3.2.4. HLMVEC culture in 6-well plates with 50 µM CuC12 and 100 - 400 pM 
H202 
A 1.25 mM CuC12 (MW 134.45, Sigma, UK) solution was prepared in full culture 
medium. The solution was filter-sterilised using a 0.2 µm filter (BD Biosciences, UK), 
and 60 µl added to the wells resulting in a final concentration of 50 µM CuCl2. Culture 
medium was added to the control wells. 
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A 10 mM H202 (MW 34, Sigma, UK) solution was prepared in full culture medium. 
The 10 mM stock solution was diluted 1: 2 to 5 mM, and a further 1: 2 to 2.5 mM. The 
solutions were filter-sterilised using a 0.2 µm filter. The addition of each solution (60 
µl) to the wells resulted in final concentrations of 400,200, and 100 µM H202 in the 
presence of 50 µM CuC12. Culture medium alone was added to control wells. 
The plates were covered and incubated for 24 hours at 37 °C and 5% CO2. 
4.3.2.5. Harvesting 
Following incubation, the plates were placed onto ice and 1500 µl of cell supernatants 
was harvested. Cell debris was cleared by centrifuging at 900 g for 10 minutes at 4 °C. 
The supernatant was retained and stored at -80 °C for analysis by Western blotting or 
ELISA. The cells in the plate were washed twice with 1000 µl ice cold Ix PBS (- 
Ca2+/Mg2+), and 500 µl of ice cold 1% Triton-X-100 (v/v) containing double strength 
protease inhibitors (Roche, UK) was added to each well. Double strength protease 
inhibitors were used since Ix strength protease inhibitors failed to prevent the 
proteolysis of RANTES in the samples. The plate was stored at -80 °C and subjected to 
2 freeze-thaw cycles. The cell lysates were removed from the plate and stored at -80 °C 
in 1.5 ml eppendorf tubes for analysis by SDS-PAGE or ELISA. 
4.3.2.6. Freeze drying for SDS-PAGE analysis 
500 
.d 
lysate and 1500 µl supernatant samples were freeze dried for a minimum of 6 
hours using a Thermo Scientific Modulyo freeze drier. 
4.3.2.7. Immunoprepitation of human RANTES for SDS-PAGE analysis 
Freeze dried samples were reconstituted to 40 µl in 1x PBS (-Ca t+/Mg2+). Samples 
were then diluted 1/5 in immunoprecipitation buffer (150 mM NaCl, 50 mM Tris, 5 mM 
EDTA, 0.1 % (w/v) SDS, 0.5 % (v/v) Tergitol Nonidet P-40, and protease inhibitor 
cocktail (2 x tablets in 10 ml, double strength) (Roche, UK)). Affinity purified rabbit 
polyclonal anti-RANTES (non-biotinylated) was added at 1 µg/m1 (4 µl of 50 µg/ml 
stock was added to a 200 µl sample). Protein A agarose bead suspension (3 . il) was 
added to the samples followed by incubation with shaking at 4°C overnight. 
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Following overnight incubation, samples were centrifuged at 3000 g and 4°C for 5 
minutes. The supernatant was removed and the pellet washed 3 times with ice-cold 
immunoprecipitation buffer with centrifugation at 3000 g. To release the 
immunoprecipitated protein from the primary antibody-protein A agarose complex, 
samples were incubated with 40 µl/sample 5x Laemmli sample buffer (8 ml 5x running 
buffer, 2.5 ml glycerol and 1.25 mg bromophenol blue) containing 100 mM DTT at 
room temperature for 30 minutes, or in the absence of DTT with boiling at 95 °C for 5 
minutes. Samples were then centrifuged for 5 minutes at 3000 g before analysis by 
Western blotting. 
4.3.2.8. Analysis by SDS-PAGE and Western blotting 
Samples were analysed by SDS-PAGE on either 14 %, or 4- 15 % gradient 
polyacrylamide gels, transferred, blocked overnight in 2% (v/v) Tween-20 / PBS (- 
Ca2+/Mg2+) and Western blots were stained for RANTES as previously described in 
Chapter 2, Sections 2.3.4 and 2.3.5. 
4.3.2.9. Quantification of human RANTES by ELISA 
The ELISA was performed according to the manufacturer's instructions (R &D 
Systems, UK) 
Wells of a 96-well plate were coated with 100 µl of mouse anti-human RANTES 
capture antibody (R &D Systems, UK) at 1 µg/ml in PBS -Ca 
t+/Mg2+, sealed and 
incubated overnight at room temperature. Following overnight incubation, the capture 
antibody was aspirated and each well washed three times with 200 µl wash buffer (0.05 
% Tween-20 (Fisher, Scientific, UK) / PBS -Ca 
t+/Mg2+). 
Plates were blocked by adding 300 µl reagent diluent / well (sterile filtered (0.2 µM) 1 
(w/v) BSA (Sigma, UK) / PBS -Cat+/Mg2+), sealed and incubated for 1 hour at room 
temperature. Following incubation, wells were washed three times with 200 µ1 wash 
buffer (0.05 % Tween-20/ PBS -Cat+/Mg2+) and 100 µl of samples or standards (50 
ng/ml) diluted in reagent diluent in the range 0-500 pg/ml were added to the wells. 
Plates were sealed and incubated for 2 hours at room temperature. Following 
incubation, wells were washed three times with 200 µl wash buffer (0.05 % Tween-20/ 
PBS -Ca 
t+/Mg2+). 
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The detection antibody (biotinylated goat anti-human RANTES -R&D Systems, UK) 
was diluted in reagent diluent to 20 ng/ml, and 100 µl added per well. Plates were 
sealed and incubated for 2 hours at room temperature. Following incubation, wells were 
washed three times with 200 µl wash buffer (0.05 % Tween-20). Streptavidin-HRP (R 
&D Systems, UK, kept at 4°C) was diluted 1: 200 to working strength in reagent 
diluent, and 100 µl added per well. Plates were incubated for 20 minutes at room 
temperature, avoiding direct sunlight. Following incubation, wells were washed three 
times with 200 µl wash buffer (0.05 % Tween-20/ PBS -Ca 
t+/Mg2+). 
A substrate solution was prepared using the following formula per one plate: 
12 ml substrate buffer (1.8 mM, pH 5.5) 
200 µl Tetramethylbenzidine (TMB) stock solution (6 mg/ml in DMSO) 
1.2 µl H202 stock solution (30 % (v/v), Sigma, UK). 
The solution was stored for up to 1 month at room temperature, protecting against light. 
100 µl of the substrate solution was added per well and plates were incubated for 20 
minutes at room temperature (or until the top standard had developed a strong colour). 
To stop the reaction, 50 µl of 2M H2SO4, (Fisher Scientific, UK) was added to each 
well. The optical density at 450 nm for each well was determined immediately using a 
micro-plate reader. 
4.3.3. Analysis of T-cell derived RANTES 
4.3.3.1. T-cell isolation 
Normal venous blood was collected by venepuncture from healthy volunteers into 
vacutainers containing EDTA and diluted 1: 1 with PBS -Ca/Mg in sterile conditions. 
Diluted blood was layered onto an equal volume of sterile Lymphoprep using a long 
necked Pasteur pipette and centrifuged at 438 g for 30 minutes at 20 °C. The peripheral 
blood mononuclear cell (PBMC) layer was harvested using a plastic pipette and diluted 
to 50 ml in Falcon tubes with HBSS - Cat+/Mg2+. PBMCs were centrifuged at 760 g for 
10 minutes and the supernatant discarded. The pellet was re-suspended and diluted to 50 
ml with HBSS - Cat+/Mg2+, and centrifuged at 190 g for 5 minutes to remove platelets 
and erythrocytes. The supernatant was discarded and the PBMC pellet re-suspended in 
RPMI/10 % FCS, 0.5 ml per 9 -10 ml of blood collected. Re-suspended pellets were 
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combined before counting. The number of viable cells was counted, and the purity of 
the final preparation was assessed by microscopic observation with x400 magnification. 
10 µl of cell suspension was mixed with 90 µl Trypan blue stain and 2x 10 pl was 
loaded onto a haemocytometer slide. 
The following formula was used to estimate the number of viable cells: 
No. of cells/m1= nx 10 x 104 (where n= no. of cells in the 25 square field) 
PBMCs were diluted to 2x 106/ml in warm RPMI/10 % (v/v) FCS containing 2 mM 1 
glutamine, 1 mM sodium pyruvate, 100 units/ml penicillin, 100 µg/ml streptomycin and 
250 ng/ml amphotericin B. The PBMC suspension was transferred into 25 ml Petri 
dishes (10 ml / dish) and incubated overnight at 37 °C and 5% C02 to remove adherent 
monocytes. 
Non-adherent T-cells were harvested and the Petri dishes washed with warm RPMI 
containing 10 % (v/v) FCS. The wash was combined with the T-cell suspension and 
centrifuged at 760 g for 10 minutes. The supernatant was discarded and the pellet re- 
suspended in RPMI / 10 % FCS. T-cells were counted and diluted to 2x 106/ml in 
RPMI/10 % FCS, supplemented with 2 mM 1-glutamine, 1 mM sodium pyruvate, 100 
units/ml penicillin, 100 µg/ml streptomycin and 250 ng/ml amphotericin B. 
4.3.3.2. T-cell activation 
The mitogen, phytohaemagglutinin (PHA), was added to activate T-cells at a final 
concentration of 1 µg/ml. The T-cell suspension was transferred to 75 cm2 tissue culture 
flasks (8-10 ml / flask) and cultured for 2 days at 37 °C and 5% CO2. Following 2 day 
incubation, interleukin-2 (IL-2) was added to the medium, final concentration 200 
units/ml. Culture was continued for 3 days at 37 °C and 5% CO2 to allow cells to 
proliferate. 
4.3.3.3. Induction of RANTES expression following T-cell activation 
Following activation, T-cells were harvested and diluted to 2x 106,5 x 106 and 1x 107 
cells/ml in RPMI/ 10 % FCS supplemented with L-glutamine, sodium pyruvate and 
antibiotics as described above. T-cells were incubated in 24-well plates (0.25 ml/well) 
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in the presence and absence of IFN-y (100 U/ml) plus TNF-a (10 ng/ml) for 2 days to 
induce RANTES production. 
Conditioned medium from activated T-cells was collected for analysis 4 hours, 1 and 2 
days following the addition of IFN-'y plus TNF-a. Cell suspensions were centrifuged at 
760 g for 10 minutes and cell-free supernatants were collected and stored at -80 °C. The 
samples were quantitatively analysed by ELISA to detect RANTES as previously 
described in section 4.3.2.9. 
4.3.4. Purification of platelets and induction of platelet derived RANTES release 
4.3.4.1. Platelet isolation 
Normal venous blood was collected from healthy volunteers into vacutainers containing 
EDTA, diluted 1: 1 with lx PBS (-Ca/Mg), layered onto lymphoprep and centrifuged at 
438 g for 30 minutes at 20 T. The platelet-rich plasma layer was extracted and 
centrifuged at 2500 g for 15 minutes to obtain platelet-rich pellets. The platelets were 
washed twice with sterile PBS (-Ca t+/Mg2+) containing 10 mM EDTA, with 
centrifugation at 2500 g for 15 minutes and re-suspended in RPMI 1640/ 0.5 % (w/v) 
BSA. Platelets were counted using a haemocytometer as previously described and 
diluted to 107,108 and 109 / ml in RPMI 1640/ 0.5 % BSA (833 µl 30 % (w/v) sterile 
BSA solution / 50 ml RPMI 1640). The purity of the final preparation was assessed by 
microscopic observation. 
4.3.4.2. Induction of RANTES release from platelets 
Purified platelets were incubated in suspension at 107,108 and 109 / ml in RPMI 1640 
(Invitrogen) / 0.5 % (w/v) BSA (Sigma, UK), 250 µl per well and cultured in a 24-well 
plate (Triple Red, UK) at 37 °C for 1 hour in the absence and presence of thrombin at 
0.5,1 and 2 U/ml. 100 U of lyophilised thrombin (Sigma, UK) was reconstituted in 1 ml 
RPMI/ 0.1 % BSA (166 ul 30% BSA / 50 ml RPMI 1640) and stored in 30 µl aliquots at 
-20 °C. 5 µl of 100,50 and 25 U/ml stock solution was added per well 
(24-well plate, 
0.25 ml/well) to give final concentrations of 2,1 and 0.5 U/ml. 
Conditioned medium from purified platelets was collected 1 hour after treatment with 
thrombin. Following centrifugation at 2500 g for 15 minutes at 4 °C, cell-free 
supernatants were collected, stored at -80 
°C and quantified for RANTES by ELISA as 
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previously described (Section 4.3.2.9), or freeze dried and analysed by SDS-PAGE and 
Western blotting as described in Sections 4.3.2.6 and 4.3.2.8. 
4.3.5. Endothelial cell and platelet co-culture 
4.3.5.1. Co-culture 
Platelets were isolated as previously described in Section 4.3.4.1 and diluted to 108 / ml 
in RPMI 1640 / 0.5 % (w/v) BSA and added (1500 µl / well) in the absence/presence of 
thrombin at 1 U/ml (Sigma, UK) (Mack, et al. 2002) to confluent HLMVECs that were 
incubated in the presence and absence of IFN--y plus TNF-a for 24 hours in a 6-well 
plate. Following the addition of platelets and thrombin to HLMVECs, the plates were 
incubated for 1 hour at 37 °C and 5% CO2. 
4.3.5.2. Harvesting 
Following incubation the plates were placed onto ice and cell supernatants and lysates 
were harvested. Cell debris was cleared by centrifuging at 2500 g for 15 minutes at 4 
T. The supernatant (1500 µl) was retained and stored at -80 °C for analysis by ELISA. 
The cells in the plate were washed twice with 1000 µl ice cold Ix PBS (-Ca 2+ /Mg 2+ ), 
and 500 µl of ice cold 1% Triton-X-100 (v/v) (Sigma, UK) containing double strength 
protease inhibitors (Roche, UK) was added to each well. The plate was stored at -80 °C 
and subjected to 2 freeze-thaw cycles. The cell lysates were removed from the plate and 
stored in 1.5 ml Eppendorf tubes for analysis by ELISA. 
4.3.5.3. Analysis by ELISA 
The cell supernatants and lysates were quantified for RANTES by ELISA as described 
in section 4.3.2.9. 
4.3.6. Analysis of lipid peroxidation in HLMVECs 
The effect of Cu/H202 on lipid peroxidation was investigated as an indicator of 
oxidative stress in HLMVECs in the absence and presence of sodium chlorate to inhibit 
GAG synthesis. 
4.3.6.1. Seeding HLMVECs in 24-well plates 
The HLMVECs were seeded into collagen IV coated 24-well plates (Triple Red, UK) at 
2x1 05/Ml in EGM-2MV culture medium and 500 µl well (this corresponds to a total cell 
number of 100,000 per well) in the absence and presence of 30 mM sodium chlorate 
(Sigma, UK. ) 
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Sodium chlorate: 
A lOX solution (300 mM) was made up in full culture medium by dissolving 319 mg in 
10 ml culture medium. The IOX solution was diluted to give a 30 mM solution in which 
the cells were seeded. The plates were covered and incubated for 24 hours at 37 °C and 5 
% CO2. 
4.3.6.2. Induction of RANTES release 
The adherence and confluence of seeded cells was checked. The growth medium was 
changed, this also removes non-adherent cells. The old medium was aspirated from 
wells, and the cells washed once with lx HBSS (-Ca t+/Mg2+). 460 µl new full culture 
medium, +/- sodium chlorate (30 mM) containing 100 U/ml IFN-, y and 10 ng/ml TNF-a 
was added per well. Cells were incubated for 24 hours at 37 °C and 5% CO2. 
4.3.6.3. Addition of CuC12 and H202 
Following incubation, CuC12 and H202 were added to wells. A 1.25 MM CuC12 solution 
was made up in growth medium, filter sterilised using a 0.2 µm filter (BD Biosciences), 
and 20 µl added in triplicate wells to give a final concentration of 50 µM CuCl2.20 µl 
of growth medium was added to control wells (no CuCl2). 
A 10 mM H202 stock solution was made up in growth medium (5.67 µl of 30 % H202 
(kept at 4 °C) in 5 ml) and diluted to 5 mM, 1.25 mM and 0.625 mM in full growth 
medium. 
All solutions were filter-sterilised using a 0.2 µm filter. 20 . tl of each solution was 
added to the wells, in triplicate to give final concentrations of 400,200,50 and 25 µM 
H202.20 µl of growth medium was added to control wells (no H202). The plates were 
covered and incubated for 24 hours at 37 °C and 5% CO2. 
4.3.6.4. FOX-2 assay for the quantification of lipid peroxides 
Lipid peroxides were assayed in endothelial cell lysates using the PeroXOquant 
Quantitative Peroxide Assay Kit (lipid-compatible formulation) (Pierce, Chester, UK) 
according to the manufacturers instructions. 
The working reagent (WR) was prepared by mixing 1 volume of reagent A with 100 
volumes of reagent C (150 µl of A and 15 ml of reagent C per microplate). 30 % (v/v) 
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hydrogen peroxide stock solution (Sigma, UK) was serially diluted in UHQ water to 
achieve 8 standards in duplicate in the concentration range 0-1000 µM. The high 
standard (1000 µM) was prepared by adding 10 µd of the stock to 88 ml of water 
Cell supernatants were removed from each well and stored at -80 °C for analysis for 
RANTES by ELISA. Cells were washed in cell medium and 60 µl of cell medium and 
600 µl of WR were added to each well (10 volumes of WR were added to 1 volume of 
sample). The samples were incubated at room temperature for 15-20 minutes in order to 
reach the endpoint. For each well, 2x 275 µl samples were removed and pipetted into a 
96-well microplate. Sample absorbances were measured at 595 nm using a plate reader, 
and the peroxide concentrations calculated by reference to the standard curve 
absorbance values. 
4.3.7. T-cell chemotaxis assays 
4.3.7.1. RANTES preparation for chemotaxis assay 
Samples containing RANTES multimers were prepared in duplicate, in the presence and 
absence of 50 µM CuC12 and 25 µM H202, as described in Chapter 2, section 2.3.1, and 
incubated for 2 days at 37 °C. The final concentration of RANTES in the samples was 5 
x 10-7 M. Following incubation, samples were diluted to 1.25 x 10-8 M (125 ng/ml) in 
Hanks Balanced salt Solution (HBSS) with Cat+/Mg2+ supplemented with 20 mM 
HEPES (0.48 g/l00 ml and adjusted to pH 7.4, and used in a chemotaxis assay. Fresh 
unincubated RANTES was used as a positive control, final concentration 1.25 x 10-8 M 
in HBSS (+Ca2+/Mg2+) supplemented with 20 mM HEPES, pH 7.4. CuC12 and H202 
alone were added to lower wells as a negative control. 
4.3.7.2. Modified Boyden Chamber technique for T-cell chemotaxis assay 
The method for chemotaxis was modified from the methods of Harvath et al. and 
Richards et al. (Harvath et al, 1980; Richards & McCullough, 1984). 
Activated T-cells were re-suspended in HBSS with Cat+/Mg2+ supplemented with 20 
mM HEPES (0.48 g/100 ml and adjusted to pH 7.4). T-cells were counted and diluted to 
2x 10 6 /ml in this buffer. RANTES was initially diluted to a concentration range of 
186 
1.25 - 500 ng/ml (1.56 x 10"10 M-6.25 x 10"8 M) in HBSS (+Ca2+/Mg2+) containing 20 
mM HEPES, pH 7.4. 
All components of the microchambers were washed thoroughly for 1h in distilled water, 
rinsed and dried prior to use. Samples and standards (25 µl) were diluted in HBSS 
(+Ca2+/Mg2+), containing 20 mM HEPES, pH 7.4 and added to the lower wells. The 
buffer was added to lower wells as a negative control. Fresh unincubated RANTES was 
used as a positive control, at a concentration of 1.56 x 10-8 M (125 ng/ml). All samples 
were analysed in duplicate. 
A 5µm pore-size, PVP-free polycarbonate filter was placed over the lower wells, with 
no cross contamination between wells. The top gasket was placed over the filter and the 
top plate on the filter and the thumb nuts secured and tightened. The upper wells were 
filled with the T-cell suspension, 50 µl per well, and the chambers were incubated at 37 
°C in an incubator with 5% CO2 for 30 minutes under humidified conditions. 
Following incubation, the thumb nuts were removed and each chamber inverted. The 
lower plate and gasket were removed so that the underside of the filter was exposed 
with the migrated cells adhered. Both ends of the filter were held firmly with clamps. 
Keeping the underside facing upwards, the topside (with non-migrated T-cells) was 
washed in lx HBSS with Cat+/Mg2 and wiped on a plate at an angle of 45 ° to remove 
non-migrated cells. Washing was repeated three times, to. ensure non-migrated cells 
were removed. The filter was allowed to dry before staining. 
4.3.7.3. Anti-CCR3 and CCR5 antibodies 
RANTES samples and isolated T-cells were incubated with 100 µg/ml anti-CCR3, anti- 
CCR5 neutralising antibodies or isotype controls (rat IgG2a and mouse IgG2b) for 30 
minutes before they were used in the chemotaxis assay. 
4.3.7.4. Hema-Gurr staining 
Filters were stained using Hema Gurr stain (BDH). Filters were fixed in methanol for 10 
seconds and stained for 10 seconds with eosin red followed by methylene blue for 10 
seconds. Finally, filters were washed in lx PBS without Cat+/Mg2+ and allowed to dry. 
Filters were placed on a glass slide with migrated cells facing up. 
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When dry, filters were covered with immersion oil and the total number of cells counted 
using a light microscope at x 400 magnification in five high power fields (hpf) per well. 
Data was presented as the mean number of cells in one hpf. 
4.3.8. Transendothelial migration assays 
4.3.8.1. Subculture of HLMVECs into fibronectin coated and uncoated Transwells 
The method was adapted from the supplier's instructions and that of (Sundstrom et al, 
2001); (Broughton-Head, 2005; Carr et al, 1994; Kanda et al, 2004). 
HLMVEC cells were seeded in T-75 flasks at a density of 5000 cells/cm2 and grown for 
1 week in 15 ml EGM-2MV fully supplemented culture medium. HLMVEC subcultures 
were used in experiments when they reached 60 - 70 % confluence at passage 5-11. 
Cells were harvested by trypsinisation as previously described in Chapter 4, Section 
4.3.1.6 (2 ml of Trypsin/EDTA / 75 cm2 of cells to be sub-cultured on Transwells. ) 
Trypsin/EDTA was neutralised with trypsin neutralisng solution as previously described 
(4 ml / 75 cm2 of cells. ) Fully supplemented EGM-2MV growth medium was pre- 
warmed to 37 °C in a water bath. In a tissue culture hood, sterile 3 µm uncoated and 
fibronectin coated polyethylene terephthalate (PET) BD Biosciences) culture inserts 
were placed into a 24-well companion plate (BD Biosciences, UK. ) Growth medium 
was transferred to the 24-well culture inserts (800 µl into the lower wells, and 300 µl 
into the upper wells) before they were placed in a humidified 37 °C incubator with 5% 
CO2 to equilibrate for 30 minutes. 
Harvested HLMVEC cells were centrifuged at 220 g for 5 minutes to pellet the cells. 
The supernatant was aspirated and the cells counted using a haemocytometer slide 
(naubayer bright line), adding 10 µl cell suspension + 90 µl trypan blue (Sigma, UK) 
and loading 10 µl onto the slide. The cells were counted and diluted to 2x 105 cell / ml 
in EGM-2MV (Lonza, UK. ) 
Growth medium was removed from the upper wells and the cells seeded onto the 
Transwell inserts at 60,000 cells / 300 µl per well. Cells were grown on Transwells for 2 
weeks, and confluency established by microscopic observation and staining with Hema 
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Gurr stain (BDH) as described in Section 4.3.7.4. When confluent, the cells were ready 
for use in a transmigration assay. 
4.3.8.2. Induction of HLMVEC RANTES synthesis 
RANTES synthesis was induced in HLMVEC monolayers using a method adapted from 
that of Hashimoto et al, 2000, Sundstrom et al, 2001 and Terada et al, 1996. 
The confluence of HLMVEC monolayers was observed and the culture medium 
changed to remove non-adherent cells. Old medium was aspirated from the wells, and 
adherent cells washed once with lx HBSS (-Ca t+/Mg2+). New full culture medium 
(EGM-2MV) containing 100 U/ml IFN--y plus 10 ng / ml TNF-a was added to each 
well. The HLMVEC monolayers were incubated for 1 day at 37 °C and 5% CO2. 
4.3.9. Purification of platelets and induction of platelet derived RANTES release 
Platelets were isolated as previously described in Section 4.3.4.1 and diluted to 108/ml 
in RPMI/ 10 % (v/v) FCS. Isolated platelets were activated with 1 U/ml thrombin 
(Mack, et al. 2002). 
4.3.10. T-cell trans endothelial migration assay 
HLMVECs were grown to confluence in EGM-2MV growth medium for 2 weeks in 
monolayers on Transwells as previously described. T-cells were isolated and activated 
with PHA and IL-2 for 5 days as previously described in Chapter 4, Sections 4.3.3.1 and 
2. Platelets were isolated as previously described in Section 4.3.4.1. HLMVECs were 
used in transendothelial migration assays at passage 5- 10. Where indicated, 
HLMVECs were pre-treated with copper chelators overnight prior to the migration 
assay. Chelators were added to both the apical and basal wells. Neocuproine (NC) or 
bathocuproine disodium salt (BCDS) were added at a final concentration of 0.1,0.25, 
and 0.5 mM, and D-penicillamine or tobramycin were added at a final concentration of 
0.01,0.1 and 0.5 mM. 
On the day of the transendothelial migration assay, 30 minutes before T cells are added, 
confluent HLMVEC layers were washed with RPMI 1640. The lower wells of the plate 
were filled either with isolated platelets at a final concentration of 1x 108/ml in RPMI 
1640 containing 25 mM HEPES and 2 mM 1-glutamine (Invitrogen, UK) supplemented 
with 10 % FCS serum (Sigma, UK) and activated with 1 U/ml thrombin, 1.25 x 10-8 M 
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recombinant RANTES (Peprotech, UK) in RPMI/10 % FCS or RPMI/10 % FCS alone 
as a control. Cu chelators were added to the basal wells containing platelets 30 minutes 
before the start of the assay. The final volume in all basal wells was 800 µl. 
Activated T-cells were counted and diluted to 2x 106/ml in RPMI 1640 containing 25 
mM HEPES and 2 mM L-glutamine (Invitrogen, UK) and supplemented with 10 % 
FCS serum (Sigma, UK) (Kawai et al, 1999). Anti-RANTES (Peprotech, UK) was 
added to T-cells (final concentration 10 µg/ml) 30 minutes before the transendothelial 
migration assay and at the start of the assay to basal wells at a final concentration of 10 
µg/ml. The PAI-1 inhibitor XR5118 (a gift from Xenova, UK) was added at final 
concentration 1,10 and 100 µM and catalase was added at a final concentration of 500 
U/ml, to basal wells 30 minutes before the start of the assay and to the apical wells at 
the start of the assay. Cu chelators were also added to the apical wells at the start of the 
assay. The confluent HLMVEC layers were overlaid with pre-treated or untreated 
activated T cells in the upper wells (in RPMI 1640 / 10 % FCS) at 2x 105/ml and in a 
final volume of 300 µl / well (Kawai et al, 1999). Transwells were incubated at 37 °C 
and 5% CO2 for 5 hours (Kawai et al, 1999). 
4.3.11. Harvesting 
Following incubation, the plates were removed from the incubator and placed on ice for 
10 minutes. 80 µl of 100 mM EDTA (Sigma, UK) was added to each lower well, 
resulting in a final concentration of 10 mM. The plate was incubated for 5 minutes at 
room temperature. The inserts were shaken gently to loosen adherent cells. All cells 
from the basal wells were collected, and the wells washed once with 600 µl RPMI 1640. 
This was added to the cells recovered from each well. The cell suspensions were 
centrifuged at 2500 g for 15 minutes. The supernatant was retained and stored at -80 °C 
for analysis by ELISA and Western blotting, and the pellet re-suspended in 100 µl PBS 
-Cat+/Mg2+. 10 pl cell of the cell suspension was added to 10 µl Trypan Blue and the 
total number of cells migrated was calculated by loading 10 µl onto a haemocytometer 
slide and using the following formula: 
No. of cells/ml =nx2x 104 (where n= no. of cells in the 25 square field) 
The apical supernatants were harvested, cleared at 2500 g and stored at -80 °C for 
immunoprecipitation and analysis by ELISA and Western blotting. The HLMVECs in 
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the Transwells were washed twice with 200 µ1 ice cold 1x PBS (-Ca t+/Mg2+). and 200 
µl of ice cold 1% (v/v) Triton-X-100 in UHQ water containing double strength 
protease inhibitors (Roche, UK) was added to each well. The plate was stored at -80 °C 
and subjected to 2 freeze-thaw cycles. The cell lysates were removed from the plate and 
stored at -80 °C in 1.5 ml eppendorf tubes for analysis by SDS-PAGE and Western 
blotting. 
4.3.12. Immunoprecipitation of human RANTES from HLMVEC lysates and 
supernatants for SDS-PAGE analysis 
Lysates (200 µl) and supernatants (300 µl of apical and 500 µl of basal supernatant) 
were freeze dried and immunoprecipitated for RANTES as previously described in 
Sections 4.3.2.6 and 4.3.2.7. 
4.3.13. Analysis of supernatants and HLMVEC monolayer lysates by SDS-PAGE 
and Western blotting 
Cell lysates and supernatants were analysed by SDS-PAGE on 4- 15 % gradient 
polyacrylamide gels, transferred and blocked overnight in 2% (v/v) Tween-20 / PBS (- 
Cat+/Mg2+) as previously described in Chapter 2, Section 2.3.4. Western blots were 
stained for RANTES as previously described in Chapter 2, Section 2.3.5. 
4.3.14. Quantification of human IFN-y in apical supernatants by ELISA 
The ELISA was performed according to the manufacturer's instructions supplied with 
the duoset (Peprotech EC, UK) 
Wells of a 96-well plate were coated with 100 µl rabbit anti-human IFN-, y capture 
antibody (Peprotech EC, UK) at 1µg/ml in PBS -Ca 
t+/Mg2+, sealed and incubated 
overnight at room temperature. Following overnight incubation, the capture antibody 
was aspirated and each well washed three times with 200 µl wash buffer (0.05 % 
Tween-20 (Fisher, Scientific, UK) / PBS -Ca 
t+/Mg2+). 
Plates were blocked by adding 300 µl reagent diluent / well (sterile filtered (0.2 µM) 1 
% (w/v) BSA (Sigma, UK) / PBS -Cat+/Mg2+), sealed and incubated for 1 hour at room 
temperature. Following incubation, wells were washed three times with 200 µ1 wash 
buffer (0.05 % Tween-20/ PBS -Cat+/Mg2+) and 100 µl of samples or standards (1 
µg/ml) were diluted in reagent diluent in the range 0- 1000 pg/ml. Supernatants from 
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transendothelial migration experiments (apical side) were assayed at a dilution of 1: 10 
in reagent diluent. 
Plates were sealed and incubated for 2 hours at room temperature. Following 
incubation, wells were washed three times with 200 µl wash buffer (0.05 % Tween-20/ 
PBS -Ca 
t+/Mg2+). 
The detection antibody (biotinylated rabbit anti-human IFN-y (Peprotech EC, UK) was 
diluted to a working concentration of 0.25 µg/ml in reagent diluent, and 100 µl added 
per well. Plates were sealed and incubated for 2 hours at room temperature. Following 
incubation, wells were washed three times with 200 µl wash buffer (0.05 % Tween-20). 
Avidin-HRP (Peprotech EC, UK), kept at -20°C) was diluted 1: 2000 to working 
strength in reagent diluent, and 100 µl added per well. Plates were incubated for 30 
minutes at room temperature, avoiding direct sunlight. Following incubation, wells were 
washed three times with 200 µl wash buffer (0.05 % Tween-20/ PBS -Ca 
t+/Mg2+). 
A substrate solution was prepared using the following formula per one plate: 10 ml of 
2,2'-Azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) solution (prepared by 
dissolving 1x ABTS tablet (Sigma, UK) in 100 ml 50 mM phosphate-citrate buffer, 
adjusted to pH 5.0) and 25 µl H202 stock solution (30 % (v/v), Sigma, UK). 
The phosphate-citrate buffer (50 mM) was prepared by dissolving 0.71 g sodium 
phosphate (Na2HPO4, Sigma, UK) in 100 ml of UHQ water and 0.961 g citric acid 
(Sigma, UK) in 100 ml distilled water, and adjusting the sodium phosphate to pH 5.0 by 
adding the citric acid. 
Substrate solution was added 100 µl per well, and plates were incubated for 20 minutes 
at room temperature (or until the top standard had developed a strong colour). To stop 
the reaction, 50 µl of 1% SDS (in water) was added to each well. The optical density 
for each well was determined immediately using a micro-plate reader set to 405 nm. 
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4.3.15. Quantification of human TNF-a in apical supernatants by ELISA 
The ELISA was performed according to the manufacturer's instructions supplied with 
the duoset (Peprotech EC, UK) 
Wells of a 96-well plate were coated with 100 µl of rabbit anti-human TNF-a capture 
antibody (Peprotech EC, UK) at 1 . ig/ml in PBS -Cat+/Mg2+, sealed and incubated 
overnight at room temperature. Following overnight incubation, the capture antibody 
was aspirated and each well washed three times with 200 µl wash buffer (0.05 % 
Tween-20 (Fisher, Scientific, UK) / PBS -Cat+/Mg2+ 
Plates were blocked by adding 300 µl reagent diluent / well (sterile filtered (0.2 µM) 1 
%o (w/v) BSA (Sigma, UK) / PBS -Cat+/Mg2+), sealed and incubated for 1 hour at room 
temperature. Following incubation, wells were washed three times with 200 µ1 wash 
buffer (0.05 % Tween-20/ PBS -Cat+/Mg2+) and 100 µl of samples or standards (1 
µg/ml) were diluted in reagent diluent in the range 0-1000 pg/ml. Supernatants from 
transendothelial migration experiments (apical side) were assayed at a dilution of 1: 10 
in reagent diluent. 
Plates were sealed and incubated for 2 hours at room temperature. Following 
incubation, wells were washed three times with 200 µl wash buffer (0.05 % Tween-20/ 
PBS -Cat+/Mg2+). 
The detection antibody (biotinylated rabbit anti-human TNF- a (Peprotech EC, UK) 
was diluted in reagent diluent to a working concentration of 0.5 µg/ml and 100 µ1 added 
per well. Plates were sealed and incubated for 2 hours at room temperature. Following 
incubation, wells were washed three times with 200 µ1 wash buffer (0.05 % Tween-20). 
Avidin-HRP (Peprotech EC, UK), kept at -20°C) was diluted 1: 2000 to working 
strength in reagent diluent, and 100 µl added per well. Plates were incubated for 30 
minutes at room temperature, avoiding direct sunlight. Following incubation, wells were 
washed three times with 200 µl wash buffer (0.05 % Tween-20/ PBS -Cat+/Mg2+). 
A substrate solution was prepared using the following formula per one plate: 10 ml of 
2,2'-Azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) solution (prepared by 
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dissolving 1x ABTS tablet (Sigma, UK) in 100 ml 50 mM phosphate-citrate buffer, 
adjusted to pH 5.0) and 25 µ1 H202 stock solution (30 % (v/v), Sigma, UK). 
The phosphate-citrate buffer (50 mM) was prepared by dissolving 0.71 g sodium 
phosphate (Na2HPO4, Sigma, UK) in 100 ml of UHQ water and 0.961 g citric acid 
(Sigma, UK) in 100 ml distilled water, and adjusting the sodium phosphate to pH 5.0 by 
adding the citric acid. 
Substrate solution was added 100 µl per well, and plates were incubated for 20 minutes 
at room temperature (or until the top standard had developed a strong colour). To stop 
the reaction, 50 µl of 1% SDS (in water) was added to each well. The optical density 
for each well was determined immediately using a micro-plate reader set to 405 nm. 
4.3.16. Quantification of human RANTES in supernatants from transendothelial 
migration assays by ELISA 
Apical and basal supernatants were analysed by RANTES ELISA as previously 
described in Section 4.3.2.9. 
4.3.17. Lactate dehydrogenase (LDH) assay 
The lactate dehydrogenase (LDH) assay (TOX-7, Sigma, Dorset, UK) was used to 
determine whether the effects of Cu chelators was due to cytotoxicity. LDH is an 
intracellular cytoplasmic protein that is released into cell culture supernatants when 
cells become non-viable and sustain damage to their membrane (Legrand, C. et al., 
1992). The assay works on the principle that LDH released from cells will reduce NAD 
to NADH. The NADH can then convert a tetrazolium dye into a coloured compound. 
The assay was adapted for use in a microtitre plate and 5 µl of cell culture supernatant 
was added to 45 µl lx PBS. The LDH assay solution was prepared by mixing equal 
volumes of substrate, enzyme and dye together. 100 µl of the mixture was added per 
well. The plate was incubated for 30 minutes at room temperature, protected from light. 
To stop the reaction, 8.33 µl of 1M HC1 was added to each well and the absorbance was 
measured at 490 nm using a microplate reader (Dynex microplate reader, West Sussex, 
UK). 
194 
4.3.18. Plasmin activity assay 
The assay was based on methods in the Chromogenix catalogue. 
The plasmin substrate stock solution was prepared by dissolving 25 mg plasmin 
substrate (S2251, Chromagenix, UK) in 11.33 ml UHQ. The stock was stored at 4 °C. 
The enzyme standard (plasmin from human plasma, Sigma, UK) was prepared by 
dissolving 0.5 mg (3.2 U/ml protein) in 0.5 ml assay buffer (50 mM Tris-HC1 with 130 
mM NaCl, pH 8.5) giving a final concentration of 1 mg/ml. The enzyme standard was 
aliquotted and stored at -20 T. Standards were diluted in assay buffer from the 1 mg/ml 
stock to a range of 0 -100 µg/ml. 
Supernatant samples and standards were assayed by adding 25 µl of sample to 75 µl 
assay buffer in a 96-well plate. The reaction was initiated by adding 25 µl of substrate 
(final concentration 0.8 mM) to the wells. The plate was incubated at 37 °C for 60 
minutes and read on a plate reader at 405 nm. 
4.3.19. Vascular amine oxidase activity assay 
HLMVECs were grown to confluence in 75 cm2 flasks and 1 flask of cells was treated 
overnight either with neocuproine, bathocuproine disodium salt, D-penicillamine or 
tobramycin (0.5 mM). Following overnight incubation, the flasks were treated for 5 
hours with IFN--y (100 U/ml) and TNF-a (10 ng/ml) before harvesting. Medium was 
aspirated from one culture vessel at a time, and the adhered cells rinsed with 5 ml lx 
HBSS (-Ca t+/Mg2+). The HBSS was aspirated from the flask and the cells covered with 
10 ml Ix HB SS (-Ca t+/Mg2+) containing EDTA (10 mM) per 75 cm2 flask. The cap was 
tightened and the cells monitored under a microscope until approximately 90 % of cells 
were rounded up. Cells were released from the culture surface by rapping the flask. The 
detached cells were transferred to sterile 50 ml centrifuge tubes and the flasks rinsed 
with 5 ml of lx HBSS (-Ca t+/Mg2+) to collect residual cells which were added to the 
centrifuge tubes. Cells were centrifuged at 220 g for 5 minutes, and the supernatants 
aspirated. Each pellet was re-suspended in 300 µl physiological HEPES buffer solution 
(UHQ water containing HEPES (50 mM), KC1 (5 mM), CaC12 (2 mM), MgC12 (1.4 
mM) and adjusted to pH 7.4 with NaOH (approximately 20 mM) with NaCl 
subsequently added such that the final concentration of sodium in the buffer is 140 
mM). 
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Whole cell samples were assayed by adding half (150 µl) of each cell suspension to 150 
µl of physiological HEPES buffer containing the SSAO inhibitors semicarbazide (100 
µM) and hydroxylamine (5 µM), and half (150 µl) of each cell suspension to 150 µl 
physiological HEPES buffer alone without inhibitors in a 24-well plate. Plates were 
incubated for 30 minutes at 37 T. The reaction was initiated by adding 150 µl of 
chromagenic solution (physiological HEPES buffer containing 4-aminoantipyrine, (500 
µM), 2-4-dichlorophenol (1 mM) and horseradish peroxidise (40 U/ml)) and 150 µl of 
methylamine substrate (16 mM in physiological HEPES buffer) to the wells. The final 
assay volume was 600 µl. The plate was incubated at 37 °C for 24 hours and read on a 
plate reader at 510 nm. 
4.4. Statistical analysis 
Data were compared with a paired student's t-test, or a1 or 2-way ANOVA followed by 
either a Dunnet's or Tukey's post-hoc test where appropriate, as indicated in the figure 
legends. p<0.05 was the minimum accepted level of significance. 
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4.5. Results 
4.5.1. The effect of copper plus H202 on RANTES expression by HLMVECs 
Whilst it is known that endothelial cells synthesise RANTES, experiments were carried 
out to analyse the form, monomer or multimer, of RANTES expressed by HLMVECs 
under basal conditions and following stimulation with IFN--y plus TNF-a. Further, in 
view of the evidence presented in Chapters 2 and 3, the effect of CuC12 plus H202 on 
the multimerisation of RANTES expressed by HLMVECs was investigated. 
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Figure 4.1. RANTES synthesised by HLMVECs and released into supernatants. RANTES in 
supernatants from HLMVECs grown for 24 hours in collagen IV coated 6-well plates followed by 
incubation for 24 hours in the absence and presence of 50 pM CuCI2,25 - 400 pM H202, IFN-y (100 
U/ml) and TNF-a (10 ng/ml). M: molecular weight markers. Lanes 1-6 show HLMVEC 
supernatants in the absence of IFN-y plus TNF-a, and in Lane 1: in the absence of CuC12 and H202, 
lane 2: in the presence of 50 µM CuCI2, lane 3: 50 µM CuCI2 and 25 µM H202, lane 4: 50 µM CuCl2 
plus 50 µM H202, lane 5: 50 µM CuC12 and 200 µM H202 and lane 6: 50 µM CuCI2 and 400 µM 
H202. Lanes 7-12 show HLMVEC supernatants in the presence of IFN-y (100 U/ml) plus TNF-a (10 
ng/ml) and in lane 7: no CuCI2 or H202, lane 8: 50 µM CuCl2, lane 9: 50 µM CuCI2 and 25 pM H202, 
lane 10: 50 µM CuC12 and 50 µM H202, lane 11: 50 µM CuCI2 and 200 pM H202 and lane 12: 50 
µM CuCI2 and 400 µM H202. Representative of two independent experiments. 
RANTES was not detectable in supernatants from HLMVECs incubated in the absence 
of IFN-y plus TNF-a (figure 4.1, lanes 1- 6). However, monomeric (8 KDa) 
endogenous RANTES was detected in supernatants from HLMVECs incubated in the 
presence of IFN-y (100 U/ml) plus TNF-a (10 ng/ml) (lanes 7- 11). The addition of 50 
µM CuC12 alone and in the presence of 25 - 400 µM H202 had no effect on the form of 
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RANTES detected in the supernatant (lanes 8-11), when compared to the control (no 
CuC12 or H202, lane 7), RANTES remains monomeric. However, high concentrations 
(400 µM) of H202 appear to destroy the RANTES monomer (lane 12). 
It was speculated that if there were any multimers of RANTES formed in the presence 
of 50 pM CuC12 and 25 - 400 pM H202 they may remain bound to glycosaminoglycans 
(GAGs) on the endothelial cell surface, rather than appear free in the supernatant. 
Therefore, endothelial cell lysates were analysed for the presence of RANTES. 
Preliminary experiments indicated that analysis of RANTES in whole cell lysates was 
affected by proteolysis and non-specific binding and very low levels of RANTES were 
recovered. Therefore the lysates were concentrated and RANTES immunoprecipitated 
in the presence of double strength protease inhibitors before analysis by SDS-PAGE 
and Western blotting. 
First, the effect of CuC12 alone on the form of endothelial bound endogenous RANTES 
was investigated. HLMVECs were grown in collagen IV coated 6-well plates in the 
presence of 12.5 - 200 µM CuC12 as previously described in Sections 4.3.2.1 - 4.3.2.3. 
The cells were harvested as described in Section 4.3.2.5 and RANTES 
immunoprecipitated from cell lysates was analysed on 4-15 % gradient gels as 
described in Sections 4.3.2.6 - 4.3.2.8. Gradient gels were used to separate the RANTES 
optimally in the mid-high molecular weight range where it was expected that GAG 
bound RANTES may be detected. 
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Figure 4.2. The effect of Cu on RANTES multimerisation in HLMVECs. Lysates from HLMVECs 
grown in collagen IV coated 6-well plates and incubated for 24 hours in the presence of IFN-y (100 
U/ml) plus TNF-a (10 ng/ml) and a further 24 hours in the presence of 12.5 - 200 µM CuCI2. 
Lysates were freeze-dried from 500 µl, reconstituted in 40 µl lx sample buffer, immunoprecipitated 
for human RANTES, analysed by SDS-PAGE on a 4-15 % gradient polyacrylamide gel and stained 
for RANTES. M: molecular weight markers. Lanes 1-6 show HLMVEC lysates in the presence of 
IFN-y (100 U/ml), TNF-a (10 ng/ml), and in Lane 1: 0 µM CuCI2 (control), lane 2: 12.5 µM CuCI2, 
lane 3: 25 µM CuCl2, lane 4: 50 µM CuC12, lane 5: 100 µM CuC12 and lane 6: 200 µM CuCI2. 
Representative of two independent experiments. 
In the presence of IFN-y (100 U/ml) plus TNF-a (10 ng/ml) and absence of CuC12 
RANTES was detected in HLMVEC lysates predominantly in 32 KDa form, which may 
be tetrameric RANTES. In addition, resistance to SDS and the disulphide reducing 
agent, dithiothreitol (DTT), during immunoprecipitation indicates that the RANTES 
tetramer is covalently linked as shown for recombinant human RANTES (Sections 2.5.1 
and 3.5.2). Using a standard curve (figure 4.3) a high molecular weight form of 
RANTES was detected with an estimated molecular weight of 73-74 KDa (arrowhead, 
figure 4.2, lanes 1-6). This Western blot shows clearly the RANTES stained band at 73- 
74 KDa which may be a RANTES complex or RANTES bound to another protein. 
However, further higher molecular weight complexes of RANTES could be seen 
following over-exposure of the Western blot (not shown). These complexes are seen 
clearly in figures 4.5 and 4.7 which show the results of other experiments. 
CuC12 in the range 12.5 - 200 µM had no effect on the form of RANTES (lanes 2-6) 
compared to the no CuC12 control, (lane 1). However, a dose-dependent increase in the 
amount of tetrameric RANTES was observed (figure 4.2, lanes 2- 6). 
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Figure 4.3. A standard curve of log molecular weight markers plotted against rf value where the rf 
value = distance moved by the protein / total distance moved by the bromophenol blue dye front 
and the RANTES complex had an rf value of 0.53. The RANTES band below the tetramer had an 
rf value of 0.73. 
The rf value of 0.73 correlates to a molecular weight of 30.3 KDa for the RANTES 
band observed below the tetramer. It is likely that despite the presence of protease 
inhibitors upon lysis of the cells, this is a post-translational proteolytically processed 
form of RANTES. 
In order to investigate whether the 73-74 KDa RANTES was a complex with GAGs in 
the cell lysates (figure 4.2), HLMVECs were grown in a collagen IV coated 6-well plate 
as before, stimulated with IFN-y (100 U/ml) plus TNF-a (10 ng/ml) for 24 hours in the 
presence of 12.5 - 200 µM CuC12 and sodium chlorate 
(30 mM) to inhibit 
glycosaminoglycan (GAG) synthesis. The agent inhibits GAG sulphation and has been 
shown to abolish chemokine presentation on the endothelial cell surface (Davies et al, 
2001; Humphries & Silbert, 1988; Humphries et al, 1989; Qiao et al, 2003; Safaiyan et 
al, 1999). 
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Figure 4.4. The effect of sodium chlorate on RANTES multimers in the presence of copper alone. 
HLMVECs were grown in collagen IV coated 6-well plates with 30 mM sodium chlorate and 
incubated for 24 hours in the presence of IFN-y (100 U/ml) plus TNF-a (10 ng/ml) and a further 24 
hours with 12.5 - 200 µM CuC12. Lysates were freeze-dried from 500 µl, reconstituted in 40 µl Ix 
sample buffer, immunoprecipitated for human RANTES, analysed by SDS-PAGE on a 4-15 % 
gradient polyacrylamide gel and stained for RANTES. M: molecular weight markers. Lanes 1-6 
show HLMVEC lysates in the presence of IFN-y (100 U/ml), TNF-a (10 ng/ml), sodium chlorate (30 
mM) and in Lane 1: 0 µM CuC12 (control), lane 2: 12.5 µM CuC12, lane 3: 25 µM CuCl2, lane 4: 50 
µM CuCI2, lane 5: 100 µM CuCI2 and lane 6: 200 µM CuCl2. Representative of two independent 
experiments. 
In the presence of 30 mM sodium chlorate (figure 4.4, lanes 1- 6) the RANTES 
complex (MW 73-74 KDa, figure 4.2) observed following HLMVEC stimulation with 
IFN-y (100 U/ml) plus TNF-a (10 ng/ml) for 1 day was not observed. The result 
suggests that this form of RANTES was bound to a sulphated GAG on the endothelial 
cell surface (figure 4.2), which was not synthesised in the presence of sodium chlorate 
(figure 4.4). The tetrameric form of RANTES remains, and there is an increase in 
expression with increasing CuC12 as previously observed in figure 4.2. 
In the presence of sodium chlorate, RANTES was detected only as a tetramer in cell 
lysates in the absence and presence of CuC12 alone. The effect of CuC12 plus H202 was 
subsequently investigated. HLMVECs were grown in collagen IV coated 6-well plates 
as before and incubated for 24 hours in the presence and IFN--y (100 U/ml) plus TNF-a 
(10 ng/ml) to stimulate RANTES synthesis, and in the presence of 50 µM CuC12 plus 25 
- 400 µM H202. 
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Figure 4.5. The effect of CuCI2 and H202 on RANTES multimers. HLMVECs were grown in 
collagen IV coated 6-well plates and incubated for 24 hours in the presence of IFN-y (100 U/ml) 
plus TNF-a (10 ng/ml), and a further 24 hours in the presence and absence of 50 µM CuC12 and 25 
- 400 pM HZO2, Lysates were freeze-dried from 500 µl, reconstituted in 40 pl lx sample buffer, 
immunoprecipitated for human RANTES, analysed by SDS-PAGE on a 4-15 % gradient 
polyacrylamide gel and stained for RANTES. M: molecular weight markers. Lanes 1-6 show 
HLMVEC lysates in the presence of IFN-y (100 U/ml) plus TNF-a (10 ng/ml) and in Lane 1: 0 µM 
CuCl2 (control), lane 2: 50 µM CuC12, lane 3: 50 µM CuC12 plus 25 µM H202, lane 4: 50 µM CuCI2 
plus 50 µM H202, lane 5: 50 µM CuC12 plus 200 µM H202 and lane 6: 50 µM CuCI2 plus 400 µM 
H202. Representative of two independent experiments. 
H202 (25 - 400 µM) had no effect on the form of RANTES in the presence of 50 µM 
CuC12 (figure 4.5, lanes 2-6) compared to the control (no CuC12 or H202, lane 1). The 
tetramer remained in the presence of 400 µM H202, unlike the monomeric RANTES 
which was destroyed in the supernatant (figure 4.1). This indicates that the tetramer in 
cell lysates is more stable than the monomer in supernatants. 
Another high MW complex was observed that was not due to an effect of CuC12 or 
H202, since it was observed in the control (lane 1). This RANTES complex was 
estimated to be approximately 116 KDa (figure 4.5). This 116 KDa RANTES complex 
is likely to be a HSPG-RANTES complex. In order to investigate further the 116 KDa 
RANTES complex, HLMVECs were grown in a collagen IV coated 6-well plate as 
before, stimulated with IFN-y (100 U/ml) and TNF-a (10 ng/ml) for 1 day in the 
presence of 50 µM CuC12,25 - 400 µM H202 and 30 mM sodium chlorate to inhibit 
glycosaminoglycan (GAG) synthesis. 
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Figure 4.6. The effect of sodium chlorate on higher order forms of RANTES in the presence of 
CuC12 plus H202. HLMVECs were grown in collagen IV coated 6-well plates with sodium chlorate 
(30 mM) , incubated for 24 hours in the presence of IFN-y (100 U/ml) plus TNF-a (10 ng/ml, and a 
further 24 hours in the presence and absence of 50 µM CuC12 and 25 - 400 µM H202" Lysates were freeze-dried from 500 µl, reconstituted in 40 µl Ix sample buffer, immunoprecipitated for human 
RANTES, analysed by SDS-PAGE on a 4-15 % gradient polyacrylamide gel and stained for 
RANTES. M: molecular weight markers. Lanes 1-6 show HLMVEC lysates in the presence of IFN- 
y (100 U/m1 plus TNF-a (10 ng/ml), sodium chlorate (30 mM), and Lane 1: 0 µM CuC12 (control), 
lane 2: 50 µM CuCl2, lane 3: 50 µM CuC12 plus 25 pM H202, lane 4: 50 µM CuCl2 plus 50 pM H202, 
lane 5: 50 µM CuC12 plus 200 µM H202 and lane 6: 50 µM CuCl2 plus 400 µM H202. Representative 
of two independent experiments. 
In the presence of sodium chlorate (30 mM, figure 4.6, lanes 1- 6) the RANTES 
complexes observed following HLMVEC stimulation with IFN-, y (100 U/ml) plus TNF- 
a (10 ng/ml) for 1 day (MW 73-74 KDa and 116 KDa, figure 4.5) were both abolished. 
The result again suggests that RANTES was bound to a protein or a proteoglycan on the 
endothelial cell surface in figure 4.5, which was not synthesised in the presence of 
sodium chlorate in figure 4.6. Again, both CuC12 and H202 had no effect on the form of 
RANTES compared to the control (no CuC12 or H202, lane 1). 
Since added CuC12 and H202 had no effect, and RANTES has so far been detected at a 
minimum MW of 30.3 KDa, it was speculated that there may already be sufficient 
physiological levels of CuC12 and H202 in the endothelial model to induce covalently 
linked tetramer formation, which has been shown to be the form which induces 
leukocyte migration in vivo (Proudfoot, 2006). To investigate this possibility, 
HLMVECs were incubated with IFN-, y (100 U/ml) plus TNF-a (10 ng/ml) for 1 day as 
before, but in the presence of the intracellular copper chelator, neocuproine (NC) and 
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the extracellular copper chelator bathocuproine disodium salt (BCDS), to chelate free 
copper. Copper chelators were added at the seeding of the cells into the collagen IV 
coated 6-well plate for maximum effect. This was 2 days before the addition of IFN-y 
plus TNF-a. 
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Figure 4.7. The effect of copper chelators on RANTES multimers. HLMVECs were grown in 
collagen IV coated 6-well plates in the presence of copper chelators, and incubated for 48 hours in 
the presence of IFN-y (100 U/ml) plus TNF-a (10 ng/ml) and Cu chelators. Lysates were freeze- 
dried from 500 µl, reconstituted in 40 pl lx sample buffer, immunoprecipitated for human 
RANTES, analysed by SDS-PAGE on a 4-15 % gradient polyacrylamide gel and stained for 
RANTES. M: molecular weight markers. Lanes 1-6 show HLMVEC lysates of cells grown in the 
presence of IFN-y (100 U/ml plus TNF-a (10 ng/ml) and Lane 1: no copper chelators (control), lane 
2: 0.1 mM neocuproine, lane 3: 0.5 mM neocuproine, lane 4: 0.1 mM bathocuproine disodium salt, 
lane 5: 0.5 mM bathocuproine disodium salt and lane 6: 0.5 mM neocuproine plus 0.5 mM 
bathocuproine disodium salt. Representative of two independent experiments. 
NC (0.1 and 0.5 mM) had no effect on the tetrameric (32 KDa) or complexed form of 
RANTES (figure 4.7, lanes 2 and 3) compared to the control (no copper chelators, lane 
1). In addition to the RANTES complex observed at 73-74 KDa, another RANTES 
complex was observed that was not due to the presence of copper chelators, since it 
appears in the control (lane 1) and the RANTES complex had an rf value of 0.6. The 
complex was estimated to be approximately 64 KDa, calculated using a standard curve 
(figure 4.8). 
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Figure 4.8. Standard curve of log molecular weight markers plotted against rf value. 
The 64 KDa complex was diminished in a dose-dependent manner following treatment 
with the extracellular copper chelator, BCDS (0.1 - 0.5 mM) (figure 4.7, lanes 4-5). A 
combination of NC (0.5 mM) and BCDS (0.5 mM) also resulted in attenuation of the 64 
KDa complex (lane 6), but this was only attributed to the effect of BCDS (0.5 mM), 
since NC (0.5 mM) had no effect alone (lane 3). While it appears that the 73/74-116 
KDa bands may be RANTES bound to GAGs, the 64 KDa band may be a RANTES 
dimer bound to duffy antigen receptor complex (DARC). 
RANTES was observed predominantly in tetrameric form (figures 4.2,4.4 4.5 4.6 and 
4.7). It was proposed that the tetramer may have been non-covalently bound to a GAG, 
and that the denaturing of the samples abolishes the GAG-RANTES interaction with the 
subsequent release of the tetramer. One suggestion was that dithiothreitol (DTT), a 
reagent which reduces disulfides, may have caused this denaturing during recovery of 
the immunoprecipitated proteins. Therefore, the recovery was performed in the absence 
and presence of DTT, with boiling at 95 °C for 5 minutes used as an alternative to DTT 
for the release of the RANTES from the agarose beads following immunoprecipitation. 
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Figure 4.9. The effect of DTT on the form of RANTES. HLMVECs were grown in collagen IV 
coated 6-well plates in the absence and presence of sodium chlorate (30 mM) and incubated for 24 
hours in the presence of IFN-y (100 U/ml) plus TNF-a (10 ng/ml). Lysates were freeze-dried from 
500 µl, reconstituted in 40 pl lx sample buffer, immunoprecipitated for human RANTES in the 
absence of DTT with boiling at 95 °C for 5 minutes or in the presence of DTT (100 µM) for 30 
minutes, analysed by SDS-PAGE on a 4-15 % gradient polyacrylamide gel and stained for 
RANTES. M: molecular weight markers. Lanes 1-4 show HLMVEC lysates of cells grown in the 
presence of IFN-y (100 U/ml plus TNF-a (10 ng/ml) and Lane 1: 30 mM sodium chlorate and 
immunoprecipitation in the absence of DTT, lane 2: 30 mM sodium chlorate with 
immunoprecipitation in the presence DTT, lane 3: immunoprecipitation in the absence of DTT, 
lane 4: immunoprecipitation in the presence of DTT. Representative of two independent 
experiments. 
In the presence of sodium chlorate (30 mM, figure 4.9, lanes 1- 2) the high MW 
RANTES complexes observed following HLMVEC stimulation with IFN-y (100 U/ml) 
plus TNF-a (10 ng/ml) for 1 day (MW 73-74 KDa and 116 KDa, lanes 3 and 4) were 
both abolished. Again, the results (lanes 3 and 4) suggest that RANTES was bound to a 
protein or a proteoglycan on the endothelial cell surface, which was not synthesised in 
the presence of sodium chlorate (lanes 1 and 2). The 30.3 KDa post-translational 
proteolytically processed form of RANTES was observed in the presence (lanes 1 and 
2), but not the absence (lanes 3 and 4) of sodium chlorate, indicating that the inhibition 
of GAG synthesis by sodium chlorate also leads to a reduced protective effect against 
proteolytic degradation. In addition, the presence of DTT (lane 4) had no effect on the 
form of RANTES recovered compared to the absence of DTT (lane 3) which was found 
to be predominantly tetrameric. 
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Subsequent experiments investigated the concentration of RANTES synthesised by 
HLMVECs in response to CuCl2, as measured by ELISA. HLMVECs were cultured as 
described in Section 4.3.2. 
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Figure 4.10. RANTES released into supernatants in response to CuC12. RANTES was measured in 
supernatants (1500 µl) from HLMVECs grown on collagen IV coated 6-well plates and incubated 
for 24 hours with IFN-y (100 U/ml) plus TNF-a (10 ng/ml) and a further 24 hours with CuC12 (12.5 
- 200 µM). RANTES was quantified by ELISA. Results are represented as mean ± SEM (* p<0.05, 
** p<0.01 compared to the no Cu control, n= 4), data were compared using a 1-way ANOVA 
followed by a Dunnett's post-hoc test. 
The addition of CuC12 in the range 12.5 - 25 µM resulted in a significant dose- 
dependent increase in RANTES synthesis and release into the HLMVEC supernatant as 
detected by ELISA (figure 4.10). The greatest increase (p < 0.01) in RANTES release 
was detected in the presence of 25 µM CuC12 (3189.8 + 124.4 pg/ml) compared to the 
no CuC12 control (2508.3 + 58.1). The effect was biphasic with another significant dose- 
dependent increase (p < 0.05) in RANTES synthesis and release in the presence of 200 
µM CuC12 (2993.6 ± 35.8 pg/ml). 
The concentration of RANTES in HLMVEC lysates was also measured by ELISA 
(figure 4.11). 
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Figure 4.11. RANTES synthesis by HLMVECs in response to CuCl2. RANTES was measured in 
lysates (500 µl) from HLMVECs were grown on collagen IV coated 6-well plates and incubated for 
24 hours with IFN-y (100 U/ml) plus TNF-a (10 ng/ml) and a further 24 hours with CuCI2 (12.5 - 
200 µM) for 1 day. Values are adjusted for relative volumes (i. e. 500/1500 µl) for comparison with 
the amount of RANTES measured in supernatants. Results are represented as mean ± SEM (n =3- 
4), data were compared using a 1-way ANOVA followed by a Dunnett's post-hoc test. 
The addition of CuC12 in the range 12.5 - 25 µM resulted in a dose-dependent increase 
in RANTES synthesis as detected by ELISA. A non-significant increase in RANTES 
was detected in the lysates (figure 4.11) at 25 µM CuC12 (709.2 + 168.6 pg/ml) 
compared to the no CuC12 control (369.9 ± 95). At 50 µM CuC12 the RANTES 
concentration fell to 220.1 + 41.4 pg/ml), with another dose-dependent increase in 
RANTES synthesis and release from 50 - 200 µM CuCl2 to levels not significantly 
different to the control. The levels of RANTES detected in the lysates (figure 4.11) 
were lower than those detected in the supernatants (figure 4.10). RANTES was detected 
at 369.9 + 95 pg/ml in the HLMVEC lysate control (0 µM CuCl2,500 µl) compared to 
2508.3 + 58.1 pg/ml in the HLMVEC supernatant control (0 µM CuCl2,1500 µl). The 
result suggests that under the incubation conditions more RANTES is released into the 
supernatant than is bound to the endothelial cell surface. 
Subsequently, the effect of H202 together with 50 µM CuC12 on the concentration of 
RANTES in HLMVEC supernatants and lysates was investigated. 
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Figure 4.12. RANTES released into supernatants in the presence of CuCI2 plus H202. RANTES was 
measured in supernatants from HLMVECs grown on collagen IV coated 6-well plates and 
incubated for 24 hours with IFN-y (100 U/ml) plus TNF-a (10 ng/ml) and a further 24 hours with 
the addition of CuCl2 (50 µM) Plus H202 (50 - 400 µM). The experiment was carried out in the 
absence (Q) and in the presence (L of sodium chlorate (30 mM). RANTES was quantified by 
ELISA. Results are represented as mean ± SEM (n = 3), data were compared using a 2-way 
ANOVA followed by a Tukey's post-hoc test. 
As seen in these experiments (figure 4.12) 50 µM CuC12 had no effect on RANTES 
levels in supernatants as previously shown (figure 4.10). Additionally, there was no 
significant difference in RANTES release into HLMVEC supernatants following 
treatment with 50 - 400 µM H202 in the presence of 50 µM CuCl2 compared to the 
control (EGM-2MV growth medium). The addition of sodium chlorate also had no 
effect, which was unexpected. 
To confirm an effect of chlorate on GAG synthesis under these conditions, the effect of 
CuC12 plus H202 on lipid peroxidation was investigated. HLMVECs were grown as 
before, in collagen IV coated 6-well plates and incubated in the presence of IFN-y (100 
U/ml) plus TNF-a (10 ng/ml) to stimulate RANTES synthesis, in the presence of 50 µM 
CuC12 plus 50 - 400 µM H202 and in the absence and presence of sodium chlorate. Cell 
lysates were analysed for lipid peroxides using a quantitative FOX-2 assay kit. 
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Figure 4.13. Lipid peroxides measured in lysates in the presence of CuCI2 Plus HZO2. HLMVECs 
were grown in collagen IV coated 6-well plates and incubated for 24 hours with IFN-y (100 U/ml) 
plus TNF-a (10 ng/ml) and a further 24 hours with the addition of CuCI2 (50 µM) plus H202 (50 - 
400 µM) in the absence ([-ý) and in the presence of sodium chlorate (30 mM) (s). Lipid peroxides 
were quantified by FOX-2 assay. Results are represented as mean ± SEM (*** p<0.001 and ** p< 
0.01 (2-way ANOVA, Tukey's post-hoc test), n= 4). 
There was no significant difference in lipid peroxide measured in HLMVEC 
supernatants following treatment with 50 - 400 µM H202 in the presence of 50 µM 
CuC12 compared to the control (EGM-2MV growth medium) either in the presence or 
absence of sodium chlorate (figure 4.13). However, in the presence of sodium chlorate 
(30 mM), there was a significant increase in lipid peroxides under all conditions tested. 
The maximum increase in lipid peroxides occurred in the EGM-2MV control group 
(increase from 238.7 + 58.6 µM in the absence of sodium chlorate to 1037.2 + 101.3 
µM in the presence of sodium chlorate, p<0.001). 
4.5.2. Platelets 
Initial experiments quantified RANTES release by thrombin-stimulated normal platelets 
using ELISA. Platelets were isolated and incubated as described in Section 4.3.4. 
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Figure 4.14. RANTES release by thrombin-activated platelets. RANTES was measured in 
supernatants (250 µl) from isolated platelets diluted to 107/ml (Q), 5x 107/mI (Q) and 108/ml (Q) 
and incubated in an uncoated 24-well plate for 1 hour with 0.5 -2 U/ml thrombin. Results are 
represented as mean ± SEM (2-way ANOVA, Tukey's post-hoc test, n= 5). 
An increase in RANTES release into supernatants was observed with increasing 
concentrations of thrombin (figure 4.14). Concentrations were significantly higher than 
unstimulated control values at 2 U/ml at platelet concentrations 107 (increase from 
200.3 + 47.5 to 330.3 + 110.6), 5x 107 (increase from 276.7 + 139.1 to 422.9 ± 361.1 
pg/ml (p < 0.05)) and 108/ml (increase from 306.1 ± 236.3 to 489 + 357.9 pg/ml (p < 
0.01)). The increase in RANTES release in response to thrombin therefore appears to be 
dose-dependent. There was no significant increase in RANTES concentration as the 
platelet concentration was increased from 107 through to 108/ml at all concentrations of 
thrombin. The data suggests that RANTES is released spontaneously from platelets and 
in response to thrombin, but that there is a limiting factor at high cell density. 
To determine the form of platelet-derived RANTES, isolated platelets were suspended 
at 108/ml and cultured in an uncoated 6-well plate for 1 hour in the presence of 
thrombin (1 U/ml). For comparison, HLMVECs were grown on collagen IV coated 6- 
well plates and incubated in the presence and absence of thrombin. The form of 
RANTES in platelet supernatants was analysed by SDS-PAGE on a 14 % 
polyacrylamide gel and Western blotting. 
211 
Figure 4.15. Platelet-derived RANTES. Platelets (108/ml) were incubated in a 6-well plate (lanes I 
and 2) for 1 hour in the presence and absence of IFN-y (100 U/ml) plus TNF-a (10 ng/ml) and in the 
presence of thrombin (1 U/ml). Supernatants were freeze-dried from 1500 µl, reconstituted in 40 pl 
lx sample buffer, analysed by SDS-PAGE on a 14 % polyacrylamide gel and stained for RANTES. 
M: molecular weight markers. Lane 1: isolated platelets in the presence of thrombin and lane 2: 
isolated platelets in the presence of IFN-y plus TNF-a and thrombin. Representative of two 
independent experiments. 
In the presence of thrombin (1 U/ml), platelet-derived RANTES was monomeric (figure 
4.15, lane 1). IFN-y (100 U/ml) plus TNF-a (10 ng/ml) had no effect on the form of 
RANTES released by thrombin stimulated platelets (lane 2), which remained 
monomeric. The results indicate that platelets release monomeric RANTES following 
stimulation with thrombin (1 U/ml), (figure 4.15). 
Whilst platelet and HLMVEC-derived RANTES has separately been determined by 
ELISA, the extent of RANTES release when platelets and HLMVECs are cocultured 
together was not known. To investigate the contribution of each, HLMVECs and 
platelets were cultured alone and together in the presence and absence of IFN--y (100 
U/ml) plus TNF-a (10 ng/ml) and thrombin (1 U/ml). RANTES was quantified by 
ELISA in both supernatants and cell lysates, which were prepared as previously 
described (Section 4.3.5). 
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Figure 4.16. HLMVEC and platelet-derived RANTES release in supernatants from co-cultures. 
RANTES was measured in supernatants from isolated platelets (108/ml) and HLMVECs co- 
cultured in collagen IV coated 6-well plates. HLMVECs were incubated for 1 day in the presence 
and absence of IFN-y (100 U/ml), TNF-a (10 ng/ml) and following incubation, platelets and 
thrombin (1 U/ml) were added to the wells for 1 hour. Supernatants (1500 µl) were analysed by 
ELISA. EC: endothelial cells, P: platelets (108/ml). Results are represented as mean ± SEM (*** p< 
0.001, ** p< 0.01 compared to EC control). Data was compared using a 1-way ANOVA and Tukey's 
post-hoc test, n= 5). 
HLMVEC activation with IFN-y plus TNF-a significantly (p < 0.01) increased 
RANTES release into supernatants in the absence of platelets (from 18.7 + 8.4 in the 
control (endothelial cells only) to 694.4 + 264.5 pg/well. Reduced levels of RANTES in 
the presence of platelets and activated HLMVECs suggests either that the platelets are 
binding RANTES synthesised by the endothelial cells, or that the addition of platelets 
results in increased binding of RANTES to the endothelium thus removing it from the 
supernatant. 
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RANTES was also measured in HLMVEC lysates. 
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Figure 4.17. HLMVEC and platelet-derived RANTES in lysates from co-cultures. RANTES was 
measured in lysates (500 µl) from isolated platelets (108/ml) and HLMVECs co-cultured in a 
collagen IV coated 6-well plate. HLMVECs were incubated for 1 day in the presence and absence of 
IFN-7 (100 U/ml), TNF-a (10 ng/ml). Following incubation, platelets and thrombin (1 U/ml) were 
added to the wells for 1 hour. Values are adjusted for relative volumes (i. e. 500/1500 µl) for 
comparison with the amount of RANTES measured in supernatants. Lysates were analysed by 
RANTES ELISA. EC: endothelial cells, P: platelets (108/m1). Results are represented as mean ± 
SEM (** p<0.01). Data was compared using a 1-way ANOVA and Tukey's post-hoc test, n= 3). 
Treatment with IFN--y plus TNF-a increased RANTES in HLMVEC lysates in the 
presence and absence of platelets but the effect was not significant compared to 
HLMVECs alone as a control (figure 4.17). The presence of unactivated platelets also 
did not significantly increase the amount of RANTES in the activated endothelium. 
However, the addition of thrombin activated platelets to HLMVECs activated with IFN- 
y plus TNF-a results in a significant increase in endothelial RANTES (from 238.3 ± 
105.1 to 1035.8 ± 168.5 pg/well (p < 0.01) indicating a requirement for thrombin 
activated platelets for RANTES binding to the activated endothelium. 
The results indicate that in both the supernatants and lysates, RANTES is measured at 
the highest concentrations in the presence of activated HLMVECs and platelets. In 
addition, under these conditions there appears to be more RANTES bound to the 
endothelium than free in the supernatant (1035.8 ± 168.5 pg/well bound compared to 
753.6 ± 213.7 pg/well free in the supernatant). 
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4.5.3. T-cells 
In order to quantify RANTES release by T-cells, T-cells were isolated, activated with 
PHA and IL-2 as described in Section 4.3.3.2 and cultured in a 24-well uncoated plate 
at 1x 106/ml, 5x 106/ml and 1x 107/ml in the absence and presence of IFN-y (100 
U/ml) plus TNF-a (10 ng/ml) for 4 hours -2 days. Supernatants were harvested and 
analysed by RANTES ELISA. 
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Figure 4.18. RANTES released into T-cell supernatants. T-cells (2 x 106/ml) were cultured in a 24- 
well uncoated plate (250 µl/well) following incubation with IFN-y (100 U/ml) plus TNF-a (10 ng/ml) 
for 4 hours C]), 1 day ) and 2 days C). Results are represented as mean ± SEM, n=3. 
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Figure 4.19. RANTES released into T-cell supernatants. T-cells (5 x 106/ml) were cultured in a 24- 
well uncoated plate (250 µl/well) following incubation with IFN-y (100 U/ml) plus TNF-a (10 ng/ml) 
for 4 hours (E]), 1 day ) and 2 days C). Results are represented as mean ± SEM, n=3. 
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Figure 4.20. RANTES released into T-cell supernatants. T-cells (1 x 107/ml) were cultured in a 24- 
well uncoated plate (250 pl/well) following incubation with IFN-y (100 U/ml) plus TNF-u (10 ng/ml) 
for 4 hours ([: ]), I day ) and 2 days Cj). Results are represented as mean ± SEM, n=3. 
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There was no significant effect of IFN-y (100 U/ml) plus TNF-u (10 ng/ml) stimulation 
and no significant time-dependent increase in RANTES release at any T-cell density 
(figures 4.18-4.20). 
4.5.4. T-cell migration assays 
The activity of RANTES multimers in assays of T-cell migration was initially 
determined using Boyden chambers. The optimum assay incubation time and RANTES 
concentration was established by adding fresh recombinant RANTES (in the absence of 
CuC12 and H202) to the lower wells, activated T-cells to the upper wells and incubating 
for 1-4 hours at 37 °C. 
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Figure 4.21. The timecourse and dose-response curve for RANTES-induced T-cell migration in 
Boyden Chambers. The response of T-cells to recombinant human RANTES (1.25 - 500 ng/ml (1.56 
x 10"10 M-6.25 x 10-8 M)) in HBSS + 20 mM HEPES, pH 7.4 was investigated. T-cells were 
activated for 2 days with PHA (1 µg/ml) and 3 days with IL-2 (200 U/ml) and added to the upper 
wells of a Boyden chamber (2 x 106/ml in HBSS + 20 mM HEPES, pH 7.4). Recombinant RANTES 
was added to the lower wells, and the chambers were incubated for 1(U), 2 (0), 3 (0) and 4 (®) 
hours. Results are represented as the mean number of cells/hpf. Results are from a single 
experiment. 
Figure 4.21 shows that maximum T-cell migration occurred following 2 hours 
incubation and in response to a concentration of 125 ng/ml (1.56 x 10-8 M) RANTES 
(47.2 cells/hpf). RANTES stimulated a maximum increase in T-cell migration from 12 
(spontaneous migration) to 47.2 T-cells/hpf following 2 hours incubation, indicating the 
most appropriate RANTES concentration and time for sensitive assay of RANTES- 
induced T-cell migration in Boyden chambers. After 3-4 hours, T-cells had begun to 
die, confirmed by the uptake of Trypan blue by T-cells from the lower chambers 
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analysed by cytospin (data not shown). This reflects the lower numbers of migrated 
cells at these timepoints. 
Migration of T-cells over 2 hours was measured using multiple T-cell donors and due to 
donor variability, the results normalised to the response observed for 125 ng/ml 
RANTES which was designated as 100 % response. 
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Figure 4.22. RANTES-induced T-cell migration. The response of T-cells to recombinant human 
RANTES (15 - 500 ng/ml (1.88 x 10-9 M-6.25 x 10"8 M)) in HBSS + 20 mM HEPES, pH 7.4 was 
measured. T-cells were activated as before and added to the upper wells of a Boyden chamber. 
Recombinant RANTES was added to the lower wells and the chamber was incubated for 2 hours. 
Following incubation, migrated cells were stained and counted as before. Results are presented as 
the mean number of cells/hpf. The results were normalised to the maximum migration at 125 ng/ml 
(151.3 ± 43.8 T-cells/hpf, ) which was designated as 100 %. Results represent mean ± SEM, and were 
compared using a 1-way ANOVA and Dunnett's post-hoc test (control =0 ng/ml RANTES, *p < 
0.05, ** p<0.01 compared to the no RANTES control, n= 6). 
Maximum migration occurred at 125 ng/ml RANTES (151.3 ± 43.8 T-cells/hpf, 100 
p<0.01), compared to the control (14.5 ± 3.1 %, figure 4.22). 
The activity of RANTES multimers in T-cell migration assays was then investigated. 
Recombinant RANTES was incubated for 2 days in the presence and absence of CuC12 
(50 µM) and H202 (25 µM) (as described in Chapter 2, Section 2.3.1) to induce 
RANTES multimerisation, diluted to 125 ng/ml (1.56 x 10-1 M), and used in a T-cell 
migration assay. 
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Figure 4.23. T-cell migration induced by RANTES multimerised in the presence of CuCI2 Plus 
H202. The response of T-cells to recombinant human RANTES (125 ng/ml (1.56 x 10-8 M) was 
measured in the presence of CuC12 and H202. RANTES (5 x 10-7 M in PBS -Caz+/Mg2) was 
incubated for 2 days in the presence and absence of 50 pM CuC12 and 25 pM H202 and diluted to 
125 ng/ml in RPMI/0.1 % (w/v) BSA. T-cells were activated as before and added to the upper wells 
of a Boyden chamber. RANTES multimers were added to the lower wells and the chamber was 
incubated for 2 hours. Following incubation, migrated cells were stained and counted as before. 
Results are presented as mean number of cells/hpf. The results were normalised to the positive 
control (fresh/unincubated RANTES at 125 ng/ml (150.8 ± 39.4 T-cells/hpf) which was designated 
as 100 %. Results represent mean ± SEM, and data was compared using a 1-way ANOVA and 
Tukey's post-Iioc test (*** p<0.001 compared to the RPMI/BSA control, n= 5). 
RANTES multimers generated in the presence of CuC12 and H202 over 2 days were 
shown to be chemotactically active, inducing 100 % migration compared to the 
RPMI/0.1 % (w/v) BSA control (19.3 + 6.7 % migration, p<0.001). RANTES 
multimers were chemotactically as active (100 + 19.9 %) as the fresh un-incubated 
RANTES control (100 %, figure 4.23). There was no observed difference between the 
chemoattractant activity of fresh un-incubated RANTES (100 % migration) and 
incubated RANTES in the absence of CuC12 and H202 (96.8 + 36 % migration). In 
addition, CuC12 and H202 alone neither induced nor attenuated T-cell migration 
compared to the RPMI/0.1 % BSA control (22.2 + 7.5 % migration). 
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Although Thl and Th2 T-cells both signal through CCR1 in response to RANTES, 
RANTES recruits Thl T-cells through CCR5 and Th2 T-cells through CCR3 receptors. 
In addition, CD8+ cytotoxic T-cells also express CCR-1 and CCR-3, and CCR-1 and 
CCR-5 receptors on Tc type-1 and Tc type-2 cytotoxic T-cells respectively 
(D'Ambrosio et al, 1998; Sallusto et al, 1998a). To determine which T-cells responded 
to RANTES, it was necessary to determine which receptors were involved. T-cell 
migration experiments were therefore conducted in the absence and presence of 100 
µg/ml anti-CCR3 and anti CCR5 antibodies. Antibodies were added to both to the upper 
and lower wells 30 minutes prior to transmigration experiments. Initially, T-cell 
responses to fresh, un-incubated RANTES were investigated in the absence and 
presence of anti-CCR3 or anti-CCR5 antibodies. 
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Figure 4.24. The effect of CCR3 and CCR5 neutralising antibodies on RANTES-induced T-cell 
migration. The response of T-cells to fresh recombinant human RANTES (0) (125 ng/ml (1.56 x 10- 
8 M) was measured in the presence of 100 pg/ml anti-CCR3 (Q) and anti-CCR5 (®) antibodies. T- 
cells were activated as before and incubated for 30 minutes with anti-CCR3 or anti-CCR5 
antibodies before they were added to the upper wells of a Boyden chamber. RANTES was 
incubated for 30 minutes with anti-CCR3/5 antibodies before adding to the lower wells and the 
chamber was incubated for 2 hours. Following incubation, migrated cells were stained and counted 
as before. Results are presented as the mean number of cells/hpf. Results are the mean of two 
independent experiments. 
Maximum T-cell migration occurred, as before, in response to 125 ng/ml RANTES 
(134 T-cells/hpf, figure 4.24). The addition of anti-CCR3 antibody (100 µg/ml) resulted 
in a 50.1 % reduction in T-cell migration (reduction from 134 to 66.8 T-cells/hpf). 
Similarly, the addition of anti-CCR5 antibody (100 µg/ml) resulted in a 56.5 % 
reduction in T-cell migration (reduction from 134 to 58.3 T-cells/hpf). The results 
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suggest that both CCR3 (CD4+, Th2 and CD8+ Tc2) and CCR5 bearing T-cells (CD4+ 
Thl, and CD8+ Tcl) may be involved in the response to fresh/unincubated RANTES 
(125 ng/ml). The results also show that there was an equal response of T-cells 
expressing either CCR3 or CCR5 receptors. 
Figure 4.25 shows the effect of anti-CCR3 and anti-CCR5 antibodies on the responses 
of T-cells from different donors to fresh, unincubated RANTES at an optimum 
concentration, and also compares the effect of isotype control antibodies. 
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Figure 4.25. The effect of CCR3 and CCR5 neutralising antibodies on RANTES-induced T-cell 
migration. The response of T-cells to fresh recombinant human RANTES (125 ng/ml (1.56 x 10-8 M) 
was measured in the absence and presence of 100 gg/ml anti-CCR3, anti-CCR5, rat IgG2a isotype 
control and mouse IgG2b isotype control antibodies. T-cells were activated as before and incubated 
for 30 minutes with anti-CCR3, anti-CCR5 (n = 4) or isotype control antibodies (n = 2) before they 
were added to the upper wells of a Boyden chamber. RANTES was incubated for 30 minutes with 
anti-CCR3, anti-CCR5 or isotype control antibodies before adding to the lower wells and the 
chamber was incubated for 2 hours. Following incubation, migrated cells were stained and counted 
as before. Results are represented as the mean number of cells/hpf. Results are presented as mean ± 
SEM, and were compared using a 1-way ANOVA and Tukey's post-hoc test (* p<0.05 compared to 
RANTES control, n= 4). 
A concentration of 125 ng/ml RANTES induced a T-cell response of 130.2 t 38.5 
cells/hpf (figure 4.25). The addition of anti-CCR3 (100 µg/ml) caused a 56.3 + 4.2 % 
reduction in T-cell migration to 60.4 f 21.6 T-cells/hpf (p < 0.05). The cells that did not 
migrate were attributed to CCR3 bearing T-cells. The addition of anti-CCR5 (100 
µg/ml) caused a 53.3 + 3.3 % reduction in T-cell migration to 58.7 + 15.6 T-cells/hpf (p 
< 0.05) and the T-cells that did not migrate can be attributed to CCR5 bearing T-cells. 
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Since the isotype controls had no effect on T-cell migration, the results suggest that two 
T-cell populations are responding to fresh RANTES through CCR3 and CCRS 
receptors. 
To determine whether RANTES multimers stimulate a response through CCR3 or 
CCR5 bearing T-cells, RANTES multimers were generated in the presence of CuC12 (50 
µM) and H202 (25 µM), and used in T-cell migration assays in the absence and presence 
of anti-CCR3 and anti-CCR5 antibodies. 
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Figure 4.26. The effect of CCR3 and CCR5 neutralising antibodies on RANTES multimer-induced 
T-cell migration. The response of T-cells to RANTES multimers (0) (125 ng/ml (1.56 x 10-8 M) was 
measured in the presence of 100 µg/ml anti-CCR3 (Q) and anti-CCR5 (®) antibodies. T-cells were 
activated as before and incubated for 30 minutes with anti-CCR3 and anti-CCR5 antibodies before 
they were added to the upper wells of a Boyden chamber. RANTES multimers were generated by 2 
day incubation in the presence of 50 pM CuC12 and 25 pM H202 and incubated for 30 minutes with 
anti-CCR3 and anti-CCRS antibodies before adding to the lower wells and the chamber was 
incubated for 2 hours. Following incubation, migrated cells were stained and counted as before. 
Results are presented as the mean number of cells/hpf. Results represent the mean of two 
independent experiments. 
Maximum T-cell migration occurred, as before, in response to 125 ng/ml RANTES 
multimers (78.9 T-cells/hpf, figure 4.26). The addition of anti-CCR3 antibody (100 
µg/ml) resulted in a 58.4 % reduction in T-cell migration to 32.8 T-cells/hpf. Similarly, 
the addition of anti-CCR5 antibody (100 µg/ml) resulted in a 64 % reduction in T-cell 
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migration to 28.4 T-cells/hpf. The results suggest that T-cells are responding to 
RANTES multimers (125 ng/ml) through both CCR3 and CCR5 receptors. 
Figure 4.27 shows the effect of anti-CCR3 and anti-CCR5 antibodies on the response of 
T-cells from different donors to RANTES multimers, and compares the effect of isotype 
control antibodies. 
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Figure 4.27. The effect of CCR3 and CCR5 neutralising antibodies on RANTES multimer-induced 
T-cell migration The response of T-cells to RANTES multimers (125 ng/ml (1.56 x 10-8 M) was 
measured in the presence of 100 µg/ml anti-CCR3, anti-CCR5, rat IgG2a isotype control and mouse 
IgG2b isotype control antibodies. T-cells were activated as before and incubated for 30 minutes 
with anti-CCR3/5 or isotype control antibodies before they were added to the upper wells of a 
Boyden chamber. RANTES multimers were generated by 2 day incubation in the presence of 50 
µM CuCI2 and 25 pM H202 and incubated for 30 minutes with anti-CCR3, anti-CCR5 (n = 4) or 
isotype control antibodies (n = 2) before adding to the lower wells and the chamber was incubated 
for 2 hours. Following incubation, migrated cells were stained and counted as before. Results are 
presented as the mean number of cells/hpf. Results represent mean ± SEM, and were compared 
using a 1-way ANOVA and Tukey's post-hoc test (** p<0.01 compared to RANTES control, n= 4). 
A concentration of 125 ng/ml RANTES caused a T-cell response of 90.8 + 21.5 
cells/hpf (figure 4.27). The addition of anti-CCR3 (100 µg/ml) caused a 66.3 + 5.5 % 
reduction in T-cell migration to 32.9 ± 11.1 T-cells/hpf (p < 0.01). The cells that did not 
migrate were attributed to CCR3 bearing T-cells. The addition of anti-CCR5 (100 
µg/ml) caused a 70.6 ± 7.04 % reduction in T-cell migration to 30.6 + 12.4 T-cells/hpf 
(p < 0.01). The cells that did not migrate were attributed to CCR5 bearing T-cells. Since 
the isotype controls had no effect on T-cell migration, the results suggest that T-cells are 
responding to RANTES multimers through both CCR3 and CCR5 receptors. 
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4.5.5. RANTES-induced T-cell transendothelial migration. 
It has been shown by others that RANTES has a minimal tetrameric quaternary 
structure for cell attractant activity in vivo and that both the monomeric and dimeric 
forms of RANTES are devoid of chemotactic activity in vivo (Czaplewski et al, 1999; 
Proudfoot et al, 2003). Since it appears that CuC12 is important for RANTES multimer 
formation in vitro, it is possible that copper is required under physiological conditions 
for T-cell recruitment and accumulation during inflammation. 
The effect of copper chelators on T-cell migration in response to RANTES was 
investigated in transendothelial migration (TEM) assays, a physiological model of the 
vascular endothelium. HLMVECs were seeded and grown on polyethylene 
terephthalate (PET) 3 µm uncoated Transwell culture inserts for 2 weeks. After 2 weeks 
the cells were confluent. 
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Figure 4.28A and B. 
A: HLMVECs grown on polyethylene terephthalate (PET) 3 µm uncoated Transwell culture 
inserts, stained with Hema-Gurr stain and photographed after 2 weeks at x200 magnification on a 
light microscope. 
B: HLMVECs grown on polyethylene terephthalate (PET) 3 µm uncoated Transwell culture 
inserts, stained with Hema-Gurr stain and photographed after 2 weeks at x400 magnification on a 
light microscope. 
Figure 4.28A shows confluent HLMVECs grown for 2 weeks on PET 3 µm uncoated 
Transwell culture inserts at x200 magnification. Figure 4.28B shows the same cells at 
x400 magnification. The photographs show that the cells were confluent after 2 weeks 
of culture, and ready to use in a transmigration assay. 
Air 
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Initially, to find the best endothelial model, HLMVECs were seeded and grown for 2 
weeks on both fibronectin coated and uncoated 3µm PET membranes. The T-cell 
response to both endogenous RANTES synthesised by IFN-y plus TNF-a activated 
endothelium and exogenously added recombinant RANTES was investigated. 
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Figure 4.29. Transendothelial migration of activated T-cells in response to endogenous RANTES 
and recombinant RANTES. HLMVECs were grown on uncoated (M) and fibronectin coated 1) 3 
µm PET membranes for 2 weeks. To induce endogenous RANTES synthesis, HLMVECs were 
stimulated with IFN-y (100 U/ml) plus TNF-a (10 ng/ml) 1 day before the transendothelial 
migration assay. Recombinant RANTES was added to the medium in the basal wells (800 µl) 30 
minutes before the assay. Activated T-cells (2 x 106/ml) were added to the apical wells (300 µl), and 
plates were incubated for 5 hours. Following incubation, migrated cells were removed and counted 
using a haemocytometer. Results are represented as mean ± SEM, n=3. Data was compared using 
a 1-way ANOVA and Dunnett's post-hoc test (control = RPMU10 % FCS, ** p<0.01). 
Endogenous RANTES synthesised by endothelial cells in response to IFN-'y (100 U/ml) 
and TNF-a (10 ng/ml) did not induce significant T-cell migration (figure 4.29), despite 
the evidence that IFN-y plus TNF-a induces HLMVEC RANTES synthesis (Section 
4.5.1, figures 4.1,4.16 and 4.17. ) The addition of recombinant RANTES (125 ng/ml) 
below the endothelial monolayer induced a significant increase in T-cell migration 
across endothelium grown on uncoated 3 µm PET membranes compared to the 
RPMI/10 % FCS control (increase from 7.2 + 3.9 % to 20.1 + 5.5 % of the total T-cells 
added at the start of the assay, p<0.01). There was no significant migration across 
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Control (RPMI / 10 % FCS) IFN (100 U/ml) /TNF (10 ng/ml) RANTES (125 ng/ml (1.56 x 
10E-8 M)) 
endothelial monolayers grown on fibronectin coated 3 µm PET membranes in response 
to recombinant RANTES. 
Platelets added to the lower well were activated with 1 U/ml thrombin, which had 
previously been shown to induce significant RANTES release (Section 4.5.2, figure 
4.16). Platelets with 1 U/ml thrombin were added to either apical or basal wells, 30 
minutes before the TEM assay. 
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Figure 4.30. Transendothelial migration of activated T-cells in response to endogenous RANTES 
and platelet derived RANTES. HLMVECs were grown on uncoated 3 µm PET membranes for 2 
weeks. To induce endogenous RANTES synthesis, where indicated, HLMVECs were stimulated 
with IFN-y (100 U/ml) plus TNF-a (10 ng/ml) 1 day before the transendothelial migration assay. 
Isolated platelets (108/ml) were activated with 1 U/ml thrombin and then immediately added to the 
basal wells (800 µl) 30 minutes before the assay. Activated T-cells (2 x 106/ml) were added to the 
apical wells (300 µl), and plates were incubated for 5 hours. Following incubation, migrated cells 
were removed and counted using a haemocytometer. Anti-RANTES (10 µg/ml) was added to T-cells 
and basal wells at the start of the assay. Results are represented as mean f SEM, n=3. Data was 
compared using a 1-way ANOVA and Tukey's post-hoc test, *p<0.05, ** p<0.01 and *** p< 
0.001. 
The addition of anti-RANTES antibody caused a significant (p < 0.05) reduction in 
spontaneous T-cell migration in the control from 9.56 + 2.2 % to 2.2 + 0.6 % which 
indicated constitutive RANTES expression. In response to IFN--y plus TNF-a stimulated 
RANTES synthesis, T-cell migration was not significantly increased, as also seen in 
figure 4.29. However, the anti-RANTES antibody significantly (p < 0.05) reduced 
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migration from 16 + 4.5 % to 6.1 ±1%, which was not significantly different from the 
control value (figure 4.30). 
Platelets in the lower wells activated with 1 U/ml thrombin induced a significant (p < 
0.01) increase in T-cell migration (24.4 + 2.2 %) compared to the RPMI/10 % FCS 
control (9.56 ± 2.2 %). However, activated platelets added apically significantly 
inhibited T-cell migration when compared to the RPMI/10 % FCS control (1.2 ± 0.5 %, 
p<0.05). T-cell migration in response to activated platelets added basally was reduced 
significantly (p < 0.01) from 24.4 ± 2.2 % to 10.7 ± 1.4 % by the anti-RANTES 
antibody and T-cell migration was 66.1 ± 8.1 % RANTES dependent. 
Since anti-RANTES blocks T-cell migration, the results indicate that endothelial cells 
synthesise low levels of RANTES in the absence of IFN-y plus TNF-a inducing low 
levels of T-cell migration and that endothelial activation with IFN--y plus TNF-a results 
in the endothelial synthesis of RANTES which contributes non-significantly to 
enhanced T-cell migration. In addition, the results show that activated platelets added 
basally release the chemokine RANTES and contribute significantly to T-cell migration 
in the absence of added IFN-y plus TNF-a in this in vitro model of the lung 
microvascular endothelium. 
It has been reported that RANTES binds preferentially to endothelial cells activated by 
IFN-y plus TNF-a (von Hundelshausen et al, 2001) and it was speculated that these 
cytokines may be released by T-cells, platelets and HLMVECs in vitro which would 
promote the binding of platelet-derived RANTES to the endothelium. It has previously 
been reported that TNF-a is stored by platelets (Muylle et al, 1993) and both IFN-'y and 
TNF-a are released by naive CD45RA+ T-cells, CD4+ memory Thl type T-cells and at 
low levels by Th2 type T-cells (Conlon et al, 1995; Mosmann & Coffman, 1989; 
Tsicopoulos et al, 1992). Therefore, IFN-y and TNF-a were measured in apical 
supernatants from experiments in which T-cell transmigration was induced by platelets 
in the basal compartment, and in which these cytokines had not been added 
exogenously to activate the endothelium. 
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Figure 4.31. IFN-y and TNF-a detected in apical supernatants from HLMVECs grown on 
Transwell inserts and used in a TEM assay. Isolated platelets (108/ml) were activated with 1 U/ml 
thrombin and added to the basal wells (800 µl) 30 minutes before the assay. Activated T-cells (2 x 
106/ml) were added to the apical wells (300 µl), and plates were incubated for 5 hours. Following 
incubation, apical wells were cleared (2500 g) and cytokines analysed by ELISA. Results are 
expressed as mean ± SEM, n=3. 
Figure 4.31 shows that both IFN--y and TNF-a were released into the supernatants. IFN- 
7 was detected at 3.6 ± 0.3 ng/ml and TNF-a was detected at 2.4 ± 1.1 ng/ml. The 
amount of IFN--y (2 x 107 U/mg) and TNF-a added exogenously to activate HLMVECs 
was 100 U/ml (or 5 pg/ml) and 10 ng/ml respectively. Thus, the amount of endogenous 
IFN-, y detected by ELISA was higher than the amount that was used to induce 
endothelial RANTES release when added in combination with TNF-a. This indicates 
that the concentration of endogenous IFN--y released in the presence of platelets and T- 
cells was sufficiently high to remove the need to add exogenous IFN-'y in the model of 
the endothelium. The amount of endogenous TNF-a detected by ELISA was of the 
same order as that which was used to induce endothelial RANTES release when added 
exogenously (10 ng/ml). Therefore, in subsequent experiments, exogenous IFN-y plus 
TNF-a was not added. 
Platelets are essential for leukocyte recruitment and have been shown to induce T-cell 
migration in the vascular endothelial model when activated with thrombin (1 U/ml) and 
added basally (figure 4.30). Since this was a physiological model, it was used to 
investigate the anti-inflammatory potential of the copper chelators neocuproine (NC), 
bathocuproine disodium salt (BCDS), D-penicillamine (D-pen) and tobramycin (Tob). 
In order to determine whether these copper chelators could attenuate T-cell migration, 
HLMVECs grown on Transwells were exposed to these copper chelators for 24 hours 
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TNF-a IFN-y 
before the TEM assay and T-cell migration was induced by adding activated platelets to 
the basal wells of the plate (figures 4.32 and 4.33). 
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Figure 4.32. The anti-inflammatory activity of the copper chelators, neocuproine (NC (0.1 - 0.5 
mM)) and bathocuproine disodium salt (BCDS (0.1 - 0.5 mM)) in a model of the vascular 
endothelium. Copper chelators were added to both the apical and basal wells 1 day before the 
transendothelial migration (TEM) assay. T-cells (2 x 106/ml) were added to the apical wells (300 µl) 
and T-cell migration was induced by the addition of activated platelets (108/ml +1 U/ml thrombin) 
to the basal wells (800 µl) 30 minutes before the assay. Results are represented as mean ± SEM, n= 
3. Data was compared using a 1-way ANOVA and Dunnett's post-hoc test, *p<0.05, ** p<0.01 
compared to RPMI/10 % FCS control. 
Treatment with NC (0.1 - 0.5 mM) induced a significant (p < 0.05) dose-dependent 
decrease in T-cell migration from a control value of 29.8 ± 8.5 % to 12.1 +5% at 0.25 
mM, and 5.9 + 1.7 at 0.5 mM (p < 0.01), (figure 4.32). Similarly, BCDS (0.1 - 0.5 mM) 
induced a significant (p < 0.05) dose-dependent decrease in T-cell migration from the 
control value to 14.3.1 + 6.4 % at 0.5 mM. 
The addition of 0.25 mM NC and BC together did not result in an additive effect and T- 
cell migration (10.4 + 4.2 %) was not significantly lower than the migration in the 
presence of 0.25 mM NC or BCDS alone. 
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Figure 4.33. The anti-inflammatory activity of the copper chelators, D-penicillamine (D-pen (0.01 - 
0.5 mM)) and tobramycin (Tob (0.01 - 0.5 mM)) in a model of the vascular endothelium. Copper 
chelators were added to both the apical and basal wells I day before the transendothelial migration 
(TEM) assay. T-cells (2 x 106/ml) were added to the apical wells (300 µl) and T-cell migration was 
induced by the addition of activated platelets (108/ml +1 U/ml thrombin) to the basal wells (800 µl) 
30 minutes before the assay. Results are represented as mean ± SEM, n=3. Data was compared 
using a 1-way ANOVA and Dunnett's post-hoc test, *p<0.05, ** p<0.01 compared to RPMI/ 10 
% FCS control. 
Treatment with D-penicillamine (0.01 - 0.5 mM) induced a significant (p < 0.01) dose- 
dependent decrease in T-cell migration from a control value of 53.3 ± 19 % to 12.4 ± 
3.6 % at 0.5 mM (figure 4.33). Similarly, tobramycin (0.01 - 0.5 mM) induced a 
significant (p < 0.05) dose-dependent decrease in T-cell migration from the control 
value to to 25.3±4.3 %at0.1 mMand 15.8±6.5 %at0.5mM(p<0.01). 
The inhibitory effect of the PAI-1 inhibitor, XR5118 (Einholm et al, 2003), a gift from 
Xenova, on T-cell migration was also investigated since inhibition of PAI-1 was 
previously shown to induce shedding of IL-8 and inhibit neutrophil migration (Marshall 
et al, 2003). It was expected that XR5118 would increase plasmin activity and induce 
the shedding of proteoglycan-bound RANTES on the endothelial cell surface, thereby 
inhibiting T-cell migration. XR5118 (1-100 µM) was added to apical and basal wells at 
the start of the TEM assay. 
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Figure 4.34. The anti-inflammatory activity of the PAI-1 inhibitor, XR5118 (1 - 100 µM) in a model 
of the vascular endothelium. XR5118 was added to both the apical and basal wells at the start of the 
transendothelial migration (TEM) assay. T-cells (2 x 106/ml) were added to the apical wells (300 µl) 
and T-cell migration was induced by the addition of activated platelets (108/ml +1 U/ml thrombin) 
to the basal wells (800 µl) 30 minutes before the assay. Results are represented as mean ± SEM, n= 
4. Data was compared using a paired student's t-test, *p<0.05. 
Treatment with the PAI-1 inhibitor, XR5118 (1 - 100 µM) induced a significant (p < 
0.05) dose-dependent decrease in T-cell migration from a control value of 53.3 + 19 % 
to 15 +3% at at 100 µM, figure 4.34. The reduction in T-cell migration at 100 µM 
X5118 was associated with an increase in plasmin activity in the basal supernatants 
from 6.3 + 1.4 in the control to 7.7 + 0.9 µg/ml following treatment with 100 µM 
XR5118 (n = 4, p<0.05). 
The analysis of basal supernatants for lactate dehydrogenase (LDH) enzyme activity 
confirmed that T-cell migration was not attenuated due to the toxicity of copper 
chelators, PAI-1 inhibititor or XR5118 (figures 4.35 - 4.37). 
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Figure 4.35. LDH release measured in basal supernatants (total volume 1400 µl) following 
treatment with NC (0.1 - 0.5 mM), BCDS (0.1 - 0.5 mM) and NC + BCDS (0.25 mM). Results are 
expressed as mean ± SEM, n=3. 
Figure 4.35 shows that there was no significant increase in LDH release after treatment 
with NC, BCDS, or both NC and BCDS together. The result indicates that NC and 
BCDS did not cause toxicity and cell death as a mechanism for the reduction in T-cell 
migration. 
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Figure 4.36. LDH release measured in basal supernatants (total volume 1400 µl) following 
treatment with D-penicillamine (0.01 - 0.5 mM) and tobramycin (0.01 - 0.5 mM). Results are 
expressed as mean ± SEM, n=3. 
Figure 4.36 shows that treatment with D-penicillamine or tobramycin caused no 
increase in LDH release. The result indicates that these copper chelators were not toxic 
to cells, and that cell toxicity did not contribute to the observed reduction in T-cell 
migration following treatment with these copper chelators. 
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Figure 4.37. LDH release measured in basal supernatants (total volume 1400 µl) following 
treatment with the PAI-1 inhibitor, XR5118 (1 - 100 µM). Results are expressed as mean ± SEM, n 
= 3. 
Figure 4.37 shows that treatment with XR5118 did not cause an increase in LDH 
release, and again, the result indicates that XR5118 does not exert its inhibitory effects 
on T-cell migration through cell toxicity and death. 
Since it was established that both copper and H202 are involved in multimer formation 
(Chapters 2 and 3), the involvement of H202 in RANTES induced T-cell migration was 
investigated. Catalase is an endogenous enzyme that catalyses the dismutation of H202 
to 02 and H2O and protects cells from peroxidation and damage induced by free 
radicals. 
HLMVECs were treated with catalase (500 U/ml) at the start of transendothelial 
migration assays. 
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Figure 4.38. The anti-inflammatory activity of catalase (500 U/ml) in a model of the vascular 
endothelium. Catalase (500 U/ml) was added to both the apical and basal wells at the start of the 
transendothelial migration (TEM) assay. T-cells (2 x 106/ml) were added to the apical wells (300 µl) 
and T-cell migration was induced by the addition of activated platelets (108/ml +1 U/ml thrombin) 
to the basal wells (800 µl) 30 minutes before the assay. Results were normalised to the control 
(mean = 24.3 % of total T-cells added, 100 %) and are represented as mean ± SEM, n=3. Data was 
compared using a paired student's t-test, ** p<0.01. 
The addition of catalase (500 U/ml) induced a significant reduction in T-cell migration 
from 100 % to 48.6 ± 3.9 % (p < 0.01, figure 4.38) indicating that H202 may be 
involved in the mechanism of RANTES induced T-cell migration. 
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Figure 4.39. LDH release measured in basal supernatants (total volume 1400 µl) following 
treatment with catalase (500 U/ml). Results are expressed as mean ± SEM, n=3. Data was 
compared using a paired student's t-test, ** p<0.01. 
Figure 4.39 shows that treatment with catalase (500 U/ml) caused a significant increase 
in LDH release. The result indicates that toxicity and cell death may have contributed to 
the reduction in T-cell migration observed following treatment with catalase. However, 
100 % Trypan blue dye exclusion of HLMVECs, platelets and T-cells at the end of the 
transmigration assay indicated that these cells were still viable. 
In order to investigate the mechanism of action of copper chelators, HLMVECs were 
lysed following a transmigration assay, and the cell lysates were analysed by SDS- 
PAGE, Western blotting and staining for RANTES. It was expected that the addition of 
copper chelators and catalase may alter the form of RANTES bound to the endothelium. 
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Figure 4.40. Lysates from HLMVECs grown for 2 weeks on uncoated 3 µm PET cell culture inserts, 
treated with copper chelators, the PAI-I inhibitor XR5118 and catalase and used in a TEM assay.. 
Lysates were freeze-dried from 200 µl 1% (v/v) triton-X-100 with protease inhibitors, reconstituted 
in 40 µl lx sample buffer, immunoprecipitated for human RANTES, analysed by SDS-PAGE on a 
4-15 % gradient polyacrylamide gel and stained for RANTES. M: molecular weight markers. Lane 
1: HLMVECs only, Lane 2: HLMVECs treated with 0.5 mM NC, lane 3: HLMVECs treated with 
0.5 mM BCDS, Lane 4: HLMVECs treated with 0.5 mM D-pen, lane 5: HLMVECs treated with 0.5 
mM tobramycin, lane 6: HLMVECs treated with catalase (500 U/ml) and lane 7: HLMVECs 
treated with 100 µM XR5118. Results from a single experiment. 
Figure 4.40 shows that RANTES was predominantly present as the 32 KDa tetramer 
and there was no change in the form of RANTES following treatment with the copper 
chelators NC, BCDS, D-pen or tobramycin, the PAI-1 inhibitor XR5118 (100 µM) or 
the preotective enzyme catalase (500 U/ml) indicating that the form of RANTES was 
not changed as a mechanism of action for the anti-inflammatory activity of copper 
chelators, XR5118 or catalase. 
Since it has already been shown that the addition of CuC12 induces production of 
RANTES by HLMVECs (Section 4.5.1) it may be that copper chelators reduce the 
amount of RANTES synthesised by the endothelium as a mechanism for decreased T- 
cell recruitment. Basal supernatants were cleared 
following a TEM assay and analysed 
for RANTES by ELISA. 
237 
250 
200 
E 
rn 
a 
ö 150 
r. d 
C 
C 
V 100 
w 
I- 
z 
50 
0 Control 0.1 0.25 0.5 0.1 0.25 0.5 025 0.01 01050 01 0105 
11l 1II 
NC BCDS NC/BCDS D-Pen Tob 
Figure 4.41. Basal supernatants from a TEM assay analysed for RANTES by ELISA. 
Representative of 2 independent experiments. 
Figure 4.41 shows that there was no change in the amount of RANTES present in the 
basal supernatants following treatment with the copper chelators, NC, BCDS, D-pen 
and tobramycin indicating that copper chelators did not alter RANTES synthesis or 
release through the removal of copper. 
A further possible mechanism of action of copper chelators is through PAI-1 inhibition. 
The subsequent activation of plasminogen by plasminogen activator results in plasmin 
accumulation and increased shedding of endothelial bound proteoglycans. 
A plasmin enzyme assay was used to confirm activity levels in basal supernatants from 
TEM assays in response to treatment with copper chelators. 
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Figure 4.42. Basal supernatants from a TEM assay analysed for plasmin. Representative of 2 
independent experiments. 
Figure 4.42 confirms that there was no change in plasmin activity levels as a result of 
treatment with copper chelators. 
Figures 4.43-4.45 show RANTES released into the apical and basal supernatants from 
transmigration assays in the absence and presence of the Cu chelators NC, BCDS, D- 
penicillamine and tobramycin and the PAI-1 inhibitor XR5118. Platelet-derived 
RANTES was the T-cell chemoattractant in the lower compartment in the absence of 
exogenously added IFN-y plus TNF-a. 
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Figure 4.43. Apical supernatants from transmigration experiments in the absence and presence of 
Cu chelators. HLMVECs were grown for 2 weeks on uncoated 3 pm PET cell culture inserts, 
treated with copper chelators or the PAI-1 inhibitor XR5118 overnight and used in a TEM assay.. 
Apical supernatants were freeze-dried from 300 pl, reconstituted in 40 pi 1x PBS (-Ca 
t+/Mg2+), 
immunoprecipitated for human RANTES, analysed by SDS-PAGE on a 4-15 % gradient 
polyacrylamide gel and stained for RANTES. M: molecular weight markers. Lane 1: HLMVECs 
no Cu chelators, Lane 2: 0.5 mM NC, lane 3: 0.5 mM BCDS, Lane 4: 0.5 mM D-pen, lane 5: 0.5 
mM tobramycin, lane 6: 100 pM XR5118. Representative of two independent experiments. 
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Figure 4.44. Basal supernatants from transmigration experiments in the absence and presence of 
Cu chelators. HLMVECs were grown for 2 weeks on uncoated 3 µm PET cell culture inserts, 
treated with copper chelators or the PAI-1 inhibitor XR5118 overnight and used in a TEM assay.. 
Basal supernatants were freeze-dried from 500 µl, reconstituted in 40 pl Ix PBS (-Ca t+/Mg2+), 
immunoprecipitated for human RANTES, analysed by SDS-PAGE on a 4-15 % gradient 
polyacrylamide gel and stained for RANTES. M: molecular weight markers. Lane 1: no Cu 
chelators, Lane 2: 0.1 mM NC, lane 3: 0.25 mM NC, Lane 4: 0.5 mM NC, lane 5: 0.1 mM BCDS, 
lane 6: 0.25 mM BCDS and Lane 7: 0.5 mM BCDS. Representative of two independent 
experiments. 
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Figure 4.45. Basal supernatants from transmigration experiments in the absence and presence of 
Cu chelators. HLMVECs were grown for 2 weeks on uncoated 3 pm PET cell culture inserts, 
treated with copper chelators or the PAI-I inhibitor XR5118 overnight and used in a TEM assay.. 
Basal supernatants were freeze-dried from 500 µl, reconstituted in 40 pi Ix PBS (-Ca 2+/Mg2+), 
immunoprecipitated for human RANTES, analysed by SDS-PAGE on a 4-15 % gradient 
polyacrylamide gel and stained for RANTES. M: molecular weight markers. Lane 1: no Cu 
chelators, Lane 2: 0.01 mM D-pen, lane 3: 0.1 mM D-pen, Lane 4: 0.5 mM D-pen, lane 5: 0.01 mM 
tobramycin, lane 6: 0.1 mM tobramycin, lane 7: 0.5 mM tobramycin and lane 8: 100 µM XR5118. 
Representative of two independent experiments. 
Despite significantly inhibited T-cell migration following treatment with the Cu 
chelators NC, BCDS, D-penicillamine and tobramycin (figures 4.32 and 4.33) there was 
no detectable change in the form of RANTES in the apical (figure 4.43) or basal 
supernatants (figures 4.44 and 4.45) from these transmigration experiments. 
Unexpectedly, RANTES was present predominantly in tetrameric form in both the 
apical and basal supernatants. The 73-74 KDa form of RANTES appeared more 
strongly in the apical supernatants than the basal supernatants. In addition, a 
proteolytically cleaved form of RANTES was also detected in both apical and basal 
supernatants (30.3 KDa) as seen previously (Section, 4.5.1, 
figure 4.2). 
Although NC (0.1-0.5 mM), BCDS (0.1-0.5 mM), D-penicillamine (0.01-0.5 mM) and 
tobramycin (0.01-0.5 mM) had no effect on the amount of soluble forms of RANTES 
released into apical or basal supernatants 
(figures 4.43 - 4.45), treatment with XR5118 
(100 µM) increased the shedding of the soluble tetrameric 
form of RANTES from the 
cell surface into the basal supernatant as shown clearly 
in figure 4.45, lane 8. 
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A VAP-1 enzyme assay (Section 4.3.1.9) was used to determine any inhibition in VAP- 
1 activity occurring in HLMVECs as a result of treatment with copper chelators. 
However, no VAP-1 activity was detected in HLMVECs using this assay. 
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4.6. Discussion 
In summary, RANTES multimers were chemotactically active, inducing T-cell 
migration via both CCR3 and CCR5 receptors suggesting the involvement of CD4+ Th2 
and Thl T-cells as well as CD8+ type 1 (Tcl) and type 2 (Tc2) T-cells. In addition, 
platelet-derived RANTES was demonstrated to be a T-cell chemoattractant when added 
to the basal compartment in a model of the lung microvascular endothelium. Platelets 
added apically induced T-cell arrest. RANTES in HLMVEC lysates was found 
predominantly present as a covalently-linked tetramer, which may have been bound to a 
HLMVEC surface-GAG via an electrostatic interaction prior to analysis. Similarly, the 
RANTES tetramer was the predominant form present in supernatants following 
transendothelial migration even though activated platelets and HLMVECs were shown 
to release monomeric RANTES. The treatment of the endothelium with Cu chelators 
and catalase inhibited T-cell migration indicating a requirement for both Cu and H202 in 
the T-cell chemotactic response to platelet-derived RANTES. 
T-cell responses to both fresh un-incubated recombinant RANTES and RANTES 
multimers generated in the presence of CuC12 and H202 were mediated through both 
CCR3 and CCR5 receptors, indicating the possible involvement of CD4+ Th2 and Thl 
T-cells as well as CD8+ type 1 (Tcl) and type 2 (Tc2) T-cells. Others have reported that 
RANTES induces both Th2 and Thl T-cell migration through CCR1, and CCR3, and 
CCR1 and CCR5 receptors respectively (Baltus et al, 2003; Gerber et al, 1997; Kawai 
et al, 1999; Sallusto et al, 1998a; Sallusto et al, 1998b; Sallusto et al, 1997) and that 
RANTES induces cytotoxic CD8+ T-cell migration through both CCR3 and CCR5 
receptors found on Tc2 and Tcl CD8+ cytotoxic cells, respectively (Hadida et al, 1998; 
lijima et al, 2003; Luangsay et al, 2003; Ohtani et al, 2004). There is no evidence to 
suggest that CD8+ cytotoxic T-cell migration 
is mediated by CCR1 receptors in 
response to RANTES, therefore it is speculated that any 
CD8+ T-cell migration would 
be predominantly mediated by CCR3 and 
CCR5 receptors. 
The result also indicates that T-cell responses to 
both fresh unincubated recombinant 
RANTES and RANTES multimers were mediated equally by CCR3 and CCR5 
receptors. It is unlikely that 
T-cells responded through CCR1 mediated chemotaxis, 
since 100 % of the responses were 
blocked by CCR3 and CCR5 neutralising antibodies. 
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CCR3 and CCR5 are also expressed on other inflammatory cells and in other tissues. 
CCR3 is also expressed by eosinophils and basophils, and CCR5 is also expressed by 
monocytes and dendritic cells (Sallusto et al, 1998b) and in addition, CCR3 is expressed 
by microvascular endothelial cells and mediates vessel wall remodelling and 
angiogenesis (Salcedo et al, 2001). There is also evidence to suggest that CCR3 may 
influence key epithelial cell functions including wound repair, and the amplification of 
profibrogenic and chemokine transcript expression (Beck et al, 2006). Therefore 
neutralising these receptors using specific antibodies may effectively limit T-cell 
migration and inflammation but not without affecting other fundamental functions that 
are mediated through CCR3 and CCR5 receptors. 
The T-cell chemotactic response to platelet-derived RANTES in transendothelial 
migration experiments indicates a role for platelets in human leukocyte recruitment 
during inflammation. It is well known that platelets release chemokines including 
RANTES upon activation with thrombin (Kameyoshi et al, 1992; Kameyoshi et al, 
1994; Klinger et al, 1995; Schroder et al, 1994) and platelets have previously been 
shown to migrate into tissues and influence the pulmonary recruitment of eosinophils 
and lymphocytes in murine allergic inflammation (Pitchford et al, 2005; Pitchford et al, 
2003). In addition, RANTES deposition by platelets has been shown to induce 
monocyte arrest in human atherosclerotic endothelium (von Hundelshausen et al, 2001) 
and platelet-derived RANTES has been shown to induce monocyte arrest on inflamed 
microvascular endothelium under flow conditions (Baltus et al, 2005). 
RANTES released from platelets on the apical side of the endothelium is likely to bind 
to the apical surface of the endothelial monolayer and prevent the formation of a 
chemotactic gradient, inducing the arrest of T-cell migration. Importantly, the 
requirement for platelets to be present and activated on the subluminal side of the 
endothelium for T-cell migration indicates that platelets must first undergo 
transendothelial migration themselves and become activated in the tissues in order to 
induce T-cell recruitment. Platelets have been reported to undergo chemotaxis in iltro 
in response to prostaglandins, autoantibodies, 
fMLP or necrotic cells (Clancy, 1972; 
Czapiga et al, 2005; Valone et al, 1974) and platelets 
have been reported to undergo 
diapedesis in sections of lung from asthmatic patients and have been detected in 
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bronchoalveolar lavage fluid from asthmatic patients (Jeffery et al, 1989; Metzger et al, 
1987). Platelets have also been detected in the bronchoalveolar lavage fluid of allergen- 
challenged mice (Pitchford et al, 2004) and have been reported to migrate out of blood 
vessels into lung tissue in vivo in allergen-sensitised mice in response to a sensitising 
allergen (Pitchford et al, 2008). Degranulated platelets have been identified in the 
bronchoalveolar lavage fluid of asthmatic individuals (Metzger et al, 1986) and it has 
also been reported that platelets promote leukocyte trafficking from blood vessels into 
lung tissue in allergen-sensitised mice (Pitchford et al, 2005; Pitchford et al, 2003). 
Furthermore, platelet depletion has been shown to reduce leukocyte accumulation in 
alveolar compartments in a murine model of lung injury (Zimmerman et al, 1984). This 
evidence demonstrates that platelets can migrate out of blood vessels into murine lung 
tissue and both murine and human alveolar spaces during inflammation and also that 
platelets influence leukocyte recruitment into the alveolar spaces in murine models. 
However, it has not yet been fully demonstrated that platelets influence leukocyte 
migration into human lung tissue or alveolar spaces or that platelets migrate into human 
lung tissue in vivo during inflammation. 
Platelet activation occurs during antigen-induced airway reactions in asthmatic subjects. 
The mechanism for platelet chemotaxis is thought to involve allergen-specific IgEs 
produced after contact with the sensitising antigen (Pitchford et al, 2008; Yoshida et al, 
2002). The IgE binds to platelet IgE receptors and, upon exposure to allergen, the 
allergen induces cross-linking of contiguous receptors and the consequent triggering of 
platelet migration (Pitchford et al, 2008). In addition, platelets of patients with asthma 
have been shown to release RANTES upon activation via IgE (Hasegawa et al, 1999), 
indicating that both platelet migration and platelet-derived mediator release may be 
triggered via an IgE dependent mechanism. However, in considering the mechanisms 
involved in murine models it must be remembered that the number of circulating 
platelets is higher in mice compared to 
humans (Mestas & Hughes, 2004; Tsakiris et al, 
1999). 
It is also feasible that platelet recruitment to sites of 
inflammation is directed by a 
number of chemokines, since 
SDF-1, CXCL 12, macrophage-derived chemokine 
(MDC), RANTES, CCL22, and CCL17 (TARC) can activate platelets via their 
receptors CXCR4, CCR3 and 
CCR4, although no migratory response has yet been 
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demonstrated in vivo or in vitro (Abi-Younes et al, 2000; Abi-Younes et al, 2001; 
Clemetson et al, 2000; Kowalska et al, 2000). It is not known whether platelets migrate 
from blood vessels into lung tissue prior to, or in conjunction with leukocyte migration. 
However, an interesting proposition is that during inflammation, platelets may initially 
migrate into lung tissue and become activated, resulting in platelet degranulation and 
release of inflammatory mediators such as the chemokine RANTES, which 
subsequently promote leukocyte migration into lung tissue. Platelet activation may 
occur in response to a variety of inflammatory stimuli including chemokines, cytokines, 
antigens, platelet activating factor (PAF), collagen, antigen-antibody complexes and 
bacterial endotoxins including lipopolysaccharides (reviewed in section 4.1.1.1). 
Following the recruitment of leukocytes into lung tissue, migrated leukocytes may be 
influenced by another epithelial derived chemotactic signal which induces leukocyte 
homing and migration across the epithelium into the alveolar spaces, such as TARC. 
TARC is synthesised by airway epithelial cells in response to IL-4, and TGF-ß (Heijink 
et al, 2007). Alternatively, platelets may migrate from lung tissue into the alveolar 
spaces themselves via an allergen-specific mechanism or in response to a chemotactic 
signal and induce subsequent leukocyte migration into alveolar spaces via degranulation 
and inflammatory mediator release. 
Interestingly, platelets are not only a source of RANTES, but also a source of 
plasminogen activator inhibitor-1 (PAI-1) and Cu. Plasmin can induce syndecan 
shedding and release of bound chemokines (Marshall et al, 2003), and is cleaved from 
plasminogen in the presence of plasminogen activator (PA). The activation of 
plasminogen is inhibited by plasminogen activator inhibitors including platelet derived 
PAI-1. Therefore PAI-1 is pro-inflammatory, its activity resulting in longer association 
of syndecan-chemokine complexes with the endothelium. 
Platelets have been shown to 
synthesise and release PAI-1 in response to thrombin stimulation 
(Booth et al, 1988; 
Brogren et al, 2004; Nordenhem & Wiman, 1997; 
Pawlowska et al, 2001), and Cu has 
been measured in platelets at 1.1 ± 1.0 µg/g 
dry weight (Hallgren et al, 1987) and 24.4 
±10.7 ng/109 cells (Milne & Nielsen, 
1996). This evidence suggests that not only do 
platelets migrate into tissues and synthesise and release 
RANTES, but they may also 
have a role in maintaining the presentation of 
RANTES on proteoglycans through the 
synthesis and release of 
PAI-1. Since platelets also contain Cu they may also have an 
important role in inducing chemokine multimerisation. 
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In addition to the release of inflammatory mediators, the mechanism of platelet induced 
leukocyte recruitment in vivo may also be contact-dependent, involving surface CD 11 b, 
which is up-regulated on leukocytes interacting with platelets. It is possible that platelet 
aggregation with leukocytes may prime and activate leukocytes for subsequent adhesion 
to and transmigration across the endothelium (Pitchford et al, 2003) (reviewed in 
Section 4.1.1.2). Cooperation between platelets and leukocytes has been observed in 
both cardiovascular disease and tumor metastasis (Karpatkin & Pearlstein, 1981; 
Mickelson et al, 1996) and activated platelets have previously been shown to bind to 
leukocytes, including T-cells (de Bruijne-Admiraal et al, 1992). 
Interestingly, endothelial progenitor cell (EPC) recruitment during new blood vessel 
formation and angiogenesis in the asthmatic inflammatory response has been reported to 
be both Thl and Th2 dependent (Asosingh et al, 2007). This finding indicates that the 
migration of platelets into tissues may induce T-cell recruitment leading to subsequent 
EPC recruitment. Thus, platelets may be central not only to the recruitment of T-cells 
and other inflammatory cells but may also be important for angiogenesis at sites of 
inflammation. 
Although as shown in Section 4.5.1, figure 4.1 and Section 4.5.2, figure 4.15, platelet- 
derived RANTES, and RANTES released into HLMVEC culture medium is 
monomeric, RANTES was predominantly found as a tetramer in HLMVEC lysates and 
in supernatants from transmigration experiments. These tetramers were found to be 
covalently-linked as reported for isolated recombinant RANTES exposed to 
Cu plus 
H202 (Chapters 2 and 3). The release of RANTES from platelets and HLMVECs in 
monomeric form has not previously been reported. 
However, it appears that when 
platelets are activated by thrombin in the transendothelial migration model, monomeric 
RANTES is released and binds to the endothelium to 
induce T-cell migration. The 
binding of RANTES to the endothelium 
is dependent on endothelial activation (von 
Hundelshausen et al, 2001) and in the transendothelial migration model, both IFN-y and 
TNF-a were present and may have 
been derived from T-cells or platelets at 
concentrations sufficient to activate 
the endothelium (discussed later) and induce 
platelet-derived RANTES 
binding to the endothelium with the formation of tetramers. 
This suggests that if Cu and 
H202 are involved in RANTES tetramer formation they 
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must be present endogenously at concentrations sufficient to induce covalent cross- 
linking. 
During T-cell transendothelial migration it is evident that there is shedding of the 
tetramer, since the tetramer appears in the supernatants from transendothelial migration 
experiments at levels as high as in the cell lysates. The shedding of the tetramer into the 
supernatants may be due to plasmin activity and increased syndecan turnover. Plasmin 
may have been activated by thrombin which was added to platelets during the 
transmigration experiments. 
In addition, it is possible that the 74 KDa RANTES-GAG complex (discussed later) was 
more predominant in the apical supernatants than basal supernatants due to the 
requirement for RANTES presentation on the apical endothelial cell surface for 
transendothelial migration of T-cells to occur. It is possible that pro-inflammatory 
cytokines released by T-cells such as IFN-, y and TNF-a up-regulate GAG expression 
during endothelial activation, and that this occurs more strongly on the apical surface of 
HLMVECs, the site at which T-cells were added. It is also possible that RANTES is 
directed to GAGs on the apical endothelial cell surface by transcytosis, which may 
involve DARC (discussed later). 
HLMVEC lysates contained a 30.3 KDa RANTES multimer, and despite the presence 
of protease inhibitors upon lysis of the cells, it is likely that this is a post-translational 
proteolytically processed form of RANTES. A 3-68 or 4-68 truncated amino acid 
variant with a monomeric mass of 7663 or 7515 KDa has previously been reported (Lim 
et al, 2005) and the formation of a tetramer with these truncated RANTES monomers 
would result in a mass of 30.7 or 30.1 KDa. 
Both RANTES (3-68) and RANTES (1-68) have been detected in the cell culture 
medium of dermal fibroblasts stimulated with 
TNF- a or IL-lß and the study showed 
that the loss of the two residues does not affect the eosinophil chemotactic activity 
towards RANTES (Noso et al, 1996). It 
has also been shown that both full-length and 
truncated RANTES induce a similar chemotactic response 
in T-cells and that RANTES 
(3-68) has impaired binding and signalling capacity through CCR1 and CCR3 but 
retains activity on 
CCR5 (Oravecz et al, 1997). This would suggest that both the 
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tetramer of full length and truncated RANTES should be chemotactically active. This is 
in agreement with previous findings that have shown that chemotactic inactivity occurs 
only in the absence of the first 8 amino-terminus amino acids (Vives et al, 2002; Wells 
et al, 1995). 
Sodium chlorate has previously been shown to abolish GAG sulphation, including 
HSPG sulphation by competing with sulphate for sulphotransferase enzymes and 
therefore blocking the sulphation of new glycosaminoglycan chains, and subsequently 
inhibiting GAG synthesis (Davies et al, 2001; Humphries & Silbert, 1988; Humphries 
et al, 1989; Qiao et al, 2003; Safaiyan et al, 1999). Thus, treatment of HLMVECs with 
sodium chlorate depleted GAG synthesis as indicated by increases in both lipid 
peroxidation (Section 4.5.1, figure 4.13) and the post-translational proteolytic 
modification of RANTES (figure 4.9). GAGs are well known as free radical scavengers 
and have been shown to have protective effects against the degradation of chemokine 
multimers (Chapters 2 and 3). Others have reported the protective effects of GAGs 
against lipid peroxidation and oxidative damage in liposome and fibroblast cultures 
(reviewed in Section 2.6). 
An increase in lipid peroxidation in the presence of sodium chlorate therefore occurs as 
a result of the reduced protective effect of GAGs against ROS which are generated by 
the dismutation of the superoxide radical (02-) and produced by the endothelium under 
normal physiological conditions. This experiment (figure 4.13) also indicated that 
exogenously added Cu and H202 did not induce further increases in lipid peroxidation 
and therefore activated HLMVECs are producing ROS at levels sufficient to induce 
maximum lipid peroxidation in the absence of GAGs. 
The activation of HLMVECs by TNF-a and IFN-y may have contributed to the 
generation of ROS resulting in lipid peroxidation, since it has been reported that ROS, 
including superoxide radicals and H202 are generated by fibroblasts in response to 
TNF-a (0.28 nM-10 nM) and IL-1 (0.145 nM-50 nM) (Meier et al, 1989). In addition, 
TNF-a (10 pM-1 nM) has also been reported to stimulate superoxide radical generation 
by neutrophils (Ferrante et al, 1988; Tsujimoto et al, 
1986). 
250 
Vascular endothelial cells have a capacity to produce superoxide anions and H202 from 
several intracellular sources, including eNOS, cyclooxygenase, lipoxygenase, 
cytochrome P450 enzymes and NAD(P)H oxidases (Kinnula et al, 1992c; Kunsch & 
Medford, 1999; Matoba et al, 2002; Matoba et al, 2000). Levels of H202 at or below 
20-50 µM appear to have limited cytotoxicity to many cell types (Halliwell et al, 2000a) 
and previous studies have claimed normal physiological levels of H202 of up to 35 µM 
in human plasma (Deskur et al, 1998; Lacy et al, 1998; Varma & Devamanoharan, 
1991). However in the absence of protective mechanisms, these otherwise harmless 
levels of H202 may become toxic, and result in DNA, protein and lipid peroxidation. In 
addition, pathophysiological levels of H202 have been reported of up to 100 µM, 
released by activated granulocytes during inflammation (Bucchieri et al, 2002). 
The toxic effects of H202 have been attributed to the spontaneous generation of highly 
reactive hydroxyl radicals from H202 (Halliwell et al, 2000a). The generation of 
reactive oxygen species (ROS) causes peroxidative damage to membrane lipids and 
cellular nucleic acids and the direct oxidation of proteins (Campo et al, 2004). 
Lipid peroxidation is initiated by the attack of any chemical species that has sufficient 
reactivity to abstract a hydrogen atom from a methylate carbon in the side chain, 
including the hydroxyl radical (OH-) (Gutteridge & Halliwell, 1990). 
The hydrogen atom is a free radical since it has a single unpaired electron and its 
removal leaves behind an unpaired electron on the carbon atom to which it was 
originally attached. 
Lipid-H + OH- -0 Lipid- + H2O 
In aerobic cells the resulting carbon centred radical undergoes molecular rearrangement 
followed by reaction with molecular oxygen to give a peroxyl radical. 
Lipid- + 02 10 Lipid-02- 
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Peroxyl radicals can attack membrane proteins but can also propagate lipid peroxidation 
by abstracting hydrogen from adjacent fatty acid side chains in a membrane. Once 
initiated, the process of peroxidation proceeds as a free radical chain reaction. 
Lipid-02- + Lipid-H . Lipid-02H + Lipid- 
The occurrence of lipid peroxidation in biological membranes causes impairment of 
membrane functioning, decreased fluidity, inactivation of membrane-bound receptors 
and enzymes ans increased non-specific permeability to ions (Gutteridge & Halliwell, 
1990). As well as lipid peroxidation, oxidative stress can also lead to protein and DNA 
oxidation, leading to oxidative damage. 
02 can be reduced to the superoxide radical 02- in inflammation. Mast cells, 
macrophages, eosinophils and neutrophils recruited and activated at sites of tissue injury 
are a major source of 02- radicals which can dismutase to H202 (van der Vliet et al, 
1997). 
202- + 2H+ 10 H202+02 
The mechanism for the oxidation of proteins is similar to that of lipid peroxidation. Free 
radicals can also abstract hydrogen ions from proteins generating amino acid radicals 
that can form disulphide bridges, protein-lipid and protein-protein covalent bonds. The 
cross-linking of proteins in this manner can give rise to high molecular weight 
aggregates (Horton & Fairhurst, 1987). 
Protein-H + OH- 10 Protein- + H2O 
Protein "+ Lipid -º Protein-Lipid 
Protein- + Protein- -0 Protein-Protein / High molecular weight aggregates 
HLMVEC -associated 
RANTES is predominantly tetrameric (32 KDa) in the presence 
of the anionic surfactant, 
SDS. It is possible though that the the RANTES tetramer may 
have been bound to a HLMVEC surface GAG through a non-covalent interaction such 
as ionic or Van der 
Waals forces. The loss of higher molecular weight forms of 
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RANTES in the presence of sodium chlorate indicates that RANTES is indeed 
presented on HLMVECs as a GAG-bound RANTES complex, but it may be that 
separation of proteins in the presence of SDS disrupts the complexes. In support of the 
finding that RANTES was not covalently bound to HLMVEC-expressed GAGs, the 
HS-RANTES interaction has previously been shown by others to be due to specific 
electrostatic interactions including hydrogen bonds, salt bridges and van der Waals 
forces involving the classical BBXB cluster in the 40s loop of RANTES (described in 
section 1.9) that is also implicated in CC receptor binding (Martin et al, 2001; 
Proudfoot et al, 2003; Rek, 2009). 
These findings are in contrast to reports of IL-8 bound to HS expressed by HUVECs 
through an interaction that is resistant to both SDS and the sulphydryl reducing agent, 
DTT (Marshall et al, 2003), suggesting that the interaction of IL-8 with HUVEC- 
expressed HSPG is covalent unlike the RANTES interaction with HLMVEC-expressed 
HSPG which appears to be electrostatic. Alternatively it may be that the form of 
chemokines presented on HUVECs differs to that on HLMVECs. 
The weak bands of complexed RANTES at MW 73-74 and 116 KDa are likely a 
RANTES-heparan sulphate proteoglycan (HSPG) complex since HS is the most 
ubiquitous GAG (50 - 90 % of all GAGs) found on the endothelium and 
is the most 
predominant GAG found in the lungs, followed by chondroitin sulphate/dermatan 
sulphate, hyaluronan and heparin (Cockwell et al, 1996; Frevert et al, 2003; Ihrcke et 
al, 1993). HS is considered the most ubiquitous and physiologically relevant cell- 
surface GAG. In addition, it has been well documented that 
RANTES binds to HSPGs 
on human microvascular endothelial cells and 
HUVECs in vitro and with a higher 
affinity than many other chemokines 
(Ali et al, 2002; Carter et al, 2003; Hillyer & 
Male, 2005; Hoogewerf et al, 1997; Kuschert et al, 1999; Proudfoot et al, 2001). So far, 
RANTES has been reported to bind both syndecan-1 and syndecan-4 proteoglycans 
(Bartlett et al, 2007; Slimani et al, 2003). 
The suggestion that RANTES 
binds to HSPG as a tetramer agrees with previous reports 
that have demonstrated RANTES 
binding to heparin as a tetramer (Hoogewerf et al, 
1997) with a minimal tetrameric structure 
for chemotactic activity in vivo and that both 
the monomeric and dimeric 
forms of RANTES are devoid of chemotactic activity. 
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Heparin was deemed structurally and chemically similar enough to serve as a good 
substitute for HS in these studies (Proudfoot et al, 2003). It has also been shown that 
RANTES binding to HS and subsequent oligomerisation is required for the chemotactic 
activity of RANTES in vitro as shown using oligomerisation-deficient RANTES 
mutants which were unable to induce leukocyte chemotaxis (Rek, 2009). 
In addition, the HS binding and oligomerisation domain of RANTES have been found 
to be structurally and functionally coupled. The binding of RANTES to HS was found 
to be positively cooperative - the binding of RANTES to HS promotes further 
RANTES binding and oligomerisation. Upon binding to HS, RANTES undergoes a 
conformational change which is dependent on a HS length greater than 6dp and this 
induced structural fit has been interpreted to be responsible for the GAG-promoted 
oligomerisation of RANTES (Rek, 2009). 
The predominance and higher stability of the tetrameric form of RANTES, indicated by 
resistance to higher concentrations of H202 than the monomeric form, suggests that the 
tetramer is the most likely form presented to circulating leukocytes since it will not be 
degraded, but will remain during inflammation which can generate high concentrations 
of H202 up to 100 µM. 
The observation that RANTES occurred as a 64 KDa complex (Chapter 4) indicates that 
in addition to GAG binding, RANTES may also bind to the Duffy antigen receptor for 
chemokines (DARC) expressed on the endothelium. RANTES can bind to DARC 
(Choe et al, 2005; Neote et al, 1994) and since DARC is 48 KDa, and the predominant 
form of RANTES detected in HLMVEC lysates is the tetramer (32 KDa) (Section 
4.5.1), it is speculated that a RANTES tetramer-DARC complex would be 80 KDa and 
a RANTES dimer-DARC complex would 
be 64 KDa. It has previously been reported 
that RANTES binds to DARC and that DARC is expressed on both apical and basal 
membrane domains of the endothelium of 
large venules and capillaries ex vivo 
(Chaudhuri et al, 1997; Peiper et al, 1995). DARC expression has also been 
demonstrated on the endothelium using HUVECs in vitro (Lee et al, 2003) and the 
expression of DARC 
has been reported on the endothelium of postcapillary venules in 
all tissues except for the 
liver (Hadley et al, 1994). DARC is also expressed on 
erythrocyte surfaces and 
it has been shown that RANTES also binds to erythrocyte 
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expressed DARC (Neote et al, 1994). In addition, it has previously been shown that IL- 
8 binds to erythrocyte DARC as a dimer (Leong et al, 1997). 
It has been shown that DARC plays a role in the transport of chemokines to the apical 
surface of the endothelium. Using HUVECs it has been shown that DARC facilitates 
the movement of IL-8 and GRO-a across the endothelium in vitro, promoting neutrophil 
transmigration both in vitro and in vivo (Lee et al, 2003). Since DARC has been shown 
to transport chemokines unidirectionally from the basolateral to the apical side of the 
endothelium (Pruenster & Rot, 2006) it is likely that RANTES is transported to the 
apical surface by endothelial expressed DARC. 
Thus DARC may intercept chemokines that are passing from the tissue into the plasma 
and may salvage their activity by redirecting these chemokines to GAGs on the luminal 
endothelial cell surface. It has been suggested that by preventing chemokines from 
entering the circulation, the surface retention of chemokines by DARC prevents 
leukocyte desensitisation in the circulation by soluble plasma chemokines leading to the 
enhancement of chemokine induced leukocyte recruitment (Rot, 2005). 
However, the weak staining of the 64 KDa RANTES complex (Section 4.5.1) indicates 
that there may be very low levels of DARC expression in cultured HLMVECs. This is 
most likely due to the lack of DARC expression in cultured endothelial cells. It has 
previously been reported that microvascular endothelial cells rapidly lose their DARC 
expression in the process of their culture in vitro (Rot, 2003) and DARC is almost 
undetectable in cultured HUVECS (Hoogewerf et al, 1997). Since others 
have reported 
the strong expression of DARC in the postcapillary venules of all tissues, and also 
in 
HUVECs, it is likely that HLMVECs do indeed also strongly express DARC, but that 
this expression has been lost during the culturing process. 
Further work using a DARC 
antibody to stain Western blots would confirm 
the presence of DARC in cultured 
HLMVECs and also whether RANTES 
forms a complex with DARC on the surface of 
these cells. 
Although Cu and H202 were not found to 
have any effect on the form of RANTES 
detected in HLMVEC lysates and supernatants, 
it is possible that the activation of the 
endothelium with IFN-y and 
TNF-a had already induced maximal ROS generation by 
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HLMVECs, as previously discussed. This may prevent Cu/H202 from having any 
further effect on multimer formation via redox and subsequent ROS generation. In 
support of this notion, RANTES tetramers were already formed prior to the addition of 
Cu/H202 (figure 4.5). However, 24 hour exposure to Cu was found to induce the 
synthesis and release of RANTES from HLMVECs. In support of this finding, others 
have reported the synthesis and release of IL-8 from HUVECs and HLMVECs similarly 
within 24 hours, indicating early gene activation and new protein synthesis rather than 
IL-8 release from preformed storage sites (Bar-Or et al, 2003). 
It has been suggested that Cu may induce NF-kB and subsequent IL-8 synthesis through 
the activation of the phosphatidylinositol 3-kinase (P13-kinase)/Akt/NF-kB pathway 
independently of ROS, possibly through the oxidation of the tumor suppressor PTEN, 
an inhibitor of the P13-kinase/Akt pathway (Bar-Or et al, 2003; Ostrakhovitch et al, 
2002) (Ozes et al, 1999) or alternatively through a MAPK (JNK, p38) / NF-kB pathway 
(Samet et al, 1998) (reviewed in Section 4.1.3). 
It has also been reported that Cu-induced ROS generation by Cu/redox mechanisms 
induces oxidative stress resulting in NF-kB activation (Persichini et al, 2006). ROS 
have also been shown to activate the P13-kinase/Akt pathway via oxidation of the tumor 
suppressor PTEN (Lee et al, 2002) and also via MAPK (Fialkow et al, 1994) (reviewed 
in Section 4.1.3). Additionally it has been suggested that Cu (11)-oxidised low-density 
lipoproteins may independently initiate the activation of activator protein-1 (AP-1), a 
transcription factor associated with endothelial IL-8 expression in endothelial cells 
(Maziere et al, 1997). 
RANTES synthesis is inducible by IL-1 ß in human bronchial epithelial cells (Manni et 
al, 1996) and IFN-y in HLMVECs (Sundstrom et al, 2001) through the regulation of 
NF-kB. Since it has been suggested that Cu-induced IL-8 synthesis in HLMVECs is 
regulated by the NF-kB pathway, and 
Cu has been shown to induce NF-kB 
independently of ROS through the activation of P13-kinase/Akt and MAPK pathways 
(Ostrakhovitch et al, 2002; Samet et al, 1998) and through the generation of ROS via 
Cu/redox (Persichini et al, 2006) and subsequent activation of the PTEN/PI3-kinase/Akt 
and MAPK pathways 
(Fialkow et al, 1994; Lee et al, 2002. Pelaia et al, 2004), this 
suggests that Cu induced 
RANTES synthesis in HLMVECs most likely occurs via the 
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NF-kB pathway. The activation of RANTES transcription may also occur through P13- 
kinase/Akt or MAPK (JNK or p3 8) activation, either independently of ROS or possibly 
through the generation of ROS via Cu/redox mechanisms. 
A possible explanation for the failure of increased concentrations of H202 to induce 
further RANTES synthesis in the presence of Cu is that in biological systems, H202 is 
present transiently and may immediately dismutate in the presence of antioxidants 
generated by HLMVECs in culture. Therefore in the presence of H202, RANTES 
synthesis would be regulated by Cu, generating a Cu-redox system as a constant source 
of H202 and ROS in order to activate NF-kB and transcription of RANTES mRNA. 
The biphasic manner in which Cu induced the synthesis of HLMVEC-derived RANTES 
can be explained in terms of the regulation of NF-kB and its inhibitor IkB. In most cells, 
the majority of NF-k13 resides in the cytoplasm, bound to the IkB inhibitory protein 
family, which include IkBa, IkBP, IkBc, Bcl-3, p 100, and p 105. These proteins function 
as inhibitors through ankyrin repeats, which bind to the REL domain of NF-kB and 
prevent NF-kB nuclear translocation (Beg & Baldwin, 1993). 
Activation of NF-kB is mediated through the IkB kinase complex (IKK), which 
functions to phosphorylate two serine residues on IkB proteins. Phosphorylation of 
these residues causes the ubiquitination and subsequent degradation of IkB proteins. 
Upon loss of IkB, NF-kB is free to translocate to the nucleus where it binds to its 
cognate DNA sequence and interacts with the basal transcription machinery and 
transcriptional co-activators to stimulate gene expression (Karin & Ben-Neriah, 2000). 
One of the numerous genes induced by NF-kB 
is the ankyrin repeat containing proteins 
that serve to recapture and inactivate 
NF-kB, including the IkB family (Brasier, 2006). 
Once resynthesised, IkB is transported to the nucleus where 
it binds and inhibits NF-kB 
DNA binding (Arenzana-Seisdedos et al, 1995). NF-kB is sequestered back to the 
cytoplasm through a nuclear export signal 
located in the amino terminus of IkB (Huang 
et al, 2000a). 
Therefore the activation of NF-kB 
by Cu would result in the transcription of both 
RANTES and the NF-kB inhibitory 
IkB proteins. It is possible that low doses (up to 25 
µM) of Cu induce 
RANTES transcription in a dose-dependent manner, but at a dose of 
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50 µM, the transcription of the NF-kB inhibitor, IkB, reaches a level sufficient to inhibit 
NF-kB, resulting in reduced RANTES synthesis. Additional increases in Cu would then 
result in further dose-dependent NF-kB mediated synthesis of RANTES. 
Although multimers of recombinant RANTES generated in the presence of Cu plus 
H202 were chemotactically active, the finding that neither the addition of either Cu plus 
H202 nor the addition of Cu chelators had any effect on the form of RANTES detected 
in HLMVEC lysates indicated that Cu is not involved in RANTES multimer formation 
and presentation in HLMVECs. However, the ability of Cu to induce RANTES 
synthesis and the Cu-dependence of the vascular adhesion protein VAP-1 (reviewed in 
Section 4.1.4) indicated that Cu may still have an important pro-inflammatory role and 
could influence leukocyte trafficking during lung inflammation. In addition, studies by 
others indicated that Cu-binding peptides were effective in preventing both Cu-redox 
and IL-8 release from endothelial cells (Rael et al, 2007), suggesting that Cu chelators 
may have therapeutic potential in inhibiting cytokine and chemokine synthesis, and 
subsequent leukocyte recruitment during inflammation. 
Much of the evidence presented in this chapter suggested that platelets may migrate into 
tissues and contribute to leukocyte recruitment, as a source of not only RANTES but 
also PAI-1 and Cu, all of which may play a role in inducing T-cell migration during the 
inflammatory response, especially in the lungs where raised levels of RANTES, PAI-1 
and excessive T-cell accumulation have been implicated in asthma, COPD and CF 
(reviewed in Sections 1.5 and 1.17). Raised levels of PAI-1 have been reported in both 
sputum and plasma from patients suffering with CF, COPD and asthma compared to 
control subjects (Ashitani et al, 2002; Kowal et al, 2007; Xiao et al, 2005). PAI-1 may 
also be derived from the HLMVECs themselves, since PAI-1 synthesis and release has 
been reported to occur in HUVECs in response to thrombin and in bovine aortic 
endothelial cells in response to TNF-a 
(Dichek & Quertermous, 1989; Gelehrter & 
Sznycer-Laszuk, 1986; Sawdey et al, 1989). Platelets have also been reported as a 
source of chondroitin sulphate 
A, which increases the binding of RANTES to 
endothelial cells (reviewed 
in Section 4.1.1.2). In addition, in lung tissue there is a high 
exposure to oxygen which promotes 
the generation of ROS through Cu/redox 
mechanisms (Section 
2.6) which are known to activate NF-kB as a regulator of cytokine 
and chemokine expression. 
Therefore. a model of the vascular endothelium was used to 
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investigate the therapeutic potential of Cu chelators as inhibitors of T-cell 
transendothelial migration in response to platelet-derived RANTES. 
Thrombin is well known as a coagulation factor, generated by the coagulation cascade 
factors and cofactors, but also induces platelet activation and degranulation (Section 
4.1.1.1). At different phases of blood coagulation, thrombin is generated in an extremely 
wide range of concentrations, varying from pM and nM amounts to the maximal level 
of 0.8-1.4 µM (Brummel-Ziedins et al, 2004; Mann et al, 2003). Hence, during blood 
coagulation, platelets can be exposed to very low and very high thrombin 
concentrations. Studies have shown that at low thrombin concentrations of 0.5-1 nM, 
almost all platelets become activated, whereas high doses (10 - 100 nM) trigger platelet 
apoptosis (Leytin et al, 2007). In addition, the low molecular weight phospholipid, 
platelet activating factor (PAF), released from inflammatory cells including neutrophils, 
eosinophils, macrophages and platelets (Barnes et al, 1988) has been shown to induce 
human platelet aggregation and degranulation including the secretion of serotonin from 
human platelets (Henson, 1976; O'Donnell et al, 1978) and to activate rabbit platelets at 
a concentration of 1 µM. This concentration, which is around 6 orders of magnitude 
above the concentration needed to induce platelet activation and aggregation, was 
required to degranulate and remove most of the releasable ATP from the platelets 
(Vargaftig et al, 1982). Although PAF has a central role in the pathogenesis of asthma 
(Barnes et al, 1988), it appears that PAF is a less potent inducer of platelet 
degranulation than thrombin, indicating that thrombin may be more important as an 
inducer of platelet degranulation than PAF during the inflammatory response. Thrombin 
was used at a concentration of 1 U/ml which correlates to 0.019 - 7.94 nM (activity of 
thrombin was 1500 - 3500 NIH Units/mg) which 
is of an order sufficient to activate 
platelets without triggering apoptosis. 
It was expected that HLMVECs grown on 
Transwells would synthesise their own 
basement membrane following 2 weeks of culture as an 
important physiological 
component of the transendothelial migration model 
(Butler et al, 2008; Butler et al, 
2005). Platelets can become activated 
during coagulation through interaction with 
collagen in basement membranes. 
In healthy, undamaged tissues, collagens which 
support the blood vessel wall 
and surrounding tissue are concealed by endothelial cell 
layers and cannot come 
into contact with the circulating platelets. However, should the 
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endothelial cell layer be removed either in disease or upon tissue injury, then collagens 
are revealed which can interact with the cellular components of the blood as well as 
with proteins in blood plasma (reviewed in Famdale, 2006). 
Collagen can bind directly to several receptors on the platelet surface, notably integrin 
a2ß1 and Glycoprotein VI (GpVI) which is considered the primary activatory collagen 
receptor expressed on the platelet surface. Indirect interactions can also occur, as when 
von Willebrand Factor (VWF) binds to the platelet surface through the Glycoprotein lb/ 
V/IX complex, interacting directly with Gplba through its Al domain and also to 
specific sites within the collagens through its A3 domain. Thus, a series of platelet 
receptors contribute to the interaction of the platelet with the collagens and subsequent 
platelet activation (Farndale, 2006). However, in the lung microvascular endothelial 
model, it was not expected that platelets would be exposed to collagen, and therefore 
thrombin was preferentially used as a platelet activator. Thrombin has been previously 
used to activate platelets and cause degranulation in studies of RANTES release and 
platelet-induced monocyte arrest (von Hundelshausen et al, 2001) and platelet-induced 
eosinophil recruitment (Kameyoshi et al, 1992; Kameyoshi et al, 1994). 
Whilst unstimulated platelets spontaneously released RANTES, thrombin induced a 
dose-dependent increase in platelet-derived RANTES release but there appears to be a 
limiting factor at high cell density. One suggestion is that this may be due to the binding 
of RANTES to platelets. The high level of spontaneous RANTES release may be due to 
activation during platelet isolation, which could be minimised by using a rapid, one-step 
density gradient (Bagamery et al, 2005). 
During transendothelial migration experiments, HLMVECs constitutively produced 
RANTES, as indicated by the inhibition of spontaneous 
T-cell migration by anti- 
RANTES neutralising antibodies 
(Section 4.5.5, figure 4.30). However, RANTES- 
dependent T-cell migration was enhanced in the presence of IFN-, y plus TNF-a, which 
increased the synthesis of RANTES as 
indicated by ELISA measurements. This finding 
is in agreement with previous studies 
that have reported IFN-'y plus TNF-a induced 
RANTES synthesis in HUVECs and 
human mucosal microvascular endothelial cells 
(HMMECs) (Marfaing-Koka et al. 
1995; Terada et al, 1996). This may also explain the 
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finding that in platelet-HLMVEC co-cultures, RANTES release was maximal in the 
presence of the activated endothelium. 
However, more RANTES was bound to the endothelium and detectable in the lysates 
than free in the supernatant under these conditions. In support of this result, it has 
previously been reported that greater amounts of platelet-derived RANTES bind to 
HLMVECs following endothelial activation with IFN-y and TNF-a when compared 
with non-activated HLMVECs (von Hundelshausen et al, 2001). It is thought that 
endothelial activation up-regulates the synthesis of many endothelial cell surface 
proteins including proteoglycans and induces specific endothelial binding sites for 
RANTES, explaining the enhanced binding of platelet-derived RANTES to the 
activated endothelium (von Hundelshausen et al, 2001). This may also explain the 
binding of monomeric RANTES released from platelets and HLMVECs to the activated 
endothelium in the presence of IFN--y, TNF-a and thrombin (Section 4.5.2, figure 4.17). 
Some previous studies have also shown enhanced RANTES-induced T-cell migration 
across IFN--y plus TNF-a activated endothelium (Ding et al, 2000; May & Ager, 1992) 
and the mechanism is thought to be due to the up-regulation of endothelial adhesion 
molecules. Endothelial activation also up-regulates the synthesis of E-selectin, P- 
selectin, VCAM-1 and ICAM-1 (Carlos & Harlan, 1994; Ding et al, 2000; Pober & 
Cotran, 1990; Springer, 1994), and IL-1 and TNF-a have been reported to induce GAG 
synthesis in human synovial fibroblast, human cervical 
fibroblasts and human lung 
fibroblast cultures. In particular, the up-regulation of 
hyularonic acid synthesis has been 
reported (Daireaux et al, 1990; Elias et al, 
1988; Ogawa et al, 1998; Yaron et al, 1989). 
It is thought that the up-regulation of GAG synthesis occurs via the activation of 
NF-kB 
and induction of cyclo-oxygenase-2 and prostaglandin 
E2 pathway (Schmitz et al, 
2003). Therefore it is speculated that endothelial activation may 
be important for the up- 
regulation of cell-adhesion molecules and 
the binding of RANTES to the endothelium. 
Thus, pro-inflammatory cytokines may play a role 
in T-cell transendothelial migration. 
The cytokines IFN-y and 
TNF-a were both present endogenously in the transendothelial 
migration model, eliminating 
the need to add them exogenously in order to activate the 
endothelium. A likely source 
for these cytokines is synthesis by T-cells, including naive 
+ T-cells, CD4+ memory Thl type T-cells and low levels of synthesis by Th2 CD45RA 
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type T-cells (Barnes, 2008; Conlon et al, 1995; Mosmann & Coffman, 1989; 
Tsicopoulos et al, 1992). It is also speculated that activated platelets may also release 
IFN-y and TNF-a upon degranulation. Although there is no evidence for platelet release 
of these cytokines, TNF-a has previously been detected in stored platelet concentrates 
(Muylle et al, 1993). In addition, activated human platelets also synthesise and release 
IL-1 ß which may play a role in endothelial activation (Denis et al, 2005). 
Since T-cells have been shown to release RANTES upon activation with the mitogen 
phytohaemagglutinin (PHA) (Section 4.5.3) (Mire-Sluis et al, 1987; Mizel, 1982; 
Palacios, 1982), in addition to platelet derived RANTES, T-cells may also contribute to 
RANTES release in the transendothelial migration model. The inability of IFN-y and 
TNF-a to induce T-cell RANTES release (Section 4.5.3, figures 4.18-4.20) is likely due 
to the prior activation of T-cells by PHA. However, there is little previous evidence to 
suggest that IFN- y and TNF-a can induce RANTES release by T-cells. A comparison 
of the relative amounts of RANTES released by IFN-y and TNF-a stimulated 
HLMVECs, PHA activated T-cells and thrombin stimulated platelets (not shown) 
indicated that are all likely to contribute equally to overall RANTES release in the 
proposed model of transendothelial migration. 
Although the intracellular Cu chelator neocuproine and the extracellular Cu chelator 
bathocuproine both inhibited T-cell transendothelial migration in response to platelet- 
derived RANTES in a dose-dependent manner, there was no synergistic effect when 
both were added together, indicating that extracellular chelation is more important for 
the inhibition of T-cell migration. 
Similarly, D-penicillamine and tobramycin also inhibited T-cell migration in response 
to platelet-derived RANTES in a dose-dependent manner and 
both had an effect at 
therapeutic concentrations (6.7 - 13 µM 
for D-penicillamine for and 4.3 - 21 µM for 
tobramycin) (British National Formulary, No. 
56, September 2008). 
D-penicillamine is a metabolite of penicillin. Although 
it has no antibiotic properties, 
D-penicillamine is a Cu chelating agent 
(Section 4.1.5). D-penicillamine is currently 
used therapeutically 
for rheumatoid arthritis, cystinuria, autimmune hepatitis, Wilson's 
disease and emergency treatment of copper and 
lead poisoning (British National 
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Formulary, No. 56, September 2008). Although the mechanism of action in the 
treatment of Wilson's disease and hepatitis remains unknown, it has been suggested that 
the Cu-binding properties of D-penicillamine may increase urinary Cu excretion, 
preventing hepatic Cu accumulation (Klein et al, 2000; McQuaid et al, 1992; Togashi et 
al, 1992). Several mechanisms have also been suggested for the anti-inflammatory 
action of D-penicillamine in rheumatoid arthritis. It has again been proposed that D- 
penicillamine increases the urinary excretion of Cu (McQuaid et al, 1992) and it has 
also been suggested that D-penicillamine inhibits macrophage-derived IL-1 and 
collagen-inhibiting factors with a subsequent increase in synovial collagen synthesis 
(Brisset et al, 1986). It is also thought that the thiol group may be a key structural 
feature of this drug (Wood et al, 2008). In the treatment of rheumatoid arthritis, D- 
penicillamine may act by directly sequestering reactive aldehydes released by 
inflammatory cells and also by restoring intracellular thiol pools that can also act to 
sequester aldehydes, which damage collagen and cartilage and ultimately result in joint 
deterioration. 
Tobramycin is an aminoglycaside antibiotic used to treat bacterial infections (Section 
4.1.5). Tobramycin is preferred over gentamicin for Pseudomonas aeruginosa 
pneumonia due to better lung penetration and bactericidal activity (Vakulenko & 
Mobashery, 2003) and is currently used as an inhaled antibiotic for the treatment of 
Pseudomonas aeruginosa infection in cystic fibrosis (CF) patients and also for the 
treatment of local infection in the eye (British National Formulary, No. 56, September 
2008). 
The finding that tobramycin inhibits T-cell transendothelial migration indicates that 
tobramycin may have potential both as an indirect (antibiotic) and direct (non- 
antibiotic) anti-inflammatory agent. 
In addition, the aminoglycoside vancomycin may 
also have potential to inhibit 
T-cell transendothelial migration, since vancomycin has 
been shown to be a highly effective copper chelator 
(Swiatek et al, 2005). This could be 
confirmed by using this 
drug in further transmigration experiments. 
It was expected that treatment with copper 
chelators would inhibit RANTES production 
through the inhibition of the 
NF-kB pathway and possibly also via the inhibition of 
Cu/redox, and alter the form of 
RANTES presented on the endothelial cell surface 
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through interference with the Cu-redox mechanisms that have been shown to mediate 
RANTES multimer formation (Chapters 2 and 3). However, RANTES concentrations 
were not altered as a result of Cu chelation. Cu chelation also did not induce any 
alteration in the multimeric form of RANTES or increase plasmin activity which 
indicates that Cu chelators did not induce syndecan shedding as a mechanism for the 
inhibition of T-cell migration. Although Cu chelation did not alter the form of RANTES 
detected in HLMVEC lysates, this was only associated with overnight treatment of the 
endothelial cells, which would likely only affect the form of newly synthesised 
RANTES and not RANTES multimers that had already formed and bound to the 
endothelial cell surface prior to treatment with Cu chelators. Since Cu has been shown 
to induce RANTES multimerisation via the formation of dityrosine cross-links 
(Chapters 2 and 3), it is possible that Cu chelation may still have a long-term effect, 
preventing RANTES multimerisation to the tetramer which is the predominant and 
active form of RANTES detected in HLMVEC lysates. This effect may occur in 
addition to the short-term inhibitory effect on T-cell transendothelial migration seen in 
this chapter, suggesting further work which would involve the incubation of HLMVECs 
with Cu chelators in longer term experiments. 
The PAI-1 inhibitor, XR5118 inhibited T-cell migration in response to platelet-derived 
RANTES a dose-dependent manner, and this was associated with an increase in soluble 
tetrameric RANTES and an increase in plasmin activity confirming that the anti- 
inflammatory action of XR5118 occurs through the inhibition of PAI-1. The inhibition 
of PAI-1 by the neutralising antibody MAI-12 
has previously been shown to induce 
syndecan shedding in HUVECs with an associated 
increase in soluble HSPG-bound IL- 
8 (Marshall et al, 2003). It therefore 
follows that treatment with XR5118 induces 
syndecan shedding as a consequence of 
PAI-1 inhibition resulting in reduced RANTES 
presentation to T-cells and reduced 
T-cell migration. 
In addition, the enzyme catalase also 
inhibited T-cell migration in response to platelet- 
derived RANTES, suggesting the 
involvement of H202 in T-cell migration, in addition 
to the involvement of 
Cu. H202 is produced by the endothelium and as a known second 
messenger, can upregulate 
endothelial E- and P-selectin, VCAM-1, ICAM-1, TNF-a 
and chemokine expression 
via NF-kB (discussed later), which may explain the 
inhibition of T-cell migration upon 
treatment of HLMVECs with catalase. However. 
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treatment with catalase induced a significant increase in LDH release, although 100 % 
Trypan blue exclusion of platelets, T-cells and HLMVECs indicated that these cells 
were still viable. 
However, by way of explanation of the conflicting results, the enzyme LDH is known to 
be sensitive to Cu-mediated inactivation (Pamp et al, 2005). Cu is associated with many 
oxidation processes. The ability of Cu to exchange between stable oxidised Cu (II) and 
unstable, reduced Cu (I) states is used by cuproenzymes involved in redox reactions, 
e. g. Cu/Zn superoxide dismutase or cytochrome oxidase (Camakaris et al, 1999). 
However, the Cu (II) to Cu (I) or vice versa transitions also results in the generation of 
reactive oxygen species (ROS) and oxidative stress (Halliwell & Gutteridge, 1988). 
Multivalent metal ions are fundamental to redox chemistry as they facilitate electron 
transfers during the redox process (Smith et al, 2007). The oxidised form, Cu (II), in the 
presence of a reducing agent, such as ascorbate, is reduced to Cu (I) which subsequently 
catalyses the generation of reactive oxygen species (ROS). Cu (I) reductively activates 
H202 to form OH radicals in a mechanism analogous to the metal-driven Haber Weiss 
reaction, or Fenton reaction (Zhu et al, 2002). In addition to OH radicals, the other ROS 
generated in the presence of Cu ions are: "O2- "RO2 and "ONOO- (peroxynitrite formed 
by the reaction of NO- (nitric oxide) with 02-. H202 can be generated by the free radical 
scavenger superoxide dismutase in the following reaction: 
02 + 2H20 10 2H202 
Cu (I) reductively activates H202 to 
form OH radicals 
H202 + Cu+ -º Cu2+ + OH" + 
OH 
Consequently a paradoxical situation arises where reducing agents, such as ascorbate 
can amplify oxidative 
damage in the presence of Cu (I) (Balogh et al, 2003). Thus, free 
radicals generated 
in the presence of Cu ions can result in lipid, DNA and protein 
peroxidation. 
It is therefore possible that free radicals may play a role in Cu-mediated 
inactivation of LDH. 
Catalase scavenges H202 and will therefore be expected to 
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influence redox cycling. If free radicals are removed it may be possible that LDH 
inactivation is reversed, resulting in increased LDH activity. This may be a mechanism 
whereby treatment with catalase could result in increased LDH activity through H202 
scavenging. 
The overnight treatment of HLMVECs with Cu chelators or XR5118 did not cause 
toxicity to endothelial cells as confirmed by lactate dehydrogenase (LDH) assay, 
indicating that cytotoxicity was not the cause of reduced T-cell migration upon 
treatment with Cu chelators. Therefore, VAP-1, a Cu-dependent membrane bound 
enzyme that can influence leukocyte transendothelial migration was investigated as a 
mechanism for the inhibitory effects of Cu chelators. VAP-1 acts as a traditional 
adhesion molecule through the binding of sialic acid residues to a leukocyte-expressed 
lectin and also oxidatively deaminates leukocyte surface primary amines via its 
semicarbazide-sensitive amine oxidase activity with a resulting transient covalent bond 
that is thought to influence leukocyte-endothelial binding during leukocyte rolling with 
important end products including H202, aldehyde and ammonium which may regulate 
NF-kB and the adhesive properties of endothelial cells including the upregulation of P- 
and E-selectin (reviewed in Section 4.1.4). 
However, failure to detect HLMVEC VAP-1 activity indicates that this enzyme is either 
not present or expressed at levels beyond the detection limit of the assay, despite reports 
that VAP-1 is expressed in the endothelium of large and mid-sized pulmonary vessels of 
normal human lungs (Singh et al, 2003) and that VAP-1 
SSAO-mediated deamination is 
involved in the recruitment of leukocytes during 
lipopolysachharide-induced pulmonary 
inflammation in transgenic mice that overexpress VAP-1 (Yu et al, 2006). Some reports 
have shown that VAP-1 is only up-regulated 
in response to inflammation (Jaakkola et 
al, 2000; Merinen et al, 2005) 
but the activation of HLMVECs with IFN-, y and TNF-a 
did not appear to induce VAP-1 expression. 
VAP-1 has so far only been 
detectable intracellularly in the cytoplasm of cultured 
HUVECs, and it has been reported 
that cultured endothelial cells including HUVECs 
lack detectable surface VAP-1. 
VAP-1 in HUVECs was not translocated onto the 
endothelial cell surface 
after stimulation with multiple c}tokines including IFN-y and 
TNF-a, mitogens or secretagogues which 
induced expression of other known 
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endothelial adhesion molecules including ICAM-1, E-selectin, and VCAM-1 
(Arvilommi et al, 1997; Salmi & Jalkanen, 1995). VAP-1 detected in HUVECs also 
lacks several types of common post-translational modifications such as sialic acids in 
contrast to naturally occurring VAP-1 in HEV, which may preclude its surface 
expression in cultured endothelial cells and also render VAP-1 functionally inactive. 
The authors of these studies have suggested that populations of cultured primary 
endothelial cell types commonly used as a model in studying lymphocyte-endothelial 
cell interactions lack surface expression of VAP-1 compared to peripheral lymph node- 
type high endothelial venules (HEV), and hence are inherently of limited use in 
analyses of lymphocyte transendothelial migration (Salmi & Jalkanen, 1995). 
It may be possible to detect HLMVEC-expressed VAP-1 using a more sensitive 
radiochemical method, such as that used-by Yu, et al., 2006, to detect VAP-1 SSAO 
activity in lung tissue from transgenic mice. The method involves the use of 14C- 
labelled benzylamine or methylamine as the substrate with the use of chlorgyline and 
deprenyl to block MAO activity. The enzyme reaction was terminated with citric acid 
and the oxidised products were extracted and quantified using a liquid scintillation 
counter. SSAO activity was detected as low as 0.1 nMol/min/mg protein using this 
method. 
Endothelial cells are known to produce H202 which is involved in redox cycling and the 
subsequent generation of ROS as described. A possible mechanism for the anti- 
inflammatory effects of copper chelators on T-cell transendothelial migration is via the 
inhibition of Cu-redox mechanisms resulting in impaired redox cycling and lowered 
levels of ROS. ROS are known to act as second messengers, upregulating gene 
expression in the vasculature, via NF-kB 
including the expression of VCAM-1 (Kunsch 
& Medford, 1999), ICAM-1 (Cheng et al, 1998), TNF-a (Valen et al, 1999), E- and P- 
selectin (Jalkanen et al, 2007) and chemokines 
(Chen et al, 2004; Lakshminarayanan et 
al, 1997) and consequently may play an 
important role in endothelial activation, 
cytokine and chemokine production and 
adhesion molecule upregulation. 
Therefore, it is postulated that 
Cu chelators may exert their anti-inflammatory effects 
via the impairment of redox 
cycling and subsequent inhibition of gene expression for 
important vascular adhesion molecules, cytokines and chemokines. 
In support of this 
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notion, the impairment of leukocyte-endothelial adhesion has been reported in the 
muscle microcirculation of the copper-deficient rat (Schuschke et al, 2001) and in 
addition, copper-deficiency has been reported to attenuate endothelial cell Ca 2+ 
mobilisation (Schuschke et al, 2000) and suppress the expression of cell surface 
molecules in human promonocytic cells and neutrophils (Huang & Failla, 2000; 
Karimbakas et al, 1998). Furthermore, the anti-inflammatory effects of the drug 
enoxaparin (EP) were shown to occur via its antioxidant potential (Manduteanu et al, 
2007). It was demonstrated that in cultured endothelial cells exposed to non-toxic levels 
of H202, treatment with EP reduced monocyte adhesion, ICAM-1 and P-selectin 
expression, decreased the nuclear levels of c-Jun and p65 proteins, and diminished the 
phosphorylation of c-Jun protein, MAPK p38 and JNK. Thus the report demonstrates 
impaired leukocyte adhesion with the reduced expression of adhesion molecules via the 
MAPK (both p38 and JNK) / NF-kB pathway in response to antioxidant therapy. In 
addition, it has been shown that D-penicillamine has anti-oxidative properties, 
preventing hyaluronan degradation induced by Cu/redox ROS generation (Valachova et 
al, 2008). The anti-oxidative effects of D-penicillamine are likely dependent on its 
ability to impair redox cycling and may also be dependent on its ability to bind Cu, 
indicating that other Cu-binding drugs may also have anti-oxidative potential. 
Since enoxaparin is a low molecular weight heparin, other GAGs may also have anti- 
oxidant potential, as demonstrated by the increases in lipid peroxidation and post- 
translational proteolytic modification of RANTES upon treatment with sodium chlorate, 
which inhibits GAG synthesis, and the protective effects of 
HS against the degradation 
of chemokine multimers (Chapters 2 and 3). 
As discussed, the protective effects of 
GAGs against lipid peroxidation and oxidative 
damage have also been reported in 
liposome and fibroblast cultures (reviewed 
in Section 2.6). 
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5. General Discussion 
This thesis provides evidence that Cu has pro-inflammatory effects and that Cu 
chelators have anti-inflammatory properties that indicate their therapeutic potential. 
However, the use of copper per se as a therapeutic agent is well documented and 
probably dates to the beginning of recorded history and even earlier as a folk remedy for 
arthritis. The use of Cu by transdermal delivery in the form of the metal from Cu 
bracelets has been a time-honoured practice since antiquity, when it was recognised for 
its anti-inflammatory activity. The potential for the use of Cu as an anti-inflammatory 
agent remains subject to controversy, because scientific studies designed to demonstrate 
therapeutic benefits for arthritic conditions through dermal contact with metallic Cu or 
its compounds have been inadequate. 
Interestingly, raised Cu levels and mildly acidic conditions are common during 
inflammation and raised Cu serum levels that correlate with disease activity have been 
reported in particular in patients with rheumatoid arthritis (Strecker, 2005)(reviewed in 
Section 1.20). Furthermore, both acute and chronic inflammation have been 
characterised by a significant increase in total serum Cu, which can be regarded as a 
factor capable of worsening pathological processes, including oxidative stress (Milanino 
& Buchner, 2006). 
Many studies have extensively claimed that there is little benefit from the use of Cu 
bracelets in the therapy of rheumatoid arthritis (Camara & Danao-Camara, 1999; 
Herman et al, 2004; Kestin et al, 1985; Rao et al, 2003; Rao et al, 1999; Struthers et al, 
1983). However, several studies reported a significantly greater number of the patients 
who stated that their condition improved while wearing a 
Cu bracelet compared to 
wearing an aluminium bracelet. The effect was attributed 
to the supply of a steady 
supplemental amount of Cu from the 
bracelets. Cu bracelets were reported to have lost 
an average of 13 mg in a month of use and 
the lost Cu was assumed to have dissolved 
into the wearers' sweat and then to 
have been absorbed into their skin (Bratton et al, 
2002; Walker et al, 1981; Walker & Keats, 
1976). 
It has been discovered that upon contact with skin, and 
in the presence of 02 and H2O, 
Cu metal oxidises and 
dissolves in sweat. Subsequent laboratory experiments showed 
that Cu bracelets could slowly release 
Cu ions that form complexes with amino acids 
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and fatty acids, which will permeate both the surrounding skin and eventually' also the 
body (Walker & Griffin, 1976; Walker & Keats, 1976; Walker & Reeves, 1977). In 
samples of artificial sweat where initial copper concentration was of the order of 2x 10- 
5 M, after 24 hours of incubation with Cu turnings the samples turned blue and the 
concentration had increased to 2x 10-3M Cu. However, quantitative data for 
percutaneous penetration of the metal's putative oxidation products, which may be 
generated in contact with skin in humans, is not available, and because no beneficial 
effect could be statistically documented for skin contact with Cu devices, the 
mechanism of action of Cu bracelets in rheumatoid arthritis, if it occurs at all, is still 
poorly understood. 
Cu is an essential trace element, present in the mammalian organism only in minimal 
concentration as free ionic Cu (10-18 M, with a range between 10-11 and 10-19 M) and is 
predominantly complexed with proteins and amino acids (reviewed in Hostynek & 
Maibach, 2006). Some studies have reported anti-inflammatory activity upon the 
parenteral administration of Cu-complexes in carrageenin rat paw oedema models 
including several tetrachlorocuprate (II) complexes (Jimenez-Hernandez et al, 1995), 
and salicylic acid Cu complexes (Beveridge et al, 1980; Beveridge et al, 1982; Walker 
et al, 1980). In addition, Cu complexes of anti-arthritic drugs, including salicylic acid, 
acetylsalicylic acid, penicillamine, and several corticoids, were found to be more active 
than the parent drugs. A comparison of Cu, gold, and silver thiomalate and thiosulfate 
complexes in models of inflammation revealed that the 
Cu complexes were effective, 
while the gold and silver complexes were virtually 
inactive (Aaseth et al, 1998). As a 
general rule, Cu complexes are less toxic and suppress the ulcerogenic effect of many of 
the ligand drugs themselves. The modem use of Cu complexes to treat arthritis 
dates 
from the 1940s, and the theory that Cu complexes of nonsteroidal anti-inflammatory 
drugs are more active and less toxic than 
the parent compounds is supported by a 
substantial body of literature 
(Hostynek & Maibach, 2006). 
Based on this evidence, compounds 
that have subsequently been investigated include 
Cu complexes of well-known antiarthritic 
drugs, including steroidal and nonsteroidal 
anti-inflammatory 
drugs niflumic acid, D-penicillamine, hydrocortisone, 
dexamethasone, dimethylsulfoxide, clopirac, 
ketoprofen, naproxen, indomethacin. 
mefenamic acid, 
diclofenaca and ibuprofen among a number of others. All the Cu 
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complexes of those drugs have been found to be active or more effective anti- 
inflammatory agents than the parent drug (Hostynek & Maibach, 2006). 
The anti-inflammatory activity of Cu-complexes has been attributed to superoxide 
dismutase (SOD) activity exhibited by these compounds (Santini et al, 2003), resulting 
in the dismutation of the superoxide anion (02-) to the less potent H202 and O2, Catalase 
or glutathione peroxidise can then decompose H202 into H2O and 02 (Rahman et al. 
2006). The superoxide dismutase activity of Cu-complexes occurs due the ability of Cu 
to participate in electron transfer reactions. Cu can accept and donate single electrons as 
it changes valency between the reduced Cu (I) and oxidised Cu (II) states, assisting in 
the catalysis of oxidation-reduction reactions involving oxygen radicals (Leary & 
Winge, 2007; Osterberg, 1980). This is used by cuproenzymes involved in redox 
reactions such as CuZnSOD and cytochrome c oxidase (Camakaris et al, 1999). Reports 
have shown that Cu-complexes have a potent inhibitory effect on the production of 
superoxide anions in serum and in tumor cell lines in vitro (Huber et al, 1987; 
Saczewski et al, 2007; Weser & Schubotz, 1981). These inhibitory effects could 
explain, at least in part, the anti-inflammatory activity of Cu-complexes (Frechilla et al, 
1990a; Frechilla et al, 1990b), since oxidative stress can determine alterations at the 
cellular level via oxidant-induced activation of signalling pathways. 
Reactive oxygen species (ROS), either directly or via the formation of lipid 
peroxidation products such as acrolein, 4-hydroxy-2-nonenal and F(2)-isoprostanes, 
may play a role in enhancing inflammation through the activation of stress 
kinases 
(JNK, MAPK, p38, phosphoinositide 3 (P1-3 )-kinase/PI- 3K-activated serine-threonine 
kinase Akt) and redox sensitive transcription 
factors such as NF-kB and AP-1 (Rahman, 
2002)(reviewed in Sections 4.1.3 and 4.6). Oxidative stress also causes disruption of 
membrane lipids and cellular 
destruction as a result of lipid peroxidation induced by 
ROS. The end products of lipid peroxidation can also activate p44/42 
(ERK 1/2) and c- 
Jun MAPK pathways (Ciencewicki et al, 
2008). In addition, oxidative stress can lead to 
rises in intracellular calcium 
ions, cytoskeleton disruption and DNA damage (Halliwell, 
1991). Recent data have also 
indicated that oxidative stress and pro-inflammatory 
mediators can alter nuclear 
histone acetylation/deacetylation allowing access for 
transcription factor 
binding to DNA, leading to enhanced pro-inflammatory gene 
expression in various 
lung cells (Rahman, 2002). 
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Oxidative stress is associated with a host of inflammatory diseases, particularly those 
associated with the lung (Ciencewicki et al, 2008). This is because of all the organs in 
the human body, the lungs are by far the most susceptible to attack by free radicals due 
to the highest exposure to oxygen and oxidants in inhaled air, and large surface area and 
blood supply to the lungs. Homeostasis of the oxidation/reduction (redox) state is 
imperative for cell viability, activation, proliferation and survival, all of which are 
necessary for the proper functioning of all organs (Rahman et al, 2006). The lungs 
defend against oxidative challenge with efficient antioxidant defenses such as 
glutathione (GSH), albumin, uric acid, vitamins C and E, SOD and catalase (Mak & 
Chan-Yeung, 2006). However, during inflammation, infiltrated phagocytic cells 
including neutrophils, eosinophils and macrophages release large amounts of ROS 
(Kinnula et al, 1995) and there is evidence that as well as inflammatory cells, non- 
inflammatory cells including the alveolar and bronchial epithelium and the endothelium 
release ROS (Folkerts et al, 2001; Holland et al, 1990; Kinnula et al, 1992a; Kinnula et 
al, 1992b). An imbalance of the redox system in the lungs leads to lung tissue damage 
and fibrosis. Oxidative stress has been increasingly recognised as one of the major 
factors contributing to the chronic inflammatory process in the lungs (Mak, 2008) and is 
well known to contribute to the inflammatory response in pulmonary hypertension 
(Bowers et al, 2004), cystic fibrosis (CF) (Brown et al, 1996; Reid et al, 2007), asthma 
(Mak & Chan-Yeung, 2006), adult respiratory distress syndrome (ARDS) (Cross et al, 
1990) and chronic obstructive pulmonarty disease (COPD) (Psarras et al, 2005). 
Antioxidant therapy using a novel antioxidant rich formulation for oral administration 
containing beta-carotene (30 mg), tocopherols (vitamin E) 
including alpha-tocopherol 
(200 IU) and gamma-tocopherol (94 mg) and other tocopherols 
(31 mg), coenzyme Q 10 
(CoQlO) (30 mg) vitamin D3 400 IU and vitamin K1 
(300 mg) has been shown to 
reduce airway inflammation in 
CF (Papas et al, 2008) and antioxidant thiol molecules, 
polyphenol salts erdosteine and carbocysteine 
lysine salt have been reported to reduce 
inflammation in COPD (Rahman, 2006). It has also been suggested that antioxidant 
therapy may be useful in the treatment of asthma 
(Garcia-Larsen et al, 2009; Nadeem et 
al, 2008; Riccioni et al, 
2007). 
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As well as increased oxidative stress, raised Cu levels have also been reported in many 
disease states including rheumatoid and osteoarthritis, cancer and angiogenesis, 
cardiovascular disease, Alzheimer's disease, chronic wounds, vasculitis and chronic 
hepatitis (reviewed in Section 1.20). Raised Cu levels induce pulmonary inflammation 
and many inflammatory diseases of the lung are associated with raised Cu status 
including COPD, CF, ARDS and asthma (Karadag et al, 2004; Percival et al, 1999; 
Rice et al, 2001). 
The evidence suggests that especially in the lung, inflammation is exacerbated by 
oxidative stress, and that Cu may also contribute to oxidative stress in these diseases 
due to its well documented role in redox reactions resulting in ROS generation (Section 
2.6). This evidence leads to the suggestion that Cu-binding compounds may be of 
therapeutic value in the treatment of pulmonary inflammation including COPD, CF, 
ARDS and asthma, both through the removal of Cu, preventing its involvement in redox 
cycling and ROS generation leading to suppressed NF-kB activation and also by acting 
directly as an antioxidant via superoxide dismutase activity. In support of this notion, 
Cu-complexes have been shown to exhibit anti-inflammatory activity which has been 
attributed to the SOD activity of these Cu-binding compounds. In addition, Cu-binding 
drugs that also have antibiotic activity may prove even more effective, such as 
gentamycin, tobramycin or vancomycin. 
Wilson's disease, an inherited disease of Cu toxicity has been the 
driving force in the 
development of anti-copper drugs. The genetic 
defect is caused by a mutation or 
deletion of the gene, ATP7B, encoding a 
P-type ATPase of 1411 amino acids. ATP7B 
is essential for Cu transport and elimination of 
Cu from the body (Bull et al, 1993). 
Wilson's disease is characterised by low ceruloplasmin concentrations 
in blood and a 
marked increase in the 
Cu contents of the liver and brain (Brewer & Yuzbasiyan- 
Gurkan, 1992). Absorbed Cu is brought to the 
liver by the Cu transporters albumin and 
transcuprein (reviewed in 
Section 1.18). Following uptake by the hepatocyte, a portion 
of the Cu is normally 
incorporated into ceruloplasmin and another portion is excreted in 
the bile. A third portion 
is incorporated into Cu-dependent intracellular enzymes such as 
CuZnSOD and cytochrome oxidase. 
In the liver of patients with Wilson disease the 
process of Cu 
incorporation into ceruloplasmin appears to be impaired, as is excretion 
of Cu into the 
bile. 
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Because the Cu cannot enter the bile nor participate in ceruloplasmin synthesis, the 
result is an accumulation of Cu by the liver. Prolonged accumulation of Cu in liver cells 
results in cirrhosis and subsequent deposition of excess Cu in extra-hepatic tissues as 
well as brain damage as a result of Cu accumulation in the brain (Linder & Hazegh- 
Azam, 1996). The accumulation results in neurologic symptoms of tremors, spasticity. 
rigidity and chorea, dystonia, unsteady gait and psychosis (Cui et al, 2005). The disease 
is very treatable with Cu-binding drugs with excellent clinical results (Brewer, 2008). 
D-penicillamine was the first drug developed for oral administration in Wilson's 
disease. The Cu chelator induces the excretion of a large amount of Cu in the urine 
(Walshe, 1956). Although highly effective, D-penicillamine has a long list of side 
effects including the worsening of neurological symptoms in newly diagnosed patients 
and many patients who worsen never recover (Brewer, 2008). The second drug 
developed was trientine (Walshe, 1982), another Cu chelator that increases the urinary 
excretion of Cu. Although trientine causes fewer side effects than D-penicillamine, it 
shares the propensity to cause worsening of neuralgia. 
Zinc was developed as the third treatment option (Brewer et al, 1998), and this 
treatment has very few side effects. Zinc acts by inducing intestinal cell metallothionein 
which then binds Cu from food and endogenous secretions and 
holds the Cu in the 
intestinal tract. The fourth drug which is not yet in the market is tetrathiomolybdate 
(TMB). This drug has been shown in clinical trials to be excellent for the stabilistation 
of neurologic status and preventing worsening. 
It acts by forming a tripartite complex 
with Cu and protein that is very tight. 
Taken with food, the drug complexes with food 
protein and endogenously secreted 
Cu and preventing its absorption. Taken without 
food, TMB is absorbed and binds free Cu and albumin so that the 
Cu is no longer 
available for cellular uptake. 
The TMB complex is metabolised by the liver, and 
excreted into the urine (Brewer, 
2008). 
Cu-binding drugs are also used in the treatment of rheumatoid arthritis. 
Rheumatoid 
arthritis is a chronic 
destructive inflammatory joint disease, characterised by massive 
synovial proliferation and 
subintimal infiltration of inflammatory cells, which along 
with angiogenesis 
leads to the formation of a very aggressive tissue called pannus 
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(Feldmann et al, 1996; Koch, 1998). Expansion of the pannus induces bone erosion and 
cartilage thinning leading to the loss of joint function. Rheumatoid arthritis is 
characterised by increased production of inflammatory cytokines including TNF-a, IL- 
1-a and IL-I-ß (Feldmann et al, 1996) as well as raised serum Cu (Honkanen et al, 
1991) which may correlate with the increased cytokine production seen in rheumatoid 
arthritis patients (Zoli et al, 1998). 
D-penicillamine has been used in the therapy of rheumatoid arthritis for many years but 
the mechanism of the effect of D-penicillamine is still unknown, although it is thought 
that D-penicillamine may induce the excretion of endogenous Cu in the urine (McQuaid 
et al, 1992). However, TMB is much more effective in inducing Cu excretion into the 
urine than D-penicillamine and has also proved effective in suppressing adjuvant- 
induced arthritis and inflammation-associated cachexia in rats (Omoto et al, 2005), 
suggesting that the two drugs may have a similar mechanism of action that in part 
involves increasing the urinary excretion of Cu. As described above, the mechanism of 
these Cu-binding drugs likely also involves the inhibition of redox cycling and ROS 
generation. NF-kB can be activated directly by Cu but can also be activated by ROS 
that are generated by Cu-redox mechanisms. This indicates both a direct and indirect 
mechanism for the inhibition of Cu-induced NF-kB activation by Cu-binding drugs, 
leading to suppressed inflammatory cytokine production since NF-kB is the master 
regulator of many proinflammatory cytokines. This effect could occur in addition to the 
superoxide dismutase activity exhibited by Cu-complexes. 
It is likely that neocuproine, bathocuproine, D-penicillamine and tobramycin inhibit T- 
cell recruitment in response to platelet-derived 
RANTES in the transendothelial 
migration model via the binding and removal of 
free Cu, since all four of these 
compounds were effective 
in inhibiting T-cell recruitment (Chapter 4) and in this 
Chapter, one common property of all 
these compounds is their ability to bind Cu. As 
discussed here and in Section 4.6, the anti-inflammatory mechanism 
is likely due to the 
antioxidant potential of 
Cu-binding compounds with the subsequent impairment of 
redox cycling which may 
result in the inhibition of gene expression for important 
vascular adhesion molecules, 
cytokines and chemokines. 
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Beyond the treatment of Wilson's disease and rheumatoid arthritis, as discussed, Cu- 
binding compounds may prove useful for the treatment of pulmonary inflammatory 
diseases via the lowering of oxidative stress which occurs in particular in the lungs, and 
this may also result in suppressed leukocyte recruitment. Cu-binding compounds may 
prove useful in the treatment of COPD, CF, ARDS, asthma, and pulmonary fibrosis, but 
could also be beneficial in the treatment of cancer and angiogenesis, prion disease and 
Alzheimer's disease (reviewed in Section 1.22) (Squitti et al, 2005). The pathogenesis 
of these diseases may be dependent on the availability of free Cu and could be inhibited 
by lowering levels of free Cu. 
Cu has been shown to play a role in Aß-peptide aggregation and plaque formation in the 
pathophysiology of Alzheimer's disease (reviewed in Section 1.21), suggesting that a 
therapy aimed at lowering free Cu levels in Alzheimer's disease might be beneficial to 
patients. Cu chelators are effective in solubilising brain Aß (Cherny et al, 2000) and in 
addition, the metal chelation of Cu with clioquinol markedly inhibits Aß aggregation in 
Alzheimer's disease transgenic mice (Cherry et al, 2001). However, during clinical 
trials, although clioquinol has been shown to steady the cognitive ability of patients 
with Alzheimer's disease, the drug was also associated with serious neurologic side 
effects known as subacute myelo-optic neuropathy (SMON), the symptoms of which 
included numbness, pain and intestinal distress, paralysis and blindness. Clinical trials 
are on-going in order to assess the therapeutic potential of clioquinol, since it is thought 
that the toxic effects of clioquinol may have been due to the formation of a toxic 
biproduct during the manufacture of clioquinol (Cahoon, 2009). It has also been found 
that Cu chelation delays the onset of prion 
disease in mice (Sigurdsson et al, 2003) 
(reviewed in Section 1.22). 
In phase I/II trials, TMB 
has also been shown to be effective in idiopathic pulmonary 
fibrosis patients (Flaherty et al, 
2007) and TMB also inhibits liver and heart 
inflammation in mouse models via the 
inhibition of TNF-a, IL- IP and IL-2 expression 
(Hou et al, 2005; 
Ma, 2004). The growth of cancers involves angiogenesis and the 
development of a blood supply 
for the growing tumor. Angiogenesis is stimulated by 
many cytokines and 
the upregulation and activity of these cytokines is dependent on Cu. 
Preclinical studies 
have strongly indicated that TMB inhibits angiogenesis in mouse 
models, including 
squamous carcinoma, mammary cancer, head and neck cancer 
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models and TMB also showed efficacy in a study of advanced cancers in pet dogs 
(reviewed in Brewer, 2008). It has been asserted that the anti-angiogenic action of TMB 
occurs via the inhibition of Cu-dependent effects on NF-kB activity (Khan & Merajver, 
2009; Pan et al, 2003; Pan et al, 2002). 
However, it is important to consider the side effects of Cu-binding drugs when 
evaluating their potential for the treatment of diseases where Cu-lowering therapy may 
be beneficial. Of all the Cu-binding drugs discussed so far, D-penicillamine has the 
highest risk with regard to side effects and toxicity. As discussed, D-penicillamine has 
in particular been associated with side effects neurological symptoms, but it has also 
been associated with reduced platelet count, proteinuria associated with immune 
complex nephritis, nausea, loss of taste and rash outbreak (British National Formulary, 
No. 56, September 2008) (Dubois et al, 1998; Magnus et al, 1987). 
The aminoglycoside antibiotics including kanamycin, gentamycin and tobramycin are 
associated with vestibular and auditory damage, nephrotoxicity, antibiotic-associated 
colitis, stomatitis, nausea, vomiting, rash and muscular weakness (British National 
Formulary, No. 56, September 2008) and the aminoglycosides are also not absorbed via 
oral administration and therefore must be administered intravenously to achieve 
effective serum concentrations. In addition, the aminoglycosides do not readily cross the 
blood-brain barrier and therefore are unlikely to be of use in the treatment of 
Alzheimer's disease (Bruckner et al, 1981; Moellering et al, 1981). 
However, so far clinical trials have shown that orally administered TMB is effective in 
the treatment of Wilson's disease (Brewer et al, 2006; Brewer et al, 2003; Brewer et al, 
1996), rheumatoid arthritis (Omoto et al, 
2005) and also has antiangiogenic effects in 
malignant pleural mesothelioma patients after resection of gross 
disease (Pass et al, 
2008), patients with advanced 
kidney cancer (Redman et al, 2003) and patients with 
hormone-refractory prostate cancer (Henry et al, 2006). The trials have shown that 
TMB exhibits minimal toxicity. 
Side effects included anaemia, neutropaenia, 
leukopaenia and transaminase elevations 
but these side effects were generally resolved 
with either a dose adjustment 
or temporary suspension of the dosing regimen (Medici & 
Sturniolo, 2008). The evidence 
indicates that TMB has greater potential for use as an 
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anti-inflammatory agent than some of the Cu-binding drugs used in the past since it can 
be administered orally and is highly effective with minimal toxicity risks. 
It is also important to consider the effective targeting of Cu-binding drugs to the site of 
inflammation. Whilst systemic administration of Cu-binding drugs via the oral or 
intravenous route is effective in the treatment of Wilson's disease and some cancers, 
local inflammation may be more difficult to target. As discussed, the lung could be an 
important target for Cu-lowering therapy since many of the inflammatory diseases of 
the lung are associated with raised Cu and the infiltration of phagocytes, both of which 
contribute to oxidative stress and exacerbate inflammation. In order to target the lung, it 
may be more beneficial to use an inhaled formulation which would directly target the 
bronchial airways and alveolar spaces, the sites at which excessive inflammation can be 
life threatening. Previous studies have reported that a formulation of aerosolised 
tobramycin is effective in the treatment of CF and Pseudomonas aeruginosa infection, 
significantly improving pulmonary function, and the inhaled formulation was well 
tolerated by patients (Chuchalin et al, 2007). Aerosolised antibiotics including 
tobramycin, gentamycin, neomycin, amikacin, aztreonam, colistin, carbenicillin, 
amphoteracin, ticarcillin and ceftazidime have also been used for non-cystic fibrosis 
bronchiectasis which has been shown to decrease sputum bacterial density (Rubin, 
2008). 
However, this route of administration of Cu-binding drugs may result in toxic side 
effects that could occur upon the removal of Cu as an essential cofactor for many 
proteins and enzymes, including the intracellular proteins cytochrome c oxidase and 
CuZnSOD and the extracellular proteins ceruloplasmin, lysyl oxidase, transcuprein and 
amine oxidases (Linder & Hazegh-Azam, 1996). Cytochrome c oxidase 
is the terminal 
enzyme of the electron transport chain in mitochondria and the site where oxygen 
is 
utilised in respiration, catalysing the reduction of 
02 to 2H202. CuZnSOD is important 
for the dismutation of superoxide anions and therefore the loss of the SOD activity of 
this enzyme would likely affect oxidative stress 
levels and exacerbate inflammation. 
Ceruloplasmin is also a Cu-dependent ROS scavenger, protecting against oxidative 
damage. As with CuZnSOD, loss of this scavenging activity would also result 
in 
increased oxidative stress, which could exacerbate 
inflammation. Inhibition of 
ceruloplasmin would also 
have detrimental effects on the transport of essential Cu from 
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the liver to other tissues. However it is likely that the activity of these anti-oxidative 
enzymes would be replaced with the anti-oxidative Cu-antibiotic complex. 
Lysyl oxidase is another Cu-dependent enzyme critical for the formation and function of 
connective tissue throughout the body. Its function is to catalyse cross-linking of newly 
formed collagen and tropoelastin fibres through the oxidative deamination of lysine side 
chains on these proteins. Cu deficiency leads to a lack of collagen maturation and 
defective sheathing of blood vessels by elastic fibres, which can result in aneurisms 
(reviewed in Linder and Hazegh-Azam, 1996). 
It was shown that Cu induces the multimerisation of isolated recombinant RANTES, IL- 
8 and ENA-78 (Chapter 2) and RANTES multimerisation was shown to occur via the 
formation of Cu-induced dityrosine cross-links (Chapter 3). Although Cu chelation had 
no effect on the multimerisation of RANTES in vitro, as discussed in Section 4.6, 
RANTES may already have formed tetramers during culture prior to the addition of the 
Cu chelators for 24 hours. The treatment of HLMVECs with Cu chelators in longer term 
experiments may prevent the formation of tetramers prior to transendothelial migration 
assays. The tetrameric form was predominant form of RANTES bound to the 
endothelium and was found to be highly stable (Chapter 4). This highly stable form of 
RANTES may be important in vivo under shear flow conditions and it is possible that 
Cu may be important in vivo for the formation of the tetramer and retention of RANTES 
on the endothelium during inflammation, and perhaps also other chemokines such as IL- 
8 and ENA-78 which also multimerise in the presence of 
Cu (Chapter 2). Therefore, 
although it has not yet been demonstrated in vitro, 
it is possible that Cu chelation may 
reduce the retention and presentation of chemokines on 
the endothelium in vivo under 
flow conditions in the bloodstream. 
The presentation of chemokines on the endothelium 
not only directs leukocyte recruitment 
but also induces the firm adhesion of leukocytes 
to the endothelium prior to transcytosis and migration 
to the site of inflammation 
(reviewed in Section 1.1). Therefore Cu chelation may 
be a useful strategy to target the 
accumulation of leukocytes as an essential 
response during inflammation. 
The endothelium controls the selectivity 
of invasive processes via its phenotype and its 
physiological or pathological 
state. Thus endothelial cells select populations of 
circulating cells via a 
multi-step process leading to leukocyte recruitment. The 
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specificity is regulated by the arrangement of cytokines, chemokines and adhesion 
molecules that guide circulating leukocytes to specific locations. The presentation of 
chemokines via GAGs on the endothelial cell surface plays an essential role in the 
selective regulation of leukocyte homing by attracting circulating cells via a gradient 
and activating integrins upon binding to specific GPCRs on leukocytes (reviewed in 
Section 1.1). 
The profile of chemokine expression varies between different endothelial types. As the 
focus of this thesis, RANTES is implicated in many diseases of the lung (reviewed in 
sections 1.5 and 1.16), but since RANTES presentation on the endothelium occurs 
predominantly via HSPGs (Hillyer & Male, 2005) and HSPGs are ubiquitously 
expressed, it is not surprising that RANTES expression has been reported in many 
endothelial types. RANTES binds strongly to several endothelia including human lung 
and dermal microvascular endothelium, saphenous and umbilical vein endothelium, 
appendix endothelium, brain endothelium, skin endothelium, bone marrow endothelium 
and mesenteric lymph node endothelium (Crola Da Silva et al, 2009; Hillyer & Male, 
2005). As a chemokine involved in T-cell recruitment, it is most likely that RANTES is 
involved ubiquitously in inflammation, as an important chemotactic signal in the 
adaptive immune response. 
Binding sites for several chemokines including RANTES have been demonstrated on 
the endothelial cells of dermal venules and small veins 
but not arteries or capillaries 
(Hub & Rot, 1998; Rot, 1992), in the afferent lymphatic vessels in the upper and lower 
dermis of human skin (Hub & Rot, 1998) and also 
in the lining of high endothelial 
venules (HEV) suggesting that RANTES may 
be implicated in directing the trafficking 
of T-cells through the afferent 
lymphatic vessels to the lymph nodes. It is thought that 
during clearance, chemokines are channelled and redistributed 
to the lymph nodes 
where they can induce leukocyte recruitment 
after association with HEV (Rot, 2003). 
The chemokines CCL19 and 
CCL21 have been shown to be essential in the 
transmigration of T-cells across 
HEVs via binding to CCR7, the shared receptor for 
these two chemokines. CCR7 
is uniformly expressed by all naive T-cells as well as 
subsets of resting memory 
T-cells (Ebert et al, 2005). However. RANTES may be 
involved in the recirculation of activated 
T-cells expressing the receptors CCR3 and 
CCR5. 
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Therefore a strategy such as Cu-lowering therapy for altering RANTES presentation on 
the endothelium may not only be important for lung inflammation where RANTES has 
been implicated with several inflammatory diseases, but also in a wide range of other 
diseases involving other major organs. However, because in addition to Cu, oxidative 
stress has also been implicated in inflammation, required both for redox cycling and 
also inducing chemokine multimer formation, as the most susceptible organ to oxidative 
stress the lungs may be the most important target for Cu chelation therapy. 
Further work: 
Possible suggestions for further work include investigating the Cu chelators TMB and 
vancomycin for anti-inflammatory activity, anti-oxidant activity and therapeutic 
potential using transmigration assays and FOX-2 assays to determine whether these Cu 
chelators inhibit T-cell migration or protect lipids from peroxidation in cell cultures. 
The effect of Cu-tobramycin or Cu-vancomycin complexes, which are easily 
synthesised by overnight incubation of tobramycin or vancomycin with CuCl2 followed 
by ethanol precipitation could also be investigated using a FOX-2 assay to determine 
whether Cu-tobramycin or Cu-vancomycin protect lipids from peroxidation or have any 
effect on the redox state of cells in culture. 
The effect of Cu on RANTES NFkB/IkB expression could be determined at the mRNA 
level. 
Further longer-term experiments could be used to evaluate the effect of Cu depletion on 
chemokine multimer formation and binding to the endothelium 
in conjunction with the 
effect on leukocyte migration. 
Transmigration experiments using several different endothelial types would 
facilitate 
the speculation of which tissues could be targeted with 
Cu-binding drugs to the greatest 
anti-inflammatory effect. 
In addition, treatment of immunoprecipitated cell 
lysates with GAG-lyases would also 
give an indication as to which 
GAGs the chemokines are binding in different 
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endothelia, and this could parallel the use of Western blotting and immunostaining for 
GAGs including HSPG, chondroitin sulphate and dermatan sulphate. 
Furthermore, to determine the mechanism of action of Cu chelators in the suppression 
of leukocyte migration it would be necessary to investigate the expression of endothelial 
expressed adhesion molecules including ICAM-1, VCAM-1, P-selectin and E-selectin 
and also the nuclear levels of NF-kB, and the phosphorylation of proteins associated 
with the MAPK pathway such as c-Jun, p65, p38 and JNK. 
283 
Aaseth J, Haugen M, Forre 0 (1998) Rheumatoid arthritis and metal compounds-- 
perspectives on the role of oxygen radical detoxification. Analyst 123: 3-6 
Abi-Younes S, Sauty A, Mach F, Sukhova GK, Libby P, Luster AD (2000) The stromal 
cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in 
atherosclerotic plaques. Circ Res 86: 131-8 
Abi-Younes S, Si-Tahar M, Luster AD (2001) The CC chemokines MDC and TARC 
induce platelet activation via CCR4. Thromb Res 101: 279-89 
Albertini R, Passi A, Abuja PM, De Luca G (2000) The effect of glycosaminoglycans 
and proteoglycans on lipid peroxidation. Int JMol Med 6: 129-36 
Albertini R, Rindi S, Passi A, Pallavicini G, De Luca G (1996) Heparin protection 
against Fe2+ -and Cu2+ -mediated oxidation of liposomes. FEBS Lett 383: 155-8 
Ali FE, Leung A, Cherny RA, Mavros C, Barnham KJ, Separovic F, Barrow CJ (2006) 
Dimerisation of N-acetyl-L-tyrosine ethyl ester and Abeta peptides via formation of 
dityrosine. Free Radic Res 40: 1-9 
Ali FE, Separovic F, Barrow CJ, Cherry RA, Fraser F, Bush Al, Masters CL, Bamham 
KJ (2005) Methionine regulates copper/hydrogen peroxide oxidation products of Abeta. 
JPeptSci 11: 353-60 
Ali S, Fritchley SJ, Chaffey BT, Kirby JA (2002) Contribution of the putative heparan 
sulfate-binding motif BBXB of RANTES to transendothelial migration. Glycobiology 
12: 535-43 
Andersen SO (1963) Characterization of a new type of cross-linkage in resilin, a rubber- 
like protein. Biochim Biophys Acta 69: 249-62 
Andersen SO (1964) The Cross-Links in Resilin Identified as Dityrosine and 
Trityrosine. Biochim Biophys Acta 93: 213-5 
Appay V, Rowland-Jones SL (2001) RANTES: a versatile and controversial 
chemokine. Trends Immunol 22: 83-7 
Arenzana-Seisdedos F, Thompson J, Rodriguez MS, Bachelerie F, Thomas D, Hay RT 
(1995) Inducible nuclear expression of newly synthesized I kappa B alpha negatively 
regulates DNA-binding and transcriptional activities of 
NF-kappa B. Mol Cell Biol 15: 
2689-96 
Arispe N, Diaz JC, Flora M (2008) Efficiency of histidine-associating compounds for 
blocking the alzheimer's Abeta channel activity and cytotoxicity. 
Biophys J 95: 4879-89 
Arvilommi AM, Salmi M, Jalkanen 
S (1997) Organ-selective regulation of vascular 
adhesion protein-1 expression 
in man. Eur J Immunol 27: 1794-800 
Ashitani J, Mukae H, Arimura 
Y, Matsukura S (2002) Elevated plasma procoagulant 
and fibrinolytic markers 
in patients with chronic obstructive pulmonary disease. Intern 
Med 41: 181-5 
284 
Asosingh K, Swaidani S, Aronica M, Erzurum SC (2007) Thl- and Th2-dependent 
endothelial progenitor cell recruitment and angiogenic switch in asthma. J Immunol 
178: 6482-94 
Atwood CS, Huang X, Khatri A, Scarpa RC, Kim YS, Moir RD, Tanzi RE, Roher AE, 
Bush Al (2000a) Copper catalyzed oxidation of Alzheimer Abeta. Cell Mol Biol (Noisy- 
le-grand) 46: 777-83 
Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, Hartshorn 
MA, Tanzi RE, Bush Al (1998) Dramatic aggregation of Alzheimer abeta by Cu(II) is 
induced by conditions representing physiological acidosis. JBiol Chem 273: 12817-26 
Atwood CS, Perry G, Zeng H, Kato Y, Jones WD, Ling KQ, Huang X, Moir RD, Wang 
D, Sayre LM, Smith MA, Chen SG, Bush Al (2004) Copper mediates dityrosine cross- 
linking of Alzheimer's amyloid-beta. Biochemistry 43: 560-8 
Atwood CS, Scarpa RC, Huang X, Moir RD, Jones WD, Fairlie DP, Tanzi RE, Bush Al 
(2000b) Characterization of copper interactions with alzheimer amyloid beta peptides: 
identification of an attomolar-affinity copper binding site on amyloid betal-42. J 
Neurochem 75: 1219-33 
Bagamery K, Kvell K, Barnet M, Landau R, Graham J (2005) Are platelets activated 
after a rapid, one-step density gradient centrifugation? Evidence from flow cytometric 
analysis. Clin Lab Haematol 27: 75-7 
Baggiolini M, Dahinden CA (1994) CC chemokines in allergic inflammation. Immunol 
Today 15: 127-33 
Balogh GT, Illes J, Szekely Z, Forrai E, Gere A (2003) Effect of different metal ions on 
the oxidative damage and antioxidant capacity of hyaluronic acid. Arch Biochem 
Biophys 410: 76-82 
Baltus T, von Hundelshausen P, Mause SF, Buhre W, Rossaint R, Weber 
C (2005) 
Differential and additive effects of platelet-derived chemokines on monocyte arrest on 
inflamed endothelium under flow conditions. JLeukoc 
Biol 78: 435-41 
Baltus T, Weber KS, Johnson Z, Proudfoot AE, Weber C (2003) Oligomerization of 
RANTES is required for CCR1-mediated arrest 
but not CCR5-mediated transmigration 
of leukocytes on inflamed endothelium. 
Blood 102: 1985-8 
Bar-Or D, Thomas GW, Yukl RL, Rael LT, Shimonkevitz RP, 
Curtis CG, Winkler JV 
(2003) Copper stimulates the synthesis and release of 
interleukin-8 in human 
endothelial cells: a possible early role 
in systemic inflammatory responses. Shock 20: 
154-8 
Barnes PJ (2008) The cytokine network 
in asthma and chronic obstructive pulmonary 
disease. JClin Invest 118: 3546-56 
Barnes PJ, Chung KF, Page 
CP (1988) Platelet-activating factor as a mediator of 
allergic disease. 
JAllergy Clin Immunol 81: 919-34 
285 
Bartlett AH, Hayashida K, Park PW (2007) Molecular and cellular mechanisms of 
syndecans in tissue injury and inflammation. Mol Cells 24: 153-66 
Beck LA, Tancowny B, Brummet ME, Asaki SY, Curry SL, Penno MB, Foster M, Bahl 
A, Stellato C (2006) Functional analysis of the chemokine receptor CCR3 on airway 
epithelial cells. J Immunol 177: 3344-54 
Beg AA, Baldwin AS, Jr. (1993) The I kappa B proteins: multifunctional regulators of 
Rel/NF-kappa B transcription factors. Genes Dev 7: 2064-70 
Bernheld M, Gotte M, Park PW, Reizes 0, Fitzgerald ML, Lincecum J, Zako M (1999) 
Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68: 729-77 
Beveridge SJ, Walker WR, Whitehouse MW (1980) Anti-inflammatory activity of 
copper salicylates applied to rats percutaneously in dimethyl sulphoxide with glycerol. J 
Pharm Pharmacol 32: 425-7 
Beveridge SJ, Whitehouse MW, Walker WR (1982) Lipophilic copper(II) formulations: 
some correlations between their composition and anti-inflammatory/anti-arthritic 
activity when applied to the skin of rats. Agents Actions 12: 225-31 
Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR (1997) The HIV coreceptors 
CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. 
Proc Natl Acad Sci USA 94: 1925-3 0 
Bogdan C, Rollinghoff M, Diefenbach A (2000) Reactive oxygen and reactive nitrogen 
intermediates in innate and specific immunity. Curr Opin Immunol 12: 64-76 
Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR (1988) Plasminogen 
activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 70: 327-3 3 
Bopp SK, Abicht HK, Knauer K (2008) Copper-induced oxidative stress in rainbow 
trout gill cells. Aquat Toxicol 86: 197-204 
Bowers R, Cool C, Murphy RC, Tuder RM, Hopken MW, Flores SC, Voelkel NF 
(2004) Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med 
169: 764-9 
Brasier AR (2006) The NF-kappaB regulatory network. Cardiovasc Toxicol 6: 111-30 
Bratton RL, Montero DP, Adams KS, Novas MA, McKay TC, Hall LJ, Foust JG, 
Mueller MB, O'Brien PC, Atkinson EJ, Maurer MS (2002) Effect of "ionized" wrist 
bracelets on musculoskeletal pain: a randomized, double-blind, placebo-controlled trial. 
Mayo Clin Proc 77: 1164-8 
Brewer GJ (2005) Anticopper therapy against cancer and diseases of inflammation and 
fibrosis. Drug Discov Today 10: 1103-9 
Brewer GJ (2007) A brand new mechanism for copper toxicity. JHepatol 47: 621-2 
286 
Brewer GJ (2008) The risks of free copper in the body and the development of useful 
anticopper drugs. Curr Opin Clin Nutr Metab Care 11: 727-32 
Brewer GJ, Askari F, Lorincz MT, Carlson M, Schilsky M, Kluin KJ, Hedera P, Moretti 
P, Fink JK, Tankanow R, Dick RB, Sitterly J (2006) Treatment of Wilson disease with 
ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a 
double-blind study of treatment of the neurologic presentation of Wilson disease. Arch 
Neurol 63: 521-7 
Brewer GJ, Dick RD, Johnson VD, Brunberg JA, Kluin KJ, Fink JK (1998) Treatment 
of Wilson's disease with zinc: XV long-term follow-up studies. J Lab Clin Med 132: 
264-78 
Brewer GJ, Hedera P, Kluin KJ, Carlson M, Askari F, Dick RB, Sitterly J, Fink JK 
(2003) Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial 
therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. 
Arch Neurol 60: 379-85 
Brewer GJ, Johnson V, Dick RD, Kluin KJ, Fink JK, Brunberg JA (1996) Treatment of 
Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 
neurologically affected patients and follow-up with zinc therapy. Arch Neurol 53: 1017- 
25 
Brewer GJ, Yuzbasiyan-Gurkan V (1992) Wilson disease. Medicine (Baltimore) 71: 
139-64 
Brisset M, Pujol JP, Arenzana-Seisdedos F, Virelizier JL, Penfornis H, Farjanel J, 
Rattner A, Bocquet J, Beliard R, Loyau G (1986) D-penicillamine inhibition of 
interleukin-1 production: a possible mechanism for its effect on synovial collagen 
synthesis? Int J Tissue React 8: 279-87 
Brogren H, Karlsson L, Andersson M, Wang L, Erlinge D, Jern S (2004) Platelets 
synthesize large amounts of active plasminogen activator 
inhibitor 1. Blood 104: 3943-8 
Broughton-Head VJ (2005) Novel Anti-Inflammatory and Mucolytic Effects of 
Heparin, PhD thesis, University of Portsmouth. 
Brown DR, Guantieri V, Grasso G, Impellizzeri G, Pappalardo 
G, Rizzarelli E (2004) 
Copper(II) complexes of peptide 
fragments of the prion protein. Conformation changes 
induced by copper(II) and the binding motif 
in C-terminal protein region. J Inorg 
Biochem 98: 133-43 
Brown RK, Wyatt H, Price JF, Kelly 
FJ (1996) Pulmonary dysfunction in cystic fibrosis 
is associated with oxidative stress. 
Eur Respir J 9: 334-9 
Brozyna S, Ahern J, Hodge 
G, Nairn J, Holmes M, Reynolds PN, Hodge S (2009) 
Chemotactic mediators of Thl 
T-cell trafficking in smokers and COPD patients. COPD 
6: 4-16 
287 
Bruckner 0, Alexander M, Collmann H (1981) Tobramycin levels in cerebrospinal fluid 
of patients with slightly and severely impaired blood-cerebrospinal barrier. 
Chemotherapy 27: 303-8 
Brummel-Ziedins KE, Pouliot RL, Mann KG (2004) Thrombin generation: phenotypic 
quantitation. J Thromb Haemost 2: 281-8 
Bucchieri F, Puddicombe SM, Lordan JL, Richter A, Buchanan D, Wilson SJ, Ward J, 
Zummo G, Howarth PH, Djukanovic R, Holgate ST, Davies DE (2002) Asthmatic 
bronchial epithelium is more susceptible to oxidant-induced apoptosis. Am JRespir Cell 
Mol Biol 27: 179-85 
Buerge-Weiricht D, Sulzberger B (2004) Formation of Cu(I) in estuarine and marine 
waters: application of a new solid-phase extraction method to measure Cu(I). Environ 
Sci Technol 38: 1843-8 
Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW (1993) The Wilson disease 
gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat 
Genet 5: 327-37 
Burrows SD, Doyle ML, Murphy KP, Franklin SG, White JR, Brooks I, McNulty DE, 
Scott MO, Knutson JR, Porter D, et al. (1994) Determination of the monomer-dimer 
equilibrium of interleukin-8 reveals it is a monomer at physiological concentrations. 
Biochemistry 33: 12741-5 
Bush Al, Pettingell WH, Jr., Paradis MD, Tanzi RE (1994) Modulation of A beta 
adhesiveness and secretase site cleavage by zinc. JBiol Chem 269: 12152-8 
Butcher EC (1991) Leukocyte-endothelial cell recognition: three (or more) steps to 
specificity and diversity. Cell 67: 1033-6 
Butler LM, Khan S, Ed Rainger G, Nash GB (2008) Effects of endothelial basement 
membrane on neutrophil adhesion and migration. Cell Immunol 251: 56-61 
Butler LM, Rainger GE, Rahman M, Nash GB (2005) Prolonged culture of endothelial 
cells and deposition of basement membrane modify the recruitment of neutrophils. Exp 
Cell Res 310: 22-32 
Cahoon L (2009) The curious case of clioquinol. Nat Med 15: 356-9 
Camakaris J, Voskoboinik I, Mercer JF (1999) Molecular mechanisms of copper 
homeostasis. Biochem Biophys Res Commun 261: 225-32 
Camara K, Danao-Camara T (1999) Awareness of, use and perception of efficacy of 
alternative therapies by patients with inflammatory arthropathies. Hawaii Med J 58: 
329-32 
Campo GM, D'Ascola A, Avenoso A, Campo S, Ferlazzo AM, Micali C, Zanghi L, 
Calatroni A (2004) Glycosaminoglycans reduce oxidative damage induced by copper 
(Cu+2), iron (Fe+2) and hydrogen peroxide (H202) in human fibroblast cultures. 
Glycoconj J20: 133-41 
288 
Carlos TM, Harlan JM (1994) Leukocyte-endothelial adhesion molecules. Blood 84: 
2068-101 
Can MW, Roth SJ, Luther E, Rose SS, Springer TA (1994) Monocyte chemoattractant 
protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA 91: 3652-6 
Carter NM, Ali S, Kirby JA (2003) Endothelial inflammation: the role of differential 
expression of N-deacetylase/N-sulphotransferase enzymes in alteration of the immunological properties of heparan sulphate. J Cell Sci 116: 3591-600 
Catalfamo M, Karpova T, McNally J, Costes SV, Lockett Si, Bos E, Peters PJ, Henkart 
PA (2004) Human CD8+ T cells store RANTES in a unique secretory compartment and 
release it rapidly after TcR stimulation. Immunity 20: 219-30 
Chaudhuri A, Nielsen S, Elkjaer ML, Zbrzezna V, Fang F, Pogo AO (1997) Detection 
of Duffy antigen in the plasma membranes and caveolae of vascular endothelial and 
epithelial cells of nonerythroid organs. Blood 89: 701-12 
Chen XL, Zhang Q, Zhao R, Medford RM (2004) Superoxide, H202, and iron are 
required for TNF-alpha-induced MCP-1 gene expression in endothelial cells: role of 
Rac 1 and NADPH oxidase. Am J Physiol Heart Circ Physiol 286: H 1001-7 
Cheng JJ, Wung BS, Chao YJ, Wang DL (1998) Cyclic strain-induced reactive oxygen 
species involved in ICAM-1 gene induction in endothelial cells. Hypertension 31: 125- 
30 
Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, 
Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther 
K, Zheng H, Tanzi RE, Masters CL, Bush Al (2001) Treatment with a copper-zinc 
chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's 
disease transgenic mice. Neuron 30: 665-76 
Cherny RA, Barnham KJ, Lynch T, Volitakis I, Li QX, McLean CA, Multhaup G, 
Beyreuther K, Tanzi RE, Masters CL, Bush Al (2000) Chelation and intercalation: 
complementary properties in a compound for the treatment of Alzheimer's disease. J 
Struct Biol 130: 209-16 
Choe H, Moore MJ, Owens CM, Wright PL, Vasilieva N, Li W, Singh AP, Shakri R, 
Chitnis CE, Farzan M (2005) Sulphated tyrosines mediate association of chemokines 
and Plasmodium vivax Duffy binding protein with the Duffy antigen/receptor for 
chemokines (DARC). Mol Microbiol 55: 1413-22 
Choi ES, Nichol JL, Hokom MM, Hornkohl AC, Hunt P (1995) Platelets generated in 
vitro from proplatelet-displaying human megakaryocytes are functional. Blood 85: 402- 
13 
Chuchalin A, Csiszer E, Gyurkovics K, Bartnicka MT, Sands D, Kapranov N, Varoli G, 
Monici Preti PA, Mazurek H (2007) A formulation of aerosolized tobramycin 
(Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa 
289 
infection: a double-blind, placebo-controlled, multicenter study. Paediatr Drugs 9 
Suppl 1: 21-31 
Chung CW, Cooke RM, Proudfoot AE, Wells TN (1995) The three-dimensional 
solution structure of RANTES. Biochemistry 34: 9307-14 
Ciencewicki J, Trivedi S, Kleeberger SR (2008) Oxidants and the pathogenesis of lung diseases. JAllergy Clin Immunol 122: 456-68; quiz 469-70 
Clancy R (1972) Cellular immunity to autologous platelets and serum-blocking factors 
in idiopathic thrombocytopenic purpura. Lancet 1: 6-9 
Clayton A, Evans RA, Pettit E, Hallett M, Williams JD, Steadman R (1998) Cellular 
activation through the ligation of intercellular adhesion molecule-1. J Cell Sci 111 ( Pt 
4): 443-53 
Clemetson KJ, Clemetson JM, Proudfoot AE, Power CA, Baggiolini M, Wells TN 
(2000) Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine 
receptors on human platelets. Blood 96: 4046-54 
Clore GM, Appella E, Yamada M, Matsushima K, Gronenborn AM (1990) Three- 
dimensional structure of interleukin 8 in solution. Biochemistry 29: 1689-96 
Clore GM, Gronenborn AM (1995) Three-dimensional structures of alpha and beta 
chemokines. Faseb J9: 57-62 
Cockwell P, Adams DH, Savage CO (1996) Glycosaminoglycans contribute to multiple 
functions of vascular endothelial cells. Clin Exp Immunol 104: 1-3 
Colditz IG, Schneider MA, Pruenster M, Rot A (2007) Chemokines at large: in-vivo 
mechanisms of their transport, presentation and clearance. Thromb Haemost 97: 688-93 
Conlon K, Lloyd A, Chattopadhyay U, Lukacs N, Kunkel S, Schall T, Taub D, 
Morimoto C, Osborne J, Oppenheim J, et al. (1995) CD8+ and CD45RA+ human 
peripheral blood lymphocytes are potent sources of macrophage inflammatory protein 1 
alpha, interleukin-8 and RANTES. Eur J Immunol 25: 751-6 
Conti P, Barbacane RC, Feliciani C, Reale M (2001) Expression and secretion of 
RANTES by human peripheral blood CD4+ cells are dependent on the presence of 
monocytes. Ann Clin Lab Sci 31: 75-84 
Conti P, DiGioacchino M (2001) MCP-1 and RANTES are mediators of acute and 
chronic inflammation. Allergy Asthma Proc 22: 133-7 
Coughlin SR (2000) Thrombin signalling and protease-activated receptors. Nature 407: 
258-64 
Cramer EM, Norol F, Guichard J, Breton-Gorius J, Vainchenker W, Masse JM. Debili 
N (1997) Ultrastructure of platelet formation by human megakaryocytes cultured with 
the Mpl ligand. Blood 89: 2336-46 
290 
Crola Da Silva C, Lamerant-Fayel N, Paprocka M, Mitterrand M, Gosset D, Dus D. 
Kieda C (2009) Selective human endothelial cell activation by chemokines as a guide to 
cell homing. Immunology 126: 394-404 
Cross CE, Forte T, Stocker R, Louie S, Yamamoto Y, Ames BN, Frei B (1990) 
Oxidative stress and abnormal cholesterol metabolism in patients with adult respiratory distress syndrome. J Lab Clin Med 115: 396-404 
Crump MP, Rajarathnam K, Kim KS, Clark-Lewis I, Sykes BD (1998) Solution 
structure of eotaxin, a chemokine that selectively recruits eosinophils in allergic 
inflammation. JBiol Chem 273: 22471-9 
Cuajungco MP, Faget KY, Huang X, Tanzi RE, Bush Al (2000) Metal chelation as a 
potential therapy for Alzheimer's disease. Ann N YAcad Sci 920: 292-304 
Cui Z, Lockman PR, Atwood CS, Hsu CH, Gupte A, Allen DD, Mumper RJ (2005) 
Novel D-penicillamine carrying nanoparticles for metal chelation therapy in 
Alzheimer's and other CNS diseases. Eur JPharm Biopharm 59: 263-72 
Culley FJ, Pennycook AM, Tregoning JS, Dodd JS, Walzl G, Wells TN, Hussell T, 
Openshaw PJ (2006) Role of CCL5 (RANTES) in viral lung disease. J Virol 80: 8151-7 
Czapiga M, Gao JL, Kirk A, Lekstrom-Himes J (2005) Human platelets exhibit 
chemotaxis using functional N-formyl peptide receptors. Exp Hematol 33: 73-84 
Czaplewski LG, McKeating J, Craven CJ, Higgins LD, Appay V, Brown A, Dudgeon 
T, Howard LA, Meyers T, Owen J, Palan SR, Tan P, Wilson G, Woods NR, Heyworth 
CM, Lord BI, Brotherton D, Christison R, Craig S, Cribbes S, Edwards RM, Evans SJ, 
Gilbert R, Morgan P, Randle E, Schofield N, Varley PG, Fisher J, Waltho JP, Hunter 
MG (1999) Identification of amino acid residues critical for aggregation of human CC 
chemokines macrophage inflammatory protein (MIP)-1 alpha, MIP-1 beta, and 
RANTES. Characterization of active disaggregated chemokine variants. J Biol Chem 
274: 16077-84 
D'Ambrosio D, Iellem A, Bonecchi R, Mazzeo D, Sozzani S, Mantovani A, Sinigaglia F 
(1998) Selective up-regulation of chemokine receptors CCR4 and CCR8 upon 
activation of polarized human type 2 Th cells. Jlmmunol 161: 5111-5 
Dairaghi DJ, Soo KS, Oldham ER, Premack BA, Kitamura T, Bacon KB, Schall TJ 
(1998) RANTES-induced T cell activation correlates with CD3 expression. J Immunol 
160: 426-3 3 
Daireaux M, Redini F, Loyau G, Pujol JP (1990) Effects of associated cytokines (IL-1, 
TNF-alpha, IFN-gamma and TGF-beta) on collagen and glycosaminoglycan production 
by cultured human synovial cells. Int J Tissue 
React 12: 21-31 
Davenpeck KL, Sterbinsky SA, Bochner BS (1998) Rat neutrophils express alpha4 and 
betal integrins and bind to vascular cell adhesion molecule-1 (VCAM-1) and mucosal 
addressin cell adhesion molecule-1 
(MAdCAM-1). Blood 91: 2341-6 
291 
Davies JA, Fisher CE, Barnett MW (2001) Glycosaminoglycans in the study of 
mammalian organ development. Biochem Soc Trans 29: 166-71 
de Bruijne-Admiraal LG, Modderman PW, Von dem Borne AE, Sonnenberg A (1991) 
P-selectin mediates Ca(2+)-dependent adhesion of activated platelets to many different 
types of leukocytes: detection by flow cytometry. Blood 80: 134-42 
De Sanctis GT, Wolyniec WW, Green FH, Qin S, Jiao A, Finn PW, Noonan T, Joetham 
AA, Gelfand E, Doerschuk CM, Drazen JM (1997) Reduction of allergic airway 
responses in P-selectin-deficient mice. JAppl Physiol 83: 681-7 
Denis MM, Tolley ND, Bunting M, Schwertz H, Jiang H, Lindemann S, Yost CC, 
Rubner FJ, Albertine KH, Swoboda KJ, Fratto CM, Tolley E, Kraiss LW, McIntyre 
TM, Zimmerman GA, Weyrich AS (2005) Escaping the nuclear confines: signal- 
dependent pre-mRNA splicing in anucleate platelets. Cell 122: 379-91 
Derian CK, Damiano BP, D'Andrea MR, Andrade-Gordon P (2002) Thrombin 
regulation of cell function through protease-activated receptors: implications for 
therapeutic intervention. Biochemistry (Mosc) 67: 56-64 
Deskur E, Przywarska I, Dylewicz P, Szczesniak L, Rychlewski T, Wilk M, Wysocki H 
(1998) Exercise-induced increase in hydrogen peroxide plasma levels is diminished by 
endurance training after myocardial infarction. Int J Cardiol 67: 219-24 
Devalia JL, Bayram H, Abdelaziz MM, Sapsford RJ, Davies RJ (1999) Differences 
between cytokine release from bronchial epithelial cells of asthmatic patients and non- 
asthmatic subjects: effect of exposure to diesel exhaust particles. Int Arch Allergy 
Immunol 118: 437-9 
Devergne 0, Marfaing-Koka A, Schall TJ, Leger-Ravet MB, Sadick M, Peuchmaur M, 
Crevon MC, Kim KJ, Schall TT, Kim T, et al. (1994) Production of the RANTES 
chemokine in delayed-type hypersensitivity reactions: involvement of macrophages and 
endothelial cells. JExp Med 179: 1689-94 
Dichek D, Quertermous T (1989) Thrombin regulation of mRNA levels of tissue 
plasminogen activator and plasminogen activator 
inhibitor-1 in cultured human 
umbilical vein endothelial cells. Blood 74: 
222-8 
Dinarello CA, Gelfand JA, Wolff SM (1993) Anticytokine strategies in the treatment of 
the systemic inflammatory response syndrome. 
JAMA 269: 1829-35 
Ding Z, Xiong K, Issekutz TB (2000) Regulation of chemokine-induced 
transendothelial migration of T 
lymphocytes by endothelial activation: differential 
effects on naive and memory 
T cells. JLeukoc Biol 67: 825-33 
Dubois B, D'Hooghe MB, De Lepeleire 
K, Ketelaer P, Opdenakker G, Carton H (1998) 
Toxicity in a double-blind, placebo-controlled pilot 
trial with D-penicillamine and 
metacycline in secondary progressive 
multiple sclerosis. ahrlt Scler 4: 74-8 
Ebert LM, Schaerli P, Moser 
B (2005) Chemokine-mediated control of T cell traffic in 
lymphoid and peripheral tissues. 
Alol Immunol 42: 799-809 
292 
Ebnet K, Simon MM, Shaw S (1996) Regulation of chemokine gene expression in human endothelial cells by proinflammatory cytokines and Borrelia burgdorferi. Ann A' YAcad Sci 797: 107-17 
Einholm AP, Pedersen KE, Wind T, Kulig P, Overgaard MT. Jensen JK, Bodker JS, 
Christensen A, Charlton P, Andreasen PA (2003) Biochemical mechanism of action of a diketopiperazine inactivator of plasminogen activator inhibitor-1. Biochem J 373: 723- 32 
Elias JA, Krol RC, Freundlich B, Sampson PM (1988) Regulation of human lung fibroblast glycosaminoglycan production by recombinant interferons, tumor necrosis factor, and lymphotoxin. J Clin Invest 81: 325-33 
Farndale RW (2006) Collagen-induced platelet activation. Blood Cells ýtlol Dis 36: 162- 5 
Fattal-German M, Le Roy Ladurie F, Cerrina J, Lecerf F, Berrih-Aknin S (1998) 
Expression and modulation of ICAM-1, TNF-alpha and RANTES in human alveolar 
macrophages from lung-transplant recipients in vitro. Transpl Immunol 6: 183-92 
Feldmann M, Brennan FM, Maini RN (1996) Rheumatoid arthritis. Cell 85: 307-10 
Ferrante A, Nandoskar M, Bates EJ, Goh DH, Beard LJ (1988) Tumour necrosis factor 
beta (lymphotoxin) inhibits locomotion and stimulates the respiratory burst and 
degranulation of neutrophils. Immunology 63: 507-12 
Fialkow L, Chan CK, Rotin D, Grinstein S, Downey GP (1994) Activation of the 
mitogen-activated protein kinase signaling pathway in neutrophils. Role of oxidants. J 
Biol Chem 269: 31234-42 
Finkel T (1998) Oxygen radicals and signaling. Curr Opin Cell Biol 10: 248-53 
Fitzgerald KA, O'Neill, L. A. J., Gearing, A. J. H. and Callard, R. E. (2001) The 
Cytokine Facts Book, second edition.: 444-447 
Fitzgerald ML, Wang Z, Park PW, Murphy G, Bernfield M (2000) Shedding of 
syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and 
mediated by a TIMP-3 -sensitive metalloproteinase. J Cell Biol 148: 811-24 
Flaherty KR, Brewer GJ, Andrei A (2007) A phase I/II trial of tetrathiomolybdate for 
patients with idiopathic pulmonary fibrosis refractory to previous therapy. Am Thorac 
Soc: A497 
Foerder CA, Shapiro BM (1977) Release of ovoperoxidase from sea urchin eggs 
hardens the fertilization membrane with tyrosine crosslinks. Proc A atl . cad Sci USA 
74: 4214-8 
Folkerts G, Kloek J, Muijsers RB, Nijkamp FP (2001) Reactive nitrogen and oxygen 
species in airway inflammation. Eur J Pharmacol 
429: 2-51-62 
293 
Frechilla D, Lasheras B, Ucelay M, Parrondo E, Craciunescu G, Cenarruzabeitia E 
(1990a) Anti-inflammatory activity of some copper(II) complexes. 
Arzneimittelforschung 40: 914-7 
Frechilla D, Lasheras B, Ucelay M, Parrondo E, Craciunescu G, Cenarruzabeitia E 
(1990b) On the mechanism of the anti-inflammatory activity of some copper (II) 
complexes. Arzneimittelforschung 40: 1008-10 
Frevert CW, Goodman RB, Kinsella MG, Kajikawa 0, Ballman K, Clark-Lewis I, 
Proudfoot AE, Wells TN, Martin TR (2002) Tissue-specific mechanisms control the 
retention of IL-8 in lungs and skin. Jlmmunol 168: 3550-6 
Frevert CW, Kinsella MG, Vathanaprida C, Goodman RB, Baskin DG, Proudfoot A, 
Wells TN, Wight TN, Martin TR (2003) Binding of interleukin-8 to heparan sulfate and 
chondroitin sulfate in lung tissue. Am J Respir Cell Mol Biol 28: 464-72 
Garcia-Larsen V, Chinn S, Rodrigo R, Amigo H, Bustos P, Rona RJ (2009) 
Relationship between oxidative stress-related biomarkers and antioxidant status with 
asthma and atopy in young adults: a population-based study. Clin Exp Allergy 39: 379- 
86 
Garrow JS, James, W. P. T. and Ralph, A. (2000) Human Nutrition and Dietetics. In, pp 
197 - 200. 
Gelehrter TD, Sznycer-Laszuk R (1986) Thrombin induction of plasminogen activator- 
inhibitor in cultured human endothelial cells. J Clin Invest 77: 165-9 
Gerber BO, Zanni MP, Uguccioni M, Loetscher M, Mackay CR, Pichler WJ, Yawalkar 
N, Baggiolini M, Moser B (1997) Functional expression of the eotaxin receptor CCR3 
in T lymphocytes co-localizing with eosinophils. Curr Biol 7: 836-43 
Gimbrone MA, Jr. (1987) Vascular endothelium: nature's blood-compatible container. 
Ann N YAcad Sci 516: 5-11 
Gimbrone MA, Jr. (1999) Endothelial dysfunction, hemodynamic forces, and 
atherosclerosis. Thromb Haemost 82: 722-6 
Giulivi C, Davies KJ (1993) Dityrosine and tyrosine oxidation products are endogenous 
markers for the selective proteolysis of oxidatively modified red 
blood cell hemoglobin 
by (the 19 S) proteasome. JBiol Chem 268: 8752-9 
Giulivi C, Davies KJ (1994) Dityrosine: a marker for oxidatively modified proteins and 
selective proteolysis. Methods Enzymol 
233: 363-71 
Goger B, Halden Y, Rek A, Mosl R, Pye D, Gallagher J, Kungl AJ (2002) Different 
affinities of glycosaminoglycan oligosaccharides 
for monomeric and dimeric 
interleukin-8: a model for chemokine regulation at inflammatory sites. Biochemistry 41: 
1640-6 
294 
Gonzalez-Iglesias R, Pajares MA, Ocal C, Espinosa JC, Oesch B, Gasset M (2002) 
Prion protein interaction with glycosaminoglycan occurs with the formation of 
oligomeric complexes stabilized by Cu(II) bridges. J Mol Biol 319: 527-40 
Gonzalez C, Martin T, Cacho J, Brenas MT, Arroyo T, Garcia-Berrocal B, Navajo JA, 
Gonzalez-Buitrago JM (1999) Serum zinc, copper, insulin and lipids in Alzheimer's 
disease epsilon 4 apolipoprotein E allele carriers. Eur J Clin Invest 29: 637-42 
Gonzalo JA, Lloyd CM, Wen D, Albar JP, Wells TN, Proudfoot A, Martinez AC, Dorf 
M, Bjerke T, Coyle AJ, Gutierrez-Ramos JC (1998) The coordinated action of CC 
chemokines in the lung orchestrates allergic inflammation and airway 
hyperresponsiveness. J Exp Med 188: 157-67 
Guclu K, Sozgen K, Tutem E, Ozyurek M, Apak R (2005) Spectrophotometric 
determination of ascorbic acid using copper(II)-neocuproine reagent in beverages and 
pharmaceuticals. Talanta 65: 1226-32 
Gupte A, Mumper RJ (2007) An investigation into copper catalyzed D-penicillamine 
oxidation and subsequent hydrogen peroxide generation. Jlnorg Biochem 101: 594-602 
Gutteridge JM, Halliwell B (1990) The measurement and mechanism of lipid 
peroxidation in biological systems. Trends Biochem Sci 15: 129-35 
Hadida F, Vieillard V, Autran B, Clark-Lewis I, Baggiolini M, Debre P (1998) HIV- 
specific T cell cytotoxicity mediated by RANTES via the chemokine receptor CCR3. J 
Exp Med 188: 609-14 
Hadley TJ, Lu ZH, Wasniowska K, Martin AW, Peiper SC, Hesselgesser J, Horuk R 
(1994) Postcapillary venule endothelial cells in kidney express a multispecific 
chemokine receptor that is structurally and functionally identical to the erythroid 
isoform, which is the Duffy blood group antigen. J Clin Invest 94: 985-91 
Hallgren R, Feltelius N, Lindh U (1987) Redistribution of minerals and trace elements 
in chronic inflammation--a study on isolated blood cells from patients with ankylosing 
spondylitis. JRheumatol 14: 548-53 
Halliwell B (1991) Reactive oxygen species in living systems: source, biochemistry, 
and role in human disease. Am JMed 91: 14S-22S 
Halliwell B, Clement MV, Long LH (2000a) Hydrogen peroxide in the human body. 
FEBS Lett 486: 10-3 
Halliwell B, Clement MV, Ramalingam J, Long LH (2000b) Hydrogen peroxide. 
Ubiquitous in cell culture and in vivo? IUBMB Life 50: 251-7 
Halliwell B, Gutteridge JM (1988) Free radicals and antioxidant protection: 
mechanisms and significance in toxicology and 
disease. Hum Toxicol 7: 7-13 
Hartwig J, Italiano J, Jr. (2003) The birth of the platelet. J Thromb Haemost 1: 1580-6 
295 
Harvath L, Falk W, Leonard EJ (1980) Rapid quantitation of neutrophil chemotaxis: use 
of a polyvinylpyrrolidone-free polycarbonate membrane in a multiwell assembly. J 
Immunol Methods 37: 39-45 
Hasegawa S, Pawankar R, Suzuki K, Nakahata T, Furukawa S, Okumura K, Ra C 
(1999) Functional expression of the high affinity receptor for IgE (FcepsilonRI) in 
human platelets and its' intracellular expression in human megakaryocytes. Blood 93: 
2543-51 
Hausler M, Schweizer K, Biesterfel S, Opladen T, Heimann G (2002) Peripheral 
decrease and pulmonary homing of CD4+CD45RO+ helper memory T cells in cystic 
fibrosis. Respir Med 96: 87-94 
Hawrylowicz CM, Howells GL, Feldmann M (1991) Platelet-derived interleukin 1 
induces human endothelial adhesion molecule expression and cytokine production. J 
Exp Med 174: 785-90 
Hebert CA, ed. (1999) Chemokines in disease. 
Heeger P, Wolf G, Meyers C, Sun MJ, O'Farrell SC, Krensky AM, Neilson EG (1992) 
Isolation and characterization of cDNA from renal tubular epithelium encoding murine 
Rantes. Kidney Int 41: 220-5 
Heijink IH, Marcel Kies P, van Oosterhout AJ, Postma DS, Kauffman HF, Vellenga E 
(2007) Der p, IL-4, and TGF-beta cooperatively induce EGFR-dependent TARC 
expression in airway epithelium. Am JRespir Cell Mol Biol 36: 351-9 
Henry NL, Dunn R, Merj aver S, Pan Q, Pienta KJ, Brewer G, Smith DC (2006) Phase II 
trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in 
patients with hormone-refractory prostate cancer. Oncology 71: 168-75 
Henson PM (1976) Activation and desensitization of platelets by platelet-activating 
factor (PAF) derived from IgE-sensitized basophils. I. Characteristics of the secretory 
response. JExp Med 143: 937-52 
Herman CJ, Allen P, Hunt WC, Prasad A, Brady TJ (2004) Use of complementary 
therapies among primary care clinic patients with arthritis. Prev Chronic Dis 1: A 12 
Herzog V, Berndorfer U, Saber Y (1992) Isolation of insoluble secretory product from 
bovine thyroid: extracellular storage of thyroglobulin in covalently cross-linked form. J 
Cell Biol 118: 1071-83 
Hileman RE, Fromm JR, Weiler JM, Linhardt RJ (1998) Glycosaminoglycan-protein 
interactions: definition of consensus sites in glycosaminoglycan binding proteins. 
Bioessays 20: 156-67 
Hillyer P, Male D (2005) Expression of chemokines on the surface of different human 
endothelia. Immunol Cell Biol 83: 375-82 
Hirano S, Ebihara H, Sakai S, Kodama N, Suzuki KT (1993) Pulmonary clearance and 
toxicity of intratracheally instilled cupric oxide in rats. Arch Toxicol 67: 312-7 
296 
Hirano S, Sakai S, Ebihara H, Kodama N, Suzuki KT (1990) Metabolism and 
pulmonary toxicity of intratracheally instilled cupric sulfate in rats. Toxicology 64: 223- 
33 
Holland JA, Pritchard KA, Pappolla MA, Wolin MS, Rogers NJ, Stemerman MB 
(1990) Bradykinin induces superoxide anion release from human endothelial cells. J Cell Physiol 143: 21-5 
Honkanen V, Konttinen YT, Sorsa T, Hukkanen M, Kemppinen P, Santavirta S, Saari 
H, Westermarck T (1991) Serum zinc, copper and selenium in rheumatoid arthritis. J 
Trace Elem Electrolytes Health Dis 5: 261-3 
Hoogewerf AJ, Kuschert GS, Proudfoot AE, Borlat F, Clark-Lewis I, Power CA, Wells 
TN (1997) Glycosaminoglycans mediate cell surface oligomerization of chemokines. 
Biochemistry 36: 13570-8 
Horton AA, Fairhurst S (1987) Lipid peroxidation and mechanisms of toxicity. Crit Rev 
Toxicol 18: 27-79 
Hostynek JJ, Maibach HI (2006) Copper and the skin. Edited by Hostynek, J. J, 
and Maibach, H. I. New York, USA: Informa Healthcare 
Hou G. Dick R, Abrams GD, Brewer GJ (2005) Tetrathiomolybdate protects against 
cardiac damage by doxorubicin in mice. JLab Clin Med 146: 299-303 
Huang TT, Kudo N, Yoshida M, Miyamoto S (2000a) A nuclear export signal in the N- 
terminal regulatory domain of IkappaBalpha controls cytoplasmic localization of 
inactive NF-kappaB/IkappaBalpha complexes. Proc Natl Acad Sci USA 97: 1014-9 
Huang X, Atwood CS, Moir RD, Hartshorn MA, Tanzi RE, Bush Al (2004) Trace metal 
contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization 
of Alzheimer's Abeta peptides. JBiol Inorg Chem 9: 954-60 
Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JD, Hanson GR, Stokes 
KC, Leopold M, Multhaup G, Goldstein LE, Scarpa RC, Saunders AJ, Lim J, Moir RD, 
Glabe C, Bowden EF, Masters CL, Fairlie DP, Tanzi RE, Bush Al (1999) Cu(II) 
potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen 
peroxide production and metal reduction. J Biol Chem 274: 37111-6 
Huang X, Cuajungco MP, Atwood CS, Moir RD, Tanzi RE, Bush Al (2000b) 
Alzheimer's disease, beta-amyloid protein and zinc. JNutr 130: 1488S-92S 
Huang ZL, Failla ML (2000) FASEB J 14: A794 
Hub E, Rot A (1998) Binding of RANTES, MCP-1, MCP-3, and MIP-1 alpha to cells in 
human skin. Am JPathol 152: 749-57 
Hubeau C, Lorenzato M, Couetil JP, Hubert D, Dusser D, Puchelle E, Gaillard D (2001) 
Quantitative analysis of inflammatory cells infiltrating the cystic fibrosis airway 
mucosa. Clin Exp Immunol 124: 69-76 
297 
Huber KR, Sridhar R, Griffith EH, Amma EL, Roberts J (1987) Superoxide dismutase- 
like activities of copper(II) complexes tested in serum. Biochim Biophys Acta 915: 267- 
76 
Humphries DE, Silbert JE (1988) Chlorate: a reversible inhibitor of proteoglycan 
sulfation. Biochem Biophys Res Commun 154: 365-71 
Humphries DE, Sugumaran G, Silbert JE (1989) Decreasing sulfation of proteoglycans 
produced by cultured cells. Methods Enzymol 179: 428-34 
Ihrcke NS, Wrenshall LE, Lindman BJ, Platt JL (1993) Role of heparan sulfate in 
immune system-blood vessel interactions. Immunol Today 14: 500-5 
lijima W, Ohtani H, Nakayama T, Sugawara Y, Sato E, Nagura H, Yoshie 0, Sasano T 
(2003) Infiltrating CD8+ T cells in oral lichen planus predominantly express CCR5 and 
CXCR3 and carry respective chemokine ligands RANTES/CCL5 and IP-10/CXCL 10 in 
their cytolytic granules: a potential self-recruiting mechanism. Am JPathol 163: 261-8 
Imlay JA, Chin SM, Linn S (1988) Toxic DNA damage by hydrogen peroxide through 
the Fenton reaction in vivo and in vitro. Science 240: 640-2 
Jaakkola K, Nikula T, Holopainen R, Vahasilta T, Matikainen MT, Laukkanen ML, 
Huupponen R, Halkola L, Nieminen L, Hiltunen J, Parviainen S, Clark MR, Knuuti J, 
Savunen T, Kaapa P, Voipio-Pulkki LM, Jalkanen S (2000) In vivo detection of 
vascular adhesion protein-1 in experimental inflammation. Am JPathol 157: 463-71 
Jackson GS, Murray I, Hosszu LL, Gibbs N, Waltho JP, Clarke AR, Collinge J (2001) 
Location and properties of metal-binding sites on the human prion protein. Proc Natl 
AcadSci USA 98: 8531-5 
Jalkanen S, Karikoski M, Mercier N, Koskinen K, Henttinen T, Elima K, Salmivirta K, 
Salmi M (2007) The oxidase activity of vascular adhesion protein-1 (VAP-1) induces 
endothelial E- and P-selectins and leukocyte binding. Blood 110: 1864-70 
Jalkanen S, Salmi M (2001) Cell surface monoamine oxidases: enzymes in search of a 
function. EMBO J 20: 3 893 -901 
Jeffery PK (1999) Differences and similarities between chronic obstructive pulmonary 
disease and asthma. Clin Exp Allergy 29 Supp12: 14-26 
Jeffery PK, Wardlaw AJ, Nelson FC, Collins JV, Kay AB (1989) Bronchial biopsies in 
asthma. An ultrastructural, quantitative study and correlation with 
hyperreactivity. Am 
Rev Respir Dis 140: 1745-53 
Jezowska-Bojczuk M, Karaczyn A, Kozlowski H (1998) Copper(II) binding to 
tobramycin: potentiometric and spectroscopic studies. 
Carbohydr Res 313: 265-9 
Jia J, Chen J (2008) Chronic nickel-induced DNA damage and cell death: the protection 
role of ascorbic acid. Environ Toxicol 23: 401-6 
298 
Jimenez-Hernandez RM, Frechilla D, Lasheras B, Gutierrez-Rios MT, Parrondo E. 
Craciunescu G, Cenarruzabeita E (1995) Inhibition of inflammation and gastric damage 
in rats by copper (II) complexes. Arzneimittelforschung 45: 277-81 
Jobling MF, Huang X, Stewart LR, Barnham KJ, Curtain C, Volitakis I, Perugini M, 
White AR, Cherny RA, Masters CL, Barrow CJ, Collins SJ, Bush Al, Cappai R (2001) 
Copper and zinc binding modulates the aggregation and neurotoxic properties of the 
prion peptide PrP106-126. Biochemistry 40: 8073-84 
Johnson WT (1999) Copper and signal transduction: platelets as a model to determine 
the role of copper in stimulus-response coupling. Biofactors 10: 53-9 
Jose PJ, Griffiths-Johnson DA, Collins PD, Walsh DT, Moqbel R, Totty NF, Truong 0, 
Hsuan JJ, Williams TJ (1994) Eotaxin: a potent eosinophil chemoattractant cytokine 
detected in a guinea pig model of allergic airways inflammation. J Exp Med 179: 8 81-7 
Junt T, Schulze H, Chen Z, Massberg S, Goerge T, Krueger A, Wagner DD, Graf T, 
Italiano JE, Jr., Shivdasani RA, von Andrian UH (2007) Dynamic visualization of 
thrombopoiesis within bone marrow. Science 317: 1767-70 
Kaburagi Y, Shimada Y, Nagaoka T, Hasegawa M, Takehara K, Sato S (2001) 
Enhanced production of CC-chemokines (RANTES, MCP-1, MIP- l alpha, MIP-1 beta, 
and eotaxin) in patients with atopic dermatitis. Arch Dermatol Res 293: 350-5 
Kadota J, Mukae H, Tomono K, Kohno S (2001) High concentrations of beta- 
chemokines in BAL fluid of patients with diffuse panbronchiolitis. Chest 120: 602-7 
Kainulainen V, Wang H, Schick C, Bernfield M (1998) Syndecans, heparan sulfate 
proteoglycans, maintain the proteolytic balance of acute wound fluids. J Biol Chem 
273: 11563-9 
Kameyoshi Y, Dorschner A, Mallet Al, Christophers E, Schroder JM (1992) Cytokine 
RANTES released by thrombin-stimulated platelets is a potent attractant 
for human 
eosinophils. J Exp Med 176: 5 87-92 
Kameyoshi Y, Schroder JM, Christophers E, Yamamoto S (1994) Identification of the 
cytokine RANTES released from platelets as an eosinophil chemotactic 
factor. Int Arch 
Allergy Immunol 104 Suppl 1: 49-51 
Kanda A, Adachi T, Kayaba H, Yamada Y, Ueki S, Yamaguchi K, Hamada K, Fujita 
M, Chihara J (2004) Red blood cells regulate eosinophil chemotaxis by scavenging 
RANTES secreted from endothelial cells. Clin 
Exp Allergy 34: 1621-6 
Karadag F, Cildag 0, Altinisik M, Kozaci LD, Kiter 
G, Altun C (2004) Trace elements 
as a component of oxidative stress 
in COPD. Respirology 9: 33-7 
Karam LR, Dizdaroglu M, Simic MG (1984) 
OH radical-induced products of tyrosine 
peptides. Int J Radiat Biol Relat 
Stud Phys Chem Med 46: 715-24 
Karimbakas J, Langkamp-Henken B, Percival SS (1998) Arrested maturation of 
granulocytes in copper deficient mice. 
JNutr 128: 1855-60 
299 
Karin M, Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of 
NF-[kappa]B activity. Annu Rev Immunol 18: 621-63 
Karpatkin S, Pearlstein E (1981) Role of platelets in tumor cell metastases. Ann Intern 
Med 95: 636-41 
Kato Y, Kitamoto N, Kawai Y, Osawa T (2001) The hydrogen peroxide/copper ion 
system, but not other metal-catalyzed oxidation systems, produces protein-bound 
dityrosine. Free Radic Biol Med 31: 624-32 
Kato Y, Wu X, Naito M, Nomura H, Kitamoto N, Osawa T (2000) Immunochemical 
detection of protein dityrosine in atherosclerotic lesion of apo-E-deficient mice using a 
novel monoclonal antibody. Biochem Biophys Res Commun 275: 11-5 
Kawai T, Seki M, Hiromatsu K, Eastcott JW, Watts GF, Sugai M, Smith DJ, Porcelli 
SA, Taubman MA (1999) Selective diapedesis of Thl cells induced by endothelial cell 
RANTES. Jlmmunol 163: 3269-78 
Kawanishi S, Oikawa S, Inoue S, Nishino K (2002) Distinct mechanisms of oxidative 
DNA damage induced by carcinogenic nickel subsulfide and nickel oxides. Environ 
Health Perspect 110 Supp15: 789-91 
Keizer DW, Crump MP, Lee TW, Slupsky CM, Clark-Lewis I, Sykes BD (2000) 
Human CC chemokine I-309, structural consequences of the additional disulfide bond. 
Biochemistry 39: 6053-9 
Kennedy T, Ghio AJ, Reed W, Samet J, Zagorski J, Quay J, Carter J, Dailey L, Hoidal 
JR, Devlin RB (1998) Copper-dependent inflammation and nuclear factor-kappaB 
activation by particulate air pollution. Am JRespir Cell Mol Biol 19: 366-78 
Kestin M, Miller L, Littlejohn G, Wahlqvist M (1985) The use of unproven remedies 
for rheumatoid arthritis in Australia. Med JAust 143: 516-8 
Khan G, Merajver S (2009) Copper chelation in cancer therapy using 
tetrathiomolybdate: an evolving paradigm. Expert Opin Investig Drugs 18: 541-8 
Kikugawa K, Kato T, Okamoto Y (1994) Damage of amino acids and proteins induced 
by nitrogen dioxide, a free radical toxin, in air. Free Radic Biol Med 16: 373-82 
Kim IH, Kim K, Rhee SG (1989) Induction of an antioxidant protein of Saccharomyces 
cerevisiae by 02, Fe3+, or 2-mercaptoethanol. Proc Natl 
Acad Sci USA 86: 6018-22 
Kim KS, Rajarathnam K, Clark-Lewis I, Sykes BD (1996) Structural characterization of 
a monomeric chemokine: monocyte chemoattractant protein-3. 
FEBS Lett 395: 277-82 
Kinnula VL, Chang L, Everitt JI, Crapo JD (1992a) Oxidants and antioxidants in 
alveolar epithelial type II cells: in situ, freshly 
isolated, and cultured cells. Am J Physiol 
262: L69-77 
300 
Kinnula VL, Chang LY, Ho YS, Crapo JD (1992b) Hydrogen peroxide release from 
alveolar macrophages and alveolar type II cells during adaptation to hyperoxia in vivo. 
Exp Lung Res 18: 655-73 
Kinnula VL, Crapo JD, Raivio KO (1995) Generation and disposal of reactive oxygen 
metabolites in the lung. Lab Invest 73: 3-19 
Kinnula VL, Whorton AR, Chang LY, Crapo JD (1992c) Regulation of hydrogen 
peroxide generation in cultured endothelial cells. Am J Respir Cell Mol Biol 6: 175-82 
Klein D, Lichtmannegger J, Heinzmann U, Summer KH (2000) Dissolution of copper- 
rich granules in hepatic lysosomes by D-penicillamine prevents the development of 
fulminant hepatitis in Long-Evans cinnamon rats. JHepatol 32: 193-201 
Klemens FK, Fanwick PE, Bibler JK, McMillin DR (1989) Crystal and molecular 
structure of [Cu(bcp)2]BF4. cntdot. CH3OH (bcp = 2,9-dimethyl-4,7-diphenyl-1,10- 
phenanthroline). Inorganic Chemistry 28: 3076-79 
Klinger MH, Wilhelm D, Bubel S, Sticherling M, Schroder JM, Kuhnel W (1995) 
Immunocytochemical localization of the chemokines RANTES and MIP-1 alpha within 
human platelets and their release during storage. Int Arch Allergy Immunol 107: 541-6 
Klinman JP, Mu D (1994) Quinoenzymes in biology. Annu Rev Biochem 63: 299-344 
Koch AE (1998) Review: angiogenesis: implications for rheumatoid arthritis. Arthritis 
Rheum 41: 951-62 
Koskinen K, Vainio PJ, Smith DJ, Pihlavisto M, Yla-Herttuala S, Jalkanen S, Salmi M 
(2004) Granulocyte transmigration through the endothelium is regulated by the oxidase 
activity of vascular adhesion protein-1 (VAP-1). Blood 103: 3388-95 
Kowal K, Bodzenta-Lukaszyk A, Pampuch A, Szmitkowski M, Donati MB, Iacoviello 
L (2007) Plasminogen activator inhibitor-1 plasma concentration in allergic asthma 
patients during allergen challenge. Int Arch Allergy Immunol 144: 240-6 
Kowalska MA, Ratajczak MZ, Majka M, Jin J, Kunapuli S, Brass L, Poncz M (2000) 
Stromal cell-derived factor-1 and macrophage-derived chemokine: 2 chemokines that 
activate platelets. Blood 96: 50-7 
Kramer ML, Kratzin HD, Schmidt B, Romer A, Windl 0, Liemann S, Homemann S, 
Kretzschmar H (2001) Prion protein binds copper within the physiological 
concentration range. J Biol Chem 276: 16711-9 
Krishnaswamy G, Kelley J, Yerra L, Smith JK, Chi DS (1999) Human endothelium as a 
source of multifunctional cytokines: molecular regulation and possible role 
in human 
disease. J Interferon Cytokine Res 19: 91-104 
Kucharewicz I, Kowal K, Buczko W, Bodzenta-Lukaszyk A (2003) The plasmin system 
in airway remodeling. Thromb Res 112: 1-7 
301 
Kunsch C, Medford RM (1999) Oxidative stress as a regulator of gene expression in the 
vasculature. Circ Res 85: 753-66 
Kurashima K, Mukaida N, Fujimura M, Yasui M, Shinagawa T, Matsuda T, Ohmoto Y, 
Matsushima K (1997) A specific elevation of RANTES in bronchoalveolar lavage fluids 
of patients with chronic eosinophilic pneumonia. Lab Invest 76: 67-75 
Kuschert GS, Coulin F, Power CA, Proudfoot AE, Hubbard RE, Hoogewerf AJ, Wells 
TN (1999) Glycosaminoglycans interact selectively with chemokines and modulate 
receptor binding and cellular responses. Biochemistry 38: 12959-68 
LaBella F, Keeley F, Vivian S, Thornhill D (1967) Evidence for dityrosine in elastin. 
Biochem Biophys Res Commun 26: 748-53 
LaBella F, Waykole P, Queen G (1968) Formation of insoluble gels and dityrosine by 
the action of peroxidase on soluble collagens. Biochem Biophys Res Commun 30: 333-8 
Lacy F, O'Connor DT, Schmid-Schonbein GW (1998) Plasma hydrogen peroxide 
production in hypertensives and normotensive subjects at genetic risk of hypertension. J 
Hypertens 16: 291-303 
Lakshminarayanan V, Beno DW, Costa RH, Roebuck KA (1997) Differential regulation 
of interleukin-8 and intercellular adhesion molecule-1 by H202 and tumor necrosis 
factor-alpha in endothelial and epithelial cells. JBiol Chem 272: 32910-8 
Lalor PF, Edwards S, McNab G, Salmi M, Jalkanen S, Adams DH (2002) Vascular 
adhesion protein-1 mediates adhesion and transmigration of lymphocytes on human 
hepatic endothelial cells. Jlmmunol 169: 983-92 
Lane BR, Markovitz DM, Woodford NL, Rochford R, Strieter RM, Coffey MJ (1999) 
TNF-alpha inhibits HIV-1 replication in peripheral blood monocytes and alveolar 
macrophages by inducing the production of RANTES and decreasing C-C chemokine 
receptor 5 (CCR5) expression. Jlmmunol 163: 3653-61 
Laurence JS, Blanpain C, Burgner JW, Parmentier M, LiWang PJ (2000) CC 
chemokine MIP-1 beta can function as a monomer and depends on Phe 13 for receptor 
binding. Biochemistry 39: 3401-9 
Leary SC, Winge DR (2007) The Janus face of copper: its expanding roles in biology 
and the pathophysiology of disease. Meeting on Copper and Related 
Metals in Biology. 
EMBO Rep 8: 224-7 
Lee JS, Frevert CW, Wurfel MM, Peiper SC, Wong VA, Ballman KK, Ruzinski JT, 
Rhim JS, Martin TR, Goodman RB (2003) Duffy antigen facilitates movement of 
chemokine across the endothelium 
in vitro and promotes neutrophil transmigration in 
vitro and in vivo. J Immunol 170: 
5244-51 
Lee SR, Yang KS, Kwon J, Lee C, Jeong W, Rhee SG (2002) Reversible inactivation of 
the tumor suppressor PTEN by H202. 
JBiol Chem 277: 20336-42 
302 
Leong SR, Lowman HB, Liu J, Shire S, Deforge LE, Gillece-Castro BL, McDowell R. 
Hebert CA (1997) IL-8 single-chain homodimers and heterodimers: interactions with 
chemokine receptors CXCR1, CXCR2, and DARC. Protein Sci 6: 609-17 
Ley K, Laudanna C, Cybulsky MI, Nourshargh S (2007) Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 7: 678-89 
Leytin V, Allen DJ, Lyubimov E, Freedman J (2007) Higher thrombin concentrations 
are required to induce platelet apoptosis than to induce platelet activation. Br J 
Haematol 136: 762-4 
Lim JK, Burns JM, Lu W, DeVico AL (2005) Multiple pathways of amino terminal 
processing produce two truncated variants of RANTES/CCL5. J Leukoc Biol 78: 442- 
52 
Linder MC, Hazegh-Azam M (1996) Copper biochemistry and molecular biology. Am J 
Clin Nutr 63: 797S-811 S 
Liu G, Huang W, Moir RD, Vanderburg CR, Lai B, Peng Z, Tanzi RE, Rogers JT, 
Huang X (2006) Metal exposure and Alzheimer's pathogenesis. JStruct Biol 155: 45-51 
Loetscher P, Seitz M, Baggiolini M, Moser B (1996) Interleukin-2 regulates CC 
chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J 
Exp Med 184: 569-77 
Loetscher P, Uguccioni M, Bordoli L, Baggiolini M, Moser B, Chizzolini C, Dayer JM 
(1998) CCR5 is characteristic of Thl lymphocytes. Nature 391: 344-5 
Lominadze DG, Saari JT, Miller FN, Catalfamo JL, Justus DE, Schuschke DA (1996) 
Platelet aggregation and adhesion during dietary copper deficiency in rats. Thromb 
Haemost 75: 630-4 
Lu BY, Beck PJ, Chang JY (2001) Oxidative folding of murine prion mPrP(23-231). 
Eur J Biochem 268: 3 767-73 
Luangsay S, Kasper LH, Rachinel N, Minns LA, Mennechet FJ, Vandewalle A, Buzoni- 
Gatel D (2003) CCR5 mediates specific migration of Toxoplasma gondii-primed CD8 
lymphocytes to inflammatory intestinal epithelial cells. Gastroenterology 125: 491-500 
Lumpkins K, Bochicchio GV, Zagol B, Ulloa K, Simard JM, Schaub S, Meyer W, 
Scalea T (2008) Plasma levels of the beta chemokine regulated upon activation, normal 
T cell expressed, and secreted (RANTES) correlate with severe 
brain injury. J Trauma 
64: 358-61 
M'Bemba-Meka P, Lemieux N, Chakrabarti SK (2005) Role of oxidative stress, 
mitochondrial membrane potential, and calcium 
homeostasis in nickel sulfate-induced 
human lymphocyte death in vitro. Chem Biol Interact 156: 69-80 
Ma S, Hou, G, Dick, R, Brewer, G. J. (2004) Tetrathiomolybdate protects against liver 
injury from acetaminophen in mice. JAppl 
Res Clim Exp Ther 4: 419-426 
303 
Madaric A, Ginter E, Kadrabova J (1994) Serum copper, zinc and copper/zinc ratio in 
males: influence of aging. Physiol Res 43: 107-11 
Magnus JH, Gran JT, Mikkelsen K, Nygaard H, Brath HK (1987) Toxicity to D- 
penicillamine in rheumatoid arthritis. Scand J Rheumatol 16: 441-4 
Mak JC (2008) Pathogenesis of COPD. Part II. Oxidative-antioxidative imbalance. Int J 
Tuberc Lung Dis 12: 368-74 
Mak JC, Chan-Yeung MM (2006) Reactive oxidant species in asthma. Curr Opin Pulm 
Med 12: 7-11 
Malencik DA, Sprouse JF, Swanson CA, Anderson SR (1996) Dityrosine: preparation, 
isolation, and analysis. Anal Biochem 242: 202-13 
Mandal RV, Mark EJ, Kradin RL (2007) Megakaryocytes and platelet homeostasis in 
diffuse alveolar damage. Exp Mol Pathol 83: 327-31 
Manduteanu I, Dragomir E, Voinea M, Capraru M, Simionescu M (2007) Enoxaparin 
reduces H202-induced activation of human endothelial cells by a mechanism involving 
cell adhesion molecules and nuclear transcription factors. Pharmacology 79: 154-62 
Mann KG, Brummel K, Butenas S (2003) What is all that thrombin for? J Thromb 
Haemost 1: 1504-14 
Manni A, Kleimberg J, Ackerman V, Bellini A, Patalano F, Mattoli S (1996) 
Inducibility of RANTES mRNA by IL-lbeta in human bronchial epithelial cells is 
associated with increased NF-kappaB DNA binding activity. Biochem Biophys Res 
Commun 220: 120-4 
Marelli-Berg FM, Cannella L, Dazzi F, Mirenda V (2008) The highway code of T cell 
trafficking. J Pathol 214: 179-89 
Marfaing-Koka A, Devergne 0, Gorgone G, Portier A, Schall TJ, Galanaud P, Emilie D 
(1995) Regulation of the production of the RANTES chemokine by endothelial cells. 
Synergistic induction by IFN-gamma plus TNF-alpha and inhibition by IL-4 and IL- 13. 
J Immunol 154: 1870-8 
Marshall LJ, Ramdin LS, Brooks T, PC DP, Shute JK (2003) Plasminogen activator 
inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition 
of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes. 
J Immunol 171: 2057-65 
Martelius T, Salaspuro V, Salmi M, Krogerus L, Hockerstedt K, Jalkanen S, 
Lautenschlager I (2004) Blockade of vascular adhesion protein-1 inhibits lymphocyte 
infiltration in rat liver allograft rejection. Am JPathol 165: 1993-2001 
Martin L, Blanpain C, Garnier P, Wittamer V, Parmentier M, Vita C (2001) Structural 
and functional analysis of the 
RANTES-glycosaminoglycans interactions. Biochemistry 
40: 6303-18 
304 
Marttila-Ichihara F, Smith DJ, Stolen C, Yegutkin GG, Elima K, Mercier N, Kiviranta 
R, Pihlavisto M, Alaranta S, Pentikainen U, Pentikainen 0, Fulop F, Jalkanen S, Salmi 
M (2006) Vascular amine oxidases are needed for leukocyte extravasation into inflamed 
joints in vivo. Arthritis Rheum 54: 2852-62 
Matoba T, Shimokawa H, Kubota H, Morikawa K, Fujiki T, Kunihiro I, Mukai Y, 
Hirakawa Y, Takeshita A (2002) Hydrogen peroxide is an endothelium-derived 
hyperpolarizing factor in human mesenteric arteries. Biochem Biophys Res Commun 
290: 909-13 
Matoba T, Shimokawa H, Nakashima M, Hirakawa Y, Mukai Y, Hirano K, Kanaide H, 
Takeshita A (2000) Hydrogen peroxide is an endothelium-derived hyperpolarizing 
factor in mice. JClin Invest 106: 1521-30 
Matsushima K, Larsen CG, DuBois GC, Oppenheim JJ (1989) Purification and 
characterization of a novel monocyte chemotactic and activating factor produced by a 
human myelomonocytic cell line. JExp Med 169: 1485-90 
May MJ, Ager A (1992) ICAM-1-independent lymphocyte transmigration across high 
endothelium: differential up-regulation by interferon gamma, tumor necrosis factor- 
alpha and interleukin 1 beta. Eur J Immunol 22: 219-26 
Mayo KH, Chen MJ (1989) Human platelet factor 4 monomer-dimer-tetramer equilibria 
investigated by 1H NMR spectroscopy. Biochemistry 28: 9469-78 
Maziere C, Djavaheri-Mergny M, Frey-Fressart V, Delattre J, Maziere JC (1997) 
Copper and cell-oxidized low-density lipoprotein induces activator protein 1 in 
fibroblasts, endothelial and smooth muscle cells. FEBS Lett 409: 3 51-6 
McEver RP (2002) P-selectin and PSGL-1: exploiting connections between 
inflammation and venous thrombosis. Thromb Haemost 87: 364-5 
McFadden G, Kelvin D (1997) New strategies for chemokine inhibition and 
modulation: you take the high road and I'll take the low road. Biochem Pharmacol 54: 
1271-80 
McQuaid A, Lamand M, Mason J (1992) The interactions of penicillamine with copper 
in vivo and the effect on hepatic metallothionein 
levels and copper/zinc distribution: the 
implications for Wilson's disease and arthritis therapy. JLab Clin Med 119: 744-50 
Medici V, Sturniolo GC (2008) Tetrathiomolybdate, a copper chelator for the treatment 
of Wilson disease, pulmonary 
fibrosis and other indications. IDrugs 11: 592-606 
Meier B, Radeke HH, Selle S, Younes M, Sies H, Resch K, Habermehl GG (1989) 
Human fibroblasts release reactive oxygen species in response to interleukin-1 or 
tumour necrosis factor-alpha. Biochem 
J263: 539-45 
Mellado M, Rodriguez-Frade JM, Manes S, Martinez AC (2001) Chemokine signaling 
and functional responses: the role of receptor 
dimerization and TK pathway activation. 
Annu Rev Immunol 19: 397-421 
305 
Merinen M, Irjala H, Salmi M, Jaakkola I, Hanninen A, Jalkanen S (2005) Vascular 
adhesion protein-1 is involved in both acute and chronic inflammation in the mouse.. 4m 
JPathol 166: 793-800 
Mestas J, Hughes CC (2004) Of mice and not men: differences between mouse and 
human immunology. J Immunol 172: 2731-8 
Metzger WJ, Richerson HB, Worden K, Monick M, Hunninghake GW (1986) 
Bronchoalveolar lavage of allergic asthmatic patients following allergen 
bronchoprovocation. Chest 89: 477-83 
Metzger WJ, Sjoerdsma K, Richerson HB, Moseley P, Zavala D, Monick M, 
Hunninghake GW (1987) Platelets in bronchoalveolar lavage from asthmatic patients 
and allergic rabbits with allergen-induced late phase responses. Agents Actions Suppi 
21: 151-9 
Meyer JE, Berner I, Teran LM, Bartels J, Sticherling M, Schroder JM, Maune S (1998) 
RANTES production by cytokine-stimulated nasal fibroblasts: its inhibition by 
glucocorticoids. Int Arch Allergy Immunol 117: 60-7 
Mickelson JK, Lakkis NM, Villarreal-Levy G, Hughes BJ, Smith CW (1996) Leukocyte 
activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent 
disease? JAm Coll Cardiol 28: 345-53 
Milanino R, Buchner V (2006) Copper: role of the 'endogenous' and 'exogenous' metal 
on the development and control of inflammatory processes. Rev Environ Health 21: 
153-215 
Milne DB, Nielsen FH (1996) Effects of a diet low in copper on copper-status indicators 
in postmenopausal women. Am J Clin Nutr 63: 358-64 
Mire-Sluis AR, Wickremasinghe RG, Hoffbrand AV, Timms AM, Francis GE (1987) 
Human T lymphocytes stimulated by phytohaemagglutinin undergo a single round of 
cell division without a requirement for interleukin-2 or accessory cells. Immunology 60: 
7-12 
Mizel SB (1982) Interleukin 1 and T cell activation. Immunol Rev 63: 51-72 
Moellering RC, Jr., Krogstad DJ, Greenblatt DJ (1981) Pharmacokinetics of 
vancomycin in normal subjects and 
in patients with reduced renal function. Rev Infect 
Dis 3 suppl: S230-5 
Mohanakrishnan P, Chignell CF (1985) Difference circular dichroism studies of copper 
and nickel binding to D-penicillamine 
in the presence of human serum albumin. 
Biochem Pharmacol 34: 675-7 
Moritani C, Ishioka S, Haruta Y, Kambe M, Yamakido M (1998) Activation of platelets 
in bronchial asthma. Chest 113: 452-8 
306 
Mosmann TR, Coffman RL (1989) TH I and TH2 cells: different patterns of 
lymphokine secretion lead to different functional properties. Annu Rev Immunol 7: 145- 
73 
Murphy PM (2002) Chemokine/chemokine receptor nomenclature. J Immunol Methods 
262: 1-3 
Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, Miller LH, 
Oppenheim JJ, Power CA (2000) International union of pharmacology. XXII. 
Nomenclature for chemokine receptors. Pharmacol Rev 52: 145-76 
Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, Miller LH, 
Oppenheim JJ, Power CA (2003) Chemokine/chemokine receptor nomenclature. 
Cytokine 21: 48-9 
Muylle L, Joos M, Wouters E, De Bock R, Peetermans ME (1993) Increased tumor 
necrosis factor alpha (TNF alpha), interleukin 1, and interleukin 6 (IL-6) levels in the 
plasma of stored platelet concentrates: relationship between TNF alpha and IL-6 levels 
and febrile transfusion reactions. Transfusion 33: 195-9 
Nadeem A, Masood A, Siddiqui N (2008) Oxidant--antioxidant imbalance in asthma: 
scientific evidence, epidemiological data and possible therapeutic options. Ther Adv 
Respir Dis 2: 215-35 
Neet KE, Timm DE (1994) Conformational stability of dimeric proteins: quantitative 
studies by equilibrium denaturation. Protein Sci 3: 2167-74 
Nelson PJ, Kim HT, Manning WC, Goralski TJ, Krensky AM (1993) Genomic 
organization and transcriptional regulation of the RANTES chemokine gene. J Immunol 
151: 2601-12 
Neote K, Mak JY, Kolakowski LF, Jr., Schall TJ (1994) Functional and biochemical 
analysis of the cloned Duffy antigen: identity with the red blood cell chemokine 
receptor. Blood 84: 44-52 
Nordenhem A, Wiman B (1997) Plasminogen activator inhibitor-1 (PAI-1) content in 
platelets from healthy individuals genotyped for the 4G/5G polymorphism in the PAI-1 
gene. Scand J Clin Lab Invest 57: 453-61 
Noso N, Sticherling M, Bartels J, Mallet Al, Christophers E, Schroder JM (1996) 
Identification of an N-terminally truncated form of the chemokine RANTES and 
granulocyte-macrophage colony-stimulating 
factor as major eosinophil attractants 
released by cytokine-stimulated 
dermal fibroblasts. J Immunol 156: 1946-53 
O'Donnell MC, Henson PM, Fiedel BA (1978) Activation of human platelets by platelet 
activating factor (PAF) 
derived from sensitized rabbit basophils. Immunology 35: 953-8 
O'Donnell R, Breen D, Wilson S, Djukanovic R (2006) Inflammatory cells in the 
airways in COPD. Thorax 
61: 448-54 
307 
O'Neill DW, Adams S, Bhardwaj N (2004) Manipulating dendritic cell biology for the 
active immunotherapy of cancer. Blood 104: 2235-46 
O'Sullivan BP, Michelson AD (2006) The inflammatory role of platelets in cystic 
fibrosis. Am JRespir Crit Care Med 173: 483-90 
Ogawa M, Hirano H, Tsubaki H, Kodama H, Tanaka T (1998) The role of cytokines in 
cervical ripening: correlations between the concentrations of cytokines and hyaluronic 
acid in cervical mucus and the induction of hyaluronic acid production by inflammatory 
cytokines by human cervical fibroblasts. Am J Obstet Gynecol 179: 105-10 
Ohtani N, Ohtani H, Nakayama T, Naganuma H, Sato E, Imai T, Nagura H, Yoshie 0 
(2004) Infiltration of CD8+ T cells containing RANTES/CCL5+ cytoplasmic granules 
in actively inflammatory lesions of human chronic gastritis. Lab Invest 84: 368-75 
Olszewska-Pazdrak B, Casola A, Saito T, Alam R, Crowe SE, Mei F, Ogra PL, 
Garofalo RP (1998) Cell-specific expression of RANTES, MCP-1, and MIP-1 alpha by 
lower airway epithelial cells and eosinophils infected with respiratory syncytial virus. J 
Virol 72: 4756-64 
Omoto A, Kawahito Y, Prudovsky I, Tubouchi Y, Kimura M, Ishino H, Wada M, 
Yoshida M, Kohno M, Yoshimura R, Yoshikawa T, Sano H (2005) Copper chelation 
with tetrathiomolybdate suppresses adjuvant-induced arthritis and inflammation- 
associated cachexia in rats. Arthritis Res Ther 7: RI 174-82 
Opazo C, Huang X, Cherny RA, Moir RD, Roher AE, White AR, Cappai R, Masters 
CL, Tanzi RE, Inestrosa NC, Bush Al (2002) Metalloenzyme-like activity of 
Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, 
cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem 277: 
40302-8 
Oravecz T, Pall M, Roderiquez G, Gorrell MD, Ditto M, Nguyen NY, Boykins R, 
Unsworth E, Norcross MA (1997) Regulation of the receptor specificity and function of 
the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) 
by dipeptidyl peptidase IV (CD26)-mediated cleavage. JExp Med 186: 1865-72 
Ortiz BD, Nelson PJ, Krensky AM (1997) Switching gears during T-cell maturation: 
RANTES and late transcription. Immunol Today 18: 468-71 
Osterberg R (1980) Physiology and pharmacology of copper. Pharmacol Ther 9: 121- 
46 
Ostrakhovitch EA, Lordnejad MR, Schliess F, Sies H, Klotz LO (2002) Copper ions 
strongly activate the phosphoinositide-3-kinase/Akt pathway 
independent of the 
generation of reactive oxygen species. 
Arch Biochem Biophys 397: 232-9 
Ozes ON, Mayo LD, Gustin JA, Pfeffer 
SR, Pfeffer LM, Donner DB (1999) NF-kappaB 
activation by tumour necrosis 
factor requires the Akt serine-threonine kinase. Nature 
401: 82-5 
308 
Paavola CD, Hemmerich S, Grunberger D, Polsky I, Bloom A, Freedman R, Mulkins 
M. Bhakta S, McCarley D, Wiesent L, Wong B, Jarnagin K, Handel TM (1998) 
Monomeric monocyte chemoattractant protein-1 (MCP-1) binds and activates the MCP- 
1 receptor CCR2B. JBiol Chem 273: 33157-65 
Palacios R (1982) Mechanism of T cell activation: role and functional relationship of 
HLA-DR antigens and interleukins. Immunol Rev 63: 73-110 
Pamp K, Bramey T, Kirsch M, De Groot H, Petrat F (2005) NAD(H) enhances the 
Cu(II)-mediated inactivation of lactate dehydrogenase by increasing the accessibility of 
sulfhydryl groups. Free Radic Res 39: 31-40 
Pan Q, Bao LW, Merajver SD (2003) Tetrathiomolybdate inhibits angiogenesis and 
metastasis through suppression of the NFkappaB signaling cascade. Mol Cancer Res 1: 
701-6 
Pan Q, Kleer CG, van Golen KL, Irani J, Bottema KM, Bias C, De Carvalho M, Mesri 
EA, Robins DM, Dick RD, Brewer GJ, Merajver SD (2002) Copper deficiency induced 
by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 62: 
4854-9 
Panoskaltsis-Mortari A. Strieter RM, Hermanson JR, Fegeding KV, Murphy WJ, Farrell 
CL, Lacey DL, Blazar BR (2000) Induction of monocyte- and T-cell-attracting 
chemokines in the lung during the generation of idiopathic pneumonia syndrome 
following allogeneic murine bone marrow transplantation. Blood 96: 834-9 
Papas KA, Sontag MK, Pardee C, Sokol RJ, Sagel SD, Accurso FJ, Wagener JS (2008) 
A pilot study on the safety and efficacy of a novel antioxidant rich formulation in 
patients with cystic fibrosis. J Cyst Fibros 7: 60-7 
Parish CR (2005) Heparan sulfate and inflammation. Nat Immunol 6: 861-2 
Partrick DA, Moore FA, Moore EE, Biffl WL, Sauaia A, Barnett CC, Jr. (1996) Jack A. 
Barney Resident Research Award winner. The inflammatory profile of interleukin-6, 
interleukin-8, and soluble intercellular adhesion molecule-1 in postinjury multiple organ 
failure. Am JSurg 172: 425-9; discussed 429-31 
Pass HI, Brewer GJ, Dick R, Carbone M, Merajver S (2008) A phase II trial of 
tetrathiomolybdate after surgery for malignant mesothelioma: final results. Ann Thorac 
Surg 86: 383-9; discussion 390 
Patel SR, Hartwig JH, Italiano JE, Jr. (2005) The biogenesis of platelets from 
megakaryocyte proplatelets. 
J Clin Invest 115: 3348-54 
Patterson C, Stouffer GA, Madamanchi N, Runge 
MS (2001) New tricks for old dogs: 
nonthrombotic effects of thrombin 
in vessel wall biology. Circ Res 88: 987-97 
Pattison JM, Nelson PJ, Huie P, 
Sibley RK, Krensky AM (1996) RANTES chemokine 
expression in transplant-associated accelerated 
atherosclerosis. J Heart Lung Transplant 
15: 1194-9 
309 
Pawlowska Z, Chabielska E, Kobylanska A, Maciaszek A, Swiatkowska M, Buczko `V . 
Stec WJ, Cierniewski CS (2001) Regulation of PAM concentration in platelets by 
systemic administration of antisense oligonucleotides to rats. Thromb Haemost 85: 
1086-9 
Peiper SC, Wang ZX, Neote K, Martin AW, Showell HJ, Conklyn MJ, Ogborne K, 
Hadley TJ, Lu ZH, Hesselgesser J, Horuk R (1995) The Duffy antigen/receptor for 
chemokines (DARC) is expressed in endothelial cells of Duffy negative individuals who lack the erythrocyte receptor. JExp Med 181: 1311-7 
Pelaia G, Cuda G, Vatrella A, Gallelli L, Fratto D, Gioffre V, D'Agostino B, Caputi M. 
Maselli R, Rossi F, Costanzo FS, Marsico SA (2004) Effects of hydrogen peroxide on 
MAPK activation, IL-8 production and cell viability in primary cultures of human 
bronchial epithelial cells. J Cell Biochem 93: 142-52 
Percival SS, Kauwell GP, Bowser E, Wagner M (1999) Altered copper status in adult 
men with cystic fibrosis. JAm Coll Nutr 18: 614-9 
Persichini T, Percario Z, Mazzon E, Colasanti M, Cuzzocrea S, Musci G (2006) Copper 
activates the NF-kappaB pathway in vivo. Antioxid Redox Signal 8: 1897-904 
Petrek M. Pantelidis P, Southcott AM, Lympany P, Safranek P, Black CM, Kolek V, 
Weigl E, du Bois RM (1997) The source and role of RANTES in interstitial lung 
disease. Eur Respir J 10: 1207-16 
Pitchford SC, Momi S, Baglioni S, Casali L, Giannini S, Rossi R, Page CP, Gresele P 
(2008) Allergen induces the migration of platelets to lung tissue in allergic asthma. Am 
JRespir Crit Care Med 177: 604-12 
Pitchford SC, Momi S, Giannini S, Casali L, Spina D, Page CP, Gresele P (2005) 
Platelet P-selectin is required for pulmonary eosinophil and lymphocyte recruitment in a 
murine model of allergic inflammation. Blood 105: 2074-81 
Pitchford SC, Riffo-Vasquez Y, Sousa A, Momi S, Gresele P, Spina D, Page CP (2004) 
Platelets are necessary for airway wall remodeling in a murine model of chronic allergic 
inflammation. Blood 103: 639-47 
Pitchford SC, Yano H, Lever R, Riffo-Vasquez Y, Ciferri S, Rose MJ, Giannini S, 
Momi S, Spina D, O'Connor B, Gresele P, Page CP (2003) Platelets are essential for 
leukocyte recruitment in allergic inflammation. JAllergy Clin Immunol 112: 109-18 
Pober JS, Cotran RS (1990) Cytokines and endothelial cell biology. Physiol Rev 70: 
427-51 
Pope CA, 3rd (1989) Respiratory disease associated with community air pollution and a 
steel mill, Utah Valley. 
Am JPublic Health 79: 623-8 
Pope CA, 3rd, Dockery DW. Spengler 
JD, Raizenne ME (1991) Respiratory health and 
PM 10 pollution. A daily time series analysis. 
Am Rev Respir Dis 144: 668-74 
310 
Power CA, Clemetson JM, Clemetson KJ, Wells TN (1995) Chemokine and chemokine 
receptor mRNA expression in human platelets. Cytokine 7: 479-82 
Proudfoot AE (2006) The biological relevance of chemokine-proteoglycan interactions. 
Biochem Soc Trans 34: 422-6 
Proudfoot AE, Fritchley S, Borlat F, Shaw JP, Vilbois F, Zwahlen C. Trkola A. 
Marchant D, Clapham PR, Wells TN (2001) The BBXB motif of RANTES is the 
principal site for heparin binding and controls receptor selectivity. J Biol Chem 276: 
10620-6 
Proudfoot AE, Handel TM, Johnson Z, Lau EK, LiWang P, Clark-Lewis I, Borlat F, 
Wells TN, Kosco-Vilbois MH (2003) Glycosaminoglycan binding and oligomerization 
are essential for the in vivo activity of certain chemokines. Proc Nail Acad Sci U SA 
100: 1885-90 
Pruenster M. Rot A (2006) Throwing light on DARC. Biochem Soc Trans 34: 1005-8 
Psarras S, Caramori G, Contoli M, Papadopoulos N, Papi A (2005) Oxidants in asthma 
and in chronic obstructive pulmonary disease (COPD). Curr Pharm Des 11: 2053-62 
Qiao D, Meyer K, Mundhenke C, Drew SA, Friedl A (2003) Heparan sulfate 
proteoglycans as regulators of fibroblast growth factor-2 signaling in brain endothelial 
cells. Specific role for glypican-1 in glioma angiogenesis. JBiol Chem 278: 16045-53 
Qin K, Coomaraswamy J, Mastrangelo P, Yang Y, Lugowski S, Petromilli C, Prusiner 
SB, Fraser PE, Goldberg JM, Chakrabartty A, Westaway D (2003) The PrP-like protein 
Doppel binds copper. JBiol Chem 278: 8888-96 
Qin K, Yang Y, Mastrangelo P, Westaway D (2002) Mapping Cu(II) binding sites in 
prion proteins by diethyl pyrocarbonate modification and matrix-assisted laser 
desorption ionization-time of flight (MALDI-TOF) mass spectrometric footprinting. J 
Biol Chem 277: 1981-90 
Rael LT, Rao NK, Thomas GW, Bar-Or R, Curtis CG, Bar-Or D (2007) Combined 
cupric- and cuprous-binding peptides are effective 
in preventing IL-8 release from 
endothelial cells and redox reactions. 
Biochem Biophys Res Commun 357: 543-8 
Rahman I (2002) Oxidative stress and gene transcription in asthma and chronic 
obstructive pulmonary 
disease: antioxidant therapeutic targets. Curr Drug Targets 
Inflamm Allergy 1: 291-315 
Rahman I (2006) Antioxidant therapies in COPD. 
Int J Chron Obstruct Pulmon Dis 1: 
15-29 
Rahman I, Biswas SK, Kode A (2006) 
Oxidant and antioxidant balance in the airways 
and airway diseases. 
Eur JPharmacol 533: 222-39 
Rajarathnam K, Sykes BD, 
Kay CM, Dewald B, Geiser T, Baggiolini M, Clark-Lewis I 
(1994) Neutrophil activation 
by monomeric interleukin-8. Science 264: 90-2 
311 
Rao JK, Kroenke K, Mihaliak KA, Grambow SC, Weinberger M (2003) Rheumatology 
patients' use of complementary therapies: results from a one-year longitudinal study. 
Arthritis Rheum 49: 619-25 
Rao JK, Mihaliak K, Kroenke K, Bradley J, Tierney WM, Weinberger M (1999) Use of 
complementary therapies for arthritis among patients of rheumatologists. Ann Intern 
Med 131: 409-16 
Rao RM, Yang L, Garcia-Cardena G, Luscinskas FW (2007) Endothelial-dependent 
mechanisms of leukocyte recruitment to the vascular wall. Circ Res 101: 234-47 
Reale M, Intorno R, Tenaglia R, Feliciani C, Barbacane RC, Santoni A, Conti P (2002) 
Production of MCP-1 and RANTES in bladder cancer patients after bacillus Calmette- 
Guerin immunotherapy. Cancer Immunol Immunother 51: 91-8 
Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK, Chenevert T, Brewer GJ, 
Merajver SD (2003) Phase II trial of tetrathiomolybdate in patients with advanced 
kidney cancer. Clin Cancer Res 9: 1666-72 
Reid DW, Misso N, Aggarwal S. Thompson PJ, Walters EH (2007) Oxidative stress and 
lipid-derived inflammatory mediators during acute exacerbations of cystic fibrosis. 
Respirology 12: 63-9 
Reinhardt PH, Elliott JF, Kubes P (1997) Neutrophils can adhere via alpha4beta l- 
integrin under flow conditions. Blood 89: 3837-46 
Rek AB, B. Geretti, E. Kungl, A. J. (2009) A biophysical insight into the RANTES- 
glycosaminoglycan interaction. Biochimica et Biophysica Acta 1794: 577-582 
Rendu F, Brohard-Bohn B (2001) The platelet release reaction: granules' constituents, 
secretion and functions. Platelets 12: 261-73 
Riccioni G, Barbara M, Bucciarelli T, di Ilio C, D'Orazio N (2007) Antioxidant vitamin 
supplementation in asthma. Ann Clin Lab Sci 37: 96-101 
Rice TM, Clarke RW, Godleski JJ, Al-Mutairi E, Jiang NF, Hauser R, Paulauskis JD 
(2001) Differential ability of transition metals to induce pulmonary inflammation. 
Toxicol Appl Pharmacol 177: 46-53 
Richards KL, McCullough J (1984) A modified microchamber method for chemotaxis 
and chemokinesis. Immunol Commun 13: 49-62 
Rot A (1992) Binding of neutrophil attractant/activation protein-1 (interleukin 8) to 
resident dermal cells. Cytokine 
4: 347-52 
Rot A (1993) Neutrophil attractant/activation protein-1 (interleukin-8) induces in vitro 
neutrophil migration by 
haptotactic mechanism. Eur Jlmmunol 23: 303-6 
Rot A (1996) Inflammatory and Physiological Roles of Chemokines. Pathol Oncol Res 
2: 16-20 
312 
Rot A (2003) In situ binding assay for studying chemokine interactions with endothelial 
cells. Jlmmunol Methods 273: 63-71 
Rot A (2005) Contribution of Duffy antigen to chemokine function. Cytokine Growth 
Factor Rev 16: 687-94 
Rot A, Hub E, Middleton J, Pons F, Rabeck C, Thierer K, Wintle J, Wolff B, Zsak M, 
Dukor P (1996) Some aspects of IL-8 pathophysiology. III: Chemokine interaction with 
endothelial cells. JLeukoc Biol 59: 39-44 
Rot A, Krieger M, Brunner T, Bischoff SC, Schall TJ, Dahinden CA (1992) RANTES 
and macrophage inflammatory protein 1 alpha induce the migration and activation of 
normal human eosinophil granulocytes. JExp Med 176: 1489-95 
Rubin BK (2008) Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J 
Aerosol Med Pulm Drug Deliv 21: 71-6 
Sablotzki A. Friedrich I, Muhling J, Dehne MG, Spillner J, Silber RE, Czeslik E (2002) 
The systemic inflammatory response syndrome following cardiac surgery: different 
expression of proinflammatory cytokines and procalcitonin in patients with and without 
multiorgan dysfunctions. Perfusion 17: 103-9 
Saczewski F, Dziemidowicz-Borys E, Bednarski PJ, Gdaniec M (2007) Synthesis, 
crystal structure, cytotoxic and superoxide dismutase activities of copper(II) complexes 
of N-(4,5-dihydroimidazol-2-yl)azoles. Arch Pharm (Weinheim) 340: 333-8 
Saetta M, Di Stefano A, Turato G, Facchini FM, Corbino L, Mapp CE, Maestrelli P, 
Ciaccia A, Fabbri LM (1998) CD8+ T-lymphocytes in peripheral airways of smokers 
with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157: 822-6 
Safaiyan F, Kolset SO, Prydz K, Gottfridsson E, Lindahl U, Salmivirta M (1999) 
Selective effects of sodium chlorate treatment on the sulfation of heparan sulfate. J Biol 
Chem 274: 36267-73 
Salcedo R, Young HA, Ponce ML, Ward JM, Kleinman HK, Murphy WJ, Oppenheim 
JJ (2001) Eotaxin (CCL 11) induces in vivo angiogenic responses by human CCR3+ 
endothelial cells. J Immunol 166: 7571-8 
Sallusto F, Baggiolini M (2008) Chemokines and leukocyte traffic. Nat Immunol 9: 
949-52 
Sallusto F, Lanzavecchia A, Mackay CR (1998a) Chemokines and chemokine receptors 
in T-cell priming and Thl/Th2-mediated responses. Immunol Today 19: 568-74 
Sallusto F, Lenig D, Mackay CR, Lanzavecchia A (1998b) Flexible programs of 
chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J 
Exp Med 187: 875-83 
Sallusto F, Mackay CR, Lanzavecchia A (1997) Selective expression of the eotaxin 
receptor CCR3 by human T helper 2 cells. Science 277: 2005-7 
313 
Salmi M, Jalkanen S (1992) A 90-kilodalton endothelial cell molecule mediating 
lymphocyte binding in humans. Science 257: 1407-9 
Salmi M, Jalkanen S (1995) Different forms of human vascular adhesion protein-1 
(VAP-1) in blood vessels in vivo and in cultured endothelial cells: implications for 
lymphocyte-endothelial cell adhesion models. Eur Jlmmunol 25: 2803-12 
Salmi M, Jalkanen S (1996) Human vascular adhesion protein 1 (VAP-1) is a unique 
sialoglycoprotein that mediates carbohydrate-dependent binding of lymphocytes to 
endothelial cells. JExp Med 183: 569-79 
Salmi M, Jalkanen S (2001) VAP-1: an adhesin and an enzyme. Trends Immunol 22: 
211-6 
Salmi M. Jalkanen S (2005) Cell-surface enzymes in control of leukocyte trafficking. 
Nat Rev Immunol 5: 760-71 
Salmi M, Kalimo K, Jalkanen S (1993) Induction and function of vascular adhesion 
protein-1 at sites of inflammation. JExp Med 178: 2255-60 
Salmi M, Yegutkin GG, Lehvonen R, Koskinen K, Salminen T, Jalkanen S (2001) A 
cell surface amine oxidase directly controls lymphocyte migration. Immunity 14: 265-76 
Samet JM, Graves LM, Quay J, Dailey LA, Devlin RB, Ghio AJ, Wu W, Bromberg PA, 
Reed W (1998) Activation of MAPKs in human bronchial epithelial cells exposed to 
metals. Am JPhysiol 275: L551-8 
Santini C, Pellei M, Lobbia GG, Fedeli D, Falcioni G (2003) Synthesis and 
characterization of new copper(I) complexes containing 4-(diphenylphosphane)benzoic 
acid and "scorpionate" ligands with "in vitro" superoxide scavenging activity. J Inorg 
Biochem 94: 348-54 
Sawdey M, Podor TJ, Loskutoff DJ (1989) Regulation of type 1 plasminogen activator 
inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by 
transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. J 
Biol Chem 264: 10396-401 
Schall TJ (1991) Biology of the RANTES/SIS cytokine family. Cytokine 3: 165-83 
Schall TJ, Bacon K, Toy KJ, Goeddel DV (1990) Selective attraction of monocytes and 
T lymphocytes of the memory phenotype by cytokine RANTES. Nature 347: 669-71 
Schall TJ, Jongstra J, Dyer BJ, Jorgensen J, Clayberger C, Davis MM, Krensky AM 
(1988) A human T cell-specific molecule is a member of a new gene family. Jlmmunol 
141: 1018-25 
Schilsky ML (1996) Wilson disease: genetic basis of copper toxicity and natural history. 
5emin Liver Dis 16: 83-95 
314 
Schmitz T, Leroy MJ, Dallot E, Breuiller-Fouche M, Ferre F, Cabrol D (2003) 
Interleukin-1 beta induces glycosaminoglycan synthesis via the prostaglandin E2 
pathway in cultured human cervical fibroblasts. Mol Hum Reprod 9: 1-8 
Schnitzel W, Monschein U, Besemer J (1994) Monomer-dimer equilibria of interleukin- 
8 and neutrophil-activating peptide 2. Evidence for IL-8 binding as a dimer and 
oligomer to IL-8 receptor B. JLeukoc Biol 55: 763-70 
Schober A, Manka D, von Hundelshausen P, Huo Y, Hanrath P, Sarembock IJ, Ley K, 
Weber C (2002) Deposition of platelet RANTES triggering monocyte recruitment 
requires P-selectin and is involved in neointima formation after arterial injury. 
Circulation 106: 1523-9 
Schroder JM, Kameyoshi Y, Christophers E (1994) RANTES, a novel eosinophil- 
chemotactic cytokine. Ann N YAcad Sci 725: 91-103 
Schuschke DA (1997) Dietary copper in the physiology of the microcirculation. J Nutr 
127: 2274-81 
Schuschke DA, Falcone JC, Saari JT, Fleming JT, Percival SS, Young SA, Pass JM, 
Miller FN (2000) Endothelial cell calcium mobilization to acetylcholine is attenuated in 
copper-deficient rats. Endothelium 7: 83-92 
Schuschke DA, Saari JT, Miller FN (2001) Leukocyte-endothelial adhesion is impaired 
in the cremaster muscle microcirculation of the copper-deficient rat. Immunol Lett 76: 
139-44 
Schwiebert LM, Estell K, Propst SM (1999) Chemokine expression in CF epithelia: 
implications for the role of CFTR in RANTES expression. Am JPhysiol 276: C700-10 
Sekine Y, Yasufuku K, Heidler KM, Cummings OW, Van Rooijen N, Fujisawa T, 
Brown J, Wilkes DS (2000) Monocyte chemoattractant protein-1 and RANTES are 
chemotactic for graft infiltrating lymphocytes during acute lung allograft rejection. Am 
J Respir Cell Mol Biol 23: 719-26 
Sigurdsson EM, Brown DR, Alim MA, Scholtzova H, Carp R, Meeker HC, Prelli F, 
Frangione B, Wisniewski T (2003) Copper chelation delays the onset of prion disease. J 
Biol Chem 278: 46199-202 
Singh B, Tschernig T, van Griensven M, Fieguth A, Pabst R (2003) Expression of 
vascular adhesion protein-1 
in normal and inflamed mice lungs and normal human 
lungs. Virchows Arch 442: 491-5 
Skelton NJ, Aspiras F, Ogez J, Schall TJ (1995) Proton NMR assignments and solution 
conformation of 
RANTES, a chemokine of the C-C type. Biochemistry 34: 5329-42 
Slimani H, Charnaux N, Mbemba E, Saffar L, Vassy R, Vita C, Gattegno L (2003) 
Binding of the CC-chemokine RANTES to syndecan-1 and syndecan-4 expressed on 
HeLa cells. Glycobiology 13: 623-34 
315 
Smail EH, Briza P, Panagos A, Berenfeld L (1995) Candida albicans cell walls contain 
the fluorescent cross-linking amino acid dityrosine. Infect Immun 63: 4078-83 
Smit H, van der Goot H, Nauta WT, Timmerman H, de Bolster MW, Stouthamer AH, 
Vis RD (1982) Mechanism of action of the copper(I) complex of 2,9-dimethyl-1,10- 
phenanthroline on Mycoplasma gallisepticum. Antimicrob Agents Chemother 21: 881-6 
Smith DG, Cappai R, Barnham KJ (2007) The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim Biophys Acta 1768: 1976-90 
Smith DP, Smith DG, Curtain CC, Boas JF, Pilbrow JR, Ciccotosto GD, Lau TL, Tew 
DJ, Perez K, Wade JD, Bush Al, Drew SC, Separovic F, Masters CL, Cappai R, 
Barnham KJ (2006) Copper-mediated amyloid-beta toxicity is associated with an intermolecular histidine bridge. J Biol Chem 281: 15145-54 
Smith GF, McCurdy WH (1952) 2,9-Dimethyl-1,10-phenanthroline. Analytical 
Chemistry 24: 371-73 
Smith GF, Wilkins DH (1953) New Colorimetric Reagent Specific for Cooper. 
Analytical Chemistry 25: 510-11 
Sozgen K, Cekic SD, Tutem E, Apak R (2006) Spectrophotometric total protein assay 
with copper(II)-neocuproine reagent in alkaline medium. Talanta 68: 1601-9 
Spillmann D, Witt D, Lindahl U (1998) Defining the interleukin-8-binding domain of 
heparan sulfate. JBiol Chem 273: 15487-93 
Springer TA (1994) Traffic signals for lymphocyte recirculation and leukocyte 
emigration: the multistep paradigm. Cell 76: 301-14 
Squitti R, Lupoi D, Pasqualetti P, Dal Forno G, Vernieri F, Chiovenda P, Rossi L, 
Cortesi M, Cassetta E, Rossini PM (2002) Elevation of serum copper levels in 
Alzheimer's disease. Neurology 59: 1153-61 
Squitti R, Pasqualetti P, Dal Forno G, Moffa F, Cassetta E, Lupoi D, Vernieri F, Rossi 
L, Baldassini M, Rossini PM (2005) Excess of serum copper not related to 
ceruloplasmin in Alzheimer disease. Neurology 64: 1040-6 
Stanczak P, Valensin D, Juszczyk P, Grzonka Z, Migliorini C, Molteni E, Valensin G, 
Gaggelli E, Kozlowski H (2005a) Structure and Stability of the Cu(II) Complexes with 
Tandem Repeats of the Chicken Prion. Biochemistry 44: 12940-54 
Stanczak P, Valensin D, Juszczyk P, Grzonka Z, Valensin G, Bernardi F, Molteni E, 
Gaggelli E, Kozlowski H (2005b) Fine tuning the structure of the Cu(2+) complex with 
the prion protein chicken repeat by proline isomerization. Chem Commun (Camb): 
3298-300 
Strecker D (2005) [Copper content in rheumatoid arthritis patients]. Ann Acad Med 
Stetin 51 Suppl 1: 129-33 
316 
Struthers GR, Scott DL, Scott DG (1983) The use of 'alternative treatments' by patients 
with rheumatoid arthritis. Rheumatol Int 3: 151-2 
Sugasawa H, Ichikura T, Tsujimoto H, Kinoshita M, Morita D, Ono S, Chochi K, Tsuda 
H, Seki S, Mochizuki H (2008) Prognostic significance of expression of 
CCL5/RANTES receptors in patients with gastric cancer. J Surg Oncol 97: 445-50 
Sundstrom JB, McMullan LK, Spiropoulou CF, Hooper WC, Ansari AA, Peters CJ, 
Rollin PE (2001) Hantavirus infection induces the expression of RANTES and IP-10 
without causing increased permeability in human lung microvascular endothelial cells. J 
Virol 75: 6070-85 
Swiatek M, Valensin D, Migliorini C, Gaggelli E, Valensin G, Jezowska-Bojczuk M 
(2005) Unusual binding ability of vancomycin towards Cu2+ ions. Dalton Trans: 3808- 
13 
Takasaki S, Kato Y, Murata M, Homma S, Kawakishi S (2005) Effects of peroxidase 
and hydrogen peroxide on the dityrosine formation and the mixing characteristics of 
wheat-flour dough. Biosci Biotechnol Biochem 69: 1686-92 
Tapiero H, Townsend DM, Tew KD (2003) Trace elements in human physiology and 
pathology. Copper. BiomedPharmacother 57: 386-98 
Taylor KR, Gallo RL (2006) Glycosaminoglycans and their proteoglycans: host- 
associated molecular patterns for initiation and modulation of inflammation. Faseb J 
20: 9-22 
Terada N, Maesako K, Hamano N, Ikeda T, Sai M, Yamashita T, Fukuda S, Konno A 
(1996) RANTES production in nasal epithelial cells and endothelial cells. JAllergy Clin 
Immunol 98: S230-7 
Teran LM, Mochizuki M, Bartels J, Valencia EL, Nakajima T, Hirai K, Schroder JM 
(1999) Th 1- and Th2-type cytokines regulate the expression and production of eotaxin 
and RANTES by human lung 
fibroblasts. Am JRespir Cell Mol Biol 20: 777-86 
Tew D, Ortiz de Montellano PR (1988) The myoglobin protein radical. Coupling of 
Tyr-103 to Tyr-151 in the H202-mediated cross-linking of sperm whale myoglobin. J 
Biol Chem 263: 17880-6 
Thienel U, Loike J, Yellin MJ (1999) CD 154 (CD40L) induces human endothelial cell 
chemokine production and migration of 
leukocyte subsets. Cell Immunol 198: 87-95 
Togashi Y, Li Y, Kang JH, Takeichi N, Fuj ioka Y, Nagashima K, Kobayashi H (1992) 
D-penicillamine prevents the 
development of hepatitis in Long-Evans Cinnamon rats 
with abnormal copper metabolism. 
Hepatology 15: 82-7 
Tripathy D, Thirumangalakudi L, Grammas P (2008) RANTES upregulation in the 
Alzheimer's disease brain: A possible neuroprotective role. Neurobiol Aging 
Tsakiris DA, Scudder L, Hodivala-Dilke K, Hynes RO, Coller BS (1999) Hemostasis in 
the mouse (Mus musculus): a review. Thromb Haemost 81: 177-88 
317 
Tsicopoulos A, Hamid Q, Varney V, Ying S, Moqbel R, Durham SR, Kay AB (1992) 
Preferential messenger RNA expression of Thl-type cells (IFN-gamma+, IL-2+) in 
classical delayed-type (tuberculin) hypersensitivity reactions in human skin. J Immunol 
148: 2058-61 
Tsujimoto M, Yokota S, Vilcek J, Weissmann G (1986) Tumor necrosis factor provokes 
superoxide anion generation from neutrophils. Biochem Biophys Res Commun 137: 
1094-100 
Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A, Suzumori K (2006) Elevated 
serum RANTES levels in patients with ovarian cancer correlate with the extent of the 
disorder. Gynecol Oncol 102: 542-5 
Tutem E, Apak R, Gunaydi E, Sozgen K (1997) Spectrophotometric determination of 
vitamin E (alpha-tocopherol) using copper(II)-neocuproine reagent. Talanta 44: 249- 
255 
Twomey PJ, Wierzbicki AS, House IM, Viljoen A, Reynolds TM (2007) Percentage 
non-caeruloplasmin bound copper. Clin Biochem 40: 749-50 
Ulfman LH, Joosten DP, van Aalst CW, Lammers JW, van de Graaf EA, Koenderman 
L, Zwaginga JJ (2003) Platelets promote eosinophil adhesion of patients with asthma to 
endothelium under flow conditions. Am J Respir Cell Mol Biol 28: 512-9 
Vaday GG, Peehl DM, Kadam PA, Lawrence DM (2006) Expression of CCL5 
(RANTES) and CCR5 in prostate cancer. Prostate 66: 124-34 
Vakulenko SB, Mobashery S (2003) Versatility of aminoglycosides and prospects for 
their future. Clin Microbiol Rev 16: 430-50 
Valachova K, Hrabarova E, Gemeiner P, Soltes L (2008) Study of pro- and anti- 
oxidative properties of D-penicillamine in a system comprising high-molar-mass 
hyaluronan, ascorbate, and cupric ions. Neuro Endocrinol Lett 29: 697-701 
Valen G, Erl W, Eriksson P, Wuttge D, Paulsson G, Hansson GK (1999) Hydrogen 
peroxide induces mRNA for tumour necrosis factor alpha in human endothelial cells. 
Free Radic Res 31: 503-12 
Valone FH, Austen KF, Goetzl EJ (1974) Modulation of the random migration of 
human platelets. J Clin Invest 54: 1100-6 
van der Vliet A, Eiserich JP, Marelich GP, Halliwell B, Cross CE (1997) Oxidative 
stress in cystic fibrosis: does it occur and does it matter? Adv Pharmacol 38: 491-513 
Vargaftig BB, Joseph D, Marlas G, Chevance LG (1982) Degranulation of rabbit 
platelets with PAF-acether: a new procedure for unravelling the mode of action of 
platelet-activating substances. Thromb Haemost 48: 67-71 
Varma SD, Devamanoharan PS (1991) Hydrogen peroxide in human blood. Free Radic 
Res Commun 14: 125-31 
318 
Venge J, Lampinen M, Hakansson L, Rak S, Venge P (1996) Identification of IL-5 and 
RANTES as the major eosinophil chemoattractants in the asthmatic lung. JAllergy Clin 
Immunol 97: 1110-5 
Versieck JaC, R (1980) Normal levels of trace elements in human blood plasma or 
serum. Analytica Chimica Acta 116: 217-254 
Vives RR, Sadir R, Imberty A, Rencurosi A, Lortat-Jacob H (2002) A kinetics and 
modeling study of RANTES(9-68) binding to heparin reveals a mechanism of 
cooperative oligomerization. Biochemistry 41: 14779-89 
Volin MV, Shah MR, Tokuhira M, Haines GK, Woods JM, Koch AE (1998) RANTES 
expression and contribution to monocyte chemotaxis in arthritis. Clin Immunol 
Immunopathol 89: 44-53 
Volpi N, Tarugi P (1999) The protective effect on Cu2+- and AAPH-mediated 
oxidation of human low-density lipoproteins depends on glycosaminoglycan structure. 
Biochimie 81: 955-63 
von Hundelshausen P, Weber KS, Huo Y, Proudfoot AE, Nelson PJ, Ley K, Weber C 
(2001) RANTES deposition by platelets triggers monocyte arrest on inflamed and 
atherosclerotic endothelium. Circulation 103: 1772-7 
Wadsworth JD, Hill AF, Joiner S, Jackson GS, Clarke AR, Collinge J (1999) Strain- 
specific prion-protein conformation determined by metal ions. Nat Cell Biol 1: 55-9 
Wagner JG, Roth RA (2000) Neutrophil migration mechanisms, with an emphasis on 
the pulmonary vasculature. Pharmacol Rev 52: 349-74 
Wagner L, Yang 00, Garcia-Zepeda EA, Ge Y, Kalams SA, Walker BD, Pasternack 
MS, Luster AD (1998a) Beta-chemokines are released from HIV-1-specific cytolytic T- 
cell granules complexed to proteoglycans. Nature 391: 908-11 
Wagner M, Klein CL, van Kooten TG, Kirkpatrick CJ (1998b) Mechanisms of cell 
activation by heavy metal ions. J Biomed Mater Res 42: 443-52 
Walker WR, Beveridge SJ, Whitehouse MW (1980) Anti-inflammatory activity of a 
dermally applied copper salicylate preparation (Alcusal). Agents Actions 10: 38-47 
Walker WR, Beveridge SJ, Whitehouse MW (1981) Dermal copper drugs: the copper 
bracelet and cu(II) salicylate complexes. Agents Actions Suppi 8: 359-67 
Walker WR, Griffin BJ (1976) The solubility of copper in human sweat. Search 7: 100 
Walker WR, Keats DM (1976) An investigation of the therapeutic value of the 'copper 
bracelet'-dermal assimilation of copper in arthritic/rheumatoid conditions. Agents 
Actions 6: 454-9 
Walker WR, Reeves RR (1977) Perfusion of intact skin by a saline solution of 
bis(glycinato) copper(II). Bioinorg Chem 7: 271-6 
319 
Walshe JM (1956) Penicillamine, a new oral therapy for Wilson's disease. Am J Med 
21: 487-95 
Walshe JM (1982) Treatment of Wilson's disease with trientine (triethylene tetramine) 
dihydrochloride 
. Lancet 1: 643-7 
Walz A, Peveri P, Aschauer H, Baggiolini M (1987) Purification and amino acid 
sequencing of NAF, a novel neutrophil-activating factor produced by monocytes. 
Biochem Biophys Res Commun 149: 755-61 
Ward SG, Bacon K, Westwick J (1998) Chemokines and T lymphocytes: more than an 
attraction. Immunity 9: 1-11 
Ward SG, Westwick J (1998) Chemokines: understanding their role in T-lymphocyte 
biology. Biochem J 333 (Pt 3): 457-70 
Warner RG, Hundt C, Weiss S, Turnbull JE (2002) Identification of the heparan sulfate 
binding sites in the cellular prion protein. J Biol Chem 277: 18421-30 
Weber C, Weber KS, Klier C, Gu S, Wank R, Horuk R, Nelson PJ (2001) Specialized 
roles of the chemokine receptors CCR1 and CCR5 in the recruitment of monocytes and 
T(H)1-like/CD45RO(+) T cells. Blood 97: 1144-6 
Weingart C, Nelson PJ, Kramer BK, Mack M (2008) Dose dependent effects of platelet 
derived chondroitinsulfate A on the binding of CCL5 to endothelial cells. BMC 
Immunol 9: 72 
Wells TN, Guye-Coulin F, Bacon KB (1995) Peptides from the amino-terminus of 
RANTES cause chemotaxis of human T-lymphocytes. Biochem Biophys Res Commun 
211: 100-5 
Wells TN, Power CA, Lusti-Narasimhan M, Hoogewerf AJ, Cooke RM, Chung CW, 
Peitsch MC, Proudfoot AE (1996) Selectivity and antagonism of chemokine receptors. J 
Leukoc Biol 59: 53-60 
Weser U, Schubotz LM (1981) Catalytic reaction of copper complexes with superoxide. 
Agents Actions Suppi 8: 103-20 
Wetlaufer DB (1962) Ultraviolet spectra of proteins and amino acids. Adv Protein Chem 
17: 303-390 
Weyrich AS, Denis MM, Schwertz H, Tolley ND, Foulks J, Spencer E, Kraiss LW, 
Albertine KH, McIntyre TM, Zimmerman GA (2007) mTOR-dependent synthesis of 
Bcl-3 controls the retraction of fibrin clots by activated human platelets. 
Blood 109: 
1975-83 
Weyrich AS, Lindemann S, Zimmerman GA (2003) The evolving role of platelets in 
inflammation. J Thromb Haemost 1: 1897-905 
320 
White AR, Huang X, Jobling MF, Barrow CJ, Beyreuther K, Masters CL, Bush Al. 
Cappai R (2001) Homocysteine potentiates copper- and amyloid beta peptide-mediated 
toxicity in primary neuronal cultures: possible risk factors in the Alzheimer's-type 
neurodegenerative pathways. JNeurochem 76: 1509-20 
Williams HL, Johnson DJ, Haut MJ (1977) Simultaneous spectrophotometry of Fe2+ 
and Cu2+ in serum denatured with guanidine hydrochloride. Clin Chem 23: 237-40 
Williams MA, Cave CM, Quaid G, Robinson C, Daly TJ, Witt D, Lentsch AB, 
Solomkin JS (2005) Interleukin 8 dimerization as a mechanism for regulation of 
neutrophil adherence-dependent oxidant production. Shock 23: 371-6 
Wood PL, Khan MA, Moskal JR (2008) Mechanism of action of the disease-modifying 
anti-arthritic thiol agents D-penicillamine and sodium aurothiomalate: restoration of 
cellular free thiols and sequestration of reactive aldehydes. Eur JPharmacol 580: 48-54 
Wozniak K, Blasiak J (2002) Free radicals-mediated induction of oxidized DNA bases 
and DNA-protein cross-links by nickel chloride. Mutat Res 514: 233-43 
Xiao W, Hsu YP, Ishizaka A, Kirikae T, Moss RB (2005) Sputum cathelicidin, 
urokinase plasminogen activation system components, and cytokines discriminate cystic 
fibrosis, COPD, and asthma inflammation. Chest 128: 2316-26 
Yamini Y, Tamaddon A (1999) Solid-phase extraction and spectrophotometric 
determination of trace amounts of copper in water samples. Talanta 49: 119-24 
Yanagishita M, Hascall VC (1992) Cell surface heparan sulfate proteoglycans. J Biol 
Chem 267: 9451-4 
Yaron I, Meyer FA, Dayer JM, Bleiberg I, Yaron M (1989) Some recombinant human 
cytokines stimulate glycosaminoglycan synthesis in human synovial fibroblast cultures 
and inhibit it in human articular cartilage cultures. Arthritis Rheum 32: 173-80 
Ying S, Meng Q, Taborda-Barata L, Corrigan CJ, Barkans J, Assoufi B, Moqbel R, 
Durham SR, Kay AB (1996) Human eosinophils express messenger RNA encoding 
RANTES and store and release biologically active RANTES protein. Eur J Immunol 
26: 70-6 
Yoshida A, Ohba M, Wu X, Sasano T, Nakamura M, Endo Y (2002) Accumulation of 
platelets in the lung and liver and their degranulation following antigen-challenge 
in 
sensitized mice. Br J Pharmacol 137: 146-52 
Yoshimura T, Matsushima K, Tanaka S, Robinson EA, Appella E, Oppenheim JJ, 
Leonard EJ (1987) Purification of a human monocyte-derived neutrophil chemotactic 
factor that has peptide sequence similarity to other host defense cytokines. 
Proc Nati 
AcadSci USA 84: 9233-7 
Yoshimura T, Yuhki N, Moore SK, Appella E, Lerman MI, Leonard EJ (1989) Human 
monocyte chemoattractant protein- i (MCP- 1). Full-length cDNA cloning, expression in 
mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse 
competence gene JE. FEBS Lett 244: 487-93 
321 
Yu PH, Lu LX, Fan H, Kazachkov M, Jiang ZJ, Jalkanen S, Stolen C (2006) 
Involvement of semicarbazide-sensitive amine oxidase-mediated deamination in 
lipopolysaccharide-induced pulmonary inflammation. Am JPathol 168: 718-26 
Zhu BZ, Antholine WE, Frei B (2002) Thiourea protects against copper-induced 
oxidative damage by formation of a redox-inactive thiourea-copper complex. Free 
Radic Biol Med 32: 1333-8 
Zimmerman GA, Renzetti AD, Hill HR (1984) Granulocyte adherence in pulmonary 
and systemic arterial blood samples from patients with adult respiratory distress 
syndrome. Am Rev Respir Dis 129: 798-804 
Ziora D, Dworniczak S, Niepsuj G, Krol W, Oklek K (1999) [Chemokine RANTES in 
bronchoalveolar lavage fluid(BAL)from two different lung segments indicated by high 
resolution tomography (HRCT) in patients with sarcoidosis]. Pneumonol Alergol Pol 
67: 525-35 
Zoli A, Altomonte L, Caricchio R, Galossi A, Mirone L, Ruffini MP, Magaro M (1998) 
Serum zinc and copper in active rheumatoid arthritis: correlation with interleukin 1 beta 
and tumour necrosis factor alpha. Clin Rheumatol 17: 378-82 
Zucker-Franklin D, Philipp CS (2000) Platelet production in the pulmonary capillary 
bed: new ultrastructural evidence for an old concept. Am JPathol 157: 69-74 
322 
